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1. Introduction
Effective tobacco product regulation is an essential component of a comprehensive 
tobacco control programme. It includes regulation of contents and emissions by 
mandated testing, disclosure of test results, setting limits as appropriate, disclosure 
of product information and imposing standards for product packaging and 
labelling. Tobacco product regulation is covered under Articles 9, 10 and 11 of 
the WHO Framework Convention on Tobacco Control (WHO FCTC) (1) and in 
the partial guidelines on implementation of Articles 9 and 10 of the WHO FCTC 
(2). Other WHO resources, including the basic handbook on tobacco product 
regulation (3), the handbook on building laboratory testing capacity (4) and the 
online modular courses based on the handbooks, which were published in 2018 
(5), support Member States in this respect.
The WHO Study Group on Tobacco Product Regulation (TobReg) was 
formally constituted by the WHO Director-General in 2003 to address gaps in 
the regulation of tobacco products. Its mandate is to provide evidence-based 
recommendations on policy for tobacco product regulation to the Director-
General. TobReg is composed of national and international scientific experts on 
product regulation, treatment of tobacco dependence, toxicology and laboratory 
analyses of tobacco product ingredients and emissions. The experts are from 
countries in all six WHO regions (6). As a formal entity of WHO, TobReg 
submits technical reports that provide the scientific basis for tobacco product 
regulation to the WHO Executive Board, through the Director-General, to draw 
the attention of Member States to WHO’s work in this field. The reports, in the 
WHO Technical Report Series, include previously unpublished background 
papers that synthesize published scientific literature and have been discussed, 
evaluated and reviewed by TobReg. In accordance with Articles 9 and 10 of the 
WHO FCTC, relevant decisions of the Conference of the Parties (COP) to the 
WHO  FCTC and relevant WHO reports submitted to the COP, the TobReg 
reports identify evidence-based approaches to regulating all forms of nicotine 
and tobacco products, including new and emerging products such as electronic 
nicotine delivery systems (ENDS), electronic non-nicotine delivery systems 
(ENNDS), heated tobacco products (HTPs) and nicotine pouches. These reports, 
now considered to be WHO global public health goods, respond to World Health 
Assembly resolutions WHA54.18 (2001), WHA53.17 (2000) and WHA53.8 
(2000). “Global public health goods” are initiatives developed or undertaken by 
WHO that are of benefit either globally or to many countries in many regions (7). 
This designation presents a unique opportunity for TobReg to speak directly to 
Member States and influence national, regional and global policy.
The 10th meeting of TobReg took place virtually on 28 September–2 
October 2020, coordinated from WHO headquarters in Geneva. Over 50 
participants, including the members of TobReg, discussed the scientific literature 
2
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on the attractiveness, toxicity, appeal, variation, marketing, health effects and 
regulation of novel and emerging nicotine and tobacco products, with a focus 
on HTPs. These products, which have a long history but have attracted increased 
international interest in the past decade, present various regulatory challenges, 
as there is a lack of capacity to regulate them, they distract from evidence-based 
interventions, conflation of product categories, unsubstantiated health claims 
and opposition to and interference with effective tobacco control policies and 
marketing and promotional activities that target children and adolescents by 
tobacco and related industries. The meeting provided a platform for discussing 
nine background papers:
 ■ toxicants in heated tobacco products, exposure, health effects and 
claims of reduced risk (section 2);
 ■ the attractiveness and addictive potential of heated tobacco products: 
effects on perception and use and associated effects (section 3);
 ■ variations among heated tobacco products, considerations and impli-
cations (section 4);
 ■ use of heated tobacco products: product switching and dual or poly 
product use (section 5);
 ■ regulations on HTPs, ENDS and ENNDS, with country approaches, 
barriers to regulation and regulatory considerations (section 6);
 ■ estimation of exposure to nicotine from use of electronic nicotine 
delivery systems and from conventional cigarettes (section 7);
 ■ exploration of methods for quantifying individual risks associated 
with electronic nicotine and non-nicotine delivery systems and heat-
ed tobacco products: impact on population health and implications 
for regulation (section 8).
 ■ flavours in novel and emerging nicotine and tobacco products (section 9);
 ■ global marketing and promotion of novel and emerging nicotine and 
tobacco products and their impacts (section 10);
TobReg also discussed two supplementary “horizon scanning” papers, on:
 ■ forms of nicotine in tobacco plants, chemical modifications and im-
plications for electronic nicotine delivery systems products (section 
11); and
 ■ EVALI: “e-cigarette or vaping product use-associated lung injury” 
(section 12).
3
Introduction
The background papers and the horizon scanning papers were prepared by 
subject matter experts according to the terms of reference or outline drawn 
up by the WHO Secretariat for each paper and were reviewed and revised by 
expert reviewers and members of the Study Group. The horizon scanning papers, 
which are new additions to the report, are short papers on emerging issues in 
product regulation for members to decide whether further work on these topics 
is warranted, such as a full background paper for a future meeting of the Study 
Group. The papers on HTPs and novel and emerging tobacco products addressed 
the request in paragraph 2a of decision FCTC/COP8(22) (8) at the eighth session 
of the COP (COP8):
2. REQUESTS the Convention Secretariat to invite WHO and, as appro-
priate, the WHO Tobacco Laboratory Network (TobLabNet):
(a) to prepare a comprehensive report, with scientists and experts, inde-
pendent from the tobacco industry, and competent national authorities, 
to be submitted to the Ninth session of the COP on research and evidence 
on novel and emerging tobacco products, in particular heated tobacco 
products, regarding their health impacts including on non-users, their 
addictive potential, perception and use, attractiveness, potential role in 
initiating and quitting smoking, marketing including promotional strate-
gies and impacts, claims of reduced harm, variability of products, regu-
latory experience and monitoring of Parties, impact on tobacco control 
efforts and research gaps, and to subsequently propose potential policy 
options to achieve the objectives and measures outlined in paragraph 5 of 
the present decision.
The request made to WHO via the Convention Secretariat on novel and emerging 
tobacco products was examined by WHO and was the basis for deciding the 
topics of the papers, with other emerging issues in nicotine and tobacco product 
regulation, including requests for technical assistance to WHO from Member 
States. The Secretariat, in consultation with the Study Group, invited experts who 
not only contributed to discussions but also provided the most recent empirical 
scientific evidence and regulations on nicotine and tobacco products in their 
background papers. The period of the literature search is indicated in each 
paper; for most, it was the second quarter of 2020. The papers were subject to 
several rounds of review before and after the meeting by independent technical 
experts, the WHO Secretariat, people in other relevant WHO departments, 
regional colleagues and members of the Study Group before compilation into the 
technical report. This eighth report of TobReg on the scientific basis of tobacco 
product regulation is designed to guide Member States in finding the most 
effective, evidence-based means to bridge regulatory gaps and address challenges 
in tobacco control and should lead to development of coordinated regulatory 
4
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
02
9,
 2
02
1
WHO Study Group on Tobacco Product Regulation   Eighth report
frameworks for nicotine and tobacco products. All experts and other participants 
in the meeting, including members of the Study Group, were required to complete 
a declaration of interests, which was evaluated by WHO to ensure independence 
from tobacco and related industries.
This report includes five papers on HTPs (sections 2–6), two on ENDS 
(sections 7 and 8) and two general reviews on novel and emerging nicotine and 
tobacco products, on the use of flavours in these products (section 9) and global 
marketing and promotion (section 10). It also includes two supplementary 
sections (11 and 12) that scan the horizon of studies on forms of nicotine in 
tobacco plants and on e-cigarette or vaping product use-associated lung injury 
(EVALI) and  concludes with a section of overall recommendations, summarizing 
the recommendations in each section. The recommendations, which represent 
syntheses of complex research and evidence, promote international coordination 
of regulation and adoption of best practices in product regulation, strengthen 
capacity-building for product regulation in all WHO regions, represent a ready 
resource for Member States based on sound science and support implementation 
of the WHO FCTC by its States Parties.
This eighth report of the Study Group addresses ENDS, ENNDS and 
HTPs; however, it does not cover all aspects of these products, because many 
of the papers were written to meet the request of COP8, which was to review 
understanding on novel and emerging tobacco products (FCTC/COP8(22)). 
Continued research is necessary on these products; the Study Group will cover 
other products of interest (including traditional products, such as waterpipes, 
cigarettes and smokeless tobacco) in its next report, guided by countries’ 
regulatory requirements and pertinent issues in tobacco product regulation. This 
will ensure continued, timely technical support to all countries and address all 
products, recognizing that their availability depends on the jurisdiction.
In summary, the outcomes of TobReg’s deliberations and its recommen-
dations will improve Member States’ understanding of the evidence on ENDS, 
ENNDS and HTPs, contribute to the body of knowledge on product regulation, 
inform WHO’s work, especially in providing technical support to Member States 
and keep Member States, regulators, civil society, research institutions and other 
interested parties up to date on product regulation through various platforms. 
States Parties to the WHO FCTC will be updated by a comprehensive report to 
be submitted to COP9, via the Convention Secretariat, on novel and emerging 
tobacco products, in line with decision FCTC/COP8(22), which will include the 
messages and recommendations in this report. Thus, the Study Group’s activi-
ties will contribute to meeting target 3.a of the Sustainable Development Goals: 
strengthening implementation of the WHO FCTC (9).
5
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Abstract
Increased marketing and the increasing popularity of novel and emerging heated 
tobacco products (HTPs) calls for urgent assessment of their potential impact on 
public health. In this report, we evaluate the published literature on the chemical 
composition of HTPs, exposure to these products and their effects in model 
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toxicological systems (in vitro and in experimental animals) and in humans. 
Such evaluation is the key initial step in characterizing the addictive, toxic and 
carcinogenic potential of HTPs and comparing them with other tobacco products 
on the market. The data indicate that the chemical profile of HTP aerosols is 
substantially different from that of conventional cigarettes or e-cigarettes. In 
the absence of standard analytical methods, however, these findings should be 
interpreted with caution. Studies also suggests that nicotine intake from some 
HTPs may be similar to or greater than that from conventional cigarettes. Studies 
of exposure in vitro and in experimental animals and humans generally confirm 
reduced exposure to some combustion-derived toxicants; however, some studies 
raise concern about potential cardiopulmonary toxicity and hepatotoxicity in 
users and harm from second-hand exposure in non-users. The report highlights 
the paucity of independent, non-industry research and recommends research 
and regulatory priorities.
2.1 Background
Heated tobacco products (HTPs), also referred to by manufacturers and some 
regulators as “heat-not-burn” or tobacco heating products, produce aerosols by 
heating tobacco at lower temperatures than in conventional tobacco-burning 
cigarettes (generally < 600 °C) in battery-powered heating systems. Early versions 
of HTPs, such as the cigarettes Eclipse and Accord, were poorly accepted by 
smokers or did not gain a meaningful market share; however, the versions of HTPs 
introduced during the past decade have started to gain popularity in some parts 
of the world. As combustion of conventional cigarettes results in many harmful 
emissions, including numerous toxicants and carcinogens, the purported aim of 
the new HTPs is to offer smokers a “less harmful alternative” to conventional 
cigarettes. HTPs are thus marketed with claims of “reduced risk products”, “cleaner 
alternatives to conventional cigarettes” and “smoke-free alternatives”. Examples 
of currently marketed HTPs are IQOS (Philip Morris International, PMI), glo 
and iFuse (British American Tobacco, BAT) and Ploom TECH (Japan Tobacco). 
Although they all heat tobacco, they differ in their construction and composition 
and in the mechanisms for heating tobacco and generating aerosol. For example, 
IQOS and glo generate aerosol containing nicotine by heating cigarette-like 
tobacco sticks at 240–350 °C, while Ploom TECH and iFuse produce aerosols by 
heating a mixture of glycerol and propylene glycol, which is then passed through 
a capsule containing tobacco material.
There are several major challenges to assessing user and non-user exposure 
to emitted chemical constituents, many of which are important toxicants and 
carcinogens, and the effects associated with the currently marketed HTPs. The 
first is that products such as IQOS were introduced relatively recently, in 2015, 
and were initially available only on limited markets. The second is the diversity of 
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HTPs, outlined above, as the chemical composition of the aerosols produced by 
these devices may differ. While the concentrations of many combustion-associated 
chemicals in HTP aerosols may be lower than in conventional cigarettes, some 
are higher, and HTPs may emit unique harmful chemicals because of their 
distinctive characteristics and how they are used. A third issue is that some of 
the tobacco sticks manufactured for one device can be used with other devices 
and can be reused; the interchangeability and misuse of products make it difficult 
to determine the toxic emissions to which the user is exposed. Fourthly, most of 
the scientific data on currently marketed HTPs were generated and published 
by the tobacco industry or funded by affiliates of the industry, and there is a 
critical lack of independent academic literature on HTPs. Given the history of 
misleading marketing and misinterpretation of research data by some tobacco 
product manufacturers, their publications must be interpreted with caution and 
after rigorous review of the raw data and methods. Unpublished data reported to 
regulators by manufacturers should be reviewed in a similarly rigorous way.
This report was commissioned by WHO in response to the request 
made by the Conference of the Parties to the WHO Framework Convention 
on Tobacco Control at its eighth session (Geneva, Switzerland, 1−6 October 
2018) to the Convention Secretariat to invite WHO to prepare a comprehensive 
report of research and evidence on novel and emerging tobacco products, in 
particular HTPs, and to propose policy options to achieve the objectives and 
measures outlined in the relevant decision (FCTC/COP8(22)). This report partly 
addresses that request. It covers a broad range of aspects of the health impacts 
of HTPs, including in non-users, their addictive potential, perception and use, 
attractiveness, potential role in initiating and quitting smoking, marketing, 
including promotional strategies and impacts, claims of reduced harm, variation 
among products, regulatory experience and monitoring by Parties, impact on 
tobacco control and research gaps.
In this paper, we review the current literature on the toxicity of and 
exposure to HTP emissions and associated health effects and evaluate claims that 
HTPs reduce risk. In particular, we cover:
 ■ toxicants in HTP emissions and in other tobacco products;
 ■ exposure to HTP emissions and their effects in model systems (in 
vitro and in experimental animals) and in humans and the implica-
tions for health;
 ■ assessment of the basis of the claims that HTPs reduce risk or harm;
 ■ implications for public health;
 ■ research gaps and priorities; and
 ■ relevant policy recommendations.
10
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The literature search was based primarily on the PubMed database and 
the SciFinder search tool, which retrieves data from the Medline and CAplus 
databases. Relevant articles cited in publications obtained in the search were also 
included. In addition, we consulted manufacturers’ websites and the websites 
of the US Centers for Disease Control and Prevention, the United States Food 
and Drug Administration (FDA) and other relevant organizations that provide 
information on the chemistry and health effects of HTPs.
2.2 Toxicants in heated tobacco product emissions
2.2.1 Laboratory methods for measuring toxicants
As outlined above, the HTP devices on the market vary in design, the main 
differences among them being how the tobacco is heated and the temperatures 
reached in the devices. The effect of temperature on the formation of harmful 
constituents in emissions of tobacco products, including conventional and 
e-cigarettes, is well documented. HTP devices produced by third parties are 
also available, mainly online, usually without product specifications. (A simple 
Google or Amazon Internet search with “IQOS sticks compatible” as keywords 
indicates a number of brands, like Uwoo, Luckten, Kacig, Hotcig, Uwell, Vaptio, 
G-taste and Smok Nord.) Reliable, analytically validated testing procedures are 
necessary to draw reliable inferences from assessments of the levels of harmful 
emissions from HTPs and to compare them with emissions from other products, 
such as conventional and e-cigarettes.
Most of the methods for analysing HTP emissions used to date by both 
the industry and independent research groups are adapted from methods used to 
analyse conventional cigarettes, mainly for determining common emissions and 
other parameters (e.g. nicotine and some other tobacco-derived constituents) 
(1,2). To analyse compounds that may be specific to HTPs, some laboratories used 
complex analytical approaches, such as multidimensional gas chromatography 
coupled with mass spectrometry or liquid chromatography–tandem mass 
spectrometry (1,3). In 2019, the Tobacco and Tobacco Products Technical 
Committee, TC126, of the International Organization for Standardization (ISO) 
created a working group on HTP, but they have not yet published HTP-specific 
methods.
While, in principle, methods used to analyse conventional cigarettes 
could be adapted for analysing HTPs, there are key differences between the two 
products. First, the tobacco material in HTPs may contain more humectant and 
water than that of conventional cigarettes (4), which may have implications for 
analysis of emissions. At a minimum, studies should be conducted to determine 
the efficiency of the usual glass-fibre Cambridge filter pads in capturing toxicants 
found in both cigarette smoke and HTP-specific constituents derived mainly 
from thermal degradation of glycerol, propylene glycol and additives. Secondly, it 
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is uncertain what puffing regimens (standardized puffing volume and frequency) 
should be used in the analysis of HTPs, as information on human topography 
in use of HTPs is lacking. The puffing parameters of HTPs are limited by HTP 
firmware and differ by device; manufacturers provide only specifications for 
“proper” product use and operation. As a result, use of different devices with 
different suggested puffing regimes (5) might result in large differences in 
desorption temperature and in toxicant emissions among studies. In addition, 
the higher intensity of HTP puffing may change the emission profile, because the 
kinetics of pyrolysis product generation is different from the kinetics of constituent 
desorption from tobacco material (6). For example, increasing puffing intensity 
to generate more nicotine in the smoke, and thus the temperature at which the 
tobacco material is heated, is likely to increase the emissions of toxic pyrolysis 
products significantly. Finally, reference materials are not yet available, for either 
HTP devices or tobacco filler, obviating adequate analytical quality control.
In the absence of standard reference materials, analytical methods and 
puffing topography, accurate comparisons of HTPs and with other tobacco 
products cannot yet be made. For these reasons, generic statements of relative 
risk for users of these products are still preliminary and should be used carefully 
and cited only with recognition of this context.
2.2.2 Nicotine
As both conventional cigarettes and HTPs contain tobacco, both emit nicotine 
during use. Nicotine is the main known addictive constituent in tobacco products 
(7); therefore, its levels in HTP emissions are of great importance. Table 2.1 
lists the reported nicotine contents and emissions in two HTPs, IQOS and glo. 
Overall, the results of the analyses are consistent in both industry-supported 
and independent academic research. The corresponding nicotine values in 
reference cigarettes, which represent popular “full-flavour” (3R4F and CM6) and 
ventilated, formerly referred to as “light” (1R5F), filtered conventional cigarettes, 
are also shown in Table 2.1. The reported levels in the tobacco material (contents) 
of regular and menthol IQOS sticks were comparable to those of conventional 
cigarettes (8,9); however, because HTP sticks are shorter and thinner than 
conventional cigarettes, they contain less tobacco material and, as a consequence, 
less total nicotine content per stick than a conventional cigarette. For example, 
Liu et al. (10) reported a nicotine content ranging from 1.9 to 4.6 mg per stick in 
three different HTPs.
12
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Table 2.1. Representative reported nicotine contents and emissions in IQOS and glo HTPs
Product brand and 
variety
Range of reported average nicotine levels
References
Contents (tobacco 
material) (mg/g)
Emissions
By ISO regimena By HCI regimena
IQOS
Regular 15.2–15.7 0.4–0.77 mg/stick
0.3 mg/14 puffsb
1.1–1.5 mg/stick
1.1–1.4 mg/12 puffs
1,6,8,9,11–13 
Menthol 15.6–17.1 0.43 mg/stick 1.2 mg/stick
1.38 mg/12 puffs
6,8,9
Mint NR 0.32 mg/stick 1.2 mg/stick 6
Essence NR NR 1.14 mg/stick 4
Glo
Regular NR 0.07 mg/stick 0.27 mg/stick 6
Bright tobacco NR 0.09–0.15 mg/stick 0.31–0.57 mg/stick 1,4,6
Fresh mix NR 0.14 mg/stick 0.51 mg/stick 6
Intensely fresh NR 0.13–0.15 mg/stick 0.36–0.51 mg/stick 1,4,6
Coolar green NR 0.068 mg/stick 0.17 mg/stick 6
Coolar purple NR 0.06 mg/stick 0.25 mg/stick 6
Reference conventional cigarettes
3R4F 15.9–19.7 mg/g 0.73–0.76 mg/
cigarette
1.4–2.1 mg/cigarette 1,6,12,14–16
1R5F 15.9–17.2 mg/g 0.12 mg/ cigarette 1.0–1.1 mg/cigarette 6,8,15,16 
CM6 18.7 mg/g 1.2 ± 0.13 mg/ 
cigarette
2.6–2.73 mg/cigarette 6,15,16
NR: not reported.
a  Smoking machine regimes used to puff HTPs for emission analyses: ISO, International Organization for Standardization (ISO) 
method; HCI, Health Canada method for testing tobacco products “Intense puffing regime”.
b  Some studies reported data based on the number of puffs taken to consume one HTP stick by using the corresponding machine-
smoking regimen.
Data on HTP emissions also show significant differences among brands. For 
example, the nicotine levels in the aerosol of IQOS puffed under ISO or intense 
smoking conditions are comparable to those found in conventional cigarettes 
(Table 2.1). This suggests that the efficiency of nicotine desorption or transfer 
from the tobacco material to aerosol or smoke is much higher for IQOS than 
for conventional cigarettes. In contrast, the nicotine levels in the aerosol of glo 
were reported to be about 40% of those reported for IQOS and 23% of those for 
reference cigarettes (17). Other studies show similar differences between the two 
products (Table 2.1). These observations indicate the importance of systematic 
surveillance and reporting of nicotine content and emissions in HTPs. Research 
should be conducted on the implications of these differences for the abuse liability 
and toxicity of the products.
13
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2.2.3 Other toxicants
HTP emissions generally contain lower concentrations of toxic chemicals than 
conventional cigarettes because of the lower temperature at which they operate, 
which is the main source of many toxicants in the smoke of conventional cigarettes. 
The levels of most of the harmful and potentially harmful constituents measured 
in HTP aerosol are lower than those in reference cigarette smoke (1,2,18–22), 
with the exception of glycidol, which is found at higher levels (23). Nevertheless, 
both independent and manufacturer-funded studies show that, even if the 
temperatures reached by HTPs are not sufficient for combustion, they are still 
sufficient for the formation of harmful chemicals. Davis et al. (24) reported that 
IQOS tobacco filler appears to char without ignition and that charring increased 
when the IQOS is not cleaned after each use. Some signs of combustion were also 
identified in another study (3). Auer et al. (11) found that the aerosol released by 
IQOS contains elements from pyrolysis and thermogenic degradation that are 
the same harmful constituents of conventional cigarette smoke.
A study by BAT researchers showed that nicotine and some cigarette 
smoke compounds were released at between 100 °C and 200 °C as a result of 
evaporative transfer or initial thermal decomposition from the tobacco blend. 
It is important to note that tobacco heated to 200 °C can generate emissions 
for a substantially longer time than a burning cigarette. With increments of 
temperature, the levels of some analytes increase gradually: between 180 °C and 
200 °C, the amounts of carbon monoxide (CO), those of crotonaldehyde and 
methyl ethyl ketone double, and that of formaldehyde triples; between 120  °C 
and 200 °C, that of acetaldehyde increases 15 times; between 160 °C and 200 °C, 
that of acetone doubles and that of propionaldehyde triples; and between 140 °C 
and 200 °C, that of butyraldehyde doubles. These chemicals can be formed by 
pyrolytic decomposition of carbohydrates and tobacco structural polymers. 
Tobacco-specific nitrosamines (TSNAs) were quantifiable, but there was no 
consistent difference at different temperatures (25).
Humectants contribute mainly to the total particulate matter of aerosols 
generated by HTPs. Much higher levels of humectants (e.g. glycerol) were found 
in HTP aerosol than in conventional cigarette smoke (4). Independent studies 
found that the content of glycerol generated from HTPs in the HCI regimen was 
approximately 360 μg/stick for IQOS, 520 μg/stick for glo and 5900 μg/stick for 
Ploom TECH, as compared with 18 μg/cigarette from conventional cigarettes. 
HTPs generated fewer chemical compounds than conventional cigarettes, except 
for water, propylene glycol, glycerol and acetol (5). The total particulate matter 
of a prototype HTP, THS 2.2, was composed mainly of glycerine (56.3%) and 
propylene glycol.
Although glycerine and propylene glycol may be safe for humans, they 
were found to produce harmful products when heated, including acrolein 
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(a strong airway irritant) and glycidol (a carcinogen), in studies of IQOS and 
e-cigarette emissions. These carbonyls have been reported as by-products of 
propylene glycol and glycerine thermal decomposition in e-cigarettes. As the 
HTP stick contains a large amount of glycerine, its degradation by-products were 
present in IQOS emissions (26).
Carbon monoxide
CO was found as a product of incomplete combustion in in HTPs emissions in 
both independent and tobacco industry studies.
Industry research
Forster et al. (1) reported that CO yields were below the reporting limits 
at temperatures < 180 °C, representing a reduction of > 99% from those in 
conventional cigarette emissions. Above this temperature (to 200 °C), the CO 
level increased with increasing temperature. The CO yield from an HTP was 
below the limit of detection, whereas that from a conventional cigarette was 
31.2 mg/cigarette (2). No correlation was found between the presence of flavours 
and CO levels: both the flavoured and unflavoured HTPs generated ≤ 0.22 mg/
stick, while conventional cigarettes generated 32.8 mg/cigarette (23).
Academic research
CO was found in IQOS aerosol (11), even though the temperature was only 330 °C, 
as compared with 684 °C in smoke from a conventional cigarette, but at lower 
levels than in mainstream smoke of conventional cigarettes. The concentration 
of CO emitted by IQOS, measured with the official WHO TobLabNet method, 
was approximately one hundredth of that emitted by conventional cigarettes (8). 
Similar results were found with the ISO and HCI regimes, THS 2.2 releasing 90% 
less CO than conventional cigarettes (3).
Tobacco-specific nitrosamines
Manufacturers of HTPs claim that the levels of tobacco-specific nitrosamines 
(TSNA) are lower in HTPs. Several studies reported considerably lower levels of 
TSNA in e-liquids and in HTPs than in conventional cigarettes (29). Independent 
studies reported less tar and more TSNA than the manufacturers did (17).
Industry research
PMI and BAT reported a mean reduction of 90% in the levels of TSNAs in HTP 
aerosols as compared with mainstream smoke of conventional cigarettes. They 
claimed that the reduction is due to lower evaporating transfer and a lower 
working temperature, which reduce pyrosynthesis and pyrorelease (27). TSNA 
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emissions from a prototype HTP, THP1.0, were reported to be reduced by 80–98% 
from those in the smoke of conventional cigarettes (1).
Academic research
Studies by non-industry researchers have also demonstrated lower levels of 
TSNA in the aerosol of HTPs than in smoke from conventional cigarettes 
(30,31), the reductions of individual TSNA ranging from 8–22 times per puff 
in the HTP aerosol as compared with cigarette smoke; the reduction in HTP 
HeatStick aerosol was 7–17 times. TSNA yields per puff in IQOS aerosol were 
an order of magnitude lower than those in the smoke of conventional cigarettes 
but an order of magnitude higher than those in the aerosol of e-cigarettes 
(32,33). Other independent studies confirmed that the levels of TSNA in tobacco 
material and mainstream smoke of IQOS were significantly lower than those 
of conventional cigarettes, although the transfer rates of N′-nitrosonornicotine 
(NNN), N′nitrosoanatabine (NAT) and 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) in IQOS were slightly higher than those in conventional 
cigarettes (8,13). Ratajczak et al. (28) reported that the concentration of TSNAs 
was one fifth that of conventional cigarettes. Li et al. (3) found that > 92% less 
NNN, NNK and NAT was released than from conventional cigarettes under both 
the ISO and the HCI regimen, and 72% less N’-nitrosoanabasine than 3R4F was 
released under both regimens.
Carbonyl compounds
HTPs emit toxic carbonyl compounds generated from thermal decomposition, 
and their levels increase gradually with temperature rising from 160 °C or 180 °C 
to 200 °C (8,25). Formaldehyde, acetaldehyde, acrolein and other aldehydes 
form during heating of mixtures of glycerol and propylene glycol in e-cigarettes 
(34,35). As these humectants are also present in HTPs, aldehydes may be derived 
from them (36). In most cases, however, the levels are lower than in conventional 
cigarette smoke, according to both manufacturer-funded and independent studies.
Industry research
Aldehydes accounted for 41% of the total estimated concentration of constituents 
in THP1.0 emissions (37). Crooks et al. (23) measured the levels of some 
aldehydes in aerosol from flavoured and unflavoured HTPs and in conventional 
cigarette smoke. They found formaldehyde at 1.52 μg/stick in aerosols from 
flavoured and 1.79 μg/stick in those from unflavoured HTPs and at 66.67 μg/stick 
in smoke from conventional cigarettes; and acetaldehyde at 35.48 μg/stick in 
aerosols from flavoured and 35.54 μg/stick in those from unflavoured HTPs 
and at 2164.73 μg/stick in smoke from conventional cigarettes. The reduction 
in formaldehyde in HTP aerosols as compared with smoke from conventional 
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cigarettes was reported to be 90% (2,18). The concentrations of formaldehyde 
(16.3 μg/m3) and acetaldehyde (12.4 μg/m3) fell within the range of the mean 
concentrations observed in residential and public environments (19).
Academic research
Studies by non-industry researchers confirm the lower carbonyl production by 
IQOS than by conventional cigarettes, although it was higher than that from 
e-cigarettes (26). The level of formaldehyde in HTP aerosols was 91.6% lower 
than in smoke from conventional cigarettes, and reductions of 84.9% were 
seen for acetaldehyde, 90.6% for acrolein, 89% for propionaldehyde and 95.3% 
for crotonaldehyde. At more intense puffing regimens, minimal differences in 
carbonyl emissions were observed between IQOS and conventional products, 
except that formaldehyde levels were increased three to four times over 
those with the HCI puffing regimen, from 6.4 to 17.1  µg/stick for regular 
IQOS. Carbonyl levels were higher in aerosols from HTPs than those from 
e-cigarettes  (38). Similar results were obtained by Ruprecht et al. (39), who 
observed that the levels of aldehydes formed by use of IQOS were 2% higher 
than with conventional cigarettes for acrolein, 6% higher for acetaldehyde and 
7% higher for formaldehyde; e-cigarettes generated only 1% of the amount of 
aldehydes generated by conventional cigarettes. Other authors observed that the 
yields of carbonyls were 80–96% lower than those from conventional cigarettes 
(12,13,30,40,43).
Uchiyama et al. (5) compared acetaldehyde production by different HTP 
types under the HCI regimen and found that IQOS generated 210 μg/stick, 
glo™ generated 250 μg/stick and Ploom TECH 0.45 μg/stick, while conventional 
cigarettes generated 1300 μg/cigarette. Salman et al. (41) estimated reductions of 
70% and 65% in the daily intake of formaldehyde and acetaldehyde, respectively, 
with use of IQOS instead of conventional cigarettes. Li et al. (3) observed 
reductions of 55.80% and 77.34% in formaldehyde and acetaldehyde, respectively, 
under the ISO regime.
Cyanidric formaldehyde can be formed from pyrolysis of the polymer 
filter in HTPs (42). This thin plastic sheet melts during IQOS use, releasing 
formaldehyde cyanohydrin (24).
Benzo[a]pyrene and other polycyclic aromatic hydrocarbons
Benzo[a]pyrene and other polycyclic aromatic hydrocarbons (PAH) are typical 
products of incomplete combustion. Their determination is important, as they 
are carcinogens (13).
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Industry research
Manufacturer-funded studies reported lower levels of PAH, including benzo[a]
pyrene, in HTPs than in conventional cigarettes. The formation of PAH, aromatic 
amines, phenols and aldehydes was reduced by > 75% (22), and acyclic, alicyclic 
and monocyclic aromatic hydrocarbons in HTP aerosol accounted for <  4%, 
as compared with 64% in mainstream smoke of conventional cigarettes (37). 
Benzo[a]pyrene levels were very low in the aerosols of all products, in contrast to 
the yields found in the mainstream smoke of conventional cigarettes (18).
Takahashi et al. (2) found < 0.531 ng benzo[a]pyrene in an HTP aerosol 
and 12.9 ng in conventional cigarette smoke, while Crooks et al. (23) found 0.44 
ng/stick benzo[a]pyrene in the aerosol of flavoured HTPs, 0.41 ng/stick in that 
from unflavoured HTPs and 12.76 ng/stick in smoke from conventional cigarettes, 
indicating that the levels were not associated with the presence of flavours.
Pyrolysed menthol could be a precursor of benzo[a]pyrene in the smoke of 
a mentholated cigarette product, although no significant contribution of menthol 
to the yield of benzo[a]pyrene was observed in THS2.2 (20).
Academic research
Auer et al. (11) found 0.8 ng/stick benzo[a]pyrene in HTP emissions and 20 
ng/cigarette in smoke from conventional cigarettes; these levels are higher than 
those found in manufacturer-funded studies. HTP released higher levels of 
acenaphthene than conventional cigarettes. St Helen et al. (12) found levels similar 
to those in tobacco industry studies, with 0.736 ng/stick benzo[a]pyrene in HTP 
aerosols and 13.3 ng/stick in smoke from conventional cigarettes, indicating a 
reduction of 94%.
Other toxic chemicals
Most of the chemical constituents of the particulate phase of HTP aerosol and 
conventional cigarette smoke were oxygenated compounds, comprising 39% 
and 70% of the total estimated concentration of analytes in cigarette and HTP 
particulate phase, respectively. The levels of oxygenated compounds are higher in 
the HTP particulate phase probably because of the large amount of glycerine and 
other humectants (43).
Industry research
Nitrogen-containing compounds. The levels of these compounds were 12% lower 
in HTP aerosols than in smoke from conventional cigarettes, accounting for 58% 
and 29% of the total estimated concentration of analytes in the cigarette and the 
HTP particulate phase, respectively (43). The level of nitrogen oxide increased 
with time in conventional cigarette smoke but remained constant in HTP aerosol. 
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The levels found in HTP aerosol were 5.5–7.3% those of smoke from conventional 
cigarettes (21).
Manufacturer-funded studies reported reductions of 25–50% in the 
levels of ammonia and some other toxicants in HTPs (20). Ammonia was found 
at a level 88% lower than in conventional cigarette smoke in HTP emissions (1). 
Crooks et al. (23) reported that the levels of ammonia, nitrogen oxides and o-cresol 
were higher in aerosol from flavoured than in that from unflavoured Neostik.
Metals. In one study, the level of mercury in HTP emissions was 69% 
lower than in cigarette mainstream smoke, while others reported reductions 
of 25–50% (1,20). The levels of chromium, nickel and selenium were below the 
limits of detection in reference cigarette smoke (2).
Volatile organic compounds. In some studies, the levels of certain 
volatile hydrocarbons in HTP emissions were 97–99% lower than in smoke 
from conventional cigarettes (13,40). Industry researchers reported that the 
concentrations of Hoffmann list volatile compounds were significantly lower in 
the aerosol of prototype HTP product THP1.0 than in smoke from conventional 
cigarettes, with the level of toluene was reduced by 99% and that of 2-propanone 
by 91% (37). After HTP use, the level of benzene in the aerosol was 0.93 µg/m3, 
and that after e-cigarette use was lower. Toluene was not detectable in HTP 
aerosol but was present at 151.1 µg/m3 after conventional cigarette use (36).
Other chemicals. The levels of many constituents of HTP emissions were 
below the level of quantification or detection, except for formaldehyde, acetone 
and ammonia (2). Aldehydes, ketones and heterocyclic compounds accounted 
for 41%, 32% and 10% of the total concentration of analytes, respectively. The 
level of 2-propanone was higher in the mainstream smoke of conventional 
cigarettes (152 μg/cigarette) than in HTP aerosol (13.3 μg/stick), whereas the 
levels of pyridine and dimethyl trisulfide in HTP aerosols were marginally higher 
(37). Forster et al. (1) calculated a reduction of 96–99% in the levels of phenols 
(except for resorcinol, p-cresol and caffeic acid) and a 99% reduction in the levels 
of ethylene oxide and propylene oxide; however, acetoin and methylglyoxal were 
present at higher levels in HTP emissions than in conventional cigarette smoke.
Particulate matter. Manufacturer-funded studies found that the levels 
of particulate matter < 2.5 µm (PM2.5) in HTP emissions were 28 times lower 
than in conventional cigarette smoke (19). The yield of total particulate matter 
from HTPs was approximately twice that of conventional cigarettes. The levels 
of water and humectants in total particulate matter were higher in HTPs than in 
conventional cigarettes: 90% (w/w) in HTP and 37% in conventional cigarettes 
(2). PMI studies showed that the respirable fraction of particles is 90% lower 
in HTP aerosols than in conventional cigarette smoke (44), equivalent to the 
concentration in background air; however, the limits were below the lower 
working range of the methods (45).
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Academic research
Reactive oxygen species. Independent studies reported that the level of total reactive 
oxygen species was 85% lower in HTP emissions than in those of conventional 
cigarettes (41). Emission of reactive oxygen species during use of IQOS can be 
harmful (46).
Metals. Independent studies found lower levels of metals in HTP 
emissions than in cigarette smoke (13,42). Ruprecht et al. (39) observed that 
use of mentholated IQOS is associated with higher metal concentrations than 
use of IQOS without menthol. They found metals such as aluminium, titanium, 
strontium, molybdenum, tin and antimony in IQOS that are not present in 
conventional cigarettes, and metals such as nickel, copper, zinc, lanthanum and 
lead in conventional cigarettes that are not detected in IQOS. One article reported 
an unusual case of criminal mercury poisoning with use of HTPs; its addition to a 
tobacco stick caused the victim to inhale vaporized mercury (47).
Volatile organic compounds. More than 70 volatile compounds were 
detected in mainstream emissions of IQOS, including isoprene, acrylonitrile, 
cresols, benzene, phenol, naphthalene, acetaldehyde, propanal, acrolein, 
formaldehyde, 2-butanone, acetone, crotonaldehyde and quinoline (26). All 
these compounds are considered potentially harmful by the FDA. Some studies, 
however, found that the levels of some volatile hydrocarbons were 97–99% lower 
in HTP aerosols than in smoke from conventional cigarettes (13,40). No PAHs 
were found in IQOS side-stream aerosol (42). Heated tobacco materials contained 
more types of volatile compounds than conventional cigarette emissions (48).
Black carbon. Ruprecht et al. (39) found the highest black carbon 
concentrations in conventional cigarettes, with 78 µg/m3 for organic compounds 
and 2.3 µg/m3 for elemental carbon. Elemental carbon was not detectable during 
puffing of IQOS, while the levels of organic compounds were 2.81–3.89% of those 
in conventional cigarettes.
Other chemicals. Results similar to those of manufacturer-funded studies 
were obtained in an independent study, with 90% lower levels of most toxicants, 
except for carbonyls, ammonia and N’-nitrosoanabasine. The level of ammonia, 
in particular, was 63.4% lower with the HCI regimen than in conventional 
cigarette smoke (3).
Particulate matter. The concentration of particles in the mainstream aerosol 
of IQOS was lower than that in emissions from e-cigarettes and conventional 
cigarettes (49), and use of HTPs resulted in the lowest levels of fine particulate 
matter (36). The concentrations of PM>0.1 and PM>0.3 were significant in aerosol 
from conventional cigarettes and that from IQOS (for PM>0.3) but were trivial 
in aerosol from e-cigarettes as compared with conventional cigarettes (39). Other 
studies found that the level of particulates in emissions from e-cigarettes and HTPs 
was about 25% that in cigarette smoke. The diameter of most particles in IQOS 
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aerosol is < 1000 nm, which is considered safer than a lower mass. The respirable 
fraction of particles is higher in glo and conventional cigarette smoke (50).
As these results show that the composition of IQOS HeatSticks is different 
from that of conventional cigarettes, including flavourings and additives, IQOS 
aerosol may contain other chemical constituents not present in tobacco smoke, 
which have not yet been investigated in untargeted analyses (12).
2.3 Exposure and effects of HTPs in vitro and in  
laboratory animals
2.3.1 In-vitro studies
Industry research
Research groups at PMI and BAT have published several reports on the results of 
in-vitro toxicological studies with prototype HTPs that differed in the device and 
tobacco characteristics. Most reported substantially lower cytotoxicity of HTP 
aerosol than of the smoke of reference cigarettes.
PMI research. PMI published a series of papers on the cytotoxicity 
(measured in the neutral red uptake assay) and mutagenicity (Salmonella reverse 
mutation assay) of a prototype electrically heated cigarette smoking system puffed 
under ISO smoking conditions and one alternative puffing condition (51–53). 
They reported that the aerosol from these devices was up to 40% less cytotoxic 
and up to 90% less mutagenic than the smoke of a reference 1R4F cigarette 
(comparisons based on total particulate matter yield). In a study published in 
2012, PMI reported toxicological evaluation of the same prototype system with 
25 additional smoking regimens that reflect human puffing behaviour (54). 
While the overall biological activity of the HTPs tested was lower than that of 
a reference cigarette, increased smoking intensity led to substantial increases 
in cytotoxicity and nearly 36 times more bacterial mutagenicity than with HTP 
aerosols generated under low-intensity ISO conditions. They concluded that the 
increases were probably due to changes in the emissions of harmful constituents, 
suggesting that the results of ISO-based testing are not informative in terms of 
potential effects in humans.
PMI also reported on the biological effects of the aerosol from another 
HTP prototype, THS2.2. In one study, the ability of THS2.2 aerosol to inhibit 
monoamine oxidase activity was investigated, to assess the potential abuse 
liability of this product (55). The authors reported significant inhibitory activity of 
a 3R4F reference cigarette aerosol but not by THS2.2. In another study, histology, 
cytotoxicity, secreted cytokines and chemokines, ciliary beating and genome-
wide mRNA/miRNA profiles were assessed in human organotypic bronchial 
epithelial cultures at various times after exposure to THS2.2 aerosol or reference 
3R4F cigarette smoke, with similar nicotine concentrations (56). Cell fate, cell 
21
Toxicants in heated tobacco products, exposure, health effects and claims of reduced risk
proliferation, cell stress and inflammatory network models 4 h after exposure to 
THS2.2 aerosol were only 7.6% of those observed after exposure to 3R4F smoke. 
No morphological changes were reported after exposure to THS2.2 aerosol, 
even at a nicotine concentration three times that in 3R4F smoke. Similar studies 
were conducted with another HTP prototype, CHTP1.2, in human organotypic 
cultures derived from buccal and gingival epithelia (57), small airway and nasal 
epithelial cells (58) and endothelial cells (59). Cells were exposed acutely (28 min) 
or repeatedly (28 min/day for 3 days) to CHTP1.2 aerosol or to 3R4F smoke. 
The authors reported lack of cytotoxicity, fewer pathophysiological alterations 
and less change in toxicological and inflammatory biomarkers after exposure to 
CHTP1.2 than after exposure to 3R4F smoke. Alterations in mRNA expression 
were, however, detected in small airway and nasal epithelial cultures exposed to 
CHTP1.2 aerosol.
BAT research. BAT researchers assessed nicotine delivery and cytotoxicity 
in H292 human bronchial epithelial cells of aerosols from IQOS and glo in 
comparison with tobacco smoke from 3R4F cigarettes; all products were smoked 
under HCI (60). The authors reported more nicotine delivery but less cytotoxicity 
of HTPs than 3R4F cigarettes. They concluded that there was no difference 
between the HTPs; however, the figures in the report suggest that IQOS was more 
cytotoxic than the glo product. In another study, RNA sequencing was used to 
compare transcriptomic perturbations after acute exposure of 3D airway tissue to 
the aerosols of the same products (61). Differential expression of 115 RNAs was 
reported with IQOS and of two RNAs with the glo product as compared with air, 
while 2809 RNAs were differentially expressed in response to 3R4F. Examination 
of the data and charts in the report suggests that the results depended on the 
thresholds set for data analyses (i.e. P values and fold change in expression) and 
that inflammatory and xenobiotic metabolizing gene expression may be affected 
by the HTPs tested. A subsequent study was conducted to complement these 
two assessments and to determine the effect of flavours on in-vitro responses to 
Neostik (62). The authors concluded that the addition of flavours does not change 
the in-vitro baseline responses to unflavoured Neostik.
Academic research
Leigh et al. (63) used an in-vitro model of an air–liquid interface with human 
bronchial epithelial cells (H292) to investigate the toxic effects of inhaling 
emissions from IQOS and from e-cigarettes and conventional cigarettes. 
The number of puffs of each product was adjusted to achieve similar nicotine 
delivery to the cells, and cytotoxicity was measured in the neutral red uptake 
and trypan blue assays. The cytotoxicity of IQOS in the neutral red assay, but 
not in the trypan blue assay, was higher than that in air controls and lower than 
that with conventional cigarette smoke. In another study, the cytotoxicity of 
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IQOS aerosols was compared with that of smoke from Marlboro Red and 3R4F 
reference cigarettes (64) in three assays with eight different cell types. The results 
with transformed mouse NIH/3T3 fibroblasts were similar to those previously 
reported by PMI (51–53); but assessments in other types of cells and with higher 
concentrations of aerosols showed comparable depression of mitochondrial and 
lysosomal activity by IOQS and cigarette smoke solutions. No adjustment was 
made in this study, however, for the levels of nicotine in the different products, 
and the puffing regimen used was described in insufficient detail.
In another study, the effect of exposure of culture medium to IQOS 
aerosol, e-cigarette aerosol and conventional cigarette smoke was studied on 
the viability and differentiation of 3T3-L1 pre-adipocytes to beige adipocytes 
(65). The authors concluded that exposure to IQOS had limited or no effect as 
compared with air. Examination of the data in this report shows that expression 
of the adipogenic markers Ppar-γ and Resistin was statistically significantly 
decreased in IQOS-treated cells at the end of differentiation (10 days), an effect 
similar to that observed in cigarette smoke-treated cells. It was noted that the 
authors of this report have a history of industry-linked research funding.
2.3.2 Studies in laboratory animals
Industry research
Most reports on the effects of HTPs in laboratory animals have been published 
by tobacco industry research groups, namely PMI and Japan Tobacco, which 
generally report substantially less toxicity and carcinogenicity with HTP aerosols 
than with the smoke of reference tobacco cigarettes.
Japan Tobacco research. Two studies have been published on the effects 
of a prototype “heated” cigarette on dermal tumorigenicity and inhalation 
toxicity in mouse models. In the first study, the effect of HTP on dermal tumour 
promotion in female SENCAR mice was studied after topical application 
of 7,12-dimethylbenz[a]anthracene as a tumour initiator (66). Condensates of 
HTP aerosol or cigarette smoke (3R4F cigarettes) generated under the modified 
HCI smoking regimen were applied repeatedly for 30 weeks at five doses up 
to 30 mg tar/application. At ≤ 15 mg tar, animals treated with HTP aerosol 
developed neoplasms with a longer latency and lower incidence and multiplicity 
and lower incidences of inflammation and squamous epithelial hyperplasia than 
animals treated with cigarette smoke. At the end of treatment, however, these 
effects were more prevalent than in untreated animals. At doses ≥ 22.5 mg of tar, 
the differences between HTP aerosol and 3R4F condensate were less clear.
In the second study, the same HTP was investigated in nose-only 5-week 
and 13-week inhalation studies (67). Lesser histopathological changes were 
found in the respiratory tracts of HTP-treated animals (respiratory epithelial 
hyperplasia in the nasal cavity and accumulation of pigmented macrophages 
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in alveoli) and less pulmonary inflammation (as measured by the percentage 
of neutrophils and activity of γ-glutamyl transpeptidase, alkaline phosphatase 
and lactic dehydrogenase in bronchoalveolar lavage fluids) than in cigarette 
smoke-treated animals. HTP treatment nevertheless had significant effects on 
the histopathological outcomes as compared with air treatment, as HTP-treated 
animals showed a 100% incidence of hyperplasia and hyperkeratosis in the larynx 
and epiglottis at all doses tested in both treatment regimens and substantial dose-
related increases (≤  100%) in the incidence of alterations in nasal epithelium, 
ventral pouch and lung tissues.
PMI research. In a 90-day study in rats exposed by inhalation through the 
nose only to the same or twice the nicotine concentration in the inhalation zone, 
CHTP1.2 aerosol resulted in significantly less exposure to harmful constituents 
and induced less respiratory tract irritation and systemic and pathological effects 
than 3R4F cigarettes (68). The toxicology arm of this study, which included 
transcriptomics, proteomics and lipidomics analyses (69), showed much weaker 
inflammatory and cellular stress responses in the respiratory nasal epithelium 
and lungs with CHTP1.2 aerosol than with 3R4F smoke. Many of these effects 
showed dose–response relations. CHTP1.2 aerosol also induced lower lipid 
concentrations in the serum of exposed animals.
PMI researchers also conducted 6-month exposure studies in the 
ApoE-/- mouse model to investigate the effects of THS 2.2 and CHTP1.2 
on the cardiorespiratory system. One report, a systems toxicology approach 
with a combination of physiology, histology and molecular measurements, 
demonstrated a lower impact of 3R4F on the cardiorespiratory system, including 
little to no lung inflammation or emphysematous changes and reduced 
atherosclerotic plaque formation (70). In another study, cardiovascular effects 
were investigated in echocardiographic, histopathological, immunohistochemical 
and transcriptomics analyses. The authors reported that continuous exposure 
to HTP aerosols did not affect atherosclerosis progression, heart function, left 
ventricular structure or the cardiovascular transcriptome (71). Review of the 
data in these publications reveals, however, consistent increases in many of 
the outcome measures in animals treated with HTPs as compared with sham 
controls, although the increases did not reach statistical significance.
Academic research
In a study to investigate whether exposure to IQOS aerosol affects vascular 
endothelial function, which is known to be impaired by conventional cigarette 
smoke (72), rats were exposed acutely through the nose only to IQOS aerosol 
generated by single HeatSticks, to mainstream smoke from single Marlboro Red 
cigarettes or to clean air. Arterial flow-mediated dilation, a measure of vascular 
endothelial function, was measured before and after exposure. The authors 
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reported that flow-mediated dilation was impaired to comparable degrees by 
exposure to IQOS aerosol and to conventional cigarette smoke, and no effect was 
observed with clean air. Serum nicotine and cotinine levels were approximately 
4.5 times higher in rats exposed to IQOS than in those exposed to cigarettes, 
even though the IQOS aerosol contained less nicotine than cigarette smoke. 
Brief exposure regimens that resulted in similar serum nicotine levels in groups 
exposed to IQOS and to cigarettes induced comparably impaired flow-mediated 
dilation. The authors concluded that IQOS use does not necessarily avoid the 
adverse cardiovascular effects of smoking cigarettes.
2.4 Exposure of humans to toxicants in HTPs and implications  
for health
2.4.1 Product use and topography
Davis et al. (24) evaluated the performance of IQOS under five conditions with 
two different protocols for cleaning devices. HeatSticks were inspected before 
and after use to determine any signs of tobacco material pyrolysis (charring) 
and melting of the polymer-film filter and to assess the effects of cleaning on 
charring. The results showed charring of the tobacco material after use, and 
gas chromatography–mass spectrometry headspace analysis of the polymer-
film filter showed release of highly toxic formaldehyde cyanohydrin at 90  °C 
(a lower temperature than during normal IQOS usage). Increases in charring 
and formaldehyde cyanohydrin emissions were observed when the device was 
not cleaned between consecutive uses of HeatSticks. The authors concluded that 
limitations of the device (i.e. short tobacco sticks and shutting of the device after 
a certain number of puffs) may contribute to decreases in inter-puff intervals, 
potentially increasing users’ intake of nicotine and other harmful chemicals.
Some industry research acknowledges the potential modifying effects of 
use topography and device characteristics on the exposure of human users. For 
example, researchers at BAT investigated the impact of puffing parameters on the 
volume of emissions (73) and found that the choice of puffing parameters affects 
the volume, with significant differences among types of HTP. They suggested 
that detailed real-world HTP puffing topography should be studied in order 
to identify the most appropriate puffing parameters for laboratory testing. In 
another study, PMI researchers presented a modelling approach, named “nicotine 
bridging”, to estimate human exposure to HTP emissions (74). The approach 
involves determination of harmful constituents and in-vitro toxicity parameter-
to-nicotine regressions for multiple machine-smoking protocols; the distribution 
of nicotine uptake is determined from 24-h excretion of nicotine metabolites in 
a clinical study. The approach was illustrated with data for a prototype HTP (54) 
that showed less exposure of HTP users than conventional cigarette smokers, 
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with little or no overlap between the distribution curves. The authors proposed 
that the method could be used to extrapolate exposure distributions to smoke 
constituents for which there are no specific biomarkers. As this method relies 
on machine-smoking protocols that are not representative of human exposure, 
extrapolation may not be justified, and additional independent research is 
required.
2.4.2 Biomarkers of exposure and effect
Industry research
As for the studies with cell cultures and animal models, many of the reports on 
biomarkers are provided by industry, particularly PMI and BAT.
PMI research. PMI researchers reported on biomarkers of exposure and 
effect in smokers who switched to prototype HTPs, some of which have been 
tested in vitro and in laboratory animals, as summarized above. Prototype HTPs 
were developed and tested by PMI for more than a decade before the release 
of IQOS and are apparently precursors of contemporary HTPs (75). A series of 
publications in 2012 reported on randomized, controlled, open-label, parallel-
group, single-centre studies on the use of type-K prototype HTPs (EHCSS-K3 
and EHCSS-K6). In a study in the United Kingdom, biomarkers of exposure to 
nine cigarette smoke constituents and urinary mutagenicity were measured in 
160 male and female smokers of Marlboro cigarettes who switched to EHCSS-K3 
or EHCSS-K6 for 8 days (76). Statistically significant mean decreases between 
baseline and day 8 (P ≤ 0.05) were found for all biomarker measures, with 
reductions in urinary mutagenicity in smokers assigned to both HTPs. In a similar 
study in the Republic of Korea, biomarkers of exposure to 12 selected constituents 
and urinary mutagenicity were measured in 72 male and female subjects who 
smoked low-yield Lark One cigarettes at baseline and switched to EHCSS-K3 
for 8 days (77). Statistically significant reductions in urinary mutagenicity and 
in 10 of 12 constituent biomarkers were found between baseline and day 8 for 
the EHCSS-K3 group. In a study in Japan, the same measurements were made 
in 128 male and female participants who smoked Marlboro cigarettes at baseline 
and switched to EHCSS-K3 or EHCSS-K6 for 8 days (78). The mean decreases 
in all constituents and in urinary mutagenicity between baseline and day 8 were 
statistically significant for participants who switched to HTPs (P ≤ 0.05). An 
additional report on Japanese smokers presented data on biomarkers of exposure 
to 12 constituents, urinary mutagenicity and serum club cell 16-kDa protein 
(CC16) in 102 male and female subjects who smoked Marlboro Ultra Light 
menthol cigarettes at baseline and switched to the menthol version of the HTP 
prototype EHCSS-K6(M) for 6 days (79). Statistically significant decreases in 
exposure to 10 of the 12 cigarette smoke constituents and in urinary mutagenicity 
were found, as in the previous studies; however, serum CC16, an indicator of lung 
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epithelial injury, was unchanged in all groups, including that assigned to use no 
product. Despite the reductions in exposure measures after switching to HTPs, 
the levels of biomarkers in all these studies remained substantially higher than 
in the group assigned to stop smoking and not to use any product (Table 2.2). 
Another PMI study, in Polish smokers, included measurement of a broad panel 
of biomarkers associated with cardiovascular risk, in addition to biomarkers of 
exposure (80). In this study, 316 male and female smokers were randomized to 
continue smoking conventional cigarettes or to switch to smoking the EHCSS-K6 
prototype HTP for 1 month. Most of the cardiovascular biomarkers did not change 
after use of the HTP device, although the biomarkers of exposure decreased, as 
in the previous studies. A substantial mean increase was seen in high-density 
lipoprotein cholesterol, from a baseline median of 36.7 ng/mL (95% CI 2.1, 3410) 
to 59.0 ng/mL (95% CI 2.1, 4535), after 1 month of using EHCSS-K6; however, 
reductions in red blood cell count, haemoglobin and haematocrit were observed 
in the EHCSS-K6 group.
Table 2.2. Reported levels of biomarkers of exposure in smokers who switched to HTPs and in smokers 
assigned to continuous smoking or abstinence from all tobacco products
Biomarker of 
exposure [source]
HTP prototype 
(duration of use)
Mean ± SD level 
after switching 
to HTP
Comparison (↑, higher, or ↓, lower)
with biomarker levels in participants 
assigned to other conditions
Re
fe
re
nc
e
HTP vs continuous 
smoking HTP vs abstinence
SPMA, µg/24 h
[benzene]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
1.26 ± 1.26
1.63 ± 0.55
0.48 ± 0.28
0.86 ± 0.81
0.57 ± 0.57
0.35 ± 0.13
↓80%
↓66%
↓78%
↓86%
↓75%
↓85%
↑473%
↑19%
↑41%
↑291%
↑68%
↓34%
66
77
68
66
68
69
MHBMA, µg/24 h
[1,3-butadiene]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
2.63 ± 2.78
0.59 ± 0.58
0.66 ± 0.69
1.54 ± 1.52
0.74 ± 0.56
0.61 ± 1.06
↓49%
↓75%
↓57%
↓70%
↓51%
↓58%
↑874%
↑111%
↑50%
↑470%
↑68%
↑69%
66
67
68
66
68
69
3-HPMA, mg/24 h
[acrolein]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
1.15 ± 0.74
2.41 ± 0.67
1.01 ± 0.36
1.28 ± 0.87
1.09 ± 0.51
0.83 ± 0.32
↓37%
↓18%
↓26%
↓30%
↓20%
↓30%
↑140%
↑44%
↑110%
↑167%
↓127%
↑110%
66
67
68
66
68
69
3-HMPMA, mg/24 h
[crotonaldehyde]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
2.59 ± 1.90
1.99 ± 1.07
0.61 ± 0.17
2.62 ± 1.29
0.63 ± 0.15
0.19 ± 0.08
↓50%
↓18%
↓52%
↓49%
↓51%
↓85%
↑49%
↑20%
↑30%
↑51%
↑34%
↓60%
66
67
68
66
68
69
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Biomarker of 
exposure [source]
HTP prototype 
(duration of use)
Mean ± SD level 
after switching 
to HTP
Comparison (↑, higher, or ↓, lower)
with biomarker levels in participants 
assigned to other conditions
Re
fe
re
nc
e
HTP vs continuous 
smoking HTP vs abstinence
Total NNAL, ng/24 h
[NNK]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
104.3 ± 55.3
80.4 ± 59.3
102 ± 48
100.6 ± 68.8
100 ± 65
95 ± 53
↓65%
↓59%
↓53%
↓66%
↓54%
↓49%
↑76%
↑78%
↑23%
↑70%
↑20%
↑19%
66
67
68
66
68
69
1-HOP, ng/24 h
[pyrene, PAH]
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K3 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6 (8 days)
EHCSS-K6M (6 days)
73.1 ± 30.4
143.62 ± 76.08
59.0 ± 35.3
71.9 ± 38.8
56.0 ± 28.4
38.4 ± 22.7
↓60%
↓40%
↓56%
↓60%
↓59%
↓64%
↓3%
↑13%
↑40%
↓4%
↑33%
↑2%
66
67
68
66
68
69
1-HOP: 1-hydroxypyrene; 3-HPMA: 3-hydroxypropyl mercapturic acid; MHBMA: monohydroxybutenyl mercapturic acid;  
NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; SPMA: S-phenylmercapturic acid.
PMI published a separate series of reports on studies in Polish smokers who 
switched to prototype HTPs. In one study, harmful exposures were assessed in 
112 male and female adult smokers who switched to a prototype carbon-heated 
tobacco product, MD2-E7, for 5 days, continued smoking or abstained (81). 
Puffing topography during HTP use was also studied. Smoking intensity and 
nicotine intake increased after the switch to the test HTP; however, despite the 
more intense puffing topography, switching to the prototype HTP decreased all 
the measured biomarkers of exposure and urinary mutagenicity, consistent with 
the previous reports. In a study of smokers who switched to the THS 2.1 prototype 
for 5 days, puff duration and frequency increased over the baseline patterns of 
smoking conventional cigarettes, and use of HTP tobacco sticks increased by 
27% during the study period (82). The total puff volume returned to baseline at 
the end of the study, however, and the mean exposure to nicotine was comparable 
to that at baseline. Increased product consumption and total puff volume were 
also observed in a larger study of the THS 2.2 prototype (83). The average puff 
duration was about 32% longer, the total puff duration was about 37% longer, 
and puff frequency was about 32% higher on day 4 than smoking patterns for 
conventional cigarettes at baseline. While the authors claimed that there was 
no change in nicotine intake, review of the data reveals an approximately 23% 
increase in nicotine biomarkers (total nicotine equivalents) between baseline and 
day 4. Although reductions in exposure to harmful constituents were observed 
consistently in these studies, the higher-intensity HTP puffing topography 
indicates that additional, longer studies are necessary to accurately assess 
reductions in the exposure to toxicants of smokers who switch to HTPs.
A longer study of 984 adult smokers in the USA has been reported (84). 
The participants were randomized to switch to a THS2.2 device or to continue 
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smoking for 6 months, and changes in a panel of biomarkers of exposure and 
effect were assessed. Reductions in biomarkers of exposure and in four biomarkers 
of effect (high-density lipoprotein cholesterol, white blood cell count, forced 
expiratory volume in 1  s as percentage predicted and carboxyhaemoglobin) 
were reported in smokers who switched as compared with those who continued 
smoking. Approximately 30% of smokers assigned to the HTP became dual users 
of conventional cigarettes and HTPs. In the group who predominantly used HTPs 
(average use, 16.5 sticks and two conventional cigarettes per day), the reductions 
in biomarkers of exposure ranged from 16% to 49% of the baseline smoking level, 
which were not as substantial as in previous, shorter switching studies. While 
some differences in the study procedures could have contributed to the lesser 
impact of HTP switching, longitudinal adaptations in HTP puffing topography 
could have played a role. The report did not provide information on product 
consumption or intensity of use of the test HTP.
BAT research. BAT researchers reported the results of a randomized, 
controlled study in Japan on switching to two commercial HTPs, glo and 
IQOS, for 5 days (85). The 180 Japanese smokers were randomized to either 
continue smoking conventional cigarettes, switch to glo (mentholated or non-
mentholated), switch to a non-mentholated IQOS or abstinence. As in the PMI 
studies, switching to HTPs resulted in significant decreases in urinary biomarkers 
of exposure and exhaled CO, as compared with baseline smoking. The reductions 
were similar for the two HTPs. An increase in HTP consumption was observed 
during the study; however, a similar increase was seen in consumption of tobacco 
cigarettes, which the authors attributed to the typical escalating product use seen 
in confinement studies.
BAT has been conducting another long-term randomized, multi-centre, 
controlled clinical switching study since March 2018 (86). Up to 280 smokers 
were randomized to switching to a commercially available HTP for 1 year or 
to continuing smoking. In addition, up to 190 participants who wished to quit 
smoking were enrolled in a smoking cessation arm, and 40 never smokers served 
as a control group. Biomarkers of exposure and effect to toxicants are being 
assessed, and the changes will be compared with those in the smoking cessation 
and never smoker cohorts.
Japan Tobacco. In 2014, Japan Tobacco researchers reported on a 
controlled, semi-randomized, open-label, residential clinical study of changes 
in levels of biomarkers of exposure to tobacco constituents in healthy Japanese 
male smokers who switched to a prototype HTP (87). A total of 70 smokers 
were enrolled and randomized to either an HTP or continued smoking for four 
consecutive weeks. As in the studies by PMI and BAT researchers, measured 
urinary biomarkers of exposure and urinary mutagenicity were significantly 
reduced in the HTP group.
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Academic research
Little independent research on the exposure of HTP users has been published. 
A randomized, cross-over laboratory behavioural trial of use of IQOS was 
conducted in Belgium (88), in which 30 participants were randomized to use of 
conventional cigarettes, e-cigarettes or IQOS for 5 min. Using an IQOS resulted 
in a small but reproducible increase in exhaled CO (0.3 ppm), although the level 
was lower than that observed after smoking a conventional cigarette (4.7 ppm). 
A similar randomized cross-over study was conducted in Italy by academic 
researchers with a history of tobacco industry-related funding (30). A total of 
12 healthy smokers were recruited, who used IQOS in the clinic (10 puffs, two 
sessions separated by 5 min) and provided exhaled CO samples at several times 
after the first puff of the first puffing session. No increase in exhaled CO was 
reported after use of IQOS. In a study in the USA, nicotine delivery and exhaled 
CO were measured in smokers of IQOS, JUUL e-cigarettes and conventional 
cigarettes (89). The researchers recruited 18 smokers with no experience of IQOS 
or JUUL to complete a within-subject, laboratory study of controlled (10 puffs, 
~30-s inter-puff interval) and ad-libitum (90 min) use of the test products or their 
own brand of conventional cigarettes. The amount of exhaled CO did not increase 
after use of IQOS, while the mean plasma nicotine increased significantly, from 
2.1 (0.2) ng/mL to 12.7 (6.2) ng/mL after 10 puffs and to 11.3 (8.0) ng/mL after 
use ad libitum. The increase in plasma nicotine was about half that after smoking 
conventional cigarettes.
2.4.3 Passive exposure
Non-industry researchers have conducted studies of the potential impact of 
passive exposure to HTP emissions. In a study of particle size distribution, 
the profiles of exposure to submicron particles (5.6–560 nm) in conventional 
cigarettes and in IQOS were evaluated to estimate their potential deposition 
in the human respiratory system (90). IQOS aerosol contained approximately 
four times lower amounts of such particles than the smoke of conventional 
cigarettes, and the particles in the IQOS aerosol dissipated rapidly; however, 
approximately half of such particles are small enough to reach the alveolar region 
upon inhalation. In a follow-up modelling study, the same group estimated 
the deposition of ultrafine particles from IQOS, e-cigarettes and conventional 
cigarettes in the respiratory tract of people of different ages in a multiple-path 
particle dosimetry model (91). IQOS delivered significantly lower doses of second-
hand particles than conventional cigarettes, but the doses were 50–110% higher 
than those from e-cigarettes, suggesting that non-users may have meaningful 
second-hand exposure. In the same study, 60–80% of the particles deposited in 
the head region of a 3-month-old infant measured < 100 nm, suggesting that 
they could be translocated to the brain via the olfactory bulb. In another study, 
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the concentrations of aerosol particles, carbonyl and nicotine were analysed in a 
model chamber during use of an unidentified HTP (19). Use of the HTP resulted 
in statistically significant increases in the amounts of several analytes, including 
nicotine, acetaldehyde and PM2.5, and in particle number as compared with 
background measurements. As in the previous study, the authors reported that 
HTP particles dissipated or evaporated within seconds and that the levels of 
particles and individual constituents were significantly lower than in smoke from 
conventional cigarettes under the same conditions. The authors concluded that 
intensive use of HTPs in a confined space with limited ventilation can substantially 
increase the exposure of bystanders to second-hand aerosol emissions.
In a study in Germany, particle size and concentrations were also 
measured to compare potential passive exposure due to use of IQOS, e-cigarettes 
and conventional tobacco cigarettes in cars (92). The results showed that use 
of an IQOS had almost no effect on the mean concentration of fine particles 
(>  300 nm) or on the PM2.5 concentration in the interior of the car, but the 
concentration of smaller particles (25–300 nm) increased in all vehicles. The 
nicotine concentrations obtained from IQOS and e-cigarette use were comparable 
and were both lower than those from conventional cigarette smoking. In a more 
comprehensive chemical analysis of IQOS emissions in the context of second-
hand exposures, the HCI smoking regimen was used to generate IQOS aerosol 
in an environmental chamber, and 33 volatile organic compounds were analysed, 
including aldehydes and nitrogenated aromatic species, in mainstream and side-
stream emissions (26). As in the studies described above, the yields from IQOS 
were substantially lower than those from conventional cigarettes and sometimes 
higher than those from e-cigarettes. Acrolein at > 0.35 μg/m3 was identified as an 
exposure of potential concern.
Passive exposure from HTP use has also been studied in population-
based research in Japan. In one study, the weighted prevalence of HTP use in 
indoor public spaces was estimated from nationally representative data in the 
International Tobacco Control Japan Survey (February–March 2018) (93). It 
was found that 15.6% of current tobacco users in Japan reported using HTPs 
in indoor public spaces. In a survey of perceived symptoms due to exposure to 
second-hand HTP aerosol (94), 8240 individuals aged 15–69 years were followed 
up between 2015 and 2017 in a longitudinal Internet survey. Of the respondents 
who reported having been exposed to second-hand HTP aerosol, 37% reported 
having experienced at least one symptom as a result. The most common symptoms 
were generally feeling ill, eye discomfort and sore throat. Nearly half of never 
smokers who had been exposed to second-hand HTP aerosol reported at least 
one symptom.
In an industry study of second-hand emissions from a prototype HTP in 
simulated “office” and “hospitality” environments with different baseline indoor 
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air quality (47), smoking an HTP under ISO conditions gave significantly lower 
yields of many constituents than smoking a Marlboro cigarette: the levels of 24 of 
29 smoke constituents were reduced by a mean of > 90%, and the concentrations 
of five smoke constituents were reduced by a mean of 80–90%. Nicotine emissions 
were on average 97% lower from HTPs than from smoking Marlboro cigarettes, 
and the total number of respirable suspended particles was reduced by 90%. These 
results are generally consistent with those of non-industry research, which show 
that HTPs are a weaker source of indoor pollution than conventional cigarettes. 
Their impact on indoor air quality and on passive exposures is, however, not 
negligible and is not well understood.
2.4.4 Impact on health outcomes
Little research has been conducted on exposure to and effects of HTPs in toxicological 
models or human participants, partly because extensive marketing and use of 
these products is relatively recent. Assessment of the health implications of HTP 
use is therefore limited, and the available data should be interpreted with caution.
The apparent reduction in exposure of smokers who switch to HTPs to 
various emissions of traditional smoked products is an important but not sufficient 
factor in assessing the health effects of HTP use. Highly efficient nicotine intake 
from HTPs is an emerging concern, and particular attention should be paid to the 
potential effects in vulnerable populations, such as individuals with pre-existing 
conditions, pregnant women and young people.
Nicotine intake. Nicotine is a powerful, addictive chemical and the main 
driver of users’ exposure to the toxic and carcinogenic constituents present in 
tobacco products. Emerging indications from studies in vitro and in laboratory 
animals and humans that more nicotine may be absorbed from HTPs than from 
cigarette smoke raise concern about the potentially high abuse liability of these 
products. In addition, nicotine is an important reproductive and neurobehavioural 
toxicant and contributes to mortality from cardiovascular diseases. Such effects 
are expected to be seen in HTP users.
Cardiovascular disease. The evidence that many cardiovascular bio-
markers are not reduced in smokers who switch to HTPs (80,95) suggests that 
HTPs may represent a similar risk for cardiovascular disease as smoking. While 
the reasons are not clear at this time, elevated levels of certain chemical con-
stituents in HTPs could play a role. These observations suggest that switching to 
HTPs is not likely to reduce the risk of cardiovascular morbidity and mortality 
associated with tobacco use.
Chronic respiratory disease. Although some research suggests relief of 
respiratory symptoms in smokers with chronic obstructive pulmonary disease 
who switch to HTPs (96), other studies and expert groups have raised concern 
about the association between e-cigarette use and respiratory diseases (97–99). 
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HTPs contain higher levels of volatile respiratory toxicants than e-cigarettes 
(Table 2.2). Furthermore, data from studies in laboratory animals suggest an 
impact of HTP exposure on respiratory organs (67) and the expression of RNAs 
associated with pulmonary response to injury (61). An industry trial showed no 
reduction in the levels of a biomarker of lung epithelial injury (CC16) in smokers 
who switched to HTPs (78). Thus, addicted adult smokers who switch to HTPs 
may not reduce their risk of chronic respiratory disease associated with tobacco 
use, and the use of these products by non-smokers may increase their risk of 
pulmonary disorder, particularly if they have other health conditions.
Pregnant women and children. Given the adverse effect of nicotine on 
development in utero and on birth outcomes, such as impaired cardiorespiratory 
and pulmonary function in infants, and the negative cognitive and neurobehav-
ioural effects of exposure to nicotine during adolescence, use of HTPs by preg-
nant women and children is of particular concern.
The above considerations are based on knowledge of the effects associated 
with specific constituents reported to be present in HTPs and indirect evidence 
from in-vitro, in-vivo and biomarker studies on HTPs. There are virtually no 
studies in which the association between HTPs and health outcomes was studied 
directly. The few relevant studies are summarized below.
Health effects in young people. A large survey was conducted in the 
Republic of Korea to evaluate the effects of cigarettes, HTPs and e-cigarettes on 
the prevalence of asthma and allergic rhinitis among 60 040 middle- and high-
school students (100). “Ever HTP use” was significantly associated with current 
asthma and allergic rhinitis in adjusted models, although the association was 
weaker than that with current use of conventional cigarettes. The odds ratio for 
current asthma was particularly increased in those who were dual users of HTP 
and/or e-cigarettes with conventional cigarettes. In an earlier study (101), the 
association between use of tobacco products and the risk of allergic diseases was 
assessed from cross-sectional data on 58 336 students aged 12–18 years from the 
2018 Korea Youth Risk Behavior Survey. Use of conventional cigarettes, HTPs 
and e-cigarettes was each significantly associated with increased risks of asthma, 
allergic rhinitis and atopic dermatitis.
Health effects in adults. A study is being conducted in Kazakhstan to 
evaluate the health outcomes in men and women aged 40–59 who use IQOS 
with HeatSticks, as compared with smokers of conventional cigarettes (102). In 
this 5-year, single-centre cohort observational study, data on the frequency of 
exacerbated respiratory symptoms, intolerance of physical exercise, abnormal 
lung function and other parameters and comorbid conditions are analysed. The 
study also includes comprehensive clinical assessments at baseline and annually, 
continuous monitoring of chronic obstructive pulmonary disease and registration 
of exacerbation of acute respiratory conditions. The clinical assessments 
33
Toxicants in heated tobacco products, exposure, health effects and claims of reduced risk
include spirometry, chest computed tomography, electrocardiography, physical 
examinations, laboratory testing of serum for biomarkers of inflammation and 
metabolic syndrome, anthropometry and the 6-min walk test. Recruitment 
began in December 2017; results were not available as of July 2020. Similar 
studies should be conducted in other countries in which IQOS and other HTPs 
are marketed, for early identification of the potential health risks associated with 
these products.
2.5 Review of the evidence for reduced risk or harm with use  
of HTPs
2.5.1 Harm reduction in the context of tobacco products
The health consequences of smoking conventional cigarettes are well documented 
– and devastating. Nicotine is a powerful addictive substance, however, and 
quitting smoking is very difficult. The concept of reducing the harm of tobacco, 
as described by some in the tobacco control community, is based on the idea 
that cigarette smokers who are unwilling or unable to quit nicotine intake should 
have a less harmful alternative to conventional combusted cigarettes (103,104). 
Over the past two decades, novel products claimed to reduce exposure and risk 
have been introduced continuously, including smokeless tobacco products, 
e-cigarettes and now HTPs. As these novel and emerging products generally 
evolve rapidly and are sometimes limited to a few markets, it has been difficult to 
generate timely research, independent of the tobacco industry, on their potential 
to reduce harm. This is particularly true for HTPs, and most of the available 
research on these products has been conducted by their manufacturers. Analysis 
of the data and the claims made on the basis of those data is essential to inform 
the research agenda and regulatory considerations.
2.5.2 Claims of reduced risk
Industry claims
All the studies conducted by the industry are based on a similar strategy for 
generating evidence to support claims of “reduced risk” associated with HTPs. 
The model is based on standard in-vitro assays, toxicological modelling, studies 
in laboratory animals and measurement of human biomarkers of exposure and 
potential harm. Importantly, the conclusions of all the published reports are 
based on comparisons of HTPs with conventional cigarettes.
To support its claim of “reduced risk” associated with use of HTPs, PMI 
modelled the population health impact of introducing IQOS (105). Using the 
PMI assessment method, the authors conducted various simulations to estimate 
the population health impact of introducing a “reduced-risk tobacco product” in 
Japan and modelled different situations over a 20-year period from 1990. They 
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estimated that, if tobacco use was stopped completely at baseline, the overall 
reduction in tobacco-attributable deaths from lung cancer, ischaemic heart 
disease, stroke and chronic obstructive pulmonary disease for men and women 
combined would be 269 916 deaths; if smoking was completely replaced by the 
reduced-risk tobacco product at baseline, they estimated 167 041–232 519 fewer 
deaths; and, if the product was introduced at baseline, with uptake rates consistent 
with the known uptake of IQOS, the estimated reduction in the number of deaths 
was 65 126–86 885.
Analysis of claims
While industry-sponsored publications fully disclose experimental data, their 
interpretation and the conclusions often omit important observations or present 
the findings inadequately. Therefore, careful analysis of industry claims and data 
is critical.
Analysis of specific claims and concerns about their accuracy. Several 
independent studies have examined the claims and conclusions of industry-
published research reports. For example, St Helen et al. (12) examined sections 
on aerosol chemistry and human exposure assessment in the PMI application 
to the United States Food and Drug Administration (FDA) for authorization of 
a “modified risk tobacco product” (MRTP) to assess the validity of the claims 
of reduced exposure and risk. The authors of the analysis noted that PMI 
reported the levels in IQOS aerosol of only 40 of the 93 harmful and potentially 
harmful constituents on the FDA list. They also noted that, while the levels of all 
58 constituents on the PMI list were lower in IQOS aerosol than in 3R4F cigarette 
smoke, the levels of 56 other constituents (not on either the PMI or the FDA list) 
were higher in IQOS emissions. The levels of some of these constituents were 
strikingly increased: 22 were > 200% higher and seven were > 1000% higher in 
IQOS aerosol than in 3R4F smoke (Fig. 2.1). The full list of constituents reported 
is available on the FDA website (https://www.fda.gov/media/110668/download). 
The impact of these constituents at the levels found in IQOS emissions on the 
overall toxicity or harm of this product should be assessed independently, as they 
may increase the overall risk for disease due to use of IQOS.
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Fig. 2.1. Constituents reported by PMI to be at levels at least 200% higher in IQOS aerosol than in the 
smoke of 3R4F cigarettes
Data and chemical compound names as listed by PMI in its application to the FDA (https://www.fda.gov/media/110668/download, 
accessed 10 January 2021).
Data on the toxicity of IQOS in vitro and in vivo included by PMI in its MRTP 
application have also been evaluated. Moazed et al. (106) reviewed the pulmonary 
and immune toxicity of IQOS in studies in laboratory animals and humans. The 
data in the MRTP application provide evidence of pulmonary inflammation 
and immunomodulation after use of IQOS and no evidence of improvement 
in pulmonary inflammation or pulmonary function in cigarette smokers who 
switched to IQOS. Another group assessed the possible hepatotoxicity of IQOS 
(107) in PMI preclinical studies (108) and in studies of human IQOS use in PMI’s 
MRTP application. They found that exposure to HTP increased liver weights, 
serum alanine aminotransferase activity and hepatocellular vacuolization in 
experimental animals, whereas these effects were not seen after exposure to 
conventional cigarettes. Clinical data showed increased alanine aminotransferase 
activity and plasma bilirubin in smokers who switched to IQOS, indicating 
hepatocellular injury. The potential impact of passive exposure to IQOS aerosol 
in non-users has not been considered.
Reduced exposure vs reduced risk. Assessment of the published studies on 
biomarkers after HTP use tend to support the claims that these products reduce 
exposure to many harmful constituents. For example, Drovandi et al. (109) 
conducted a meta-analysis of trials published between 2010 and 2019 to compare 
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the levels of biomarkers of exposure with use of conventional combusted cigarettes 
and various HTP devices. The authors identified 10 non-blinded, randomized 
controlled trials involving a total of 1766 participants, all conducted by industry 
researchers. The analysis showed that the levels of 12 biomarkers of exposure 
to toxicants were significantly lower in participants assigned to an HTP than in 
those who smoked conventional cigarettes. In comparison with abstinence from 
smoking, the levels of eight biomarkers were similar and those of four biomarkers 
were significantly elevated in people who switched to HTPs. An analysis of the 
results for 24 biomarkers of potential harm in PMI studies of smokers who 
switched to IQOS or prototype HTPs (95) found no statistically detectable 
difference between users of IQOS and conventional cigarettes for the majority of 
the biomarkers, suggesting that reductions in exposure to tobacco constituents 
do not necessarily result in proportional reductions in risk for disease.
Analysis of the strategies used by the industry to support their claims of 
reduced risk. The overall approach of the industry to assessing the public health 
impact of HTPs, particularly PMI’s modelling with regard to IQOS, has also been 
analysed. Max et al. (110) reviewed the “population health impact model” used 
by PMI in its application to the FDA to market IQOS as an MRTP and compared 
it with the FDA guidelines for MRTP applications; more general criteria for 
evaluating reduced-risk tobacco products were also considered. They found 
that the model addressed the impact of IQOS on mortality from four tobacco-
attributable diseases but not morbidity, that it underestimates mortality rates, 
does not apply to tobacco products other than cigarettes, does not include FDA-
recommended impacts on non-users and underestimates the impact on other 
population groups. Thus, the industry model underestimates the health impact 
of IQOS. Although even an improved model will have to rely on industry data 
and on a number of assumptions, the health outcomes and/or surrogate measures 
of health effects associated with HTP use must be assessed by independent 
researchers to provide regulatory agencies with information on the impact of 
HTPs on public health.
A review was reported of previously secret internal PMI documents 
on Accord, a precursor product similar to IQOS, with regard to public 
communications and the application for IQOS as an MRTP (111). Like IQOS, 
Accord was marketed as a product that reduced users’ exposure to harmful 
tobacco constituents; however, PMI consistently emphasized that such reductions 
did not render Accord safer. The review concluded that claims that use of IQOS 
reduces risks to health are not supported, given the similarity of the two products 
and the absence of consistent reductions in toxic emissions from IQOS aerosols 
as compared with Accord.
Even when there is no claim of reduced risk, however, a claim of reduced 
exposure may suggest the safety of currently marketed HTPs. A review (112) 
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was conducted of PMI’s qualitative and quantitative studies of perceptions of the 
claims of reduced risk submitted to the FDA in the MRTP application, which 
found that adult consumers perceived claims of reduced exposure as claims of 
reduced risk.
2.6 Summary and implications for public health
Although HTPs are not a new concept, the active marketing and uptake by users of 
the newer generation of these products around the world is relatively recent. Most 
of the information on HTP contents and emissions and the exposure and effects 
in HTP users was generated and published by the industry, although some more 
recent studies have been published by independent research groups. The current 
literature shows some agreement and some inconsistencies among publications. 
The industry-published reports tend to be biased towards favourable conclusions 
about the benefits of switching to HTPs, even when they contain clear data in 
tables and figures that do not fully support those conclusions.
2.6.1 Summary of data
The main conclusions from this review of publications on HTP toxicant emissions, 
exposures and effects in model systems and humans, and implications for health 
are outlined below.
Toxicant emissions and comparison with other tobacco products: The 
machine puffing regimens that have been used to test HTP emissions are based 
mainly on those used for conventional cigarettes, such as ISO and HCI. There 
may, however be important differences in how HTPs and conventional cigarettes 
are puffed by human users, which adds complexity to the known limitations of 
interpreting data generated by smoking machines. Nevertheless, in the absence 
of other data, approximate comparisons can be made of the emissions of HTPs 
and of conventional and e-cigarettes. Most publications, including non-industry 
studies, show that the levels of nicotine in HTPs and conventional cigarettes (on 
per-stick basis) are comparable. The levels of many harmful constituents that 
derive from the combustion process are consistently reported to be significantly 
lower in HTP aerosol than in conventional cigarette smoke. These include 
CO, PAH, some carbonyl compounds (formaldehyde, acetaldehyde) and other 
volatile toxicants, as well as components such as black carbon, nitrogen oxide and 
ammonia. The levels of TSNAs are also lower in HTP aerosols than in cigarette 
smoke. Some reports, however, indicate that the levels of other constituents, such 
as pyridine, dimethyl trisulfide, acetoin and methylglyoxal, may be comparable 
to or higher than those in the smoke of conventional cigarettes, and the levels 
of toxicants such as TSNA, CO, benzo[a]pyrene and carbonyls are higher in 
emissions of HTPs than in e-cigarettes.
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Effects of HTPs in vitro: Studies in cell cultures can provide important 
mechanistic insights into any acute or chronic harmful effects associated with 
HTP use. Industry-published studies generally claim reduced cytotoxicity and 
mutagenicity and lower levels of a range of toxicological and inflammatory 
biomarkers after exposure in vitro to HTP aerosols as compared with conventional 
cigarette smoke. Increasing smoking intensity, however, results in substantial 
increases in these effects. Furthermore, more nicotine is delivered into cells 
exposed to HTPs than into those exposed to smoke from reference cigarettes. 
Both industry and independent publications show that cytotoxicity, mutagenicity 
and expression of certain RNAs are higher after exposure to HTP aerosol than 
after exposure to air. Differences in outcome measures have also been seen among 
HTPs, such as between IQOS and glo™.
Effects of HTPs in experimental animals: Industry studies of dermal 
tumorigenicity and acute and chronic inhalation toxicity in rodents reported that 
animals treated with HTP aerosol had lower tumour incidence and multiplicity, 
fewer inflammatory and cellular stress responses and fewer histological changes 
than animals treated with conventional cigarette smoke. Analysis of these 
publications, however, reveals dose–response relations for many of these effects 
and consistently greater responses in animals treated with HTPs than in air 
controls. Limited data suggest that exposure to HTPs delivers more nicotine than 
conventional cigarette smoke, consistent with the in-vitro results. 
Exposure and effects in smokers who switch to HTPs and comparison 
with use of e-cigarettes or abstinence from tobacco: Industry publications 
report reductions in biomarkers of exposure to certain constituents, less urinary 
mutagenicity and reduction in some biomarkers of effect in smokers who switch 
to HTPs. Examination of the publications, however, shows substantially higher 
levels of biomarkers of exposure than in groups assigned to stop smoking and 
not use any product (Table 2.2). In addition, the levels of biomarkers of many 
cardiovascular and other diseases did not decrease and in some cases increased 
(CC16, alanine aminotransferase activity, plasma bilirubin) after a switch to HTPs 
over baseline levels. This suggests that HTPs have similar or greater cardiovascular 
toxicity than conventional cigarettes. Lastly, HTP consumption and nicotine 
intake clearly increased over time in the switching studies, suggesting increasing 
exposures to other aerosol constituents.
Passive exposure to HTPs and comparison with other tobacco products 
or clean air: Research on passive exposure to HTP aerosol has been limited. 
The results to date suggest that use of HTPs may expose bystanders to certain 
constituents at levels lower than with passive exposure to conventional cigarette 
smoke but at higher levels than exposure to clean air or e-cigarette aerosol.
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2.6.2 Implications for public health
Real-world exposure and its effects on HTP users are not well characterized, and 
it is impossible at this time to accurately evaluate the long-term health outcomes 
in users who switch completely to HTPs or use them in combination with 
conventional cigarettes, e-cigarettes or other tobacco- or nicotine-containing 
products. Careful analysis of data from industry and academic studies calls 
attention to the following potential public health consequences of HTP use.
 ■ Addictive potential. HTPs may be more efficient in delivering nic-
otine to users than other tobacco products, including conventional 
cigarettes. Therefore, in the absence of clear understanding of the 
health consequences of HTP use, the potential for addiction and 
subsequent long-term use of these products by various population 
subgroups, including young people and adults with comorbid condi-
tions, HTPs are a public health concern.
 ■ Significant differences in exposure of users to toxicants. Increasing 
the intensity of HTP puffing dramatically increases the yields of toxi-
cants and the cytotoxic and mutagenic effects of HTP emissions in a 
dose–response manner. There could therefore be significant variation 
in toxic exposures and subsequent risks among individuals who use 
the same HTP, depending on the product type and use topography.
 ■ No reduction in the chronic disease burden among smokers who 
switch to HTPs. Some smokers may choose to switch to HTPs to 
reduce harmful exposure without quitting tobacco use. As summa-
rized above, the data indicate no improvement in several pulmonary 
and cardiovascular indicators and a high prevalence of dual use (with 
smoking) in participants in switching studies. Therefore, uptake of 
HTPs by smokers may not significantly reduce the prevalence of 
smoking-associated chronic diseases.
 ■ Increased risk of chronic diseases in non-smokers who initiate 
HTP use. Studies conducted to date consistently show higher ex-
posure and more effects with HTPs than with no exposure (such as 
sham controls in experimental studies and smoking abstinence in hu-
man trials). Uptake of HTPs by non-users of any tobacco product will 
therefore increase their risk for adverse outcomes such as respiratory, 
cardiovascular and potentially other diseases.
 ■ Unknown or unique toxic effects of HTPs. Most research on HTP 
aerosols has been limited to analyses of key combustion and tobacco-
specific constituents and comparisons with conventional cigarette 
smoke. HTP aerosols may contain unique harmful constituents that 
have not yet been identified or well characterized, as suggested by 
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indications of hepatocellular injury in response to HTPs but not to 
conventional cigarettes in experimental and clinical trials.
 ■ Second-hand exposure of non-users. Exposure to particulates, 
nicotine and other components of HTP aerosols may pose risks to 
non-users.
 ■ Perceptions of safety among users. Claims of reduced exposure 
from HTPs may be perceived by users and non-users of other to-
bacco products as claims of reduced risk, which may lead to uptake 
of HTPs by individuals who would otherwise quit smoking or not 
initiate tobacco use.
Lastly, there is sufficient variation among HTP brands to suggest that the 
technologies used in HTPs will continue to evolve. This may include changes 
in the chemical composition of aerosols produced by HTPs and in subsequent 
exposure and effects in users. Therefore, the limited data available on currently 
marketed HTPs, much of which was generated by industry, may not be directly 
applicable in the future.
2.7 Research gaps and priorities
This review of the toxicants in HTPs and reports on in vitro and in vivo toxicity 
and levels of exposure and effects in humans indicates the following areas for 
research:
 ■ sound, more rigorous, innovative laboratory assessment of HTP 
emissions, such as non-targeted analyses to identify toxicants that 
may be responsible for the lack of improvement in biomarkers of po-
tential harm to smokers who switch to HTPs;
 ■ better characterization of human topography to understand how 
HTPs are used in the real world (as opposed to clinical confine-
ment trials), including potential increases in product consumption 
over time and how they affect addictiveness, harmful exposures and 
health outcomes;
 ■ better characterization of nicotine uptake by HTP users and the po-
tential impact on abuse liability;
 ■ use of toxicological models (e.g. cells or laboratory animals) to bet-
ter understand nicotine absorption in cells and tissues and to predict 
unique or unknown toxicity of HTPs;
 ■ identification of biomarkers of exposure and effect that are specific 
to HTPs to facilitate research on the amount of HTP use, associated 
exposure and potential health effects;
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 ■ the impact of dual or poly use of HTPs with other tobacco products, 
particularly conventional cigarettes;
 ■ the effects of second-hand exposure on non-users, particularly vul-
nerable populations (those with pre-existing medical conditions, 
children, pregnant women); and
 ■ monitoring of health outcomes in longitudinal population-based co-
horts of HTP users and exposed non-users in various countries and 
comparison with non-users of any tobacco product.
2.8 Policy recommendations
The following recommendations are proposed for consideration by policy-
makers, researchers and the public health community, as appropriate.
 ■ Thoroughly examine industry research data on HTPs to ensure ac-
curate interpretation.
 ■ Prioritize and support independent research of the public health im-
pact of HTPs.
 ■ Develop standards for HTP surveillance and research, such as 
product-related terminology, standard testing procedures for HTP 
emissions, including puffing regimens, and HTP-specific reference 
products that could be used as quality controls.
 ■ Conduct surveillance of the prevalence of use of the available HTPs 
and the potential associations with health outcomes, by country.
 ■ Until further, independent evidence on the public health impact of 
HTPs is available, prohibit all manufacturers and associated groups 
from making claims about reduced harm as compared with other 
products, including advertisements and modifications to health 
warnings, and from portraying HTPs as appropriate for cessation 
of use of any tobacco product; and prohibit use of HTPs in public 
spaces, as they are tobacco products.
 ■ Policy-makers should clearly communicate to the public that there 
is currently no evidence that HTPs reduce the risks associated with 
tobacco products.
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Abstract
Decision FCTC/COP8(22) requests a report on several aspects of novel and 
emerging tobacco products, in particular heated tobacco products (HTPs). This 
paper addresses the aspect of addictive potential, perception and use, attrac-
tiveness, potential role in initiating and quitting smoking, marketing including 
promotional strategies and impacts, and claims of “reduced harm”. We reviewed 
the attractive and addictive features of HTPs and the effects of those features on 
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consumer perception and use. The available literature on HTPs was complement-
ed by information from the wider body of knowledge on e-cigarettes.
We searched the bibliographic database PubMed, with no restriction on 
time, up to January 2020. Studies on toxicity in users (i.e. toxicants in emissions, 
in-vitro studies, biomarkers of exposure) and environmental smoke and studies 
in a language other than English were excluded. We also included studies in 
the application of Philip Morris International (PMI) to the United States Food 
and Drug Administration (FDA) for their IQOS modified risk tobacco product 
(MRTP) were also used.
With regard to features that increase attractiveness, information 
was found on sensory attributes, ease of use, cost, reputation and image, and 
assumed risks and benefit. Little is known about how these different features 
affect consumer perception and use; a recent study reported that six important 
factors were health, cost, enjoyment and satisfaction, ease of use, use practices 
and social aspects. With regard to addictiveness, currently marketed HTPs 
deliver significant levels of nicotine in aerosol, and their pharmacokinetics and 
physiological and subjective effects are similar to those of contemporary ENDS 
products, suggesting comparable abuse liability.
HTPs have become popular in some markets, probably due to factors such 
as marketing as a “clean”, modern, elegant, “reduced harm” product. Their sensory 
properties and ease of use are generally rated lower than those of conventional 
cigarettes but are directly correlated with their attractiveness, perceived risk and 
appeal, thus determining their uptake. The history of e-cigarettes shows that any 
new tobacco and related product that comes onto the market can quickly become 
popular. Knowledge of e-cigarettes indicates that the factors of concern for HTPs, 
and therefore potential regulatory targets, are nicotine levels and “throat hit”, 
flavour variety, design of the device, marketing and perception of reduced harm.
Common regulatory principles for e-cigarettes include minimizing 
product appeal and thus potential uptake by young people, increasing product 
safety and minimizing false beliefs about health effects. A similar strategy could 
be followed for HTPs. Policy-makers are advised to monitor the HTP market, 
communicate the risks to the general public, limit marketing, consider regulating 
flavours and stimulate research, especially on perceptions and use.
3.1 Background
Since the 1980s, tobacco companies have tried to promote HTPs on the market 
as “healthier” than conventional cigarettes. Until recently, they failed (1), but 
HTPs are now increasingly marketed as an alternative to smoking combustible 
products, primarily cigarettes, although controversy has surrounded the public 
health context of their marketing and use (2). Since 2014, various new products 
have been introduced – including Philip Morris International (PMI)’s IQOS, 
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and industry analysts predict that HTPs will absorb 30% of the regular cigarette 
market in the USA by 2025 (3). Other examples are Ploom TECH from Japan 
Tobacco International, glo from British American Tobacco and PAX from PAX 
Labs (4). Production of HTPs is expected to grow quickly (5).
Like e-cigarettes, HTPs are rechargeable battery-powered devices that 
heat the product; however, the product consumed is tobacco (6,7). According to 
WHO (4), HTPs
… produce aerosols containing nicotine and toxic chemicals when to-
bacco is heated or when a device containing tobacco is activated. These 
aerosols are inhaled by users during a process of sucking or smoking in-
volving a device. They contain the highly addictive substance nicotine as 
well as non-tobacco additives and are often flavoured. The tobacco may 
be in the form of specially designed cigarettes (e.g. “heat sticks” and “Neo 
sticks”) or pods or plugs.
In decision FCTC/COP8(22) on novel and emerging tobacco products (8), 
the Conference of the Parties to the WHO  FCTC at its eighth session noted 
the evolution of HTPs, their marketing as “harm reduction” products and the 
resulting regulatory challenges, with “limited guidance to guide Parties on the 
classification and regulation of heated tobacco products”. Hence, they requested 
a report to be submitted to the ninth session
on novel and emerging tobacco products, in particular heated tobacco 
products, regarding their health impacts including on non-users, their 
addictive potential, perception and use, attractiveness, potential role 
in initiating and quitting smoking, marketing including promotional 
strategies and impacts, claims of reduced harm [italics added], variability 
of products, regulatory experience and monitoring of Parties, impact on 
tobacco control efforts and research gaps, and to subsequently propose 
potential policy options ….
The objectives of this paper address the italicized part of the request, as below, by 
reviewing current literature on:
 ■ the attractive features of HTPs, in light of WHO’s definition of attrac-
tiveness (section 3.2), including filling gaps in the available literature 
with expectations from studies on e-cigarettes, for which there is a 
larger body of information;
 ■ the addictive features of HTPs, including nicotine delivery (section 
3.3), also complemented by data on e-cigarettes and with an assess-
ment of the overall abuse potential of HTPs; and
 ■ the effects of attractiveness and addictiveness on the perception and 
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use of consumers (section 3.4), including the following, related con-
structs: awareness, attitude, knowledge, intention, reasons for use and 
risk perception. Consumer use includes prevalence, user behaviour 
(such as frequency, intensity and duration and place of use), user pro-
files, initiation, switching, complementing and quitting conventional 
tobacco products. Again, lessons learnt from e-cigarettes are used to 
hypothesize factors that could play a role.
The behavioural implications of different patterns of use among different groups 
and the implications for public health are covered in the discussion. We conclude 
with recommendations for research and policy.
A search was conducted of the bibliographic database PubMed, with 
no restrictions on time, up to January 2020, with the following (combinations 
of) keywords: heated tobacco products, heat-not-burn tobacco products, HTP, 
heat sticks and heatsticks and heets, tobacco sticks and IQOS. Studies on toxicity 
(toxicants in emissions, in-vitro data, biomarkers of exposure) and environmental 
smoke and studies in a language other than English were excluded. We also used 
data sent in 2016 by Philip Morris International (PMI) to the US Food and Drug 
Administration (FDA) seeking authorization to market its IQOS HTP system and 
flavoured “HeatSticks” in the USA as a modified risk tobacco product (MRTP), 
and the resulting files of the FDA assessment (9–12).
3.2 Attractiveness of HTPs
3.2.1 Definition of attractiveness in the context of Articles 9 and 10  
of the WHO FCTC
“Attractiveness” has been defined by WHO (13) as
factors such as taste, smell and other sensory attributes, ease of use, flex-
ibility of the dosing system, cost, reputation or image, assumed risks and 
benefits, and other characteristics of a product designed to stimulate use.
Data on all of these aspects are reviewed below. We will also cover marketing, 
including promotional strategies, and claims of reduced harm.
3.2.2 Attractive features of HTPs
Taste, smell and other sensory attributes
Few studies are available on the taste, smell and other sensory attributes of HTPs 
in humans. Three PMI studies (14–16), report that smoking IQOS suppressed 
the urge to smoke to the same extent as smoking cigarettes but was consistently 
rated as providing less sensory and psychological satisfaction than cigarettes (17). 
An independent study similarly showed that the HTP PAX was considered 
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significantly less satisfying, good tasting and calming than own-brand cigarettes 
but showed no significant effect of PAX on the urge to smoke (17,18). Participants 
in focus groups in Japan and Switzerland also reported less satisfaction with the 
IQOS than with combustible cigarettes, a strange or unpleasant taste and smell, 
milder taste and reduced sensory cues, but less throat discomfort (19).
Information on the availability and variability of flavours in HTPs is also 
important, as it is known that a variety of available flavours plays an important 
role in liking tobacco and related products such as e-cigarettes (20). For example, 
in the Republic of Korea, IQOS HeatSticks (HEETS) are available in tobacco, 
menthol, bubble gum and lime flavours and glo Dunhill Neosticks in tobacco, 
menthol and lemon ginger, cherry and grape flavours (7). KT&G “lil” sticks 
(Fiit) contain novel flavour capsules (menthol, mint, apple mint, bubble gum and 
apricot flavours) (7,21). Like capsule cigarettes, capsule sticks contain menthol 
and other flavours that can mask the harshness of tobacco and may appeal to 
female and young non-smokers (7). Perhaps in reaction to this novelty, British 
American Tobacco introduced Dunhill Neosticks containing capsules (strong 
menthol and tobacco/menthol), and PMI introduced Sienna Caps (“Sienna 
selection with a menthol capsule”). These flavoured HTPs are marketed only in 
countries outside the USA, where HEETS are considered a cigarette product, 
for which characterizing flavours are not allowed1 (22), and only menthol and 
tobacco may be sold (11).
Ease of use
Focus group participants in Japan and Switzerland reported using IQOS indoors 
instead of combustible cigarettes, “because it creates no ash or odour” (19). Many 
participants in both countries commented that the product felt unfamiliar and 
complicated to use and that using IQOS was cumbersome, as the charger and 
HeatSticks may be bulky, and the IQOS must be charged and cleaned. In the 
newer generation IQOS, the holder is integrated with the charger and the product 
can be used up to 10 times before recharging (23). This could make use easier and 
thus increase its appeal.
Flexibility of the dosing system
Nicotine dosing is described in the sections on addictiveness, under the broader 
heading of abuse liability. No other information was found.
1 A cigarette or any of its component parts (including the tobacco, filter or paper) shall not contain, as a 
constituent (including a smoke constituent) or additive, an artificial or natural flavour (other than tobacco 
or menthol) or a herb or spice, including strawberry, grape, orange, clove, cinnamon, pineapple, vanilla, 
coconut, liquorice, cocoa, chocolate, cherry or coffee, that is a characterizing flavour of the tobacco product 
or tobacco smoke. 
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Cost
Unlike combustible cigarettes, which can be used directly from the package, use 
of an HTP generally requires the purchase of an external device. The price of 
such devices can far exceed the price of the consumables, for example, about 25 
times the price of a pack of HEETS in the Republic of Korea (3). While the excise 
tax on HTPs is generally lower than that on combustible cigarettes, HTPs were 
less expensive to use than combustible cigarettes in fewer than half the countries 
studied (21,24). In Israel in 2018, HEETS were sold at prices on average 9.5% 
higher than those of cigarettes (25). In Japan, younger non-users participating in 
a focus group commented that price could be a potential barrier, but overall, the 
price contributed to the cachet of the product as luxurious and prestigious (19).
Reputation or image: marketing at point of sale, package and device
Advertising and promotion of HTPs are not always banned in the countries in 
which they are on the market (6). A systematic Internet search for new tobacco 
and related products showed that common terms used in marketing or promoting 
HTPs include “reduced risk”, “alternative”, “clean”, “smoke-free” and “innovative” 
(26). Expert interviews and IQOS packaging and marketing analyses in Japan 
and Switzerland also showed that the product is marketed as a clean, chic, pure 
product (19). In Israel, PMI promoted IQOS as part of its “Smoke-free Israel 
vision”, focusing on “harm reduction” and stressing that the product was clean 
with less smell and no ash (27). Retailers described the IQOS products as less 
harmful, a cessation device and not producing smoke (25).
IQOS shops are situated prominently and strategically in selected cities 
as a core component of marketing. When HTPs were released in futuristic IQOS 
flagship stores across Italy, Japan and Switzerland, awareness and use of these 
products increased dramatically (28). In Italy, the “IQOS embassy” and “IQOS 
boutique” are fancy concept stores where IQOS is promoted as a status symbol 
and people can try it for free (6). Similarly, in Canada, IQOS was marketed in 
many tobacco retail outlets (1029 in Ontario) (29). In IQOS boutiques, promotion 
activities include exchanging a pack of cigarettes or a lighter for an IQOS device, 
launch parties, “meet and greet” lunches and after-hours events. Promotional 
elements outside the shops are IQOS signs, sandwich-board signs reading 
“Building a smoke-free future” and sales representatives regularly smoking 
IQOS. In Ontario. however, the IQOS signage had to be taken down to comply 
with national and provincial laws on display and advertising (30). In the Republic 
of Korea, IQOS flagship shops are located at prime locations in Seoul, again with 
shop design and product display giving a clean, refined look and feel to IQOS (3). 
In the USA, IQOS was launched in Atlanta, Georgia, and IQOS shops are located 
in shopping malls in affluent areas (31).
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The IQOS name, device, packaging and shops resemble those of popular 
cell phones that attract children and adolescents; in combination with the 
purchasing process, this positions IQOS as a high-demand, upscale product 
for tech-savvy users, rather different from regular cigarettes (3). Focus group 
participants in Japan and Switzerland found the product packaging appealing, 
and even non-users were intrigued, indicating that the product’s sleek appearance 
compared well with that of tech devices (19).
For stick packaging, in Israel, displays of HEETS packages were 
prominently placed close to consumers, in most cases near youth-oriented 
merchandise and pack colours indicating tobacco flavourings and strength (25). 
While cigarette packs in many countries are required to feature graphic warning 
labels showing various negative consequences of smoking, with explicit colour 
pictures, to the best of our knowledge this is not required for HTPs in any 
country as yet. In the Republic of Korea, for example, HEETS packs have only a 
black-and-white warning label about nicotine addiction (3). The visual design of 
tobacco products can influence consumers by implying product characteristics. 
Tests with three IQOS packages that decreasingly linked the product to the 
Marlboro brand but that were similarly noticeable showed that the packaging 
appeal, uniqueness and brand equity was significantly lower for the HEETS 
package than for the Marlboro package (32); however, perceived safety of the 
Marlboro pack was lower than for the other two packs.
Assumed risks and benefits
HTPs are part of a long tradition in tobacco companies of developing and 
marketing products that they claim to be less dangerous than conventional 
cigarettes, beginning with so-called “safer cigarettes” in the 1960s (33). Marketing 
and media accounts of HTPs explicitly or implicitly claim that they are safer than 
cigarettes, and some HTPs are claimed by the tobacco industry to help smokers 
to quit (5,33). HTPs are often claimed to be less harmful than cigarettes because 
they expose users to lower levels of some toxicants (33). While IQOS may 
contain lower levels of some toxicants, the data in the PMI application to the 
FDA for IQOS as an MRTP do not support claims of reduced risk (34). The data 
do demonstrate, however, that adult consumers in the USA perceive claims of 
reduced exposure as claims of reduced risk (35), as confirmed in an independent 
study of adults and adolescents in the USA (36). Analysis of the first nine waves 
of a survey of the population aged ≥ 14 years in Germany also showed that the 
majority of 61 HTP users perceived HTPs as somewhat (41.0%) or much (14.8%) 
less harmful, and 37.7% perceived them as harmful as tobacco cigarettes (37). In 
Italy, the pilot results of a questionnaire administered to 60 high-school students 
showed that 40 considered HTPs to be harmful to health, while 24 students said 
they would accept one of these products if offered by a friend (38).
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Several perceived benefits of IQOS use have been identified by focus group 
participants in Japan and Switzerland, including less throat discomfort, appealing 
packaging, cleanliness, lack of ash and smoke and greater social acceptability, 
but only few reported any health benefits of use as compared with combustible 
tobacco products (19). Use in smoking cessation might be another perceived 
benefit. In Italy, 19 of 60 high-school students said they would recommend HTPs 
to a person who wished to stop smoking (38).
Two interesting study protocols have been published, but, unfortunately, 
neither is independent of industry. PMI cross-sectional surveys are under way 
in Germany, Italy and the United Kingdom (Greater London) to estimate the 
prevalence and use patterns of IQOS and other tobacco- and nicotine-containing 
products (39). The questionnaire also contains items on potential benefits (self-
reported improvement in teeth colouring, breath smell, exercise capacity and skin 
appearance), use experience, perceived risk and experienced reinforcing effects, 
such as satisfaction, psychological rewards, aversion, enjoyment of respiratory 
tract sensations and reduced craving. The other protocol (40) is for a prospective 
study to compare changes in cigarette consumption and adoption rates among 
smokers randomized to HTPs or electronic cigarettes. Product acceptability, 
tolerability and their harm reduction potential will also be compared. There 
is, however a potential conflict of interest, as the research is supported by an 
Investigator-initiated Study award by Philip Morris Products SA, although the 
authors state that PMI “had no role in the design of the study protocol and will 
not have any role during its execution, analysis, data interpretation or writing 
of the manuscript”. Further, some of the authors have undeclared conflicts of 
interest related to tobacco companies, both directly and through funding from 
tobacco industry front groups.
3.2.3 What we can learn from studies on ENDS and ENNDS  
and relevance to HTPs
The history of e-cigarettes should make us cautious about any new tobacco 
or related product coming onto the market, as e-cigarettes have attracted 
young people who may then proceed to cigarette use (33). As many features of 
e-cigarettes are also found in HTP, knowledge about their attractiveness may 
be useful. For example, a study of e-cigarette users showed that the attractive 
characteristics were the variety of e-liquid flavours (69%), e-cigarette design 
(44%), ability to adjust e-liquid nicotine levels (31%), ability to adjust settings 
of device (25%), variety of e-cigarette design (21%), ability to do “cloud chasing” 
(16%) and price (13%) (41). Fewer dual users, smokers and non-users found 
these product characteristics attractive, but in the same order. Similarly, analysis 
of self-reported data showed the importance of the following factors in the 
choice of an e-cigarette: flavour (39%), price (39%), amount of nicotine (27%), 
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type of e-cigarette (22%), health claims (12%), design (10%), brand (9.4%) and 
packaging (3.7%) (20).
With regard to sensory properties, users reported that they were 
dissatisfied with some aspects of e-cigarettes as compared with cigarettes, because 
many do not deliver nicotine into the bloodstream as quickly as cigarettes and 
lack the “throat hit” of cigarettes (1). Although this observation was made before 
nicotine salt-containing e-liquids with a stronger nicotine hit came on the 
market, this may be one reason why smokers try HTPs instead of e-cigarettes. 
The sensory studies on HTPs described above show that smokers rate the taste, 
smell and throat hit are lower than for cigarettes. Flavours and flavour variety 
are considered the most attractive features of e-cigarettes (20,41). Therefore, 
banning or restricting available HTP flavours might be helpful in decreasing their 
popularity among never users.
Although the ease of use of e-cigarettes and HTPs appears to be similar, 
e-cigarettes are much cheaper to use. Cost has been mentioned as a reason for 
using e-cigarettes (20,41) and could be a barrier for use of HTPs by some groups, 
especially children and adolescents.
Many e-cigarette users have accepted the marketing claim that non-
combustible devices are safer than conventional cigarettes and may see HTPs 
as a means of enjoying an authentic tobacco taste with lower perceived risk (1). 
Moreover, like e-cigarette users, HTP consumers may not understand that they 
must completely quit smoking cigarettes to achieve the claimed health benefits of 
HTPs and probably also wrongly believe that unsubstantiated claims of reduced 
risk by the tobacco industry mean that HTPs are risk-free (33).
3.3 Addictiveness of HTPs
Addictiveness is a summary indicator of the abuse liability or abuse potential of 
a drug and its delivery system. In one model (42), the abuse liability of tobacco 
products is considered to comprise the likelihood of repeated use (summarized 
as pharmacokinetics, drug effects and reinforcement) and the consequences of 
use (effects on functioning, physical dependence, adverse effects).
3.3.1 Addictiveness
The nicotine emissions under machine-smoking conditions from the three types 
of HTP for which there are the most published data can be summarized as follows 
(in µg/cigarette): Eclipse under ISO conditions, 0.18 (43); an electrically heated 
cigarette smoking system under ISO conditions, 0.313 (44); tobacco heating 
system (THS) 2.2 (IQOS) under Health Canada Intense (HCI) conditions, 1.32 
(45); and tobacco heating product (THP) 1.0 under HCI conditions, 0.462 (46), 
keeping in mind that the data were published by the manufacturers. In general, 
the nicotine levels are lower than those in a comparison reference cigarette, 1R6F, 
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which has certified values for many of the emissions of concern (47), for which 
the values are 0.721 µg/per cigarette under ISO conditions and 1.90 µg/cigarette 
under HCI conditions. The levels for the HTPs have been largely replicated by 
studies inside (48) and outside (49,50) the industry. Note in particular the lower 
levels of nicotine for Eclipse and the electrically heated cigarette smoking system. 
At the meeting of the Society for Research on Nicotine and Tobacco in 2017, 
British American Tobacco presented two posters on its HTP (THP 1.0) (46,51) 
and in late 2017 published eight studies in a supplement to a journal (52–60). The 
studies generally report lower nicotine emissions from HTP than from cigarettes 
smoked under standard machine conditions.
Bekki et al. (50) showed that the rate of transfer of nicotine from tobacco 
filler to aerosol in IQOS was comparable or slightly higher than in conventional 
cigarettes. Salman and colleagues (61,62) showed that IQOS and traditional 
cigarettes delivered similar quantities of total nicotine in aerosol under ISO 
conditions (0.77 and 0.80 mg/cigarette) and slightly less under HCI conditions 
(1.5 and 1.8 mg/cigarette). They also showed levels of 13% free nicotine in 
IQOS aerosol under ISO and 5.7% under HCI conditions. Meehan-Atrash and 
colleagues, using nuclear magnetic resonance, found a level of 0.53 mg/cigarette 
free nicotine (63). Uchiyama et al. (64), in an extensive investigation of the 
aerosols emitted by IQOS, glo and PloomTECH (Table 3.1), found that IQOS 
delivered by far the most nicotine in aerosol and also had more than three times 
the amount of nicotine in the rod than glo (5.2 mg vs 1.7 mg), although the 
transfer rates were comparable (23% for IQOS, 30% for glo).
Table 3.1. Nicotine concentrations emitted by IQOS, glo and PloomTECH with various flavours
HTP and flavour ISO (µg/cig) HCI (µg/cig)
IQOS tobacco 400 1200
IQOS menthol 430 1200
IQOS mint 320 1200
glo bright tobacco 150 570
glo fresh mix 140 510
glo intensely fresh 150 440
PloomTECH regular 70 270
PloomTECH green 68 170
PloomTECH purple 60 250
Source: reference 64.
The FDA concluded from the data submitted by PMI that “nicotine 
pharmacokinetics (PK) in smokers who switched [to IQOS]… is similar to 
those who continued to smoke CC [conventional smoke, RT]” and that “IQOS is 
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addictive and has nicotine delivery, addiction potential, and abuse liability similar 
to combustible cigarettes”; however, no comparisons with other substitutes, such 
as e-cigarettes, were available. The FDA concluded (11) that IQOS “provides 
nicotine at a high enough level to satisfy the withdrawal and craving symptoms 
of current smokers”, but with no comparisons with ENDS. Fig. 3.1 shows the 
pharmacokinetics of nicotine delivery from IQOS and cigarettes in four studies 
conducted by PMI. The average Cmax of IQOS in smokers in the USA was 
substantially lower than that in smokers in the other countries, although the Cmax 
of cigarettes was remarkably consistent. No differences among products were 
found that explain this finding. Maloney et al. (65) found in a laboratory study 
that IQOS increased mean plasma nicotine significantly, from 2.1 to 12.7 ng/mL 
after 10 puffs and to 11.3 ng/mL after ad-libitum use, comparable to the rate with 
JUUL and somewhat lower than that with own-brand cigarettes.
Fig. 3.1. Pharmacokinetics of nicotine in four PMI studies of IQOS
United Kingdom (Northern Ireland) (N=42)
Tmax = 6 min
Cmax = 9.6 ng/mL (THS), 12.4 ng/mL (CC)
Japan (N=42)
Tmax = 6 min
Cmax = 14.3 ng/mL (THS), 13.8 ng/mL (CC)
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Fig. 3.1. Pharmacokinetics of nicotine in four PMI studies of IQOS (continued)
Source: reference 11.
THS 2.2, IQOS precursor or prototype; CC, conventional cigarette
Limit of quantification in all studies, 0.2 ng/mL
British American Tobacco has published one study on use patterns of its glo 
product (58). Three groups took glo menthol, glo tobacco and glo + IQOS home 
for up to 14 days, with up to four laboratory visits. A fourth group used glo in the 
laboratory only. Laboratory measures included puffing topography, mouth level 
exposure and depth of mouth insertion. Participants who took the products home 
completed daily diaries of product use. Overall, the puff volume was about 60 mL 
with the glo product, with an average of 10–12 puffs per session, a duration of 
1.8–2.0 s and a mean interval of 8.8 s. The volume per puff and total volume were 
Japan (N=43)
Tmax = 6 min
Cmax = 10.7 ng/mL (THS), 12.1 ng/mL (CC)
USA (N=41)
Tmax = 7 min (THS), 10 min (CC)
Cmax = 7.4 ng/mL (THS), 13.1 ng/mL (CC)
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significantly higher than with comparison cigarettes but comparable to those 
with the IQOS product. Participants reported using 12–15 cigarettes per day at 
baseline and used 8–12 units per day of the glo/IQOS products during the 4 days 
at home. The mouth level exposure per product used was lower for glo than for 
cigarettes, especially to nicotine.
In a longer (90 days) study of HTP use (16), total nicotine equivalents in 
urine were comparable in people who used tobacco heating systems and those 
who smoked cigarettes (7 vs 6 mg/g creatinine).
There is a dearth of published independent research on exposure to 
nicotine, puffing topography and other metrics of abuse liability for currently 
marketed HTPs; however, this is an area of active research, and new results 
are published frequently, so that peer-reviewed literature should be monitored 
continuously. There is emerging evidence that IQOS has the hallmarks of a 
product liable to abuse. Detailed information on other HTPs is not yet available. 
Two conclusions can be reached.
 ■ Mainstream aerosol from IQOS delivers about 70% of the nicotine in 
the smoke of cigarettes. Relative nicotine delivery by IQOS is between 
57% and 103%, with a median of 64.7% as compared with a reference 
cigarette. The median in studies funded by the tobacco industry is not 
statistically significantly different from the median in independent 
studies.
 ■ Other HTPs analysed appear to be less efficient than IQOS in deliver-
ing a proportion of nicotine in their mainstream smoke.
3.3.2 What we can learn from ENDS and ENNDS and relevance to HTPs
A number of studies of the abuse liability of e-cigarettes have been published, 
which indicate broadly that the design features that affect nicotine delivery 
should be considered in evaluating the abuse potential of ENDS (66–69). As at 
least one HTP delivers nicotine and suppresses craving in the same way as an 
ENDS (65), it is reasonable to hypothesize that the usage patterns observed for 
ENDS could be generalized to HTPs. Both HTP and ENDS are, however, broad 
classes of products, and the findings for one product might not be generalizable 
to others. More studies of direct comparisons of the use of leading HTPs and 
leading ENDS could clarify this issue.
3.3.3 Overall abuse liability of HTPs
As noted earlier, abuse liability comprises the likelihood of repeated use 
(summarized as pharmacokinetics), drug effects, reinforcement (rewarding 
effects that support future use) and consequences of use (effects on functioning, 
physical dependence, adverse effects). HTPs appear to deliver nicotine at least as 
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well as cigarettes and suppress withdrawal and craving for nicotine. HTP users 
also show signs of nicotine dependence (16,58,65). Thus, the abuse liability of at 
least some HTPs for which data are available is likely to be comparable to that of 
conventional cigarette. The liability may differ by HTP brand and type according 
to factors such as nicotine delivery, sensory properties and ease of use.
3.4 Effects of the attractiveness and addictiveness of ENDS, ENNDS and 
HTPs on perceptions of risk and harm and use
3.4.1 Contributions of attractiveness and addictiveness to initiation, switching, 
complementing and quitting conventional tobacco products
Few studies were found on awareness, use, user profile, initiation, switching, 
complementing or quitting conventional tobacco products in relation to the 
attractive aspects of the product. A few addressed perception and reasons for 
using HTPs. One study implied a direct link between marketing and initiation 
of IQOS. Google search query data showed that, in Japan, the largest Internet 
search volume for IQOS was in the week after a popular national television show 
introduced IQOS (70). Furthermore, the prevalence of use of IQOS increased 
from 0.3% in January–February 2015 to 0.6% in January–February 2016 and up 
to 3.6% in January–February 2017, while the estimated rates of use of other HTP 
remained low in 2017. Respondents who had seen the TV programme in 2016 were 
more likely to have used IQOS than those who had not seen it (10.3% vs 2.7%).
An online survey of 228 young adults, including current, ever and non-
users, in the Republic of Korea indicated that the reasons for using IQOS were 
a belief that they are less harmful or useful for stopping smoking (71). A PMI 
premarket observational study showed that the main predictors of adoption were 
liking the smell, taste, aftertaste and ease of use (72). Adoption was higher among 
participants who used both regular and menthol THS than among those who 
used only one variant. In wave 1 of the International Tobacco Control survey 
in Japan of 4684 adult participants, menthol was the most common flavour 
reported (41.5%) (73). It has been reported1 that the levels of menthol in IQOS 
vary markedly in different markets.
In an exploratory study among adults in London, United Kingdom (74), 
with 22 current and eight ex-users of IQOS, the six main factors that influenced 
initiation and use of IQOS were health (wanting to reduce or quit smoking and 
perceptions of reduced harm), cost (high start-up cost but cheaper continuous 
cost than smoking), enjoyment and satisfaction (e.g. discretion, cleanliness, 
less smell, tactile qualities comparable to combustible cigarettes), ease of use 
(accessibility, shortcomings of maintenance or operation limited continuous use 
but increased use in smoke-free places), use practices (similar to smoking but 
new practices developed to charge and clean, new technology) and social aspects 
1  Goniewicz ML, unpublished data. See Annex 3.1.
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(improved social interactions with use of IQOS rather than smoking, but fewer 
shared social experiences for some).
Studies published by PMI on IQOS precursors (75,76) include 
information on subjective responses to the product, which are often important 
for understanding why it is used and how effective it might be as a substitute. 
The cigarette evaluation questionnaire consisted of 12 items in five categories 
(77): smoking satisfaction, aversion, reduced craving, enjoyment of respiratory 
tract sensation and psychological reward. The questionnaire on smoking urges 
consisted of 10 items, with a single score on a seven-point scale (78).
In a laboratory study of THS in Japan (14), the mean satisfaction scores 
during the study decreased more for THS than for conventional cigarettes. In a 
similar study in Poland (15), the observed differences in evaluation scales between 
THS and cigarettes were large and statistically significant. Broadly, cigarettes were 
rated more highly on satisfaction, craving reduction, sensation and reward and 
lower on aversion. An earlier study of THS 2.1 showed a similar pattern of results, 
with satisfaction scores on day 5 an average of 1.4 points lower for THS than for 
conventional cigarettes (P < 0.001) (79). Significant differences were also seen on 
the reward, sensation and craving subscales, THS scoring lower than cigarettes 
in all cases. Adriaens and colleagues (80) conducted a small study of subjective 
responses to IQOS and to a tank-style ENDS in comparison with own-brand 
cigarettes. They found that IQOS and ENDS were equivalent in reducing craving 
for a cigarette but that both were less effective in suppressing craving than the 
own-brand cigarette. A study on longer-term use in Japan (16) suggested that 
the difference between cigarettes and HTP with regard to satisfaction fades with 
continued use over 90 days. These studies show that scores on questionnaires 
on smoking urges increase for THS over time, as do scores for withdrawal (as 
measured on the Minnesota nicotine withdrawal scale (81)), which may suggest 
some dissatisfaction with the product as a longer-term substitute for smoking.
3.4.2 Learning from ENDS and ENNDS and application to HTPs
As summarized above, few data are available on the effects of attractiveness 
and addictiveness on perceptions and reasons for using HTP and on initiation, 
switching, complementing and quitting conventional tobacco products. Below we 
summarize the available evidence on those factors in relation to the attractiveness 
and addictiveness of ENDS.
A review of reasons for e-cigarette use reported by e-cigarette users, 
cigarette smokers, dual users and non-users among both adults and young people 
showed that adults’ perceptions and reasons for e-cigarette use are often related 
to smoking cessation, while the young like the novelty of the product (82). Young 
non-users perceived e-cigarettes as a cool, fashionable product that mimics the 
smoking routine and is safe to use. In general, the perceived benefits included 
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avoidance of smoking restrictions, the product being cool and fashionable, having 
health benefits, lower cost than cigarettes, positive experiences (mimics smoking 
routine, enjoyable taste, throat hit, weight control, increases concentration), safe 
to use, smoking cessation or reduction, social acceptability and perceived benefits 
for bystanders. Another review of studies in young adults (83) showed that their 
reasons for using e-cigarettes are more varied than only smoking cessation. 
Independently of smoking status, curiosity was the most frequently reported 
reason for initiating use of e-cigarettes. Continued use of e-cigarettes could be due 
to either replication of smoking habits or a different, personalized use of nicotine 
by inhalation. In Europe (84), the most frequently mentioned reason (61%) for 
taking up e-cigarettes was to stop or reduce tobacco consumption. Other reasons 
included a perception of e-cigarettes as less harmful (31%) and lower cost (25%). 
Reducing tobacco consumption and being less harmful were cited more often by 
participants aged > 40 (76–78%) than those aged 15–24 (59%).
Flavours attract both young people and adults to e-cigarettes (85). Flavours 
decrease the perception of harm and increase willingness to try and initiate use of 
e-cigarettes. Among adults, e-cigarette flavours increase product appeal and are a 
primary reason for using the product. “Pod mod” devices have become popular, 
especially among adolescents, due to their design, user-friendliness, less aversive 
vaping experiences, desirable flavours and discretion in places where smoking is 
forbidden (86). Currently marketed HTPs share several of these characteristics, 
suggesting some generalizability of the ENDS experience.
3.5 Discussion
3.5.1 Behavioural implications of different patterns of use in different groups
Few studies are available on the perception and reasons for using HTPs among 
users, ex-users, smokers, dual users and never users of tobacco and related products 
(section 3.1). While the role of attractive or addictive aspects of HTPs is little 
known, studies are available on awareness, use, user profile, initiation, switching, 
complementing and quitting conventional tobacco products. Information on the 
patterns and prevalence of use in several groups is important for regulators, as 
the risk profile of smokers is different from that of never smokers.
An important question is whether HTPs are used primarily by smokers, 
or whether non-smokers also use the product. It would appear that, currently, 
most HTP users are smokers. For example, in Japan, virtually all HTP users were 
current (67.8%) or former smokers (25.0%), and only 1.0% were never smokers 
(73). According to the premarket review by the FDA (5),
… although the data for IQOS uptake by never smokers, former smokers, 
and youth is limited, there are some data from countries where IQOS is 
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marketed – Italy and Japan – which show low uptake by youth and cur-
rent non-smokers. In these countries, the likelihood of uptake is slightly 
higher in former smokers, but still low.
While most HTP users may be smokers, most are dual users of both HTPs and 
conventional cigarettes and are therefore exposed to emissions from both. PMI 
studies showed that most people who use IQOS, concurrently use cigarettes (33). 
Studies in the Republic of Korea showing that 96% of current HTP users (2% 
of the study population) were dual users and that dual use with conventional 
cigarettes was not associated with an intention to quit cigarette smoking (87). 
A survey of adolescents aged 12–18 years showed that 75.5% of the ever HTP 
users (2.8%) were current cigarette users, 45.6% were current e-cigarette users 
and 40.3% were concurrent users of cigarettes and e-cigarettes (88). No difference 
in cigarette quit attempts was found with ever use of HTPs.
PMI and independent data suggest that IQOS will attract adolescent and 
young adult non-users to initiate tobacco use (3). In Italy, marketing led to an 
increase in IQOS use, with an intent to use IQOS among non-smokers and long-
term former smokers (6,89). According to the FDA (5),
Certainly, the potential for rapid uptake of a novel tobacco product among 
youth exists. In the decade since e-cigarettes were introduced to the U.S. 
market, youth use rose rapidly but the limited flavour choices may reduce 
IQOS’ appeal to youth. The limited options in terms of flavour choice and 
the price of the IQOS device may reduce the appeal to youth.
Evidence from Japan indicates that younger (< 30 years), wealthier people adopt 
IQOS (90), and emerging evidence from Canada, United Kingdom (England) and 
the USA suggests that HTP have at least some appeal for young adults, including 
non-smokers (91,92).
3.5.2 Implications for public health
HTPs have probably become popular in some markets because of factors 
such as their marketing as a “clean”, modern, elegant, reduced-harm product. 
Factors that enhance their attractiveness appear to be sensory attributes, ease of 
use, cost, reputation and image and perceived risks and benefits. While HTPs 
suppress the urge to smoke, they are generally considered less satisfactory than 
cigarettes; however, different flavours are available, and this is known to be an 
attractive feature of tobacco and related products. Users find the fact that they 
create less ash and smell appealing and may use them indoors for that reason. 
Other attractive features include their marketing as an exclusive, modern and less 
harmful product suitable for smoking cessation. The product is, however, often 
considered to be less easy to use than cigarettes, and cost may be a barrier.
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With regard to addictiveness, currently marketed HTPs deliver signifi-
cant levels of nicotine in aerosol, and their pharmacokinetics, drug and subjec-
tive effects are similar to those of contemporary ENDS products, suggesting com-
parable abuse liability. Little information is available on how these features affect 
consumer perception and use, including initiation, switching, complementing 
and quitting conventional tobacco products. Industry studies show that the main 
predictors of adoption are liking of the smell, taste, aftertaste and ease of use. 
The only independent study that explored reasons for use and continuation and 
discontinuation of IQOS among smokers and ex-smokers found that the six im-
portant factors were: health, cost, enjoyment and satisfaction, ease of use, use 
practices and social aspects.
As described above, the vast majority of current IQOS users are current 
or ex-smokers, and most are dual users of HTPs and conventional cigarettes, 
with no intention to quit smoking cigarettes. Hence, the expected reduction in 
exposure to smoking-related toxicants will be much smaller than if they switch 
completely, and the reduction in risk, if any, will probably be much lower. For 
dual users, any risk reduction would be smaller than for people who switched 
completely, and reduced risk has not been proven even for complete switchers. 
Although few users of HTPs are never users or ex-users of cigarettes, their 
potential interest in HTPs is still a risk at population level, especially for never 
users. The history of e-cigarettes shows that any new tobacco or related product 
coming onto the market quickly becomes popular. Knowledge of e-cigarettes 
indicates that the factors of concern with regard to HTPs, and therefore potential 
regulation, are nicotine levels and “throat hit”, flavour variety, marketing and 
perception of reduced harm. Furthermore, like e-cigarettes (85), HTPs could be 
a gateway towards cigarette smoking.
3.5.3 Research gaps, priorities and questions
 ■ There is almost no information on perceptions and reasons for using 
HTPs among users, ex-users, smokers, dual users and never users of 
tobacco and related products. Only one independent study addressed 
the reasons for use, continuation and discontinuation of IQOS among 
smokers and ex-smokers.
 ■ There is also little information on how the attractiveness of HTPs af-
fects consumer perception and use, including initiation, switching, 
complementing and quitting conventional tobacco products.
 ■ There is no information on whether HTPs could be a gateway to use 
of combustible tobacco.
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Most independent studies on HTPs have focused on emissions and toxicity 
rather than attractiveness and addictiveness. Instead of trying to reproduce PMI 
emission data and claims of assessing reduced harm, researchers should study the 
actual trajectory of smokers, never smokers and ex-smokers to initiating use of 
HTPs and the role of appealing product characteristics.
Additional independent research should be conducted on all the features 
that enhance the attractiveness and addictiveness of HTPs described in this 
paper. The studies should include:
 ■ sensory studies, including the roles of flavourings and flavours and 
other attractiveness-enhancing content and additives, such as sugars 
and humectants, in the use of HTPs;
 ■ behavioural studies, both qualitative and quantitative, on knowledge, 
attitude and risk perceptions, including health messages;
 ■ studies on all the features that enhance attractiveness and addictive-
ness in relation to consumer perception and use, with, preferably, 
groups of smokers, dual users, HTP users and never users, ideally 
in longitudinal quantitative studies that include use of other types of 
tobacco and related products to establish the impact of several fea-
tures of perception of different types of tobacco products and to study 
transitions from e.g. current or never smoking to HTP use or even to 
combustible tobacco products; and
 ■ studies on the pharmacokinetics of use of HTPs other than IQOS, to 
establish patterns of use and nicotine delivery under real conditions.
3.5.4 Policy recommendations
Policy-makers might consider adopting regulatory principles that have been 
applied successfully to tobacco and related products in many jurisdictions in 
order to minimize product appeal and uptake among young people, increase 
product safety and minimize false beliefs about health with regard to HTPs. They 
should thus consider the following measures, with a focus on protecting young 
people and non-users.
 ■ Ban sale to minors, price promotions, flavours that appeal to young 
people and flavour capsules; limit marketing at points of sale and 
elsewhere; and introduce plain packaging to minimize the appeal of 
HTPs and their uptake by young people.
 ■ Ensure that the public is not misled by their appeal and by claims 
from the manufacturers but is well informed about the risks of 
HTPs, including the risk of dual use with cigarettes and use during 
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pregnancy; correct false perceptions, counter misinformation, and 
clarify that reduced exposure does not necessarily mean reduced harm.
 ■ Monitor the prevalence of use and user profiles; establish or extend 
surveillance of the product and users, including demographics, use 
of other tobacco and related products, devices, brands, types and fla-
vours used.
3.6 Conclusions
HTPs have become popular in some markets probably because of a combination 
of factors, including their marketing as a “reduced risk”, “clean”, modern, 
elegant product. Their sensory properties and ease of use are generally rated 
lower than those of conventional cigarettes but are important dimensions of 
their attractiveness, thus determining their uptake. Little is known about how 
these features affect consumer perceptions and use. Factors such as packaging, 
labelling, risk communication, price and smoke-free policies appear to influence 
initiation and use.
Currently marketed HTPs deliver significant levels of nicotine in aerosol, 
and their pharmacokinetics and drug and subjective effects are similar to those of 
contemporary ENDS products, suggesting comparable abuse liability. The history 
of e-cigarettes has shown that any new tobacco or related product coming onto 
the market may quickly become popular. Knowledge about e-cigarettes indicate 
that the factors of concern with regard to HTPs – and therefore potential aims of 
regulation – are nicotine levels and “throat hit”, variety of flavours, design of the 
devices, marketing and a perception of reduced harm.
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Abstract
Heated tobacco products (HTPs) have attracted interest in the past few years 
and are now available on approximately 50 markets. The interest is attributed 
to factors that include aggressive marketing by manufacturers, users’ perception 
that HTPs represent a “safer alternative” to other smoked products, their 
capacity to deliver nicotine to users, the variety of flavours, including tobacco 
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and menthol, technological advances and the variety of products and product 
features from which users can choose. The wide variation among the products, 
devices and their features result in the delivery of different levels of nicotine and 
toxicants, which has important regulatory implications. It is therefore important 
to understand how HTPs differ and how the differences affect the emissions of 
nicotine and other toxicants in order to formulate effective regulatory strategies 
and policies. The aim of this paper is thus to describe variations among the HTPs 
on the market in their characteristics and design features and how those features 
influence product toxicity, appeal and implications for regulations.
4.1  Background
4.1.1  Overview
HTPs are an emerging class of “potentially reduced exposure products” promoted 
by manufacturers as associated with “reduced risk”, as “cleaner alternatives” and 
as “smoke-free” products. The concept of these products proceeds from the 
principle that most of the harm associated with tobacco smoking is from the 
combustion process. In a conventional tobacco cigarette, the temperature of the 
burning cone can reach up to 900 °C, with a median temperature across the rod 
of 600 °C (1). This leads to myriad thermal reactions, including combustion, 
pyrolysis and pyrosynthesis, that result in the > 7000 compounds identified in 
tobacco smoke (1). As burning tobacco is ultimately unnecessary to aerosolize 
nicotine (although it is efficient), alternative means for liberating nicotine 
from tobacco in an inhalable form have been explored; these might modify the 
toxicological risk associated with conventional tobacco cigarettes and influence 
consumer acceptability, which the earlier generation of these products failed to do.
4.1.2  Decision FCTC/COP8(22) of the Conference of the Parties
This paper was commissioned by WHO to address a component of the request 
to the Convention Secretariat in paragraph 2 of decision FCTC/COP8(22) by 
the Conference of the Parties to the WHO Framework Convention on Tobacco 
Control (WHO  FCTC) at its eighth session, on novel and emerging tobacco 
products to address key topics related to those products and to submit a 
comprehensive report.
4.1.3 Scope and objectives
This report contains reviews of research on variations among novel and 
emerging HTPs and examination of the findings in the context of relevant 
aspects of the request. To the extent possible, the paper includes descriptions of 
the characteristics and design features of different types of HTPs, their contents 
and emissions, product diversity, market distribution and manufacturers and 
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discussion of the evidence for implications for users, non-users and regulators. 
Research gaps and priorities, some key questions and some recommendations for 
policy-makers are identified.
4.2 Variations among products on the market
4.2.1 Overview of product categories and types
HTPs have a different operating system from those of electronic nicotine 
delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS) 
(Table 4.1). HTPs contain a source of heat, which heats tobacco and vaporizes 
the tobacco constituents into an inhalable nicotine-containing aerosol, which 
contains other toxicants. Although HTPs contain tobacco material (as opposed 
to liquid in ENDS), they differ from conventional tobacco cigarettes, which must 
be combusted to create and deliver an aerosol to the user. HTPs do not achieve 
high temperatures during combustion and therefore aerosolize the nicotine from 
tobacco at a lower temperature (contemporary HTPs operate at < 350 °C) than 
conventional tobacco cigarettes (800  °C) (2,3). Like ENDS, they are products 
that are purported to emit smaller amounts of toxicants than in the smoke from 
conventional cigarettes.
Table 4.1. Product performance characteristics and primary ingredients of heated tobacco products (HTPs), 
tobacco cigarettes and electronic nicotine delivery systems (ENDS)
Characteristic Tobacco cigarettes HTPs ENDS
Nicotine Yes Yes Yesa
Tobacco Yes Yes No (nicotine derived mainly 
from tobacco)
Combustion Yes No (potential risk of incomplete 
combustion)
No (risk of thermal degradation 
of ingredients in the nicotine 
solution)
Temperature Yes (very high during puffs) Yes (generally lower than in 
tobacco cigarettes; may be 
overheated)
Yes (generally lower than in 
tobacco cigarettes; may be 
overheated)
Electronic system No Yes Yes
Example of product
a Electronic non-nicotine delivery systems (ENNDS) do not contain nicotine.
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HTP systems have three common components: an insert (such as a stick, capsule 
or pod) that contains processed tobacco; a means for heating the tobacco (battery, 
carbon tip or aerosol); and a charger for electrically heated devices. Manufacturers 
have used four basic design approaches to HTPs that could serve as a useful basis 
for product classification. They differ in how the tobacco material is heated and 
whether it is separated from the heating element (Table 4.2).
Table 4.2. Classification of heated tobacco products according to the tobacco heating mechanism
Key characteristics Examples of products
Integrated heating element Premier, Eclipse, PMI “Platform 2” (TEEPS)
External heating element with specialized “cigarettes” Accord, Heatbar, IQOS, glo
Hybrid devices: “vapour” plus tobacco; indirect heating iFuse, PloomTECH
Heating chamber for loose tobacco material PAX
The first and arguably the oldest type is a cigarette-like device with an embedded 
heat source that can be used to aerosolize nicotine (HTP type 1). The second 
approach is use of an external heat source to aerosolize nicotine from specially 
designed cigarettes (HTP type 2). This is the basic design of the Philip Morris 
International (PMI) IQOS (and its progenitors Accord and Heatbar) and the 
British American Tobacco (BAT) glo. For regulatory purposes, these represent 
two classes, one based on the heating device and the other on tobacco-containing 
sticks. Sticks generally meet the World Customs Organization classification of a 
cigarette (roll of tobacco in paper; harmonized system 2402.20). In the USA, the 
IQOS device is regulated as an accessory by the Food and Drug Administration 
(FDA) (much like ENDS, ENNDS and waterpipes), while the HeatSticks meet the 
statutory definition of cigarettes (4). A third approach is to use ENDS technology 
to derive nicotine and tobacco flavour from small amounts of tobacco (HTP 
type 3). BAT’s iFuse product appears to be a hybrid ENDS–tobacco product, 
in which the aerosol is passed over tobacco before reaching the user. Japan 
Tobacco International’s (JTI) PloomTECH operates similarly, except that the 
solution from which the aerosol is created appears not to contain nicotine. A 
fourth approach is use of a heated sealed chamber to aerosolize nicotine directly 
from loose tobacco (HTP type 4). This class is represented by personal dry-herb 
vaporizers such as PAX, which have been marketed mainly for use with cannabis 
but can also aerosolize nicotine from tobacco. In the USA, since at least the 1970s, 
tobacco companies have been interested in marijuana and its legalization as both 
a potential and a rival product. Heating devices such as HTPs could be used with 
inserts containing marijuana and marketed for use with cannabis.
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4.2.2 Variations among heated tobacco products
The concept of heating rather than burning tobacco emerged in the 1980s from 
the tobacco companies Philip Morris and RJ Reynolds in the USA, with Accord 
and Premier, respectively. These products and conceptually similar ones have 
continued to evolve and may now be poised to capture a significant market share. 
The introduction, aggressive marketing and growing popularity of ENDS may 
have set the conditions for these products to succeed, in part by changing social 
norms and perceptions of cigarette smoking and of devices that deliver nicotine. 
Strategies similar to those for promoting ENDS and ENNDS have been used 
for aggressive promotion and marketing of HTPs, and these products are now 
available in about 50 countries with plans for expansion to other markets.
4.2.3 Market distribution of product types and categories
Owing to declining sales of cigarettes, increased awareness of the health risk of 
smoked tobacco, increasing implementation of the WHO FCTC and the recent 
commercial success of ENDS and ENNDS, tobacco companies have reintroduced 
HTPs on the global market. Even as their usefulness for public health remains 
unclear, the marketing strategies of PMI, BAT and JTI are based on claims that 
the products reduce harm. Each of those companies has launched new-generation 
HTP brands in several countries since 2014 (5). The international HTP market 
was valued at US$ 6.3 billion in 2018 (6), with substantial market growth forecast 
over the next few years (7). HTPs have attained a significant share of the tobacco 
market, particularly in Japan. Reports from market analysts indicate that Japan 
has the best-developed HTP market in the world, accounting for 85% of HTP sales 
in 2018 (6), and tobacco inserts for PMI’s primary HTP brand (IQOS) comprised 
17% of all tobacco sales in July–September 2019 (8). Table 4.3 shows product 
and pricing information for the three main HTPs in Japan. In the Republic of 
Korea, IQOS and domestic HTPs (KT&G, lil®) were launched simultaneously 
in 2017 (9). HTPs are also gaining popularity elsewhere. BAT reported that its 
HTP brand, glo, had at least a 5% share of national tobacco markets in Poland, 
Romania and Serbia in June 2019 (10). IQOS has been retailed online and in 
selected metropolitan shops in the United Kingdom (England) since December 
2016 and in Canada since April 2017, while BAT launched glo in Vancouver, 
Canada, in May 2017. Early data suggest that, in both countries, awareness of 
HTPs was limited and uptake negligible 3–6 months after entry of HTPs to the 
market, and BAT halted glo sales in Canada in September 2019 (11). Nevertheless, 
since 2018–2019, PMI has reported revenue increases of 92.5% in the United 
Kingdom (England) and 44.2% in Canada in their so-called “reduced risk” 
product line (including IQOS) (7), suggesting that demand for HTPs is growing. 
In stark contrast, the sale of HTPs is effectively barred in Australia (12), banned 
in a few other countries, including India, Saudi Arabia and Singapore, and, 
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until recently, the USA prohibited sales of IQOS, glo and other contemporary 
HTPs. In April 2019, however, IQOS and three varieties of “HeatSticks” were 
authorized for sale as tobacco products (13), with other HTP brands expected 
to follow suit. On 7 July 2020, the FDA authorized IQOS as a “modified risk 
tobacco product” after an assessment of scientific studies that indicated 
that switching completely from conventional cigarettes to the IQOS system 
significantly reduced exposure to harmful or potentially harmful chemicals (14).
Table 4.3. Product and pricing information for the three most popular heated tobacco products in Japan
IQOS glo Ploom TECH
Device image
Manufacturer Philip Morris International British American Tobacco Japan Tobacco International
Launched November 2014 December 2016 March 2016
Type of tobacco insert Stick Stick Capsule
Device generations 1st: IQOS
2nd: IQOS 2.4
3rd: IQOS 3 and IQOS 3 Multi
1st: glo
2nd: glo Series 2 and glo 
Series 2 Mini
1st: Ploom TECH
2nd: Ploom TECH+ and 
Ploom Sa
Brand name of insert Marlboro Heatsticks Kent Neostick Mevius for Ploom TECH
Flavours of inserts Balanced Regular, Menthol, 
Mint, Purple Menthol, 
Smooth Regular 
Bright Tobacco, Citrus Fresh, 
Dark Fresh, Fresh Mix, Intense 
Fresh, Refreshing Menthol, 
Regular, Rich Tobacco, 
Smooth Fresh, Spark Fresh, 
Strong Menthol 
Brown Aroma, Cooler Green, 
Cooler Purple, Red Cooler, 
Regular
Priceb IQOS 2.4: ¥ 7980 (~US$ 76)
IQOS 3 Multi: ¥ 8980 
(~US$ 85)
Marlboro Heatsticks: ¥ 500 
(~US$ 4.73)
glo: ¥ 2980 (~US$ 28)
glo Series 2: ¥ 2980 (~US$ 28)
glo Series 2 Mini: ¥ 3980 
(~US$ 38)
Kent Neostick: ¥ 420 
(~US$ 3.97)
Ploom TECH: ¥ 2980 (~US$ 
28)
Ploom TECH+: ¥ 4980 
(~US$ 47)
Ploom S: ¥ 7980 (~US$ 76)
Mevius for Ploom TECH: ¥ 490 
(~US$ 4.64)
Source: reference 15.
a Has a stick instead of a capsule.
b In comparison, the price of a pack of conventional cigarettes is approximately ¥ 500 (about US$ 4.73). 
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4.3 Characteristics and design features of products
4.3.1 Temperature profiles of products and operational capabilities
In PMI’s IQOS, the tobacco stick (“HeatStick”) is heated by a blade inserted into 
the end, so that the heat dissipates through the tobacco plug on a puff (2). The 
aerosol then passes through a hollow acetate tube and a polymer-film filter on the 
way to the mouth. The product is designed not to exceed 350 °C, at which point the 
energy supplied to the blade is cut off. BAT describes its glo product as a heating 
tube consisting of two separately controlled chambers, which are activated by the 
user by a button on the device, and reach an operating temperature of 240 °C, 
within 30-40 s (3). BAT’s iFuse product appears to be a hybrid HTP, which has 
a liquid component but also contains tobacco; it passes the aerosol generated 
from the liquid over tobacco before it reaches the user. One study indicated a 
small heat loss in the aerosol when it is passed over the tobacco chamber (from 
35 °C to 32 °C), implying some tobacco heating (16). The delivery of toxicants 
under machine-smoking conditions without the tobacco chamber is reported to 
be nearly identical to that from an ENDS, implying a minimal contribution of the 
tobacco. JTI’s PloomTECH operates in a similar manner, except that the solution 
used to create the aerosol appears not to contain nicotine.
4.3.2 Battery characteristics
Different sources of heat are used in different HTP devices, including electric 
energy from a battery and carbon tip that is lit with a match or lighter. Most HTPs 
have lithium ion batteries, which are rechargeable and are used in many products, 
such as laptops, mobile phones and electric cars. All lithium ion batteries operate 
in the same way: the ions flow, in a solvent, between two oppositely charged 
poles separated by a permeable thin sheet. The direction of the flow depends on 
whether the battery is charging or discharging. Generally, lithium ion batteries 
are considered safe, however, if the separator between the poles is breached, the 
poles short-circuit, causing an increase in temperature, which in turn causes the 
highly flammable electrolyte solvent to combust, with an explosion.
4.3.3 Properties of tobacco inserts, sticks and capsules
The sticks for PMI’s IQOS (45 mm long, 7 mm diameter) contain approximately 
320 mg of tobacco material, whereas a conventional cigarette is 84–100 mm long, 
7.5–8.0 mm in diameter and contains about 700 mg of tobacco material (17). The 
tobacco in IQOS appears not to be typical tobacco cut-filler but rather a reinforced 
web of cast-leaf tobacco (a type of reconstituted tobacco), which contains 5–30% 
by weight of aerosol-forming components such as polyols, glycol esters and fatty 
acids (17). This composition is advantageous as an aerosol-forming substrate for 
use with a heating system. A tobacco insert for BAT’s glo product is an 82-mm 
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long, 5-mm diameter stick inserted into the heating chamber. The stick consists 
of a tobacco rod, a tubular cooling section, a filter and a mouthpiece. It contains 
approximately 260 mg of reconstituted sheet tobacco with 14.5% glycerol as 
the aerosolizing agent (3). BAT’s iFuse product appears to be a hybrid, with a 
cartridge containing nicotine solution at a concentration of 1.86 mg/mL, with 
machine delivery of 20–40 µg/puff (16), and tobacco. It is, however, difficult to 
estimate the contribution, if any, of the tobacco in the iFuse device to the delivery 
of aerosolized nicotine, which the user inhales. JTI’s PloomTECH operates in 
a similar manner, except that the liquid ENDS-like component appears not to 
contain nicotine (Fig. 4.1).
Fig. 4.1. Tobacco sticks and capsules in different heated tobacco products
4.4  Content, emissions and general design of products
4.4.1 Content and emissions
Little is currently known about the individual ingredients and the emissions of 
HTPs products, and the health effects of many aerosolized constituents from 
tobacco and the other contents of the products, including humectants and 
additives, should be investigated to determine their effects on the health of users 
and non-users. HTP tobacco inserts often contain and emit toxicants, including 
cancer-causing chemicals, respiratory irritants and cardiovascular toxicants such 
as tobacco-specific nitrosamines, metals, volatile organic compounds, phenolic 
compounds, polycyclic aromatic hydrocarbons and minor tobacco alkaloids and 
organic solvents (18–21). Many of those chemicals are classified as carcinogens 
and as harmful and potentially harmful when inhaled. These toxicants are present 
in HTPs in various amounts, although typically at levels lower than those found 
in conventional cigarettes (Fig. 4.2).
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Fig. 4.2. Percentage decrease in yields of selected harmful chemicals in emissions from IQOS from those in 
smoke from conventional cigarettes
Source: reference 18.
A toxicological review by the FDA found lower levels of some harmful and 
potentially harmful constituents in IQOS aerosol than in smoke from 3R4F 
standard reference research cigarettes and commercially available conventional 
tobacco cigarettes; however, the FDA also found that 80 chemicals in HeatStick 
aerosols, including four that are possibly carcinogenic, are unique to IQOS or 
present at higher levels than in 3R4F smoke. Additionally, IQOS aerosol contains 
15 other chemicals that are possibly genotoxic and 20 more compounds generally 
recognized as safe for ingestion that have potential adverse health effects (22,23). 
The FDA Technical Project Lead Review concluded that “although some of the 
chemicals are genotoxic or cytotoxic, these chemicals are present in very low levels 
and potential effects are outweighed by the substantial decrease in the number 
and levels of harmful and potentially harmful chemicals found in conventional 
cigarettes” and that the presence of these chemicals does “not raise significant 
concerns from a public health perspective” (24).
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The risks associated with inhaling large doses of the humectants used in 
HTPs, e.g. propylene glycol and vegetable glycerine, are not well characterized, 
although they have been approved for use for other purposes. For example, 
propylene glycol is commonly used as an additive in foods and cosmetics, a 
solvent in pharmaceuticals, an antifreeze and as an ingredient of theatrical mist or 
fog. Studies of the health effects in theatre staff exposed to such mists concluded 
that massive, prolonged exposure results in irritation of the airways (25,26). 
Vegetable glycerine, although widely used in the food and chemical industry as 
a non-toxic additive, may pose risks as used in HTPs because they can generate 
toxic aldehydes (including formaldehyde, acetaldehyde, acrolein and acetone) at 
high temperatures, some of which are classified as carcinogens.
Some HTPs contain flavouring agents, including menthol and fruit 
(Fig. 4.3). (See also section 6.) Although most of the flavourings are also 
commonly used in foods and indoor fragrances, little is known about their health 
effects when inhaled. Use of flavours in HTPs is widespread and is often cited as 
the main reason for using each product (15). Flavours also reportedly play an 
important role in shaping consumer perceptions of emerging tobacco products, 
as their use is associated with experimentation or initiation of use (27). A wide 
range of flavours is available on the market, which include tobacco, menthol, 
fruity and coffee. Certain chemicals (e.g. vanillin, limonene, isoamyl alcohol) and 
classes of chemicals that are used to provide the taste and odour of these flavours 
have been associated with respiratory toxicity (28). Few studies have addressed 
the role of flavours in use of HTPs. There is also little information on whether 
smokers who initiate use of flavoured HTPs do so to substitute completely for 
conventional cigarette use or whether the same association is seen in countries 
with different regulatory environments for HTPs.
Fig. 4.3. Varieties of flavoured tobacco inserts, cartridges and capsules for heated tobacco products
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HTPs, as a product class, are exceptionally heterogeneous, with differences in 
the source of heat, heating elements and heating temperature. Each of these 
characteristics can influence the emissions of nicotine and non-nicotine toxicants 
and their delivery to users. Heating temperature in particular affects emissions 
of respiratory toxicants (including carbonyl compounds like formaldehyde, 
acetaldehyde and acrolein) that are generated by thermal degradation of 
humectants. Some HTPs may generate high levels of toxic chemicals.
4.4.2 Nicotine delivery
In most HTPs, nicotine is released from tobacco by heating the tobacco to a 
temperature that aerosolizes nicotine but may not achieve complete combustion 
of the plant material. In some hybrid HTPs, nicotine is present in the solution 
used to create inhalable aerosols. Volatilized nicotine that is not derived from 
combustion would, in principle, produce a less complex aerosol, with fewer 
toxic constituents than that from conventional tobacco cigarettes. Nicotine is 
not efficiently delivered as a gas; to deliver nicotine to a user’s lungs, an aerosol-
forming agent must be added to suspend nicotine on aerosol particles.
Nicotine is present in HTP aerosol in one of two forms: an unprotonated 
free base and a protonated salt. Nicotine is a weak base, and the fraction of any 
one form can be increased or decreased by altering the pH of the liquid. Free-
base nicotine is volatile, is absorbed more readily than the monoprotonated form, 
produces enhanced electrophysiological and subjective responses in humans and 
may therefore be more addictive (29). Free-base nicotine is, however, harsher on 
the throat than protonated nicotine when inhaled (29). Laboratory studies have 
shown that nicotine in IQOS aerosol is present primarily in a protonated salt 
form (20,30).
Nicotine is a pharmacologically active compound with a wide range 
of health effects. Although it can be used safely under controlled conditions 
in adults, it has been associated with various adverse health outcomes for the 
developing fetus, including fetal growth restriction, risk of preterm delivery and 
stillbirth, and may have effects on brain development during adolescence (31–
33). In addition, evidence suggests that nicotine poses a risk of acute toxicity or 
poisoning after ingestion of high doses (34,35).
4.4.3 Risk profiles
As HTPs have appeared on the tobacco marketplace only recently, scientific 
evidence of their toxicity and possible harm reduction potential, both biochemical 
and behavioural, is still accumulating. Industry-funded sources have reported 
reduced concentrations of toxicants in serum and urine after a complete switch 
from conventional cigarettes to HTPs (36–43), while independent studies have 
reported less cytotoxicity (44) and lower levels of tobacco-specific nitrosamines 
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after use of HTPs than after smoking conventional cigarettes, although the levels 
are higher than with ENDS (21). Unlike ENDS, HTPs contain tobacco and, 
therefore, if there is no combustion, are expected to expose users to numerous 
chemicals present in the tobacco material. Moreover, some tobacco constituents 
that would be completely burnt and decomposed during combustion may be 
present in emissions from HTPs. Thus, HTPs may deliver a unique chemical 
mixture with a distinct toxicity profile, and the potential benefits of reductions 
in exposure to selected toxicants might be replaced by new health risks. Side-
stream emissions and second-hand exposure are also a concern with HTPs. Some 
tobacco manufacturers claim that certain HTPs result in minimal side-stream 
exposure, whereas other studies show more substantial levels (45). This may 
depend in part on the design of each product.
In the studies of human exposure currently available (all conducted by 
manufacturers), IQOS appears to deliver fewer toxicants than cigarettes and may 
serve as an effective short-term substitute for cigarettes, as assessed by nicotine 
delivery and subjective effects. Published data on BAT’s HTPs are limited, although 
a study protocol for a randomized trial was published recently, suggesting work 
in this area by BAT. No published studies are available on JTI’s Ploom product. 
Recent studies have, however, suggested a high prevalence of concurrent use of 
HTPs with conventional cigarettes and/or ENDS (46–48). Studies on concurrent 
use of ENDS and conventional cigarettes did not generally show any significant 
reduction in exposure to tobacco-specific toxicants (49–51). Thus, it is unlikely 
that the exposure of dual users of HTPs and conventional cigarettes to toxicants 
is significantly decreased.
4.4.4 Regulatory implications of the contents of heated tobacco products
Introduction of HTPs into the current landscape of nicotine and tobacco products 
presents a regulatory challenge (see also section 3), as it is currently impossible to 
determine whether these products could play a role in reducing risk or harm to 
smokers. The variation in regulations on new and emerging nicotine and tobacco 
products among countries will probably affect nicotine content and emission, use 
of devices, uptake by non-smokers and substitution for conventional cigarettes 
among smokers. The differences in regulatory environments could also influence 
overall use and consumer behaviour by affecting the availability of these products. 
Thus, it is important to understand the nature of the emerging tobacco product 
market, including the diversity of HTPs and how they are used, to fully appreciate 
the impact of the regulatory environment, the potential implications of different 
types of devices on use and their potential harm.
HTPs are often not subject to mandatory manufacturing standards, 
resulting in minimal oversight to prevent inaccurate labelling of ingredients or 
the presence of toxic components. Although the commercial sensitivity of flavour 
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recipes may limit disclosure of constituents, especially for ingredients of natural 
origin, governments and health authorities should require reporting of HTP 
constituents to appropriate government agencies. Several constituencies have 
enacted policies to regulate both the manufacture and marketing of flavoured 
tobacco products, including HTPs, to reduce their public appeal and health 
impact; these include the European Union, Canada, Ethiopia and the Republic 
of Moldova (52). Some countries consider HTPs to be tobacco products, and 
the provisions that apply to other tobacco products apply also to HTPs. Various 
product standards may be imposed on HTPs by a regulatory body, such as 
maximum nicotine content and yields and thresholds for tobacco-related 
toxicants, heavy metals, pesticides, residual solvents, mould, yeast, mycotoxins 
and other chemical and biological impurities. Product standards for HTPs 
may also specify chemicals that are prohibited, including certain flavourings, 
colouring agents and sweeteners.
Regulators should also be alert to changes in the design and composition 
of a product. In a presentation to the Consumer Analyst Group of New York (53), 
PMI claimed that IQOS had been modified from the original Japanese design 
in 2014–2017 in its aesthetics, blade self-cleaning technology, improved user 
interface, faster charging, Bluetooth connectivity, an accompanying mobile 
application and use of colours to increase the appeal of the device. Thus, a 
product may change after its introduction, as seen in the tobacco industry’s 
practice of making minor adjustments to their cigarette products over time and 
among markets, such that a 2017 Marlboro is not necessarily identical to a 2010 
Marlboro, and a Marlboro sold in France is not necessarily the same as one sold 
in the USA. In addition, research on a product may be done not with the product 
currently available to consumers but with a prototype (or even a series of different 
prototypes). While this practice is not in itself nefarious, any differences in design, 
function or presentation between the studied and the marketed product should 
be established and if and how such differences might affect consumer use. In 
the USA, the FDA follows a marketing authorization pathway in which changes 
to a product must be reported and can be monitored, with greater scrutiny and 
requirements for changes that impinge on public health (e.g. changes to delivery 
of harmful constituents; substantial design changes). European Union Member 
States, in the Tobacco Products Directive, have similar provisions. Regulators 
in other countries should consider a similar requirement for notification and 
justification of changes to products.
4.4.5 Regulatory implications of emissions
Given that HTPs have been found to contain various toxicants, product testing 
and constituent analysis can indicate the potential exposure of consumers 
to chemicals of concern for health. New tobacco products could be tested at 
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independent laboratory facilities licensed for analytical testing. It is unclear 
whether the toxicants potentially emitted by HTPs differ among markets. For 
example, whether these products are covered by smoke-free legislation depends 
on the specific wording (53,54). The precautionary principle would support their 
inclusion in such regulations.
An additional concern with respect to emissions from HTPs is variation 
in the results reported by laboratories, which may result from use of differences 
in the analytical methods, the products tested and the puffing regimens used. For 
example, the puff duration for sampling aerosols may differ among laboratories, 
which will influence the toxicants emitted, as increasing the puff duration 
increases the mass of aerosol inhaled and exposes users to higher levels of 
toxicants. Other aspect of puffing protocols that may influence emissions include 
the number of puffs, flow rate and inter-puff intervals. Use of a standard puffing 
protocol designed for conventional cigarettes, such as those of the International 
Organization for Standardization or Health Canada (intense), could limit 
differences in results for emissions. A standardized puffing regimen may not, 
however, always be applicable, as the design of some products may limit it. For 
example, IQOS is designed to ensure the same puff duration and number of 
puffs as a cigarette, i.e. up to 14 puffs or 6 min of use. The puffing protocol may 
therefore be dictated by the device tested. This aspect of HTPs raises an additional 
challenge for designing regulations.
While the major ENDS and HTP companies sell their products worldwide, 
some smaller companies sell entire devices and device parts. For example, some 
tobacco inserts that are not manufactured by PMI can be used in IQOS devices 
(55,56). Tobacco sticks manufactured by Imperial Brands Plc in the United 
Kingdom for their Pulze HTP system also fit the IQOS device. Such combinations 
might yield toxicants different from those from the original product, due to 
changes in features such as electrical power. In general, combinations of products 
should be considered in designing regulations.
4.5  Variations among products, manufacturers and selling points
4.5.1 Manufacturers and selling points
Most current HTPs are manufactured and marketed by major transnational 
tobacco companies. While the distribution of HTPs is markedly unique, the 
inserts for HTPs are commonly sold at conventional retail outlets, and the 
devices are sold in specialty shops and online. The specialty shops therefore rely 
on a single product, and sales representatives explain the device, provide free 
cleaning of customers’ devices and propose a free trial of the product (Fig. 4.4). 
HTP specialty shops usually have clean, sleek, modern designs (like the aesthetic 
of an Apple outlet).
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Fig. 4.4. HTP shops in Japan and the Republic of Korea (2019)
4.5.2 Implications for customer pulling power
Cigarette smoking remains one of the leading causes of preventable morbidity and 
mortality worldwide, even as the prevalence of smoking continues to decrease in 
many countries. The main driver of the health consequences of tobacco smoking 
is inhalation of combustion by-products during use. Newer nicotine and tobacco 
products might therefore reduce health risks if smokers switch to exclusive use 
of products, with modified chemical and physical properties. The potential 
usefulness of HTPs for reducing harm has been examined. Industry data suggest 
that HTPs can serve as a long-term substitute in highly controlled settings 
(36–41). As noted elsewhere in this report, however, the issues should be addressed 
by independent research. There is also concern that “real-world” concurrent use 
of cigarettes and HTPs might prolong smoking behaviour, whereby smokers 
initiate HTPs according to the situation, rather than switching from smoking 
completely (57). Additionally, population studies in several Asian countries have 
found substantial use of other tobacco products with HTPs, raising concern about 
whether the products can replace conventional tobacco smoking or are rather 
used as complementary products (15,46–48,58). Large tobacco companies use a 
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variety of marketing strategies to promote HTPs to different sociodemographic 
groups, and differentiated marketing of cigarettes has disproportionately 
appealed to population subgroups such as adolescents and young adults, women, 
minorities and health-concerned smokers. (See section 10.)
Some concern has been raised about HTP users’ privacy and security 
and how their personal information is collected and handled by HTP devices 
and by tobacco companies. HTPs are the first tobacco products that can harvest 
personal data on users’ tobacco habits. PMI is already building a database of 
IQOS customers who register with the company (59). Some HTP devices, 
including PMI’s IQOS, are equipped with microcontroller chips that can store 
usage information and potentially transmit the information to the producer. 
The data could include details such as the number of puffs taken and how many 
times the user smoked the device in each day. The acquired data could potentially 
be used by tobacco industry in marketing. According to a statement by a PMI 
representative, the company extracts data from the device when investigating a 
malfunction (59).
4.6 Discussion
HTPs are battery-operated devices that deliver nicotine aerosolized from tobacco, 
as well as other toxicants, to users. They are an emerging class of “potentially 
reduced exposure products” promoted by manufacturers as “reduced risk”, 
“cleaner alternatives” and/or “smoke-free” products. HTPs have been marketed 
around the world with claims that they are less harmful than conventional 
cigarettes because they expose users to lower levels of some toxicants. There is, 
however, little evidence from independent studies on the chemistry of the aerosol 
produced by various types and brands of HTPs, the toxicology, effects on clinical 
measures, perceptions of the product and its packaging and behavioural factors.
HTPs present numerous regulatory challenges. The amounts of nicotine 
and non-nicotine toxicants depend on product features such as the composition 
of the tobacco insert, the temperature to which the heating element can rise and 
device design and characteristics. Understanding how these features influence 
important product characteristics such as temperature and emissions of nicotine 
and non-nicotine toxicants is essential for designing effective regulations and 
limiting the toxicity of these products. There is currently wide variation among 
the devices on the market, and users can control many of the devices’ features 
that affect emissions, including those of numerous harmful chemicals, such 
as aldehydes, metals, volatile organic compounds and reactive oxygen species. 
As HTPs may emit chemicals that are not present in conventional cigarettes, 
chemical assessment of emissions from HTPs should go beyond those found in 
cigarette smoke. Additionally, the technology of HTPs is evolving rapidly, with 
new, more advanced devices constantly entering the market. These devices may 
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have new features that could increase the levels of toxicants in emissions. Keeping 
track of the HTPs on the market and of any new features they may have will allow 
assessment of how the new features affect the emissions of aerosol toxicants and 
therefore users’ health.
An important concern is that HTPs could increase concomitant use of 
other tobacco products. Although industry data suggest that HTPs could be used 
as a long-term substitute in highly controlled settings, there is concern that “real-
world” concurrent use of cigarettes and HTPs might prolong smoking behaviour, 
whereby smokers initiate HTPs for use according to the situation rather than 
switching completely from smoking. Current smokers may not understand 
that “switching completely” means that they would have to quit conventional 
cigarettes to achieve any claimed health benefits of HTPs. According to WHO, 
however, “quitting” is complete cessation of tobacco use for at least 6 months with 
no use of cessation aids. As HTPs are tobacco products, conversion from use of 
conventional cigarettes to HTPs would not constitute cessation (60). Currently, 
there is no information on how HTPs affect smokers’ intentions to quit smoking.
4.7 Conclusions
 ■ HTPs are an emerging class of “potentially reduced exposure prod-
ucts” promoted by manufacturers as “reduced risk”, “cleaner alterna-
tives” and/or “smoke-free” products.
 ■ HTPs, as a product class, are exceptionally heterogeneous, differing in 
materials, configuration, content of tobacco inserts and temperature 
to which the heating element can rise. Each of these characteristics 
can influence emissions of nicotine and non-nicotine toxicants.
 ■ HTPs contain and emit nicotine.
 ■ HTPs emit numerous toxic chemicals, including tobacco-specific ni-
trosamines, aldehydes and metals, although exclusive users of those 
products appear to be exposed to lower levels of toxicants than ciga-
rette smokers.
 ■ Unlike ENDS, HTPs contain tobacco and are therefore expected to 
expose users to numerous chemicals present in the tobacco material.
 ■ HTPs may emit chemicals that are not present in conventional ciga-
rettes.
 ■ While HTPs may expose users to lower levels of some toxicants than 
cigarettes, they might expose them to higher levels of other toxicants.
 ■ As these products have been introduced recently into the tobacco 
marketplace, scientific evidence on their toxicity and long-term 
health effects is still accumulating.
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 ■ Although the public health utility of these new tobacco products re-
mains unclear, tobacco companies are extensively using marketing 
strategies based on potential harm reduction.
 ■ Although industry data suggest that HTPs could be used as a long-
term substitute in highly controlled settings, independent popula-
tion-based studies have raised concern that “real-world” concurrent 
use of cigarettes and HTPs might prolong smoking behaviour.
4.8 Research gaps, priorities and questions
Research conducted independently of the industry is required to inform product 
users, public health professionals and regulatory agencies about the potential 
public health impact of HTPs. As the tobacco marketplace continues to evolve 
in various regulatory environments, it is vital to assess trends in awareness and 
use of HTPs.
The chemical profile and toxicity of all emerging tobacco products, 
including HTPs, must be thoroughly investigated. It is important to understand 
where these products are positioned along the continuum of risk relative to 
conventional cigarettes, ENDS and other smoked tobacco products.
Studies of the prevalence of use and of substitution for tobacco cigarettes 
are limited. Many of these products were test-marketed in a single country or 
small geographical region. Thus, it can be difficult to predict the uptake of novel 
products, particularly among young people. The characteristics of current and 
potential users of new tobacco products should be considered in assessing their 
potential public health impact. The concept of a continuum of harm is often 
based on the toxicity profile of a product as compared with cigarette smoke, with 
less attention to the characteristics of users and other important factors.
It is important to understand whether HTPs could play a role in reducing 
the risks to smokers by reducing their exposure to certain toxic chemicals as 
compared with conventional tobacco smoke. They might either reduce the risk of 
smokers or impose serious risks to health. How this balance is viewed depends 
on the context.
4.9 Policy recommendations
Key recommendations
 ■ Tobacco companies should be required to investigate the chemical 
profile and toxicity of all HTPs. HTP manufacturers should disclose 
the findings of product testing and provide detailed descriptions of the 
testing methods used to the appropriate regulatory agencies. The effects 
of the combination of factors in the product should be investigated.
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 ■ Policy-makers should continuously monitor the market to identify 
new HTPs and similar products and changed features of products 
and emissions. Changes to an existing product must be reported to 
regulatory agencies so they can be monitored, with greater scrutiny 
and requirements for changes that affect public health (e.g. changes 
to the delivery of harmful constituents; substantial design changes).
 ■ New or modified products should be subjected to premarket review 
by appropriate regulatory agencies before marketing. All HTP com-
ponents should be regulated as stringently as other tobacco products, 
including restrictions on labelling, advertising, sales to minors, price 
and taxation policies and smoke-free measures.
Other recommendations
 ■ Research independent of the tobacco industry should be conducted 
to inform product users, public health professionals and regulatory 
agencies of the potential public health impact of HTPs and to assess 
trends in awareness and use of HTPs.
 ■ The chemical profile and toxicity of all emerging tobacco products, 
including HTPs, should be established.
 ■ Studies of the prevalence of use and of substitution for tobacco ciga-
rettes should be conducted in several marketplaces, with considera-
tion of the characteristics of current and potential users of newer to-
bacco products and assessment of the potential public health impact 
of the products.
 ■ Carefully designed, independent studies should be conducted to un-
derstand the toxicity profile of the chemicals emitted from HTPs in 
order to assess the risks of smokers relative to those of non-smokers 
and smokers of conventional cigarettes. Such evaluations should ad-
dress differences in prevalence, user behaviour and the population 
risk of other tobacco products.
 ■ The privacy and security of HTP users should be protected. The col-
lection and handling of personal information on HTP devices and by 
tobacco companies should be regulated.
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Abstract
New-generation heated tobacco products (HTPs) are claimed by their 
manufacturers to assist smokers of conventional tobacco products to quit and 
switch completely to HTPs as a “safer alternative” source of nicotine. Concurrent 
use of two or more nicotine or tobacco products (poly use) consists of various 
types of behaviour, with heterogeneous frequencies of product use and different 
health risks, influenced by user characteristics. The capacity of newer-generation 
HTPs to substitute completely for conventional cigarette use is likely to depend 
on product features and on the characteristics of smokers, including experience, 
preparedness to switch to and use HTPs for a long time and perhaps the tobacco 
control regulatory environment. We reviewed literature on HTP use in both 
the laboratory and real-world contexts. Contemporary HTPs appear to deliver 
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nicotine in pharmacologically meaningful doses in a similar manner to cigarettes 
or ENDS. Emerging independent studies indicate that poly use of cigarettes and 
HTPs is more common than implied by initial industry-sponsored studies. Little 
information is available on transitioning from cigarette smoking to HTPs, but 
the evidence suggests that smokers who use HTPs are more nicotine-dependent. 
Research is required on awareness about HTPs and the use behaviour in countries 
in which they have been introduced, including national surveys in the countries in 
which the products are available. Where their sale is permitted and the distinction 
is legally meaningful, HTPs should be considered as cigarettes rather than 
ENDS for the purposes of smoke-free laws, taxation, marketing and purchase.
5.1 Introduction
New-generation heated tobacco products (HTPs) are claimed by their 
manufacturers to assist smokers of conventional tobacco products to quit 
and switch to HTPs as a “safer, alternative” source of nicotine. This paper was 
commissioned by WHO to explore the potential role of HTPs in transitioning 
from conventional cigarettes (CCs) and other tobacco products. In particular, we 
addressed whether, as with use of electronic nicotine delivery systems (ENDS) and 
electronic non-nicotine delivery systems (ENNDS), the marketing of HTPs leads 
to significant concurrent use of HTPs and CCs or additional tobacco products 
and if dual or poly use with HTPs helps or prevents smokers of conventional 
tobacco products in switching completely to HTPs. As regulators are pressured 
by industry to apply more lenient regulations to HTPs than to other tobacco 
products, claims that these products are “reduced risk” or can help “smokers” to 
switch to other products must be carefully evaluated.
The difficulty in responding to these questions is due to the paucity of 
information on the use of HTPs at population level, whether the use is mainly dual 
or poly use and the health effects of such use. Data on exposure from exclusive or 
poly use are limited. Secondly, we found no empirical studies on whether HTPs 
can transition cigarette smokers completely from smoking (smoking cessation) 
or nicotine use (nicotine cessation); therefore, it is not possible to explore the 
relation between cigarette smoking cessation with HTPs among exclusive HTP 
users or poly users. Finally, no studies have been reported on cessation of HTPs 
per se.
5.2 Information on HTP use at population level
Table 5.1 summarizes the 13 studies found on the prevalence of HTP use (1–13), 
half of which describe experience of use of these products in Japan. Studies are 
available from only six countries between 2015 and 2019. All the data are from 
studies conducted at one time, except for one study in United Kingdom and one 
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in Japan. Therefore, except for the United Kingdom, it is difficult to establish any 
trends in the use of HTPs in the general population. According to the most recent 
studies, in 2018 and 2019, about 3% of the adult population in Japan currently 
uses HTPs, with far lower numbers in the United Kingdom (England) and Poland. 
The studies do not provide any real sense of the frequency of dual use of HTPs 
and cigarettes or other smoking products (cigars, bidis, hookahs).
Table 5.1. Prevalence of HTP use (2015 – 2019): studies by country and year of data collection
Year Germany Italy Japan Poland Republic of 
Korea
United 
Kingdom
2015 Adults aged 
15-69a
IQOS, current 
use, 0.3%
Ploom, current 
use, 0.3%
Adults aged 
16-69b
HTP, ever use, 
0.5%
HTP, never 
smokers, 0.1%
HTP, former 
smokers, 1.0%
HTP, current 
smokers, 1.8%
Adult patients 
with NCDs aged 
40–69c
HTP, ever use, 
♂1.7% ♀ 0.6%
HTP, current 
HTP use, ♂ 0.8% 
♀ 0%
2016 Adults aged 
15–69a
IQOS, current 
use, 0.6%
Ploom, current 
use, 0.3%
2017 Current smokers 
and recent 
ex-smokers aged 
≥ 14d
Current HTP use, 
0.3%
Adults aged 
≥ 15e
Ever tried IQOS, 
1.4% 
Adults aged 
15–69a
IQOS, current 
usec 3.6%
Ploom, current 
use, 1.2%
glo, current use, 
0.8%
Young adults 
aged 19–24g
IQOS, current 
use, 3.5%
Adultsh
HTP, ever use, 
1.7%
Adultsf
Current IQOS 
use, 1.8%
English adultsi
Current HTP use
• Quarter 1, 0.1%
• Quarter 2, 0.1%
• Quarter 3, 0.1%
• Quarter 4, 0.1%
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Year Germany Italy Japan Poland Republic of 
Korea
United 
Kingdom
2018 Adultsf
Current IQOS 
use, 3.2%
Secondary 
school studentsk
HTP, ever use,
♂ 4.4% ♀1.2%
English adultsi
Current HTP use
• Quarter 1, 0.1%
• Quarter 2, 0.1%
• Quarter 3, 0.1%
• Quarter 4, 0.1%Adult population 
≥ 15j
Current HTP use, 
2.7%
Daily HTP use, 
1.7%
2019 Adults aged ≥ 15l
Current HTP use, 
0.4%
English adultsi
Current HTP use
• Quarter 1, 0%
• Quarter 2. 0.1%
• Quarter 3, 0.1%
• Quarter 4, 0.2%
HTP: heated tobacco product; NCD: noncommunicable disease.
a Prevalence of current HTP use (i.e. use in the previous 30 days) was calculated from a longitudinal internet survey of a nationally 
representative sample of 8240 Japanese individuals (15-69 years old in 2015) followed up to 2017 (1,2).
b Internet survey conducted between 31 January and 17 February 2015 among 7338 respondents aged 18–69 from a panel by 
Rakuten Research (3).
c Among 4432 Japanese patients with chronic diseases aged 40–69 years from an Internet survey in 2015 (4).
d Among 18 415 Germans over the age of 14 in a representative sample of people participating in a household survey between 
June 2016 and November 2017; 0.3% (95% CI = 0.09–0.64) of current tobacco smokers and new ex-tobacco smokers (< 12 months 
smoke-free) currently used HTPs. Use of HTPs increased with increasing education and income (5).
e Among a sample of 3086 people selected by multistage sampling to be representative of the general Italian population aged ≥ 15 
years and interviewed face-to-face (6).
f Of 4878 Japanese adults in 2017, 1.8% used IQOS. Of 2394 Japanese adults in the first half of 2018, 3.2% used IQOS. Of “platform 1” 
registered users, 1.3% and 1.6% in 2017 and 2018, respectively, were never smokers, and 98% in 2016 and 98.6% in 2017 were dual 
users with tobacco (7).
g Online survey in 2017 of 228 general young adults aged 19–24 years (8).
h Among a nationally representative sample of 12 696 adults aged ≥ 17 interviewed by the market research company YouGov Plc in 
Great Britain in February–March 2017 (9).
i From the Smoking Toolkit Study, a monthly household survey with a new representative sample of ~1800 English respondents 
aged > 15 each month. The fieldwork is conducted by the British Market Research Bureau. Cigarette smokers and recent ex-smokers 
(who smoked in the previous year) who agreed to be re-contacted are followed up 3 and 6 months later by postal questionnaire. 
The data on HTPs cover 63 499 adults since January 2017 (10).
j Among 4684 Japanese adult participants in a nationally representative Internet survey conducted in February–March 2018; 2.7% 
used HTPs at least once a month and 1.7% daily. Among current smokers, 1.8% used HTPs at least once a month and about 50% 
daily. Among never smokers, 0.02% used HTPs at least once a month, all of them daily (11).
k Among 60 040 adolescents attending secondary schools in the Republic of Korea as of April 2018, 4.4% of males and 1.2% of 
females ever used HTPs. About 6% were current smokers. Of these, 32.4% had ever used HTPs. Of the 86% never smokers, only 0.3% 
had ever used HTPs (12).
i Among a representative nationwide sample of 1011 people aged ≥ 15 in Poland in September 2019; 0.4% used HTPs, all of whom 
were current smokers, representing 1.9% of current smokers (13).
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5.3 Dynamics of switching from conventional cigarettes to HTPs: 
Is dual or poly use a transitional or permanent state?
Concurrent use of two or more nicotine or tobacco products (poly use) comprises 
many types of behaviour and heterogeneous frequencies of product use and 
health risks, influenced by user characteristics. In the USA, poly users of tobacco 
tended to be male, use other drugs and be more nicotine-dependent (14–23). 
Use of several tobacco products tends to be unstable over time (24–27). Table 5.2 
outlines some common definitions of poly use drawn from the published 
literature on ENDS and ENNDS.
Table 5.2. Types of poly use described in studies on tobacco and nicotine
Type of use Reported use Pros Cons
Lifetime poly use Ever use of two products or 
more in a lifetime
Broadest measure; captures 
a number of potential use 
patterns
Captures use that may have 
occurred years before or 
minimal experimentation 
that may have little impact on 
current behaviour or disease risk 
Recent poly use Use of two or more products in 
past 30 days
Captures contemporary use Does not account for quantity 
or frequency of use; one use 
of two products is considered 
equivalent to daily use of each 
product
Predominantly poly 
user
Use of two or more products in 
past 30 days, used one of the 
products more than the other, 
daily or nearly daily 
More comprehensive 
assessment of use pattern
Requires more questioning. 
Potentially subject to recall 
bias, particularly for the less 
frequently used product 
Balanced poly user Use of two or more products 
in past 30 days, in equivalent 
amounts, daily or nearly daily 
More comprehensive 
assessment of use pattern
Requires more questioning. 
Potentially subject to recall 
bias, particularly for the less 
frequently used product 
Intermittent poly user Use of two or more products in 
past 30 days on at least some 
days, but no consistent pattern 
of use of any product
More comprehensive 
assessment of use pattern
Requires more questioning. 
Potentially subject to recall 
bias, particularly for the less 
frequently used product 
While few studies are available on HTP poly use per se, studies of ENDS may 
be instructive. Borland and colleagues (28) analysed survey data from Australia, 
Canada, the United Kingdom (England) and the USA and described four 
subgroups of concurrent use of cigarettes and ENDS who differed in nicotine 
dependence, quitting behaviour and perceptions (28): 1) dual daily users, 2) 
predominantly smokers (who used cigarette daily and ENDS less than daily), 3) 
predominantly vapers (who used ENDS daily and cigarette less than daily); and 4) 
concurrent non-daily users (who used both cigarette and ENDS less than daily). 
While many concurrent cigarette–ENDS users report trying to reduce smoking 
(29,30), this claim tends not to be reflected in biomarkers of exposure (31,32), and 
reductions in cigarettes per day may not meaningfully reduce the risk of mortality 
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from smoking (33–36). A study by Baig and Giovenco (37) on dual use of ENDS 
and cigarettes suggests some probable transition pathways for different dual use 
behaviour. Broadly, dual users who had higher education or income were more 
likely to completely switch to e-cigarettes or to quit tobacco use over two years.
Currently, there is insufficient evidence to conclude that HTPs are less 
harmful than CCs. In fact, there is concern that, while they may expose users 
to lower levels of some toxicants than CCs, they expose users to higher levels of 
other toxicants (38–40). Studies indicate that up to 65% of HTP users in Japan 
and nearly all (96.2%) users in the Republic of Korea also smoked cigarettes 
(2,11,41–43). Sutanto and colleagues (44) analysed subgroups of poly users in 
Japan and found the overall distribution shown in Table 5.3.
Table 5.3. Proportions in four subgroups of concurrent users of HTPs in Japan, 2018
Weighted percentages (95% confidence interval)
 Daily HTP user (n=594) Non-daily HTP user (n=265)
51.5 (46.7–56.3)a 48.5 (43.7–53.3)a
Daily smoker (n=3686) Dual daily user Predominantly smoker
94.4 (91.9–96.2)b 51.0 (46.2–55.7) 43.4 (38.6–48.4)
Non-daily smoker (n=213) Predominantly HTP user Concurrent non-daily user
5.6 (3.8–8.1)b 0.5 (0.2–1.3) 5.1 (3.4–7.6)
Source: reference 44.
a Values shown are the sum of the overall column.
b Values shown are the sum of the overall row.
In 2018, most HTP users in Japan concurrently smoked cigarettes, and most 
used both products every day (44). While there was no difference between 
exclusive daily smokers and dual daily users in the number of cigarettes per day, 
predominant smokers reported smoking more cigarettes per day than exclusive 
daily smokers, and predominant smokers used fewer tobacco-containing inserts 
per day than dual daily users; exclusive HTP users used more tobacco-containing 
inserts per day than dual daily users. Apart from greater frequency of use, this 
suggests that HTPs may not effectively substitute for cigarettes, consistent with 
the data from the Republic of Korea (41). Cigarette–HTP users were younger 
than exclusive smokers, while a study of actual use in the USA found greater 
interest among middle-aged smokers (45). Novel and emerging tobacco products 
often appeal to younger users for various reasons, including a perception of lower 
risk, marketing messaging and imagery and product appearance (29,46–49). 
Only about 10% of concurrent cigarette–HTP users planned to quit smoking in 
the next six months. This finding is in contrast to that of Borland et al. (28) that 
50% of concurrent cigarette–ENDS users planned to quit but consistent with the 
findings of Baig et al. (37).
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British American Tobacco (BAT) reported one study on use of its glo 
product (50). Three groups took glo menthol, glo tobacco, glo and IQOS home 
for up to 14 days (with up to four laboratory visits). Participants reported using 
12–15 cigarettes per day at baseline and used 8–12 units per day of the glo and 
IQOS products.
An application by Philip Morris International (PMI) to the US Food 
and Drug Administration for registration of IQOS as a “modified risk tobacco 
product” included a series of observational studies conducted by PMI on product 
switching in Germany, Italy, Japan, the Republic of Korea, Switzerland and the 
USA (51). The study in the USA comprised 1106 current daily smokers who, 
after a 1-week baseline, were given access to IQOS (for free) for four weeks. The 
amount of product used (cigarettes and HeatSticks) was recorded in a diary. For 
this study, “switching” to IQOS was defined as using > 70% of total consumption 
as HeatSticks. About 15% of the participants met this definition by the end of the 
study, whereas 22% were dual users (30–70% of consumption as HeatSticks) and 
63% were primarily smokers. In a second study, the product and its associated 
marketing were offered to 2089 daily smokers in Germany, Japan, Poland, the 
Republic of Korea and the USA. The prevalence of complete switching to a tobacco 
heating system (THS) ranged from 10% in Germany to 37% in the Republic of 
Korea, while dual use ranged from 32% in Japan to 39% in the Republic of Korea 
at the end of the 4-week trial. A 90-day use study on IQOS was conducted in the 
USA in 2013–2014, in which 88 of the 160 enrolled completed the study. It is 
noted that compliance with abstinence was substantially less in this study than 
in a similarly designed study in Japan, suggesting that experiences in one context 
cannot be generalized to others.
Limited post-market data are presented in the PMI application for IQOS. 
Those that are available are primarily from Japan, drawing on PMI’s register of 
IQOS purchasers (51). The proportion of exclusive IQOS use (>  95% of total 
consumption) increased from 52% to 65% between January and July 2016. 
Markov modelling of the transition in two cohorts of IQOS purchasers in Japan 
(in September 2015 and May 2016) suggested that those who transitioned to 
exclusive IQOS use are unlikely to transition back to exclusive cigarette use.
The Tobacco Products Scientific Advisory Committee of the US Food and 
Drug Administration expressed concern about some of the evidence on IQOS, 
and particularly the definition of “complete switching” and limitations of studies 
of consumer understanding of the claim of modified risk. The Committee offered 
qualified support only for a claim of exposure modification and expressed concern 
that the claims as worded would not be effective in communicating risk (52).
In December 2017, the Committees on Toxicity, Carcinogenicity and 
Mutagenicity of Chemical Products in Food, Consumer Products and the 
Environment in the United Kingdom evaluated two HTPs on the market and 
concluded (53) that
106
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
02
9,
 2
02
1
WHO Study Group on Tobacco Product Regulation   Eighth report
… while there is a likely reduction in risk for smokers switching to “heat-
not-burn” tobacco products, there will be a residual risk and it would be 
more beneficial for smokers to quit smoking entirely. This should form 
part of any long-term strategy to minimize risk from tobacco use.
As few studies are available specifically on exposure to and the health effects of 
contemporary HTP poly use and are short-term, studies on older HTPs were 
evaluated. A study of an early-generation HTP (Accord) (54) analysed concurrent 
use with use of subjects’ own-brand cigarettes. After 6 weeks of use, Accord 
appeared to reduce cigarette smoking and exposure to carbon monoxide dose-
dependently, i.e. more use of Accord was associated with fewer cigarettes smoked, 
and participants did not appear to increased their puff intensity when they 
reduced the number of cigarettes per day. A study of an early-generation HTP, 
Eclipse, was reported by Fagerstrom and colleagues (55). After an initial 4-week 
randomized study, participants self-selected to use Eclipse (n=10), a nicotine 
inhaler (n=13) or cigarettes (n=13) for an additional eight weeks. At baseline, 
those who chose Eclipse smoked fewer cigarettes per day (18.0) on average than 
the other groups (20.4 for inhaler, 21.3 for cigarette). Over the 8 weeks, 30–60% of 
participants reported smoking no cigarettes at all, and an average of 2.6 cigarettes 
were smoked per day, with little change over time. Overall, the older literature 
suggests incomplete substitution of HTPs for cigarettes, which is generally 
not associated with a meaningfully lower health risk (56–58), rather than the 
complete switching on which HTP’s promotion of harm reduction is predicated.
5.4 Potential role of HTPs as a substitute for conventional 
cigarettes
PMI stated in January 2018 that “more than 3.7 million smokers outside the US 
have switched exclusively to IQOS in only two years. At the same time, non-
smokers and former smokers show very little interest in the product” (59). We 
were unable, however, to find any empirical study to substantiate this claim or 
any other with regards to use of new-generation HTPs to transition cigarette 
smokers from smoking. Some surveillance was conducted in the United Kingdom 
(England), where 0–1.4% of 4155 adults who smoked and tried to stop or who 
had stopped in the 12 months before the survey mentioned HTPs as a method for 
switching after 2016, depending on the quarter, with a median quarter prevalence 
of 0.4% (10).
The capacity of the newer-generation HTPs to substitute for use of CCs 
probably depends on product features, the characteristics of smokers, including 
their experience and their preparedness to switch to HTPs for a prolonged period, 
and perhaps the characteristics of the tobacco control regulatory environment. In 
the absence of direct empirical evidence of the potential efficacy and effectiveness 
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of HTPs in aiding switching, we used information on product features, such as 
their desirability and whether they deliver nicotine at a sufficient dose to reduce 
craving or withdrawal symptoms from CCs. The published studies of nicotine 
pharmacokinetics and evidence of the appeal of HTPs to smokers are described 
below, on the assumption that greater nicotine delivery and greater appeal might 
lead to greater substitution for cigarettes.
5.5 Exposure to nicotine and potential health risks among  
poly users
In this section, we compare use of HTPs with CCs among current smokers 
with regard to total nicotine delivered in mainstream emissions and key 
pharmacokinetics in plasma and urine.
Table 5.4 describes the 12 papers from 11 studies that we found up to 
January 2020 (60–71), of which five were carried out or funded by the tobacco 
industry. The table updates and expands on that of Simonavicius et al. (72). 
Comparison of the nicotine delivery in the aerosol of HTPs and the mainstream 
smoke of CCs is complicated by the variety of products and the methods used. The 
HTPs studied were IQOS (PMI), glo (BAT), iFuse (BAT) and a tobacco vaporizer. 
The reference products differed among studies. They included those developed 
for research, 3R4F 1R5F and 1R6F (most used 3R4F) and commercially available 
cigarettes, in which the yield of nicotine differs by brand, country and year. 
Mainstream emissions were obtained under the Health Canada Intense (HCI) 
regimen in most studies but with the International Standards Organization (ISO) 
regimen in others. It should be borne in mind that no machine-smoking regimen 
corresponds to human smoking and exposure, and their relevance to HTP use 
has not been validated. With these caveats, two conclusions can be reached from 
the studies.
 ■ IQOS delivers about 70% of the nicotine contained in the smoke of 
CC. The relative nicotine delivery of IQOS is 40.7–102.8% (median 
76.9%) when the reference is a commercial cigarette and 57–103% 
(median 64.7%) when the reference CC is one developed for research. 
The median in studies funded by the tobacco industry is not statisti-
cally significantly different from that in independent studies.
 ■ The other HTPs studies appear to be less efficient (< 50%) than IQOS 
in delivering nicotine as compared with CC.
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5.6 Pharmacokinetics in animals
We found only one study in experimental animals. In this independent research, 
Nabavizadeh et al. (67) exposed three groups of eight rats each to IQOS aerosol 
from a single HeatStick, mainstream smoke from a single Marlboro Red cigarette 
or clean air. Exposure was for 1.5–5 min in a series of consecutive 30-s cycles, 
each cycle consisting of 5 or 15 s of exposure. After exposure, serum nicotine 
was about 4.5 times higher in rats exposed to IQOS than in those exposed to 
cigarettes, even though the IQOS aerosol contained about 63% the amount of 
the nicotine measured in smoke. When exposure to IQO emissions was shorter, 
the serum nicotine was similar in rats exposed to IQOS and cigarette emissions.
5.7 Pharmacokinetics in people
In most of these studies, values for biomarkers were reported after use of HTPs, 
ENDS and CCs. We report only the pharmacokinetics of nicotine after use of 
HTPs and CCs. The methods are summarized in Table 5.5.
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Independent studies
Two independent studies were found, one conducted with IQOS and the 
other with a loose-leaf tobacco vaporizer from PAX. Biondi-Zoccai et al. (85) 
performed a randomized, cross-over trial to compare the effects on smokers of 
using one stick of IQOS, ENDS and one CC. Exposure to nicotine was evaluated 
by measuring serum cotinine before use, after a 1-week washout from any 
tobacco or nicotine product, and immediately after product use. Use of CC and 
IQOS increased cotinine plasma levels significantly: for CC, from 34.4 ng/mL 
(SD±19.3) before using a CC to 65.5 ng/mL (SD±10.2), afterwards, and, for 
IQOS, from 30.4 ±12.0 ng/mL to 61.0 ±16.7 ng/mL. In each case, the difference 
was statistically significant at P < 0.001, but no significant difference was found 
between products.
Lopez et al. (86) compared plasma nicotine in current smokers before 
and after use of a loose-leaf tobacco vaporizer HTP from PAX (Ploom), an ENDS 
and the participant’s own brand of CC. Mean plasma nicotine concentration 
increased significantly immediately after each of two bouts of scheduled product 
use, from baseline (all P ˂ 0.025) to 24.4 (SD±12.6) ng/mL after use of CC and 
14.3 (±8.1) ng/mL after use of HTP in bout 1, and 23.7 (SD±14.5) ng/mL after 
use of CC and 16.4 (SD±11.3) ng/mL after use of an HTP in bout 2. The level 
of plasma nicotine attained immediately after each bout was higher with CCs 
than with HTPs; however, only the difference between nicotine levels in CCs and 
HTPs immediately after bout 1 was statistically significant (all P ˂ 0.017). The 
mean plasma nicotine concentrations after use of CC were significantly higher 
than those after use of HTPs from the beginning to the end of experimental use.
Tobacco industry studies
Ten studies conducted by the tobacco industry were found: nine papers derived 
from eight studies by PMI (74– 82), one by BAT (83) and one by Japan Tobacco 
International (JTI) (84) (see Table 5.5). All the PMI studies are randomized trials 
with allocation to use mainly of IQOS (a carbon-tip HTP was used in one study), 
the participant’s regular brand of CC or, in five studies, abstinence or nicotine 
replacement therapy. Exposure was usually for about 5 days of ad-libitum use of 
the assigned product. The studies of BAT and JTI were randomized trials with 
participants assigned to use of an HTP (IQOS or glo in the case of BAT and 
Tobacco Vaporizer in the case of JTI) or a commercial CC. Participants were 
exposed to 5 days of ad-libitum use of the assigned product in the BAT trial and 
to use of one stick for 2 days in the JTI trial.
Levels of biomarkers in plasma
Three studies (76,77,84) compared pharmacokinetics after use of the products 
(Table 5.6), as the area under the plasma concentration versus time curve from 
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time 0 to the last quantifiable concentration (AUC0–last), an indicator of total 
exposure to nicotine on the assumption of equal clearance of the drug in all 
participants; the maximum observed plasma concentration attained (Cmax), an 
indicator of the uptake of nicotine; the time to reach Cmax (tmax), an indicator of the 
speed at which Cmax is attained; and the half-life (t1/2), an indicator of the duration 
of significant pharmacological effects. The values for IQOS THS2.2 were similar 
to those for CCs, with a tmax of 6 min. IQOS THS2.1 appeared to be less effective 
than CCs and IQOS THS2.2 in the uptake of nicotine and in providing the same 
maximal concentration. However, it presented a very similar tmax to CCs (8 min) 
and a slightly longer half-life than CCs. The tobacco vaporizer tested by Yuki et al. 
(84) reaching the tmax at the same time as CCs (3.8 min) but reached less than half 
of the Cmax of CCs and generated < 70% of the nicotine taken up from CCs. Three 
studies in which IQOS, THS2.1 and THS2.2 were compared with CCs reported 
mean levels of nicotine and cotinine in plasma after 5 days of ad-libitum use of 
the HTP of about 85% for THS 2.1 and 100% for THS 2.2 of the levels reached 
after use of CCs.
Table 5.6. Pharmacokinetics of plasma nicotine after single use of IQOS and conventional cigarettes
Reference 76 76 77 84
Year of publication 2017 2017 2016 2017
Industry affiliation or funding Yes Yes Yes Yes
Reference CC Own non-menthol 
brand
Own menthol brand Own brand CC1
HTP THS2.2 IQOS THS2.2 menthol IQOS THS2.1 PNTV
HTP (single use) t to Cmax (min) 6 6 8 3.8
AUC0-last (ng*h/mL) Ratio of 
geometric LS means
96.3%
85.1–109.7%
98.1%
80.6–119.5%
77.4%
70.5–85.0a
68.3%
54.3–85.9%
Cmax ng/mL Ratio of geometric 
least-squares means
103.5%
84.9–126.1%
88.5%
68.6–114%
70.3%
60.0–82.2%
45.7%
34.1–61.4%
t Cmax (min) Median difference 0.04
-1.0–1.05
1.0
0.0–2.5
0.1
-1.0–2.0
-0.5
-1.1–0.03
t1/2 (h) Ratio of geometric 
least-squares means
93.1%
84.6–102.4%
102.3%
85.3–122.7%
110.9%
101.7–120.9%
89.1%
78.2–102%
PNTV: prototype novel tobacco vapour. a 90% confidence interval.
Levels of biomarkers in urine
Six studies presented the value for nicotine equivalents in 24-h urine. The total 
with THS 2.2 and a carbon-tip HTP was ≥ 100% of that after use of CCs. For 
THS 2.1, the total was 87% of that of CCs. Use of glo resulted in urinary nicotine 
equivalents that were 57% and 74% of those of the comparable CCs, depending 
on whether they had menthol.
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5.8 Subjective effects of use of HTPs and conventional cigarettes
We identified 10 studies in which the subjective effects of HTPs and CCs were 
compared (74–77,79,81,82,86-88). IQOS was the HTP tested in all but one. The 
psychometric instruments most often used to assess the subjective impacts of 
HTPs and CCs were the brief questionnaire on smoking urges (QSU-brief) (89) 
and the modified cigarette evaluation questionnaire (mCEQ) (90). The QSU-brief 
is a 10-item questionnaire, usually presented before use of the assigned product 
and then at the end of use to measure craving. The score may be reported as the 
total scale for its two components, desire to smoke with anticipation of pleasure 
from smoking and relief from nicotine withdrawal or negative affect with an urgent 
and overwhelming desire to smoke. The mCEQ assesses the reinforcing effects 
of product use, with three multidimensional domains, “smoking satisfaction”, 
“psychological reward” and “aversion”, and two single-item domains, “enjoyment 
of respiratory tract sensations” and “craving reduction”.
The QSU-brief was used in eight studies, two independent (86,88) and 
six linked to industry (74–77,79,82). All found, as expected, that the score for 
craving was high in all groups immediately before the start of the intervention. 
The score fell significantly immediately after use of IQOS or CC; however, the 
only independent study of IQOS reported that smoking resulted in lower craving 
scores than after use of IQOS (all P < 0.001) (88), but the six industry studies 
did not. The least-squares mean differences between the IQOS and CC groups 
in the total QSU-brief scores in the industry studies, covering all times from the 
beginning to the end of use of the products, were generally small and none was 
statistically significant. The two independent studies (86,88), which reported 
scores as the two-factor composition of the QSU-brief scale, found similar results 
over time. The study (77) that reported the QSU-brief scores for single-use and 
ad-libitum use found no difference in the mean total score (least square mean 
difference, 1.4 (95% CI: −1.0, 3.7) ad-libitum vs 0.2 (95% CI: −2.9, 5.3) for single 
use). This study, in which a loose-leaf tobacco vaporizer was compared with CCs, 
found that craving decreased significantly more after use of CC than after use of 
the vaporizer.
The mCEQ was used in seven studies (74,75,77,79,81,82,88). In all the 
studies, the questionnaire was administered at the end of exposure, sometimes 
immediately. The only independent study (88) found that use of both products, 
IQOS and CCs, had a reinforcing effect on all subscales; however, CCs had a more 
substantial subjective effect than IQOS in terms of satisfaction, psychological 
reward, enjoyment of respiratory tract sensations and reduced craving. The 
industry studies tended to report significantly less reinforcing effect of IQOS use 
than of CC use on all or some of the mCEQ subscale scores, except aversion. Two 
studies (75,79) reported significant differences in all subscales at the beginning 
and one at the end of the exposure period, with the greatest difference for 
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satisfaction and craving reduction. Another study (81) found that CC smokers 
had greater smoking satisfaction than IQOS users highlighted on the last day of 
exposure as compared with baseline. In another study (82), the average results 
on the mCEQ for the entire 5-day exposure period were significantly lower for 
participants who switched to IQOS use than for participants who continued to 
smoke CC, after adjustment for baseline, smoking satisfaction, craving reduction, 
enjoyment of respiratory tract sensation and psychological reward. One study (77) 
indicated that the differences between the two products for smoking satisfaction, 
psychological reward, craving reduction and enjoyment of respiratory tract 
sensations were more significant after ad-libitum use. In an independent study, 
Biondi-Zoccai et al. (85) used neither the QSU-brief nor the mCEQ but a seven-
question product satisfaction questionnaire (91), which was administered after 
each session of product use. Satisfaction scores were higher for CCs than HTPs.
This limited body of research shows that HTPs overall deliver nicotine at a 
lower dose and more slowly than CCs. Of the HTPs analysed, only IQOS THS2.2 
reaches the nicotine delivery of CCs. IQOS can reduce craving for smoking, 
perhaps to a lesser degree than CCs. Industry-linked studies showed little 
difference, and the one independent study showed significantly less reduction in 
craving than CCs. The sole study on other HTPs showed that a loose-leaf tobacco 
vaporizer was less able to quench smoking craving than CCs; however, IQOS and 
the vaporizer were perceived as less satisfying than CCs.
5.9 Discussion and implications
Little published information is available on use of HTPs at population level or 
whether the use is part of a poly use pattern or associated with cessation of use of 
CCs or nicotine. While research in this area is increasing and HTP use is being 
assessed in a number of surveys (e.g. International Tobacco Control, Japan Society 
and New Tobacco Internet Survey), publication will take months to years (44,92–
107). Independent studies do indicate that dual use of cigarettes and HTPs is more 
common than implied by initial industry-sponsored studies (44,98,100). More 
information is required, however, on usage patterns in view of sociodemographic 
confounders (95,99,106). There is little empirical support for the suggestion 
that new-generation HTPs overall help to transition smokers from CCs, and no 
studies on nicotine cessation have been published. Most of the available studies 
are industry-linked, and most studied IQOS. Laboratory studies suggested that 
only one of the HTPs analysed could deliver nicotine at a dose comparable to 
that of cigarettes (76,77,84); however, other factors, including attractiveness and 
appeal, are often important in substitution behaviour. HTPs appear to reduce 
smoking craving subjectively, although perhaps not as significantly as CCs. It is, 
however, clear that HTPs are not as satisfying to smokers as CCs.
117
Use of heated tobacco products: product switching and dual or poly product use
5.10 Research gaps
 ■ Independent data on population-level usage patterns other than ever 
use. The key metrics include use with other products, amount used, 
daily or non-daily use and flavour preferences (where applicable) to 
determine the validity of claims of reduced risk.
 ■ Studies on lil (KT&G), an HTP available in the Republic of Korea and 
now being marketed elsewhere by PMI, for which no published data 
were found.
 ■ Independent studies of the pharmacokinetics of nicotine in HTPs 
other than IQOS, preferably between subjects to allow direct com-
parisons.
 ■ Studies of the pharmacokinetics of nicotine delivery by HTPs, of 
leading ENDS products and/or of nicotine replacement therapy to 
compare the potential abuse liability of HTPs with that of products 
used to stop smoking.
 ■ Independent studies of smoking cessation and use behaviour after 
adoption of HTPs expressly to cease smoking of conventional products.
 ■ Studies of cessation of HTP use.
5.11 Policy recommendations
Policy-makers should consider the following recommendations for policy on the 
potential role of HTPs in cessation of smoking conventional tobacco products, 
particularly in the context of poly use of tobacco products.
5.11.1 Cessation policy
There is insufficient evidence that HTPs aid a switch from smoking. Therefore, 
claims should not be made to that effect. Even if future evidence supported HTPs 
as effective switching aids (i.e. substituting one tobacco product for another), they 
should never be considered as treatment for smoking cessation, which includes 
quitting nicotine use.
5.11.2 Surveillance policy
Surveillance of the prevalence and patterns of use of HTPs in various sociodemo-
graphic groups over time is rarely conducted at country level and should urgently 
be implemented. Understanding patterns of use among vulnerable populations 
(e.g. young people, racial and ethnic minorities, pregnant women) is of particu-
lar importance. The variables surveyed should include frequency of use (daily 
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or non-daily use), amount used, concurrent use of other tobacco and nicotine 
products (poly use) and flavours used (where applicable). Surveillance systems 
might also include making it mandatory to record tobacco use, including HTPs, 
in medical notes.
5.11.3 Research policy
Studies should be conducted of consumers’ use of HTPs to substitute completely 
for conventional cigarettes. Policy-makers are encouraged to prioritize funded 
research on ways to increase the reach, demand, quality, dissemination, imple-
mentation and sustainability of evidence-based smoking treatments.
5.11.4 Cooperation and partnership policy
Given the rapid dissemination of use of HTPs in the absence of the necessary 
scientific evidence of their effectiveness as aids for switching to conventional 
tobacco smoking, policy-makers are urged to share national experiences and to 
collaborate in developing an appropriate regulatory framework for HTPs.
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Abstract 
Heated tobacco products (HTPs) are increasingly marketed by the tobacco 
industry as part of a newer portfolio of products that are claimed to pose fewer 
risks to users and non-users than conventional tobacco products. These products 
have gained a considerable market share since they became available and are 
now found on about 50 markets worldwide. The new generation of HTPs, 
owing to their novelty, their unconventional technology and industry claims 
that they pose fewer risks to health than conventional tobacco products, are 
classified in various ways by different countries. The classifications have filtered 
through to the mechanisms adopted by countries to regulate these products, 
resulting in inconsistencies among countries, including the extent to which they 
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apply the provisions of the WHO Framework Convention on Tobacco Control 
(WHO  FCTC). This paper reviews the markets on which HTPs are available, 
the common classifications of these products and how the classifications 
affect regulatory outcomes. Further, we describe commonly used regulatory 
frameworks, barriers to regulation, considerations for regulations and unforeseen 
consequences. We also present guidance from WHO and the WHO  FCTC to 
countries in formulating regulatory strategies for HTPs according to their 
national laws and ensuring strong protection of human health.
6.1 Background
6.1.1 Introduction and the request of the Conference of the Parties  
(FCTC/COP8(22))
HTPs produce aerosols containing nicotine and toxic chemicals when their 
tobacco material is heated or when a device containing tobacco is activated (1). 
The tobacco may be in the form of specially designed cigarettes (e.g. “heat sticks” 
and “neo sticks”), pods or plugs. The resulting aerosols are inhaled by users after 
heating of tobacco in a device specifically designed for that purpose (1). HTPs 
are aggressively marketed and promoted by the tobacco industry in a number 
of ways, including as “smoke-free”, “cleaner alternatives”, “safer alternatives” and 
“reduced risk” products relative to conventional cigarettes. They were available 
for sale legally in over 50 markets in all six WHO regions as of July 2020 (2), 
examples of which are given in Table 6.1.
Table 6.1. Examples of markets on which HTPs are available
Device Company Markets
IQOS Philip Morris 
International
Andorra, Albania, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, 
Croatia, Cyprus, Czechia, Denmark, Dominican Republic, France (including La Réunion), 
Germany, Greece, Guatemala, Hungary, Israel, Italy, Japan, Kazakhstan, Latvia, Lithuania, 
Malaysia, Mexico, Monaco, Netherlands (including Curaçao), New Zealand, Poland, Portugal, 
Republic of Korea, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, 
Slovenia, South Africa, Spain (including the Canary Islands), Sweden, Switzerland, Ukraine, 
United Arab Emirates, United Kingdom, USA and occupied Palestinian territory, including 
east Jerusalem
iFuse, glo British American 
Tobacco
Canada, Italy, Japan, Republic of Korea, Romania, Russian Federation and Switzerland
Lil KT&G Japan, Republic of Korea, Russian Federation and Ukraine
Ploom Japan Tobacco 
International
Italy, Japan, Republic of Korea, Russian Federation, Switzerland and United Kingdom
HTPs are one of the three broad categories of products, with electronic nicotine 
delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS), 
that have become popular in several jurisdictions, especially in Japan and the 
Republic of Korea. While the technology for HTPs has been available since the 
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1980s, earlier attempts to introduce these products were unsuccessful, and the 
newer generations of these products became popular only in the past seven years 
(Fig. 6.1; see also sections 3 and 5).
Fig. 6.1. Dates of launch and withdrawal from the market of early-generation heated tobacco products
Source: adapted from reference 3.
HTPs pose significant challenges to tobacco regulation, specifically because 
of their novel operating mechanisms and inadequate knowledge about their 
effects on health. The tobacco industry has exploited these challenges by using 
marketing tactics especially for “harm reduction” or “reduced risk” to facilitate 
their entry onto the market and have argued that HTPs should be categorized 
differently from tobacco products and specifically conventional cigarettes. The 
lack of an internationally agreed approach for assessing the risks of their use, 
because of insufficient knowledge, further complicates tobacco control. Novelty, 
misinformation and industry manipulation have resulted in disparate approaches 
to their classification and their regulation.
Decision FCTC/COP8(22) of the eighth session of the Conference of the 
Parties (COP) to the WHO FCTC on novel and emerging tobacco products) (4) 
requests the Convention Secretariat to invite WHO to prepare a comprehensive 
report on these products, covering several areas of research. WHO is expected 
to report to the ninth session of the COP on the regulatory experience and 
monitoring of Parties, effects on tobacco control and research gaps and to 
subsequently propose policy options for achieving the objectives and measures 
outlined in paragraph 5 of the decision. The aim of this paper is to map regulation 
of HTPs, review the regulatory experiences of WHO Member States with regard to 
HTPs, consider the impact of HTPs on tobacco control and identify research gaps.
6.1.2 Scope and objectives
We describe the regulatory experience of countries with HTPs after explaining 
common classifications for these products that may dictate specific regulatory 
pathways. For instance, classification in a certain category may result in a 
Heated tobacco products (Htps) 
market monitoring information sHeet  
What are heated tobacco products?
Heated tobacco products (HTPs) are those that produce aerosols containing nicotine and 
other chemicals, which are inhaled by users through the mouth. They contain the highly 
addictive substance nicotine (in the tobacco), which makes them addictive. They also contain 
non-tobacco additives, and are often flavoured. HTPs mimic the behaviour of conventional 
cigarette smoking, and some make use of specially designed cigarettes to contain the tobacco 
for heating. Although HTP technology has existed since the 1980s (see Fig. 1), the early 
products were unsuccessful (see Fig. 2).  
Fig. 1: HTP Timeline
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complete ban on HTPs, although the regulatory implications of a category differ 
by country and the classifications in a country determine the degree of application 
of tobacco control laws. An HTP classified as an “e-cigarette” product may result 
in a ban in one country and in regulation in another.
The common regulatory frameworks that follow from classifications 
with respect to product bans; advertising, promotion and sponsorship; smoke-
free places; sales restrictions; packaging and labelling; and product design are 
described. Because of limitations and interpretation of the available data, we 
do not provide an authoritative list of policies implemented to date but provide 
information about the types of approaches adopted by regulators with respect to 
HTPs and examples of such regulation. We also describe the barriers to regulation 
and inconsistent application of conventional tobacco control measures to use of 
these products.
6.1.3 Sources
The summaries of legislation and policy were drawn from data collected by WHO 
in 2019–2020, the legislative database managed by the Campaign for Tobacco Free 
Kids (5), desk research on specific countries and internal WHO correspondence 
with country regulators. The data are, however, limited, because they may depend 
on interpretation of domestic legislation to application of general tobacco control 
measures to these newer products.
6.2 Regulatory mapping of novel and emerging nicotine  
and tobacco products
6.2.1 Availability of HTPs
HTPs are currently available on over 50 markets (2) (see Table 6.1). The number 
is, however, increasing rapidly, as 15 markets have been added in only the past two 
years. The availability of these products has increased recently in some countries 
where HTPs are gaining a market share from conventional tobacco products, 
mainly cigarettes, although HTP sales revenue represents a small fraction of what 
the industry earns from cigarettes (6). The tobacco industry plans to expand the 
market share and to increase the availability, visibility and access to these products 
globally (7), in particular by maintaining their availability on the market and 
avoiding strict tobacco control measures resulting from Parties’ obligations to the 
WHO FCTC. Regulatory exception would advance the tobacco industry’s long-
term objective of increasing the acceptability of a wide range of its newer tobacco 
products, undermining the WHO FCTC.
HTPs are not only sold legally in countries but are also traded illegally in 
some countries where they are banned and in countries where the products have 
not met regulatory requirements or have not had premarketing authorization.
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6.2.2 Product classification
According to WHO guidance, HTPs should be classified as tobacco products (8). 
At its eighth session, the COP to the WHO FCTC recognized these products as 
tobacco products and reminded Parties of their obligation to do so under the 
WHO  FCTC. Some regulators have, however, classified HTPs into categories 
distinct from conventional cigarettes or tobacco products because of their 
unconventional characteristics. These distinct categories result mainly from 
industry arguments for weaker or no regulation of so-called “reduced-risk” 
products and insufficient knowledge about the products. To date, countries have 
classified HTPs into categories, including:
 ■ tobacco products
 ■ HTPs
 ■ smokeless tobacco products
 ■ novel, emerging, new or next-generation tobacco products and
 ■ e-cigarettes (9).
Table 6.2 lists examples of countries in which these categories are used.
Table 6.2. Examples of regulatory classification of HTPs
Classification Example of countries (non-exhaustive lists)
Tobacco products Republic of Korea, United Arab Emirates
More than 110 other countries, where HTPs are classified as tobacco 
products by definition
ENDS Brazil, India, Russian Federation, Saudi Arabia
Novel tobacco products European Union countries, United Kingdom
Emerging and imitation tobacco products Singapore
Smokeless tobacco products New Zealand
ENDS: electronic nicotine delivery systems; HTPs: heated tobacco products.
HTPs may also fall into hybrid or exempt categories (9), often resulting in more 
favourable treatment of HTPs than of conventional cigarettes. The nature of the 
device may also affect its classification: sticks (which contain tobacco) may be 
classified as tobacco products, while a heating device into which the sticks are 
inserted may be classified differently (9).
The definitions of products are closely linked to their classification or 
categorization, as the definition of “tobacco products” under domestic law differs 
from one jurisdiction to another. Some countries define “tobacco products” as 
all tobacco-derived materials, including nicotine, as well as the way in which the 
product is consumed (e.g. sucked, smoked, chewed), and some may extend the 
definition to the way in which the products are presented or how the nicotine is 
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derived. Some may include all nicotine-containing products. The way in which 
tobacco products are defined determines the extent to which existing tobacco 
control regulations and legislation are applicable to HTPs in that country, unless 
exceptions are specifically made for HTPs or specific laws that apply to HTPs.
Tobacco products
Many national laws and regulations in all regions of WHO define tobacco products 
broadly enough to include HTPs. If the tobacco control law includes no specific 
regulation, HTPs can be regulated through other applicable regulations, such as 
consumer protection or poisons laws. For example, Australia’s Poison Standards 
Act classifies nicotine as a Schedule 7 poison, so that its sale and possession 
are largely illegal, although, in some states, a 3-month supply may be imported 
under the Therapeutic Goods Administration “personal importation scheme” 
with a medical prescription. Not surprisingly, this restrictive approach has been 
challenged by the tobacco industry. Philip Morris filed a regulatory application 
to the Advisory Committee on Chemicals and Poisons of the Therapeutic Goods 
Administration to seek an exemption from the poisons standard to allow legal 
sale of the nicotine in tobacco prepared and packed for “heating”. The proposed 
amendment was rejected by the Therapeutic Goods Administration in June 
2020 (10).
e-Cigarettes
Some countries have classified HTPs as “e-cigarettes” or “electronic smoking 
devices” on the basis of legislative definitions. This may result in regulation similar 
to that for e-cigarettes or, in other countries, in a ban on the sale or importation of 
the entire category of products. For instance, in the Republic of Korea, although 
HTPs are primarily classified as tobacco products, under the law, tobacco products 
in which electronic devices are used to consume tobacco (e.g. by heating) are sub-
categorized as e-cigarettes. This subcategory is thus applicable to HTPs, as they 
contain electronic devices, which heat the tobacco. In the country’s regulatory 
context, this means that most tobacco product regulations, including on smoke-
free areas, taxation, advertising, health warnings and labels, and prohibition of 
sale to minors, apply to HTPs; however, only 90% of the cigarette tax rate applies 
to HTPs. Depending on national legislation, classification of HTPs as e-cigarettes 
or electronic smoking devices could result in a range of measures, from a ban 
(Brazil) to regulation.
Novel tobacco products
In the European Union, HTPs are regulated as novel tobacco products according 
to the European Union Tobacco Product Directive 2014/40/EU (11). “Novel 
tobacco products” are defined as tobacco products that are required to comply 
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with the provisions of the Directive, including a ban on misleading elements 
foreseen by Article 13 and, notably, any suggestion that a particular tobacco 
product is less harmful than others (12).
In line with Article 19 of the Directive on notification of novel tobacco 
products, tobacco manufacturers and importers are required to provide 
information and supporting documentation for all products that they intend 
to place on the national market and that fall into the category of novel tobacco 
products. Specifically, manufacturers and importers of these products are 
required to notify the competent authorities of Member States, in electronic 
form, 6 months before the products are placed on the market, accompanied by 
information about the products’ ingredients and emissions.
Manufacturers and importers are also required to provide the competent 
authorities with:
(a) available scientific studies on toxicity, addictiveness and attractiveness 
of the novel tobacco product, in particular as regards its ingredients and 
emissions; (b) available studies, executive summaries thereof and market 
research on the preferences of various consumer groups, including young 
people and current smokers; and (c) other available and relevant informa-
tion, including a risk/benefit analysis of the product, its expected effects 
on cessation of tobacco consumption, its expected effects on initiation of 
tobacco consumption and predicted consumer perception.
Additionally, they are required to submit to their competent authorities any new 
or updated information on the studies, research and other information referred 
to in a–c above and conduct additional tests or submit additional information as 
required by the competent authority in question. In addition to notification of 
these products to the relevant national authorities, Member States may introduce 
an authorization process, if deemed appropriate, and may charge manufacturers 
and importers proportional fees for authorization.
Countries including Poland (Article 11a of the Act of 9 November 1995 
on the Protection of Health against Consequences of Consumption of Tobacco 
and Tobacco Products) and Spain (Royal Decree 579/2017) classify HTPs as novel 
tobacco products. France regulates HTPs as tobacco products under the French 
Public Health Code, Article L3512-1, 1° and as a novel tobacco product under 
Article L3512-1, 2°. French law does not establish an authorization system for 
products but includes a system for reporting product information (notification). 
HTP manufacturers are required to report the names, quantities and associated 
health effects of the ingredients to the national authorities. Use of HTPs in public 
places is banned under French Public Health Code Article L3512-8. Use of 
health claims, sale of HTPs to people under 18 and advertising, promotion and 
sponsorship of HTPs are also prohibited. Warning labels are required.
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Emerging and imitation tobacco products
In Singapore, HTPs are treated in the same way as e-cigarettes that contain 
nicotine and electronic nicotine delivery systems, as both are considered to be 
emerging imitation tobacco products. Products that fall into this category include 
any device or article that:
 ■ resembles, or is designed to resemble, a tobacco product;
 ■ can be smoked;
 ■ may be used in such a way as to mimic the act of smoking; or
 ■ the packaging of which resembles, or is designed to resemble, the 
packaging commonly associated with tobacco products (13).
It is prohibited to import, distribute, sell, purchase use or possess such products 
under the Tobacco (Control of Advertisement and Sale) Act, amended in 2011 (13).
Smokeless tobacco
Article 2 of the European Union Tobacco Product Directive defines smokeless 
tobacco as “a tobacco product not involving a combustion process, including 
chewing tobacco, nasal tobacco and tobacco for oral use”. Consequently, a 
number of countries in the European Union, such as Czechia (Section 2 (1) t) of 
Act No. 110/1997 Coll) and Portugal (Law 109/2015), classify HTPs as smokeless 
tobacco products.
In the Netherlands, HTPs are also regulated as smokeless tobacco under 
the Dutch Tobacco Act (14), which is enforced by the Netherlands Food and 
Consumer Products Safety Authority. In line with the requirements of the European 
Union Directive for notification, the Dutch National Institute for Public Health 
and the Environment (RIVM) analyses and processes premarketing notification 
documents (15). Requirements for HTPs include: warning labels similar to those 
for smokeless tobacco, a ban on health claims, a ban on sales to persons under the 
age of 18 and a ban on promotion and marketing, with few exceptions. HTPs are 
taxed at € 99.25/kg, like other smoked tobacco products. According to the Dutch 
Government, categorization of HTPs as smokeless tobacco could be changed 
if new evidence or information about their use becomes available. RIVM is 
currently analysing and conducting research on the contents and emissions of 
different IQOS HeatStick flavours and other HTPs for the Ministry of Health.
Next-generation products
In Italy, HTPs are regulated as next-generation products. Because of alleged belief 
that HTPs can reduce harm, these HTPs are exempt from the fiscal regimes of 
tobacco products. Rather, they are taxed under the category “inhalation product 
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without combustion” under a specific excise structure (16). Thus, these products 
enjoy the same tax reduction as electronic cigarettes, which is half the excise tax 
applied to conventional cigarettes (17). Although the sale of HTPs to minors is 
banned (Decree n°6/2016 Chapter II Art. 24,3), enforcement of tobacco control 
regulations is only minimal for HTPs. Health warnings are required to cover only 
30% of HTP packages (instead of 65% for conventional cigarettes), and they are 
not required to have pictorial images (18). Comprehensive regulations prohibiting 
smoking in all public places and workplaces do not apply to HTPs. In addition, 
advertising and promotion of HTPs are not banned, and “IQOS embassies” and 
“IQOS boutiques”, fancy concept stores in which people can try the products 
for free, are present in several strategic Italian cities. Therefore, for HTPs, the 
country has weakened the best-recognized tobacco control policies, i.e. price and 
tax increases, smoking bans, advertising bans and health warnings.
International approaches to the classification of HTPs
Discrepancies in national approaches to the classification of HTPs and legal 
challenges by the tobacco industry have raised concern about the lack of 
international standards for classifying HTPs. WHO is collaborating with experts 
and researchers on a classification tree for tobacco products, which will include 
HTPs, and will publish its findings once the project is finalized. A report will 
also be made to the next COP to the WHO  FCTC, in November 2021, on 
appropriate classification of HTPs in accordance with paragraph 3(b) of decision 
FCTC/COP8(22), in which the COP requested the Convention Secretariat to 
advise on adequate classification of novel and emerging tobacco products such 
as HTPs (19). The World Customs Organization is facilitating a revision of the 
“harmonized system code” to introduce new, specific customs codes for HTPs. 
The annex to the International Convention on the Harmonized Commodity 
Description and Coding System currently states that:
 ■ heated tobacco units do not have a specific customs code and fall un-
der the subheading of “other” (2403.99) in Chapter 24 of the Interna-
tional Convention on the Harmonized Commodity Description and 
Coding System, which addresses tobacco products; and
 ■ devices used to heat tobacco units (i.e. HTPs) do not have a specific 
customs code and fall under the subheading of “other machines and 
apparatus” (8543.70) in Chapter 85, which concerns electrical ma-
chinery.
Mandatory changes have been made for 2022, to standardize these 
headings so that the products fall under heading 24.4:
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Products containing tobacco, reconstituted tobacco, nicotine, or tobacco 
or nicotine substitutes, intended for inhalation without combustion; 
other nicotine-containing products intended for the intake of nicotine 
into the human body (20).
Countries will be obliged to amend their domestic customs codes in 2020. The 
World Customs Organization will determine how disposable devices are to be 
classified later in the year.
The Harmonized System Code is not intended to affect domestic 
regulation of HTPs, but, as described in a WHO FCTC Secretariat information 
note (21), in practice, these codes affect the entry and exit of goods at borders 
for the purposes of levying excise taxes and classification in domestic legislation. 
Such measures could be used by the tobacco industry to lobby for more favourable 
treatment of HTPs.
6.2.3 Regulatory frameworks and measures to reduce tobacco demand
As noted above, the classification of a tobacco product determines the regulations 
that are applicable. This in turn affects the availability and use of these products, 
as well as regulations on taxation, restrictions on advertising, promotion and 
sponsorship, use of the products in smoke-free places and packaging and labelling 
requirements. Some countries choose to ban the importation, sale or use of HTPs 
entirely, through a ban on an entire category of products, such as e-cigarettes or 
emerging and imitation tobacco products. For example, if a country has banned 
e-cigarettes and then makes a regulatory decision to classify HTPs as e-cigarettes, 
the classification will ensure that the HTPs do not enter the market (e.g. India). 
Nevertheless, the same product classification (i.e. “e-cigarettes”) may result in a 
ban in one country and regulatory restrictions in another.
Various mechanisms have been adopted by WHO Member States to 
regulate HTPs. While many countries have used existing tobacco control laws, 
some have formulated specific provisions. Information held by WHO indicates 
the following common mechanisms.
Existing laws
HTPs could be defined in the same way as products that are already covered by law, 
such as in South Africa, where HTPs are considered tobacco products. As noted 
above (section 6.2.1), in Australia, HTPs are regulated under the Standard for the 
Uniform Scheduling of Poisons, with products containing nicotine categorized 
under Schedule 7, “dangerous poison”. The Therapeutic Goods Administration 
recently refused to amend the Poisons Standard to allow sales of HTPs (11).
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Amendment of existing laws
Existing legislation can be amended to include HTPs if the definitions do not 
clearly cover these products. In Malaysia, an amendment to the Control of 
Tobacco Product Regulations 2004 changed the definition of “smoking” in 2015 
to include use of HTPs (22).
New legislation and other mechanisms
New legislation and other mechanisms may be used to regulate HTPs or to 
include them explicitly in existing legislation. The United Arab Emirates enacted 
an Electronic Nicotine Products (Equivalents of Traditional Tobacco Products) 
standard (23), which regulates e-cigarettes, e-liquids with and without nicotine 
and HTPs, with a requirement to specify their production, import, retail and 
display. Consequently, these products now fall within the same regulatory 
framework as tobacco products, provided by Federal Law 15/2009. In the 
Philippines, the President issued an executive order in February 2020 regulating 
the commercialization and use of electronic cigarettes, HTPs and other novel 
tobacco products (24). The executive order excludes HTPs from the definition of 
tobacco products but includes them in the definition of smoking.
As noted earlier, HTPs were recognized as tobacco products at COP8 
(decision FCTC/COP8(22)) (19). This decision reminded Parties of their 
commitments under the WHO  FCTC when addressing the challenges of 
novel and emerging tobacco products such as HTPs and devices designed for 
consuming such products, to consider prioritizing specified tobacco control 
measures in accordance with the WHO FCTC and national law. These, listed in 
paragraph 5 of the decision, are:
(a) to prevent the initiation of novel and emerging tobacco products;
(b) to protect people from exposure to their emissions and to explicitly 
extend the scope of smoke-free legislation to these products in ac-
cordance with Article 8 of the WHO FCTC;
(c) to prevent health claims from being made about novel and emerging 
tobacco products;
(d) to apply measures regarding advertising, promotion and sponsorship 
of novel and emerging tobacco products in accordance with Article 
13 of the WHO FCTC;
(e) to regulate the contents and the disclosure of the contents of novel 
and emerging tobacco products in accordance with Articles 9 and 10 
of the WHO FCTC;
(f) to protect tobacco-control policies and activities from all commer-
cial and other vested interests related to novel and emerging tobacco 
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products, including interests of the tobacco industry, in accordance 
with Article 5.3 of the WHO FCTC;
(g) to regulate, including restrict, or prohibit, as appropriate, the manu-
facture, importation, distribution, presentation, sale and use of novel 
and emerging tobacco products, as appropriate to their national laws, 
taking into account a high level of protection for human health; and
(h) to apply, where appropriate, the above measures to the devices de-
signed for consuming such products.
Advertising, promotion and sponsorship (Article 13)
Article 1 of the WHO  FCTC provides a comprehensive definition of tobacco 
advertising, promotion and sponsorship. Tobacco advertising and promotion are 
defined as “any form of commercial communication, recommendation or action 
with the aim, effect or likely effect of promoting a tobacco product or tobacco use 
either directly or indirectly” and sponsorship as “any form of contribution to any 
event, activity or individual with the aim, effect or likely effect of promoting a 
tobacco product or tobacco use either directly or indirectly” (25).
Although most countries do not specifically regulate the advertising, 
promotion and sponsorship of HTPs, the products should be covered by the bans 
on advertising, promotion and sponsorship applied to conventional tobacco 
products, in accordance with the guidance of WHO and the COP. If a distinction 
is made between HTP sticks and devices and if the definition of tobacco product 
covers only the sticks, advertising of the device may not be banned.
A comprehensive ban on tobacco advertising, promotion and sponsorship 
covers not only traditional forms of advertising such as television, radio and print 
but also “brand stretching”, displays of products at points of sale and tobacco-
industry-sponsored corporate social responsibility programmes, among others. 
Nevertheless, the fast-changing media landscape creates regulatory loopholes 
that allow tobacco product advertising in social media campaigns and by 
influencers, often targeting young people. For example, the tobacco industry 
engages in public relations and corporate social responsibility-related activities, 
sponsors events and uses social media and online platforms to promote HTPs, all 
of which have contributed to the proliferation of the products around the world. 
Early in 2020, the State Council in the Republic of Korea passed an amendment 
to the country’s National Health Promotion Act banning any direct or indirect 
promotional activity by tobacco manufacturers to consumers. The Ministry of 
Health and Welfare plans to ban practices such as discounts on ENDS and HTPs 
and free distribution of these products, including the devices, during promotional 
events (26).
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Smoke-free spaces (Article 8)
HTPs are commonly referred to by some as “heat-not-burn” products, a term 
coined by the industry, which has positive connotations. Manufacturers suggest 
that the products are “ash-free”, “smoke-free” and “cleaner alternatives” to 
conventional cigarettes, which may create confusion about their categorization. 
To reduce the confusion created by this terminology, especially in regulations on 
the application of smoke-free laws, WHO introduced the term “heated tobacco 
products”. Philip Morris has tried to distinguish IQOS from conventional smoking 
by creating partnerships with hundreds of “IQOS-friendly” restaurants and bars 
in countries such as Romania and Ukraine (27), which may ban cigarettes but 
allow use of IQOS, undermining prohibitions on indoor smoking. Romania does 
not classify HTPs as “tobacco products for smoking” with regard to smoke-free 
policies on the grounds that these products do not generate smoke (28).
Packaging and labelling (Article 11)
Article 11 of the WHO FCTC states that regulators should ensure that tobacco 
product packaging and labelling
do not promote a tobacco product by any means that are false, misleading, 
deceptive or likely to create an erroneous impression about its character-
istics, health effects, hazards or emissions, including any term, descriptor, 
trademark, figurative or any other sign that directly or indirectly creates 
the false impression that a particular tobacco product is less harmful than 
other tobacco products. These may include terms such as “low tar”, “light”, 
“ultra-light” or “mild”.
The aim of these prohibitions is to avoid misleading consumers into thinking that 
one tobacco product is healthier than another, an especially important aim with 
respect to HTPs. Currently, however, health warning requirements for HTPs tend 
to be less onerous than for those for conventional cigarettes. Even where health 
warnings are imposed, in some countries (Japan and Netherlands), they apply 
only to inserts and not to the devices.
Articles 9–12 of the European Union Tobacco Product Directive address 
health warnings and their dimensions. For novel tobacco products considered to 
be “smokeless tobacco”, text (but not pictorial) health warnings must cover 30% 
of each of the two largest surface areas; for novel tobacco products intended for 
smoking, combined health warnings (graphic and text) must cover 65% of the 
two largest surfaces. Categorization as smokeless tobacco is therefore preferable 
for the tobacco industry. Article  13 of the Directive on product presentation 
prohibits labelling or packaging with any element or feature that creates an 
erroneous impression about the characteristics, health effects, risks or emissions 
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of the product. Labelling or packaging may not include any information about 
the nicotine, tar or carbon monoxide content of the tobacco product; suggest that 
a particular tobacco product is less harmful than others, reduces the effects of any 
harmful components of smoke or has vitalizing, energizing, healing, rejuvenating, 
natural or organic properties or other health or lifestyle benefits; or refer to taste, 
smell, any flavourings or other additives or the absence thereof.
In the USA, the Food and Drug Administration (FDA) requires that all 
HTP package labels and advertisements include an additional warning about the 
addictiveness of nicotine, as well as the other warnings required for cigarettes. 
The aim of this requirement is to correct a misperception among users that IQOS 
pose a lower risk of addiction than conventional cigarettes. An application for 
designation as a modified risk tobacco product may be submitted to the FDA to 
allow a product to be marketed with a claim of reduced risk (29), i.e. “any tobacco 
product that is sold or distributed for use to reduce harm or the risk of tobacco-
related disease associated with commercially marketed tobacco products”. In 
2016, Philip Morris Products S.A. sought authorization to market IQOS with 
the claims that the product “can reduce the risks of tobacco-related diseases”, 
“significantly reduce[s] your body’s exposure to harmful or potentially harmful 
chemicals” and “presents less risk of harm than continuing to smoke cigarettes”. 
The FDA concluded, however, that the company had not provided sufficient 
evidence that consumers would not be misled by those claims, and Philip 
Morris were consequently not allowed to market HTPs with a claim of reduced 
risk (30). Under US law, the FDA may issue two types of order for a modified 
risk tobacco product: a “risk modification order” or an “exposure modification 
order”. Philip Morris Products S.A. had requested both types of order. Although 
the FDA determined that the evidence did not support issuance of the first 
type, the evidence supported issuance of an exposure modification order for 
the IQOS device and the tobacco HeatSticks. The exposure modification order 
authorizes Philip Morris to make claims about how tobacco is heated and about 
the production of harmful and potentially harmful chemicals and exposure to 
those chemicals in advertising and marketing of the products. On 7 July 2020, 
the FDA authorized the marketing of an “IQOS tobacco heating system”, which 
includes the IQOS device, Marlboro Heatsticks, Marlboro Smooth Menthol 
Heatsticks and Marlboro Fresh Menthol Heatsticks, as a modified risk tobacco 
product (31). The FDA stressed that this authorization does not indicate that 
the products are safe or approved by the FDA, and it rejected claims that the 
company had adequately demonstrated that use of the products is less harmful 
than use of another tobacco product or reduces risks to health (32). Philip Morris 
hailed the exposure authorization as a milestone for public health and cited it as 
“an important example of how governments and public health organizations can 
regulate smoke-free alternatives to differentiate them from cigarettes in order to 
promote the public health”.
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The Republic of Korea, which primarily regulates HTPs as tobacco 
products, requires graphic health warnings on HTP packages. The move by 
the Ministry of Health and Welfare to mandate use of graphic images of the 
consequences of tobacco use, such as cancer-ridden organs, and more concise 
written warnings with specific risk figures was part of a set of measures to deter 
smoking implemented in late 2018. The strengthened measures followed a one-
year deliberation by a 13-member special committee comprising Government 
officials and private experts and a survey of 1500 smokers and non-smokers to 
gauge public opinion (33). All the regulations that apply to tobacco products, such 
as taxation, smoke-free areas, advertising, package warnings and labels, also apply 
to HTPs (1), in line with WHO recommendations that HTPs be subject to the 
same policy and regulatory measures as applied to all other tobacco products (34).
In Canada, the Tobacco Products Regulations (Plain and Standardized 
Appearance), which came into force on 9 November 2019, apply to tobacco 
products, including devices necessary for the use of a product made in whole or 
in part of tobacco, such as HTPs, as they are defined as “tobacco products” under 
the Act (35). Israel and New Zealand also require plain packaging for HTPs.
Sales restrictions
In most countries, the sales restrictions imposed on tobacco products are also 
applicable to HTPs. These include prohibition of certain methods of sale (e.g. 
from vending machines or the Internet), restricted locations, age restriction 
for purchasers and licensing or requirements for retailers. For example, Cyprus 
prohibits the sale of HTPs from automatic tobacco vending machines, sales to 
minors and free distribution of HTPs (36). In Slovenia, the premises for the sale 
of tobacco, tobacco products and related products, including HTPs, must be 
registered under Article 35(1) of the Restriction of the Use of Tobacco Products 
Act 2017 (37). The Act prohibits sales to minors and sale of HTPs at temporary 
and mobile points of sale, via the Internet, telecommunications or any other 
developing technology or cross-border distance sales and in single units, except 
in the manufacturer’s original packaging (Article 30). The law in Saudi Arabia 
prohibits the sale of HTP sticks in packages of more than 20 sticks (38).
All countries that ban the sale of tobacco products to minors implicitly 
extend the ban to HTPs; however, some countries apply different age limits. 
Japan for instance applies a sales ban to persons under 20 (39), while Austria and 
Belgium prohibit HTP sales only to children under 16 (40). Federal systems, such 
as those of Canada, Switzerland and the USA, may have different subnational 
limits. In Switzerland, an age restriction of either 16 or 18 years applies to the 
purchase of HTPs, depending on the canton, while, in Canada, the age restriction 
is between 18 and 19 years. In December 2019, the USA enacted a ban on sales 
of all tobacco products, including HTPs, to any person under the age of 21 years.
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Contents and emissions (Articles 9 and 10)
Most countries in the European Union require manufacturers to report the 
names, quantities and health effects of ingredients, including flavours. Under 
the European Union Tobacco Product Directive, tobacco products with a 
characterizing flavour are prohibited. A “characterizing flavour” is defined in 
Article 1(25) of the Directive as:
a clearly noticeable smell or taste other than one of tobacco, resulting 
from an additive or a combination of additives, including, but not limited 
to, fruit, spice, herbs, alcohol, candy, menthol or vanilla, which is notice-
able before or during the consumption of the tobacco product.
The prohibition on characterizing flavours currently applies only to cigarettes 
and roll-your-own tobacco and not to HTPs. Article 7(2) notes, however, that the 
Commission may determine that a particular tobacco product is subject to this 
ban, either on the initiative of the European Commission or at the request of a 
Member State. Characterizing flavours in HTPs may therefore be banned in the 
European Union in the future.
Education, communication, training and public awareness (Article 12)
The tobacco industry, with its new portfolio of products, uses marketing 
and promotion mainly as “reduced harm”, “reduced risk” and alternatives to 
conventional cigarette as a strategy to manipulate governments to open their 
markets to HTPs. These claims are, however, unsubstantiated, as these products 
have not been proven to be different from conventional cigarettes in terms of 
tobacco-related risk, and the claims have distracted attention from evidence-
based tobacco control policy measures to reduce tobacco use and protect public 
health. Article 12 of the WHO FCTC states:
Parties shall promote and strengthen public awareness of tobacco control 
issues, using all available communication tools, as appropriate, and adopt 
and implement effective legislative, executive, administrative or other 
measures to promote the following:
(a) broad access to effective and comprehensive educational and pub-
lic awareness programmes on the health risks including the addic-
tive characteristics of tobacco consumption and exposure to tobacco 
smoke;
(b) public awareness about the health risks of tobacco consumption and 
exposure to tobacco smoke, and about the benefits of the cessation of 
tobacco use and tobacco-free lifestyles as specified in Article 14.2;
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(c) public access, in accordance with national law, to a wide range of 
information on the tobacco industry as relevant to the objective of 
this Convention;
(d) effective and appropriate training or sensitization and awareness 
programmes on tobacco control addressed to persons such as health 
workers, community workers, social workers, media professionals, 
educators, decision-makers, administrators and other concerned 
persons;
(e) awareness and participation of public and private agencies and non-
governmental organizations not affiliated with the tobacco industry 
in developing and implementing intersectoral programmes and strat-
egies for tobacco control; and
(f) public awareness of and access to information regarding the adverse 
health, economic, and environmental consequences of tobacco pro-
duction and consumption.
These are evidence-based measures for sensitizing the public and raising aware-
ness about the ill-effects of use of tobacco products. All countries, and not just 
Parties to the WHO FCTC, should consider prioritizing these measures to pro-
tect public health.
6.3 Considerations and barriers to regulation, implementation 
and enforcement of policies
6.3.1 Regulatory considerations in implementing policies
HTPs may be considered differently from conventional cigarettes because of 
insufficient knowledge about the products, tobacco industry lobbying, regulatory 
classification of smokeless products based on arguments that these products are 
“smoke-free”, “ash-free” or “cleaner alternatives” than conventional cigarettes, 
and differential approaches to the devices and the inserts. The tobacco industry 
has aggressively marketed these products, lobbied governments for more lenient 
regulations and exerted substantial pressure on regulatory decisions concerning 
HTPs. This has resulted in only partial application of comprehensive tobacco 
control regulatory measures to HTPs, which will ultimately undermine existing 
tobacco control.
The authors of a study (41) on an IQOS campaign in Israel described 
ways in which the industry attempts to define a new product as part of a 
category not covered by existing tobacco laws, in this case by using the term 
“smoking” in the argument. When IQOS was launched in Israel in December 
2016, Philip Morris International organized high-level meetings and other direct 
communications with the Israeli Ministries of Health and Finance to put pressure 
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on the Government to exempt IQOS from existing tobacco regulations, which 
were reversed after three petitions to the Supreme Court. The authors warned 
that, in the absence of requirements for specific health warnings for HTPs, the 
industry may voluntarily place warnings on newer products, such as “research 
suggests that cigarettes cause addiction”, which may introduce doubt about well 
accepted evidence regarding cigarettes.
The industry categorizes HTPs in the way that ensures the most favourable 
treatment under applicable national law. In New Zealand, HTPs were banned as 
a “smokeless product”, but the ban was successfully challenged in court by Philip 
Morris International on the basis that HTPs are not “smokeless”. New Zealand 
now applies all tobacco control laws for smoked products to HTPs, including 
plain packaging. In Romania, regulation of HTPs as smoked products was 
challenged in an industry submission on the basis of arguments of reduced harm, 
no combustion and therefore no smoke.
In determining the most appropriate approach to regulation of HTPs, 
countries should consider factors such as:
 ■ the absolute and relative health risks to users and non-users;
 ■ whether HTPs can be regulated continuously as scientific knowledge 
is gained on these products;
 ■ the risk that tobacco use and smoking will be “renormalized”;
 ■ the risk of initiation by non-users of tobacco products, particularly 
young people;
 ■ the possibility that smokers who have quit tobacco use, thereby im-
proving their health, might switch to HTPs, although these are tobac-
co products and have not been proven to reduce tobacco-related risk;
 ■ use with other nicotine and tobacco products, so that users are ex-
posed to the emissions of two or more products; and
 ■ capacity to assess industry claims regarding the relative harm of 
HTPs relative to conventional cigarettes and to prevent claims that 
could mislead consumers.
As noted previously, Parties to the WHO FCTC could go beyond its provisions in 
accordance with Article 2.1 of the Convention, which states that:
In order to better protect human health, Parties are encouraged to imple-
ment measures beyond those required by this Convention and its proto-
cols, and nothing in these instruments shall prevent a Party from impos-
ing stricter requirements that are consistent with their provisions and are 
in accordance with international law.
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6.3.2 Barriers to implementing and enforcing policies
In addition to lobbying, industry litigation threatens the passage, implementation 
and enforcement of policies. In New Zealand, a district court decision in 2018 
(Philip Morris vs Ministry of Health) (42) overturned the previous classification 
of HTPs as “any tobacco product labelled or otherwise described as suitable for 
chewing, or for any other oral use (other than smoking)”, which are banned under 
Section 29(2) of the Smokefree Environments Act 1990 (43). Philip Morris Ltd 
was charged with violating the law by selling “Heets”, the HTP inserts for IQOS. 
The holding found that, because the law was originally intended to control the 
sales of chewing tobacco and other tobacco products consumed orally, it should 
not apply to tobacco inserts for HTPs. Therefore, the district court ruled in favour 
of Philip Morris, and HTPs may be legally imported, sold, packed and distributed 
in New Zealand under the Act. Consequently, the Smokefree Environments Act 
regulations, including the ban on sales to minors and restrictions on advertising, 
apply to HTPs. This case highlights the challenges of regulating these products 
and the importance of legislation that can be adapted to the changing tobacco 
product landscape.
Much of the litigation is based on claims of combustion or non-
combustion, whichever determines the most favourable treatment for the 
industry. As described earlier, regulation of HTPs as smoked products may be 
challenged by the industry on the basis of no combustion, while their regulation 
as smokeless products may be challenged on the basis that these products are not 
“smokeless”.
6.3.3 Other considerations and unintended consequences
When countries regulate HTPs as smoked tobacco products, the health warnings 
for other smoked tobacco products apply. The same principle applies when HTPs 
are regulated as smokeless tobacco products. Many countries may be under the 
impression that these products require specific provisions, whereas they are 
already covered by their current tobacco control law. The Pan American Health 
Organization has made recommendations to countries in the Region of the 
Americas on regulation of HTPs under existing regulations for tobacco products. 
As the way in which tobacco products are defined in some regulations may make 
application of tobacco control laws difficult, regulations should be broadened 
to encompass novel and emerging nicotine and tobacco products. This would 
limit exploitation of regulatory loopholes by the tobacco industry. The WHO 
report on the global tobacco epidemic, 2019 (44) provides useful information 
and recommendations for countries.
 ■ HTPs contain tobacco and should be regulated in the same way as 
tobacco products.
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 ■ HTPs produce toxic emissions, many of which are similar to those 
found in cigarette smoke.
 ■ HTP users are exposed to toxic emissions from the products, and by-
standers could also be exposed to toxic second-hand emissions.
 ■ Although the levels of several toxicants in HTPs are generally lower 
than those in conventional cigarettes, the levels of others are higher. 
A lower level of a toxicant does not necessarily indicate a lower health 
risk.
 ■ HTPs contain nicotine. Nicotine is highly addictive and is linked to 
harm, particularly in children, pregnant women and adolescents.
 ■ The long-term health effects of HTP use and exposure to their emis-
sions remain unknown. There is currently insufficient independ-
ent evidence on the relative and absolute risks. Independent studies 
should be conducted to determine the health risks they pose to users 
and bystanders.
This information includes important considerations for HTPs, as their availability 
on the market could have unintended consequences for public health, which 
should be considered in formulating policies and determining a regulatory path 
for HTPs.
6.4 Discussion
HTPs are tobacco products, defined in the WHO  FCTC as “products entirely 
or partly made of the leaf tobacco as raw material which are manufactured to 
be used for smoking, sucking, chewing or snuffing”. These products have gained 
a considerable market share in some countries and are now available on over 
50 markets worldwide. Their unique characteristics, intensive industry lobbying, 
lack of clarity about their health risks and the absence of international approaches 
all pose challenges to regulators.
While limited data are available, as regulations depend on national 
interpretations of laws, which cannot be assessed independently, different 
countries clearly regulate HTPs in different ways, on the spectrum from bans 
to no regulation. Some countries consider HTPs to be in the same category as 
conventional tobacco products. Many countries already have domestic legislation 
and regulations with respect to basic tobacco control measures, including 
advertising, promotion and sponsorship, smoke-free spaces and packaging and 
labelling. A misconception is that regulating HTPs would be a new, resource-
intensive initiative, when, in fact, these products are already covered by current 
tobacco control law.
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The marketing of HTPs is, however, strategic, and its regulation presents 
challenges. The fact that devices and inserts are sold separately may exempt 
the devices (which do not contain tobacco) from, for instance, restrictions 
on advertising, promotion and sponsorship and even on sale to minors. 
The tobacco industry claims that there is no combustion in HTPs, and many 
European Union countries classify them as novel smokeless tobacco products, 
such that requirements for warnings and restrictions such as smoke-free areas 
may differ from those for conventional cigarettes. This paper poses a number of 
considerations for addressing regulation of these products.
6.5 Conclusions
In the past several years, the industry has significantly expanded its “reduced 
risk” portfolio with newer generation tobacco products, such as HTPs. The 
innovative technologies, design, marketing and health claims associated with 
these products have weakened tobacco control measures in some countries 
where there were relatively strong laws to regulate conventional cigarettes and 
attempts by the tobacco industry to reposition itself as a public health partner. 
Regulators were largely unprepared for these new products, especially their 
claims of “no combustion”, “no smoke” and “no ash”, which the industry has used 
to lobby governments for favourable regulatory treatment and in particular to 
circumvent smoke-free laws. As a result, the current regulations on HTPs are 
specific to each country. HTPs generate aerosols that contain toxicants, many at 
levels lower than those in conventional cigarette smoke, but in some cases higher. 
A lower level of a toxicant does not, however, necessarily mean lower risk. As 
the long-term effects on health of the use of and exposure to emissions from 
these products remain unknown and there is currently insufficient independent 
evidence on the relative and absolute risks, they should be fully subject to the 
provisions of the WHO FCTC, including a ban on their use in indoor spaces. The 
aim of this paper was to increase awareness about the inconsistent approaches 
used to regulate HTPs and to prepare regulators should a case be made by the 
industry to introduce HTPs and other novel and emerging tobacco products onto 
their markets.
Countries that are examining their legislative options can learn from 
regulatory successes and challenges in other countries. New tobacco control laws 
should anticipate not only HTPs but other emerging products, with definitions that 
are broad enough to encompass all innovative developments. Tobacco industry 
interference, including lobbying and misinformation, should be monitored and 
subjected to protection under WHO FCTC Article 5.3.
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6.6 Research gaps
 ■ Global surveillance of HTP products and their use to understand in-
dustry marketing strategies.
 ■ Systematic monitoring of industry mechanisms to limit application 
of the WHO FCTC to HTPs and to undermine tobacco control.
 ■ Comprehensive mapping of legislation on HTPs to identify regula-
tory loopholes that could be exploited by the industry and the level 
of implementation of existing policies, in order to improve it and to 
provide evidence on the regulatory approaches that promote maxi-
mum protection for public health.
 ■ Effective surveillance for better understanding of the availability, 
marketing and use of HTPs.
6.7 Policy recommendations
As HTPs evolve and their availability spreads, regulators must address questions 
about these products in the face of industry pressure and scientific uncertainty. 
The varied approaches used by governments to classify and regulate these 
products reflect the absence of internationally agreed approaches. One thing is 
clear: HTPs are tobacco products. Therefore, policy-makers are urged to consider 
the following recommendations.
 ■ Classify HTPs as tobacco products, except in countries where such 
classification would result in the more lenient regulations, under-
mine existing tobacco control provisions or allow market entry when 
similar products have been banned.
 ■ Apply all the regulatory measures of the WHO FCTC to HTPs and 
especially those in Articles 5.3, 6, 8, 9 and 10, 11, 12, 13, 14 and 20. 
These include protecting tobacco control activities from all com-
mercial and other vested interests, application of excise tax on these 
products, requiring reporting and disclosure of product information, 
requiring combined health warnings on HTPs and covering HTPs 
under smoke-free laws and bans and restrictions on tobacco advertis-
ing, promotion and sponsorship.
 ■ In line with Article 13.4(a), prohibit “all forms of tobacco advertising, 
promotion and sponsorship that promote a tobacco product by any 
means that are false, misleading or deceptive or likely to create an 
erroneous impression about its characteristics, health effects, hazards 
or emissions”.
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 ■ Use existing regulations for tobacco products to regulate HTPs, and 
broaden the scope of those regulations to ensure that regulatory loop-
holes cannot be exploited by the industry, even in countries in which 
these products are not currently (legally) on the market.
 ■ Include HTPs in surveillance to understand their use and availability 
through existing channels, to inform regulation of these products and 
to ensure maximum protection of public health.
 ■ Put the burden of proof on manufacturers to support claims about 
the products, and prohibit unsubstantiated claims about the relative 
risk or harmfulness of HTPs relative to other tobacco products.
 ■ Monitor misinformation with respect to HTPs and claims about the 
risk or harm of these products relative to other products, and take 
appropriate regulatory action to curb such practices.
 ■ Require premarket notification of novel and emerging tobacco prod-
ucts to enable the government to assess whether to authorize their sale.
 ■ Define and classify these products to ensure that public health ob-
jectives are protected and to avoid regulatory loopholes. Given the 
variety of products on the market and under development, legal defi-
nitions must cover all product designs and be adaptable to product 
innovations.
 ■ Closely monitor the products and their markets in the country, and 
institute effective measures to enforce adherence to relevant policies 
and regulations.
 ■ Make clear regulatory distinctions among products and categories of 
products, and clearly define products and their components to ensure 
effective regulation.
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Abstract
Electronic nicotine delivery systems (ENDS) are a diverse class of products 
intended to deliver aerosolized nicotine. ENDS comprise a rapidly evolving range 
of technologies and a wide variety of types, from the first-generation “cig-a-like” 
devices to the currently popular “pod”-based devices. Factors such as device 
design, liquid ingredients and user behaviour all affect the content of nicotine 
and non-nicotine toxicants in ENDS aerosol. Although some evidence suggests 
that ENDS may help some smokers to replace conventional cigarettes, dual use 
of ENDS with combustible cigarettes and the increasingly common initiation of 
ENDS use among previously nicotine-naïve individuals raise clear public health 
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concern. We reviewed the literature on nicotine emissions and delivery from 
ENDS and explored the factors that influence ENDS users’ exposure to nicotine 
and non-nicotine toxicants. The review revealed that: ENDS are a heterogeneous 
product class that is evolving at a rate that outpaces regulation; flavoured ENDS 
liquids contribute to initiation and maintenance of their use by previously 
nicotine-naïve individuals; under certain circumstances, ENDS that deliver 
nicotine effectively might help some smokers to quit smoking combustible 
cigarettes; most ENDS users do not quit combustible smoking; regulation of 
ENDS nicotine emissions would be difficult because of the numerous inputs that 
control the emissions; and a regulatory focus on the rate of nicotine emission 
(e.g. nicotine “flux”) might be useful, which would involve a requirement that 
only “closed-system” ENDS be marketed. In this context, future research needs 
and policy recommendations are proposed.
7.1 Background
Electronic nicotine delivery systems (ENDS) are a diverse class of products 
intended to deliver aerosolized nicotine to their users. They contain a battery-
powered heating element known as a “coil” or “atomizer”, which heats a liquid 
solution that contains nicotine, carrier liquids (e.g. propylene glycol, vegetable 
glycerine) and, usually, flavouring chemicals. The user inhales the resulting 
aerosol, which contains certain concentrations of nicotine and other toxicants. 
ENDS are a rapidly evolving class of products and include a wide variety of types, 
ranging from the first-generation “cig-a-like” devices to the currently popular 
“pod”-based devices in which a disposable cartridge holds the liquid (1). Product 
design features and characteristics (such as wattage and coil dimensions), liquid 
constituents (such as carriers and nicotine concentration) and use behaviour 
(such as puff volume and duration) may be combined in numerous ways to affect 
the content (yield) of nicotine and other toxicants in the aerosol that the user 
inhales (2).
Use of ENDS has risen substantially in some places during the past 
decade (3,4). Use by children and adolescents has increased particularly rapidly 
in some countries, particularly in Europe, Canada and the USA, to the point that 
ENDS are now the most commonly used tobacco products in these age groups in 
the USA (5,6). This raises concern, as ENDS emissions contain toxic chemicals 
that may be harmful to health (7) and also the dependence-producing drug 
nicotine. Nicotine is the primary addictive component of all tobacco products 
(e.g. combustible cigarettes, smokeless tobacco, heated tobacco) and in ENDS. In 
addition to causing dependence, nicotine can also have negative effects on health 
(8). Children, adolescents and young adults are especially susceptible to the long-
term neurocognitive effects of nicotine, as brain maturation continues into the 
early 20s (9). It has been hypothesized that adolescents experience enhanced 
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nicotine reward and reduced withdrawal via enhanced excitation and reduced 
inhibition of dopaminergic striatal cells, making them more vulnerable to long-
term nicotine dependence than adults (10). In addition, ENDS may serve as a 
“gateway” to smoking; several studies have found that their use is associated with 
an increased risk of initiating cigarette smoking among adolescents and young 
adults (11).
Although some ENDS may help some smokers to replace cigarettes by 
providing nicotine in a similar amount and form (i.e. protonated state) (12), 
initiation of ENDS use by young non-smokers raises clear concern (11). Regulators 
might have to characterize and control the factors that influence nicotine delivery 
to users from ENDS in order to minimize their abuse liability and health impact 
while maximizing any opportunities to reduce the risk for cigarette smokers. 
As nicotine delivery is a combined result of product design, liquid composition 
and user behaviour (2), however, it might be difficult for regulation to account 
for all these factors together. As nicotine delivery from ENDS is a function of 
so many variables (e.g. device characteristics and liquid constituents), it has 
been suggested that regulation focus on the rate at which ENDS emit nicotine 
and other toxicants, which would account simultaneously for all the device, 
liquid and user factors that control the emission rate. Nicotine flux – the rate 
at which ENDS emit nicotine – has thus been suggested as a regulatory target 
(e.g. 13). As described in more detail below, regulation of ENDS nicotine flux 
(and also potentially the rate at which other toxicants are emitted) would have 
the advantage of directly controlling the factors that affect public health, rather 
than proxy factors (e.g. liquid nicotine concentration), which, when regulated 
individually, may not achieve public health goals.
This background paper provides a narrative review of the literature (as 
of March 2020) on emission and delivery of nicotine from ENDS and explores 
factors that influence users’ exposure to nicotine and non-nicotine toxicants in 
ENDS emissions. We searched PubMed for relevant publications in the past five 
years using the search terms “ENDS” OR “E-cigarette” OR “electronic cigarette” 
AND “Nicotine” AND “exposure” OR “emission” OR “yield” OR “delivery”. To 
find relevant literature about use patterns, an additional search was performed 
with the search terms “ENDS” OR “E-cigarette” OR “electronic cigarette” AND 
“topography” OR “behavior”. Additional searches were performed for information 
about specific user groups, with the search terms “ENDS” OR “E-cigarette” OR 
“electronic cigarette” combined with terms related to specific hypothesized 
user groups, such as “race”, “ethnicity”, “gender”, “male”, “female” and “dual use”. 
Relevant articles cited in publications obtained through the database search were 
also included (i.e. snowball method). As the aim of this document is to provide a 
narrative review, no formal selection criteria were applied to the results of these 
searches.
154
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
02
9,
 2
02
1
WHO Study Group on Tobacco Product Regulation   Eighth report
7.2 Exposure to nicotine from ENDS
7.2.1  ENDS nicotine emission
“Nicotine emission” can be defined as the amount of nicotine in the ENDS aerosol 
that leaves the device, in other words the nicotine yield. The nicotine yield can be 
analysed in the aerosol from a smoking machine with a predetermined puffing 
regime. The aerosol can be trapped on filter pads and extracted with suitable 
solvents, and the extract is analysed by chromatographic methods (2). Studies 
with these methods and a variety of puffing regimes have shown various amounts 
of nicotine in ENDS aerosol, some showing yields below those generally obtained 
from combustible cigarettes and others showing yields equal to or exceeding that 
of combustible cigarettes (i.e. 1.76–2.20 mg/cigarette) (2,14,15). Importantly, 
if machine puffing regimes do not mimic human puffing behaviour, they are 
not valid measures of human exposure. Arbitrarily chosen machine puffing 
regimens, however, allow valid comparisons when the regimen is applied equally 
to all products under study.
7.2.2  Influence of ENDS electrical power on nicotine emission
The amount of nicotine per puff in the aerosol is influenced by factors that include 
the electrical power flowing through the device, the nicotine concentration in 
the liquid aerosolized by the device and the puffing behaviour of the user (2). 
Electrical power (W) is a function of battery voltage (V) and coil resistance (Ω), 
such that W=V2/Ω. The power of ENDS ranges from ≤ 10 W in early models to 
≥ 250 W in currently marketed models (16). Higher power is often achieved by 
integrating low resistance coils (i.e. < 1 Ω) into the device, colloquially referred to 
as “sub-ohm vaping” (17). The voltage of the battery and default power settings 
differ widely among ENDS models, and more advanced devices often allow the 
user to adjust the power settings. Devices that cannot be adjusted in this manner, 
“closed-system” ENDS, often have lower power because they are smaller and 
more closely resemble combustible cigarettes, whereas “open-system” ENDS are 
larger and can thus contain larger batteries and lower-resistance heating elements 
(1,18). An ENDS that is truly a “closed system” does not allow the user to alter any 
of the elements of the device or liquid that influence nicotine yield, e.g. battery 
voltage, coil resistance and liquid nicotine concentration; it may also limit user 
puffing behaviour (e.g. puff duration (19)).
Increasing the power flowing through the heating element that vaporizes 
the liquid can increase the amount of aerosol produced and may also lead the 
element to overheat, which can cause thermal degradation of the liquid, with 
resulting toxicant formation. The impact of electrical power on aerosol nicotine 
yield has not been studied extensively, but one study found that increasing the 
power output from 3 to 7.5 W increased the nicotine yield by four or five times (2). 
Increased power can also increase the emissions of non-nicotine toxicants (20).
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7.2.3 Contribution of the concentrations of nicotine and other compounds in 
ENDS liquids to nicotine emissions
The nicotine-containing liquids used in ENDS come in refill bottles or prefilled 
cartridges or pods, with a wide range of nicotine concentrations, usually reported 
on the label in mg/mL or as a percentage of total volume. The maximum nicotine 
concentration may differ from country to country according to differences in 
regulations. For instance, the European Tobacco Products Directive states that 
liquids should not contain nicotine concentrations exceeding 20 mg/mL (21). 
The rationale for this regulation, as described in the Directive, is that this 
concentration would allow delivery of nicotine at a concentration comparable to 
the permitted dose of nicotine from a standard cigarette during the time required 
to smoke the cigarette. The relation between the nicotine concentration in liquid 
and nicotine delivery to the ENDS user is not, however, straightforward, because 
of the interplay of factors in the device (e.g. electrical power), the composition of 
the liquid and user behaviour.
In the USA, up to about 2017, the nicotine concentration in commonly 
available liquids was usually 0–36 mg/mL (1,22–25). Some newer products, 
however, contain nicotine at levels up to 67 mg/mL (26,27), and there is concern 
that innovations in ENDS liquid formulations are spurring a “nicotine arms 
race” (28). Furthermore, the nicotine concentrations in ENDS liquid often do not 
match the labelled content, with deviations of up to 52% (15), and several studies 
have demonstrated measurable amounts of nicotine in some liquids labelled as 
not containing nicotine (24,25,29).
Some studies have shown that the nicotine concentration in ENDS liquids 
directly influences nicotine yield, that is, higher liquid nicotine concentrations 
result in higher emissions of nicotine in the aerosol (2,14). Power settings also 
play a role, as increasing the device power increases nicotine yields (14,30). 
Furthermore, users of ENDS liquids with low nicotine strength can obtain the 
same amount of nicotine per puff as high-nicotine ENDS users by adjusting 
their puffing behaviour (2,31). In this way, they may also be exposed to higher 
amounts of toxicants (see next section). Other chemicals in ENDS liquids also 
influence the nicotine yield in ENDS aerosols. For instance, liquids usually 
contain the solvents propylene glycol and/or vegetable glycerine in various 
ratios; higher levels of propylene glycol than vegetable glycerine result in higher 
nicotine yields at low device power settings (30). This might be a consequence of 
the greater volatility of propylene glycol at relatively low temperatures, resulting 
in greater vaporization. As vegetable glycerine becomes more volatile at higher 
temperatures, the putative difference is thought to become less pronounced at 
higher power settings (30).
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7.3  Overview of exposure to accompanying substances
In addition to nicotine, ENDS emissions contain other toxicants, which are either 
present in the liquid or are formed by thermal breakdown of the liquid’s ingredients. 
The toxicants present in liquids include propylene glycol, vegetable glycerine and 
various flavouring chemicals (32,33). In addition, because the nicotine in ENDS 
is derived from tobacco plants, the liquid may contain tobacco-related toxicants 
such as tobacco-specific nitrosamines (1). The flavouring agents used in ENDS 
liquids are “generally recognized as safe” when added to food, but their risk 
profiles when heated and inhaled are unknown (34). Some flavouring chemicals 
such as diacetyl (buttery flavour) (35,36), benzaldehyde (fruity flavour) (37,38) 
and cinnamaldehyde (cinnamon flavour) (36,38–40) are known to be toxic when 
inhaled (41,42). Moreover, findings from the Population Assessment of Tobacco 
and Health study indicate that users of fruit-flavoured ENDS have significantly 
higher concentrations of the biomarker for the carcinogen acrylonitrile than 
users of other flavours (43). Toxicants present after heating ENDS liquid include 
carbonyls, volatile organic compounds and polycyclic aromatic hydrocarbons, 
which are also present in tobacco smoke. Toxicant production from ENDS is 
affected by factors such as user behaviour and the type and power settings of 
the device (2,44). For instance, more intensive puffing patterns can increase the 
production of carbonyls such as formaldehyde, acetaldehyde and acetone (14,44), 
which have been correlated with pulmonary disease in smokers (45).
ENDS emissions may also contain substances that potentiate the addictive 
effects of nicotine. For example, menthol is a common component of both ENDS 
and combustible cigarettes, and it is present in many ENDS liquids even when 
they are not labelled as containing menthol or mint flavour (46). Menthol can 
enhance the reinforcing properties of nicotine in various ways, e.g. by facilitating 
inhalation and by acting on relevant nicotinic acetylcholine receptor subtypes 
in the brain (46). Other examples are the popular ENDS flavouring agents 
vanillin and ethyl vanillin, which have been found to act as monoamine oxidase 
inhibitors and reinforce the brain’s response to nicotine (47). The green apple 
flavouring chemical farnesene can cause reward-related behaviour by stimulating 
nicotinic acetylcholine receptors and the potency of nicotine for activating those 
receptors (48). Other compounds that may potentiate the effects of nicotine and 
affect its metabolism are alcohol and the minor tobacco alkaloid nicotyrine. The 
interaction of alcohol and nicotine in ENDS emissions has not been studied, but 
one study has shown that high levels of alcohol in ENDS liquid can acutely impact 
psychomotor function (49). In addition, alcohol and tobacco are commonly used 
together (50), and alcohol drinking can increase smoking (46). Nicotyrine is a 
thermal reaction product of nicotine and is present in ENDS emissions at levels 
2–63 times higher per unit of nicotine than in emissions from tobacco cigarettes 
(51). It inhibits nicotine metabolism in vivo and may thereby increase nicotine 
delivery from ENDS (1,46,51).
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7.4 Nicotine delivery from ENDS
ENDS vary in their ability to deliver nicotine to users’ blood and brain. Evaluation 
of the nicotine delivery profile of ENDS is important, as ENDS that deliver nicotine 
as effectively as a combustible cigarette are probably more effective substitutes 
for combustible cigarettes (52). The nicotine delivery profile of ENDS is also 
influenced by the combination of device type and power, the composition of the 
liquid and user behaviour (15,17,53). For instance, higher-wattage ENDS models 
deliver nicotine more effectively than lower-wattage models (16,54,55), higher 
liquid nicotine concentrations deliver more nicotine, especially in experienced 
users (17,56), and liquids with a higher propylene glycol than vegetable glycerine 
content increase nicotine delivery (probably due to the lower threshold of 
propylene glycol for evaporation and/or smaller particles that are more likely to 
reach users’ lungs) (57).
One study showed that cherry and menthol flavours increase nicotine 
delivery (i.e. maximum concentration of nicotine in the blood) as compared 
with tobacco flavour (58). Another showed that more nicotine is delivered from 
a strawberry-flavoured liquid than from a tobacco-flavoured one, even though 
similar amounts of nicotine are inhaled, which may be related to differences in 
the pH of the liquids (59). Overall, substantial variation is seen in the nicotine 
delivery from different devices and liquids, some not increasing plasma nicotine 
concentrations and others delivering nicotine at a level approaching that of a 
tobacco cigarette (i.e. 10–30 ng/mL) (15,16,58,60–65).
Nicotine delivery to ENDS users may also depend on the bioavailability 
of nicotine in the liquid or aerosol. Thus, at a higher pH, a larger proportion of 
nicotine is in unprotonated form (free-base), which causes more irritation and 
increases the unpleasant taste of nicotine (28,66). At lower pH, more nicotine is 
present in protonated form, which reduces absorption in the upper respiratory 
tract and also reduces harshness and unpleasant taste, allowing users to inhale 
more deeply without experiencing discomfort, so that a larger portion of the 
aerosol reaches the lower lungs with enhanced absorption of nicotine. Originally, 
with very few exceptions, ENDS liquids contained only free-base nicotine. New 
liquids have been introduced onto the market, however, to which acids are added 
to increase the proportion of protonated nicotine (i.e. nicotine salts) (67). Liquids 
with a high nicotine concentration and small proportion of free-base nicotine are 
thought to be more likely to provide effective “cigarette-like” delivery of nicotine 
(66). In line with this notion, one study showed that the concentrations of urinary 
cotinine (a major metabolite of nicotine) in adolescents using “pod”-system ENDS 
containing nicotine salts were higher than those of adolescents who regularly 
smoked conventional tobacco cigarettes (26). The pH of ENDS liquids also varies 
widely, not only with brand and nicotine concentration but also within the same 
brand and nicotine concentration (68). ENDS liquids that have the same nicotine 
concentration and the same device characteristics, including electrical power but 
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that differ in pH may have differing nicotine delivery profiles as well as differing 
sensory effects when the aerosols are inhaled. All other things being equal, 
protonated nicotine aerosol would be less harsh; however, this notion has not 
yet been tested empirically, as no studies have yet been reported in which liquid 
pH was manipulated systematically when all other variables were held constant.
7.5 Behavioural patterns of exposure according to use
7.5.1  Definition of user groups and user patterns
An important factor in exposure to nicotine is user behaviour, or puff topography. 
User puff topography includes variables such as the number, duration and volume 
of puffs and inter-puff interval and is highly individual. Various factors influence 
the way ENDS are used, such as the experience of the user and the composition of 
the liquid. Exposure to nicotine may also be affected by individual characteristics, 
and various user groups might be distinguished by the way in which they use 
ENDS. For example, experienced ENDS users typically take longer, larger puffs 
than ENDS-naïve users, resulting in higher nicotine delivery (15,56,69). A study 
of “naturalistic” puffing topography identified three types of users: one that 
almost exclusively had “light” sessions (i.e. low puff volume (59.9 mL), flow rate 
(28.7 mL/s) and puff duration (2 s)), one with mainly “heavy” sessions (i.e. high 
puff volume (290.9 mL), flow rate (71.5 mL/s) and puff duration (4.4 s)) and a 
third with mainly “light” sessions (75%) and some “heavy” sessions (25%) (70).
While some people use only ENDS, many ENDS users use tobacco 
cigarettes concurrently. In the USA, almost 70% of adult ENDS users also 
currently smoke cigarettes (71), while the percentage of dual users among young 
people is lower, at 33% (72). One study showed that cigarette smokers had longer 
puff duration and larger puff volume when using ENDS than non-smoking 
ENDS users (73). Two other studies in users of both ENDS and tobacco cigarettes 
showed lower plasma nicotine concentrations after short-term ENDS use than 
after cigarette smoking in standardized laboratory settings (55,74); however, the 
values were not compared in the same study to those for exclusive ENDS users. 
Other individual characteristics, such as gender and race, have been shown to 
affect exposure to nicotine from cigarette smoking (75–77) but have not been 
investigated for ENDS.
7.5.2  Factors that influence behavioural patterns
Various lifestyle and social factors also encourage or discourage ENDS use, 
potentially influencing exposure to nicotine. (See also section 3.) For example, 
local or national policies or regulations may prohibit the use of ENDS in certain 
enclosed public spaces (e.g. prohibition under smoke-free laws), and companies 
and institutions may ban ENDS use on their property, so that users have to 
restrict their use to home or outdoors. As smoke-free policies have reduced the 
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social acceptability of smoking (78) and smoking (79,80), a similar effect might 
be seen on ENDS use if it was included in such policies.
Advertisements and other information to which people are exposed 
through public channels may also influence their perception and use of ENDS 
(81). Several studies have shown that e-cigarette advertising can increase interest 
in, purchase of and use of e-cigarettes (82–84). Policy measures such as health 
warnings and public education campaigns may discourage people, especially 
children and adolescents, from initiating use of these products. For example, in 
the USA, an education campaign called “The real cost” has been highly successful 
in preventing young people from initiating smoking and has been extended to 
ENDS (85). Such information may influence non-users’ and users’ knowledge 
and beliefs about the risks and benefits of ENDS use and thereby the likelihood 
of sustained use among users and uptake by non-users.
The social networks of ENDS users also play a role in uptake of the 
product (86–91). Especially among young users, ENDS use tends to take place in 
the presence of peers (92–94).
Design and characteristics of ENDS devices
Other factors that influence ENDS use and exposure to nicotine are the design 
and characteristics of the ENDS device. For example, several newer ENDS 
models are similar in appearance to a USB stick, which facilitates concealed use 
in schools and other public places (95,96). They are also “smart”-looking and 
hence appeal to the e-generation. Other ENDS models are highly customizable, 
so that users can change power settings and use liquids with different nicotine 
concentrations and flavours, factors that are known to influence use. For example, 
power settings influence puff behaviour, such that higher power reduces the puff 
number and duration (97). This change in response to device power may reflect 
users’ attempt to titrate nicotine and/or the sensory effects of the inhaled aerosol. 
Use patterns also are correlated with the nicotine concentration in the liquid, 
such that lower concentrations of nicotine are associated with larger, longer puffs 
(17,98). The first use of nicotine-containing ENDS may increase exposure to 
nicotine throughout life, as one study showed that adolescents who initially used 
an ENDS with nicotine tended to use ENDS on more days during the first year of 
high school than adolescents who initially used an ENDS without nicotine (99).
Solvents (propylene glycol and vegetable glycerine)
Higher ratios of propylene glycol to vegetable glycerine in ENDS liquid have 
been related to reduced puff duration and size but increased nicotine delivery 
(57). Liquids with higher propylene glycol ratios were also rated as less “pleasant” 
and less “satisfying” by participants in the same study. This may be because pure 
propylene glycol liquids produce little to no visible exhaled aerosol, which is 
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usually considered a positive aspect by users and may be a conditioned reinforcer 
for nicotine. Another study showed that liquids with more vegetable glycerine 
were preferred to those with more propylene glycol and that “good taste” was the 
most important consideration when using and purchasing liquids (100).
Flavours (See also section 6.)
ENDS liquid flavours have also been shown to affect puffing behaviour. For 
instance, one study showed that smokers took significantly longer puffs from 
flavoured ENDS (vanilla, cherry, menthol, espresso or tobacco flavours) than 
from tobacco cigarettes and tended to puff less frequently on vanilla- than on 
tobacco-flavoured ENDS (58). In another study, experienced ENDS users took 
longer puffs from a strawberry-flavoured liquid than from a tobacco-flavoured 
one; however, they took even larger and more puffs when using their usual brand 
of ENDS liquid (101). A third study found that ENDS liquid flavours influenced 
puff flow rate and puff volume but not puff duration (102), although the direction 
of the effect was unclear. Flavours not only affect use behaviour but are also 
an important reason for initiating and continuing ENDS use, particularly for 
adolescents and young adults (99,103,104).
7.6 Passive exposure to nicotine and other toxicants  
(See also section 8.)
ENDS users are exposed directly to nicotine and other toxicants by inhaling the 
aerosol emitted by their device. Non-users may be exposed to nicotine and other 
toxicants by “second-hand” exposure (also known as environmental exposure) 
or “third-hand” exposure to emissions that have settled onto surfaces, from skin 
contact or by ingestion of nicotine-containing liquid (46). A growing body of 
literature suggests that ENDS use has a negative effect on indoor air quality (105–
109), supporting the idea that non-users may be exposed to toxicants exhaled 
by ENDS users when they share the same indoor space. Several studies have 
reported effective methods for assessing second- and third-hand exposure (110). 
One study showed delivery of various levels of nicotine to non-users after acute 
second-hand exposure to ENDS aerosol in a real social setting (100). Another, 
of exhaled breath of ENDS users, concluded that bystanders may experience 
systemic effects of nicotine, including increased heart rate and higher systolic 
blood pressure (111). A further study confirmed that 30 min of second-hand 
exposure to ENDS aerosol caused sensory irritation and respiratory symptoms, 
which were related to the concentration of volatile organic compounds in the 
emissions (112).
In pregnant women, nicotine readily crosses the placenta (113) and 
binds to nicotine acetylcholine receptors in the fetal brain, which play a critical 
role in brain development (114). Early activation and desensitization of these 
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receptors by nicotine can disrupt development, with long-term consequences 
(9). Although there are no published studies on how ENDS use affects pregnancy 
outcomes or fetal development, nicotine is considered to contribute substantially 
to a range of adverse effects of maternal smoking, and CO is thought to be a 
cause of low birthweight. Neonates exposed prenatally to nicotine and tobacco 
have a lower birthweight and earlier gestational age, have a higher risk of lung 
and cardiorespiratory problems and are more prone to asthma and allergy in 
childhood (9,115). They are also at higher risk of neurocognitive effects that 
can lead to poor academic performance and significant behavioural problems 
throughout life, including attention deficit hyperactivity disorder, aggressive 
behaviour and future substance abuse (116). Although it is difficult to conclude 
that these effects are caused specifically by nicotine or by other components of 
tobacco smoke, nicotine is considered to be the substance mainly responsible for 
most of the adverse effects on fetuses from maternal smoking (9,116). Studies 
of pregnant women who use smokeless nicotine-containing products have 
also found associations with preterm birth, stillbirth and orofacial cleft defects 
(117–120). Use of nicotine replacement therapy during pregnancy is associated 
with lower exposure to nicotine (121) and a lower risk of preterm delivery and 
low birth weight than with smoking (122). As some ENDS deliver nicotine in 
amounts comparable to those in combustible cigarettes, some of the adverse 
effects of maternal smoking also may occur after exposure to nicotine from 
maternal ENDS use. It should be noted that ENDS emissions contain other 
possibly harmful compounds, with effects on fetal development that have not 
been thoroughly studied. For example, one study showed that flavouring agents 
in ENDS refill solutions are cytotoxic to human embryonic stem cells (123).
7.7  Nicotine flux
ENDS nicotine “flux” is the rate at which an ENDS device emits nicotine, or 
the ENDS nicotine yield per unit time (e.g. µg/s). The rate of drug delivery has 
long been a relevant metric for understanding drug abuse, as faster drug delivery 
leads to greater abuse potential (124,125). When nicotine was delivered to 
cigarette smokers intravenously at different rates, faster delivery was considered 
to give more rewarding positive effects (126). Combustible cigarettes are used by 
millions of people worldwide, and, generally, they emit nicotine at approximately 
100 µg/s (calculated from data obtained by Djordjevic et al. (127)) and deliver 
nicotine to blood and brain very quickly (128,129). While combustible cigarette 
nicotine flux is generally stable for all combustible cigarette brands, similar 
stability is not seen for ENDS, mainly because of the heterogeneity of the product 
class. When all possible combinations of device power, construction, liquid and 
nicotine and other ingredients are accounted for, ENDS fluxes may range from 
0 µg/s (i.e. no nicotine emission) to > 100 µg/s. This vast range of nicotine flux 
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explains the considerable variation in ENDS nicotine delivery profiles, with low-
power devices and liquids with a low nicotine concentration delivering little or 
no nicotine and higher-power devices and liquids with higher concentrations 
delivering as much as or more nicotine than a combustible cigarette in the same 
number of puffs (1). Importantly, nicotine flux is independent of user behaviour 
(e.g. longer puff durations do not alter flux), but flux and behaviour combined 
determine nicotine yield and exposure and the amount of drug delivered to the 
blood and brain. For example, a flux of 100 µg/s and a 1-s puff duration yields 100 
µg nicotine, but a 4-s puff yields 400 µg nicotine. This explains why longer puffs 
result in greater nicotine delivery even when flux is controlled (56). Longer puffs 
deliver a larger inhaled nicotine dose to the user.
While the heterogeneity of ENDS devices and liquids makes it difficult 
to measure flux in all possible combinations, ENDS flux can be predicted 
mathematically in a physics-based model (130). As described elsewhere (131), 
the model accounts for the time it takes for a coil to heat up after electricity begins 
to flow, cooling of the coil between puffs and the various ways in which heat can 
be transferred from the coil. Inputs to the model include the length, diameter, 
electrical resistance and thermal capacitance of the coil, the composition and 
thermodynamic properties of the liquid (including nicotine concentration), the 
ambient temperature and user behaviour (puff velocity and duration, inter-puff 
interval). In a validation study, model predictions were generated, and actual 
nicotine flux was measured in 100 conditions, in which power, device type, liquid 
composition and user behaviour were varied. The model accounted for 72% of 
the variation in nicotine flux under the conditions tested. This model could be 
used to predict the nicotine flux of any ENDS on the market today (open or 
closed system) as well as of ENDS that are being designed. Thus, mathematical 
modelling of nicotine flux presents a potential tool for policy-makers who wish 
to regulate ENDS nicotine emissions.
As has been noted (18), if the goal of regulation is to decrease the 
likelihood that ENDS will be abused by a population such as non-smoking young 
people, an effective way may be to decrease ENDS nicotine flux. As the nicotine 
flux is a result of all of the ENDS characteristics (construction, wattage, liquid 
nicotine content), regulators can focus on a single product performance target 
– nicotine emission rate (i.e. nicotine flux), and manufacturers can choose the 
device and liquid characteristics that fall safely within that range. The flux target 
is not necessarily a single value but a range of allowable nicotine flux conditions (a 
nicotine emission rate no less than X and no greater than Y), allowing for a range 
of products designed to minimize abuse and maximize any potential benefit for 
smokers seeking to quit smoking combustible cigarettes and an eventual end to 
nicotine dependence, if ENDS can be demonstrated to provide such a therapeutic 
benefit. In sum, a mathematical model of nicotine flux allows regulators to 
examine an array of products efficiently to determine whether they meet or fall 
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outside a specified nicotine flux range. Unfortunately, such a regulatory approach 
cannot succeed if users have control over key parameters such as device power 
and liquid nicotine concentration. Therefore, policy-makers also may wish to 
consider the extent to which “open-system” devices are amenable to effective 
regulation (18).
7.8  Discussion
ENDS are a diverse, evolving product class with growing global popularity, 
particularly among children, adolescents and young adults. Some ENDS users 
were former cigarette smokers who used ENDS to quit smoking combustible 
cigarettes, and there is some empirical evidence from randomized clinical trials 
that ENDS assist smoking cessation, although results are inconsistent. Many 
ENDS users are dual users, who continue to use ENDS with other tobacco 
products, in particular conventional cigarettes. Others were nicotine-naïve 
before using ENDS and may be at risk for subsequent initiation of conventional 
cigarette smoking. The myriad flavours of ENDS liquids available on the market 
may help some smokers to quit smoking, may encourage dual or poly use and 
almost certainly encourage nicotine-naïve young people to initiate ENDS use. The 
proportion of naïve ENDS users who were potential smokers and of those who 
would have remained non-smokers is a potential confounder in such analyses.
Some ENDS can deliver as much or more nicotine than a combustible 
cigarette in the same number of puffs. Some ENDS also deliver much less nicotine 
than a combustible cigarette. The extent to which ENDS deliver or do not deliver 
nicotine depends on a variety of device characteristics (e.g. electrical power, coil 
dimensions), liquid constituents (e.g. nicotine concentration, ratio of propylene 
glycol to vegetable glycerine) and user behaviour (e.g. puff duration). These same 
factors influence the extent to which ENDS emit non-nicotine toxicants that may 
be injurious to users’ health. A recent influence on ENDS nicotine delivery is the 
marketing of liquids that contain protonated nicotine (nicotine salts). The aerosol 
formed from a protonated liquid is less harsh to inhale than aerosol formed from 
free-base nicotine, so that manufacturers can increase the nicotine concentration 
of the liquid without making the resulting aerosol unpalatable.
In view of all the factors that influence nicotine and non-nicotine 
emissions from ENDS, regulation of this product class may be difficult. There is 
a temptation to focus on single factors when regulating ENDS nicotine delivery, 
such as liquid nicotine concentration; however, such an approach may drive users 
to obtain more nicotine by manipulating unregulated factors such as using higher-
powered devices and/or increasing puff duration. Such behaviour could reduce 
the effectiveness of regulation, such that nicotine delivery remains higher than 
intended by the regulators, while also exposing users to more aerosol that may 
be more toxic than if they used lower-powered devices and/or took shorter puffs. 
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Thus, it has been suggested that regulators focus on the rate at which nicotine is 
emitted from ENDS, the nicotine flux, as a regulatory target. This focus would 
also require that ENDS products not allow users to access many of the device, 
liquid and user behaviour characteristics that influence nicotine flux, such as 
“closed-system” ENDS with built-in limits on puff duration. These devices exist 
in some markets and are therefore clearly feasible. Exactly which nicotine flux 
parameters are conducive to promoting smoking cessation by current cigarette 
smokers while limiting abuse liability in nicotine-naïve young people are yet to 
be determined.
7.9  Conclusions
The data reviewed lead to the following conclusions.
 ■ ENDS are a heterogeneous product class that continues to evolve at a 
speed that outpaces current regulatory efforts.
 ■ ENDS performance characteristics are also heterogeneous, some us-
ers being exposed to very low levels of nicotine and other toxicants 
and others being exposed to much higher levels.
 ■ ENDS use by previously nicotine-naïve individuals is inconsistent 
with public health goals.
 ■ Flavoured ENDS liquids contribute to initiation and maintenance of 
ENDS use among previously nicotine-naïve individuals. They may 
also be attractive for smokers who want to quit cigarettes.
 ■ Under certain circumstances, such as in the context of intensive be-
havioural counselling, ENDS that deliver nicotine effectively might 
help some smokers to quit combustible smoking, with positive public 
health effects. Most of these individuals, however, continue to use 
ENDS, with uncertain individual health consequences and thus an 
uncertain public health impact.
 ■ Most ENDS users do not quit smoking combustible cigarettes but 
rather use both ENDS and combustible cigarettes, which, at the least, 
maintains the substantial health risks associated with cigarette smok-
ing and may increase their health risks.
 ■ Regulation of the emissions of nicotine and other toxicants from 
ENDS is complicated by the numerous inputs to emissions.
 ■ Regulation of the emissions of nicotine and non-nicotine toxicants 
from ENDS may be necessary. This would require that marketed 
ENDS be constructed so that users cannot alter important character-
istics such as device power and liquid constituents.
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 ■ The profile of nicotine emission and delivery from ENDS that would 
be most likely to achieve cessation of conventional smoking, ideally 
while also reducing the abuse liability of ENDS among nicotine-na-
ïve individuals, is not known. Identification of that profile, if it ex-
ists, will require careful empirical work similar to that conducted for 
other pharmacological compounds that are used therapeutically even 
though, in some forms or via some routes, they can also be abused 
(e.g. opioids).
7.10  Research gaps, priorities and questions
The data reviewed here raise many research questions, including those listed 
below.
 ■ Studies to determine the range of nicotine flux, if any, that will reduce 
the abuse liability of ENDS products and limit initiation by young 
people while helping smokers to eliminate their use of cigarettes and 
other smoked products with ENDS.
 ■ Studies to compare fetal exposure to nicotine and other toxicants 
from ENDS with that from maternal cigarette smoking.
 ■ Which way of achieving a given ENDS nicotine flux poses the least 
risk for users? Many different combinations of device power and liq-
uid nicotine concentration can achieve the same flux, and some may 
lead to more non-nicotine toxicants than others.
 ■ To what extent are flavoured ENDS liquids required for ENDS-fa-
cilitated cigarette cessation? Could unflavoured ENDS liquids, made 
only of nicotine, propylene glycol and vegetable glycerine, when 
paired with a device that emits nicotine as effectively as a combustible 
cigarette, facilitate cigarette smoking cessation in a current smoker?
 ■ To what extent is intensive behavioural counselling a requirement for 
ENDS-facilitated cigarette smoking cessation?
 ■ Which smokers are most likely to achieve smoking cessation with an 
ENDS product that delivers nicotine effectively? Is cessation more 
likely to be facilitated by ENDS in some smokers than others?
 ■ Given the diversity of regulatory approaches to ENDS (i.e. different 
countries have different approaches), which policies are most effec-
tive in protecting public health with respect to ENDS use?
 ■ To what extent does the availability of ENDS at numerous retail 
outlets facilitate initiation among nicotine-naïve individuals? Would 
restricting ENDS sales to regulated venues (perhaps where individu-
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alized smoking cessation counselling is available) be more consistent 
with public health goals?
 ■ What is the effect of increased levels of protonated nicotine in ENDS 
liquids on toxicity (additional acid ingredients) and abuse liability 
(by making inhalation of high doses of nicotine less harsh)?
7.11  Policy recommendations
The data reviewed here support the following three recommendations.
 ■ Regulators should not permit ENDS in which users can control 
device features and liquid ingredients (i.e. open-system ENDS) and 
should ensure that the ENDS that are permitted do not appeal to 
young people.
 ■ Regulators should focus on nicotine emission rate or flux (i.e. out-
come) as a regulatory target, instead of any single input variable (e.g. 
liquid nicotine concentration or device power).
 ■ ENDS should not have a higher abuse liability than combustible ciga-
rettes. Thus, the ENDS nicotine emission rate or flux should not be 
higher than the emission rate of combustible cigarettes.
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Abstract
e-Cigarettes heat and aerosolize e-liquids for inhalation. Many of the liquids 
contain nicotine (electronic nicotine delivery systems, ENDS), while others do 
not (electronic non-nicotine delivery systems, ENNDS). Although the basic 
design of ENDS or ENNDS is similar or the same, the devices that are used to heat 
liquids vary widely in details of their use, operation temperature or performance 
standards. The health risk depends not only on the properties of the device but 
also on the composition of the e-liquids, of which several thousand flavour 
varieties are commercially available or could be prepared at home.
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Initial assessments suggest that the toxicological risks of individual 
ENDS depend on the devices and e-liquids, but the risk associated with high-
powered devices may be relatively high. In this paper, we summarize methods 
that can be used to quantify the health risks associated with the use of ENDS, 
ENNDS and heated tobacco products (HTPs), due to either the individual 
compounds or the mixture in emissions. Most methods require substantial data 
on both emissions and hazards, only some of which are available. Currently, 
quantitative risk assessment methods cannot be used in regulation, although the 
most promising approaches are based on the relative potency of the compounds 
in emissions. Because of the diversity of ENDS and ENNDS, risk assessments 
remain a challenge, and the results cannot be generalized to the entire spectrum 
of devices. The wide variety of both liquids and devices indicates that different 
health risk assessments should be conducted for different combinations of liquid 
and device and for individual products. Relevant indicators of high risk could be 
characterized, such as specific ingredients or specific device settings.
8.1 Background
Tobacco use is the major cause of premature death worldwide. Each year, about 
8 million people die from tobacco-related diseases, including an estimated 
1.2 million non-smokers who were exposed to second-hand smoke (1). Although 
cigarettes are the most common tobacco product, especially in developed 
countries, other tobacco products and replacement products also pose serious 
health risks. In India, more than 350 000 deaths are attributed to use of chewing 
and oral tobacco each year (2).
While addiction is the driving force for maintenance of this hazardous 
behaviour, nicotine does not trigger the major toxic effects associated with 
the high mortality rate associated with tobacco consumption, which is due 
to carcinogenic and otherwise hazardous combustion products and tobacco 
constituents. The contributions of individual compounds to the carcinogenicity 
of tobacco use have been estimated (3,4), leading to identification of the major 
carcinogens and ranking of smoke constituents by their potency in inducing 
tumours. Similar approaches have been used for cardiovascular and other 
health risks.
Strategies have been proposed to reduce the exposure of smokers to 
toxicants, including mandatory limits on the most relevant toxicants in cigarette 
smoke (5–7). Attempts to restrict toxicant levels in conventional cigarettes have 
not, however, been successful because of technical limits to reducing combustion 
and combustion products (8). HTPs contain electrical heating and other 
exothermic processes for generating an aerosol from tobacco material that consists 
of humectants, nicotine and other tobacco constituents and pyrolysis products. 
Aerosols from HTPs have generally been found to contain fewer hazardous and 
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potentially hazardous compounds than cigarette smoke (9); however, it is not yet 
known whether reduced exposure to toxicants markedly reduces health risks.
e-Cigarettes are the most common form of ENDS, and the two terms are 
often used synonymously. In contrast to HTPs, ENDS no longer link nicotine 
consumption to tobacco use. While ENDS are clearly defined as nicotine delivery 
systems, the name “electronic non-nicotine delivery systems” (ENNDS) refers 
only to the absence of nicotine. According to current understanding (10), ENDS 
and ENNDS are similar products, except for nicotine. Glycerol and/or propylene 
glycol are usually the major components of the liquids that form the aerosol. 
Liquids also contain various flavours and other ingredients to increase the 
palatability and attractiveness of the aerosol (11–13). First-generation e-cigarettes 
are shaped like conventional cigarettes and consist of a battery, a liquid reservoir 
and an aerosolizing chamber containing a filament for heating liquid through 
wicks made of various materials (14). The generated aerosol is directed to the 
mouthpiece and can be inhaled. Liquids are also provided in cartridges, either 
designed for single use or refillable. The initial devices were not very efficient at 
delivering nicotine to the user; however, this basic function has been gradually 
improved. Open systems have emerged, which are sophisticated devices that can 
be refilled and reused. Other improvements include increased battery capacity, 
variable electrical power, removal of tin solder joints and coiled filaments. Recent 
developments include sub-ohm-atomizing units that can be operated at higher 
variable voltages because of low electrical resistance (14). Modern atomizers can 
evaporate a much higher volume of liquid per puff than the original cigarette-
like devices (15). These systems are highly adaptable. For example, users can 
build their own coils or customize performance parameters such as wattage, 
airflow and, indirectly, nicotine delivery. The operation of advanced systems 
is, however, also increasingly complicated, and products have been developed 
that are easier to use, with modules that contain prefilled liquid reservoirs and 
atomizers designed for single use (16). (See also section 6.) These products have 
been termed “pod” systems, possibly as an analogy to coffee capsules. A nicotine-
containing pod may be attached to a stick- or pen-shaped device containing a 
low-powered battery and a mouthpiece. A popular example is JUUL, which has 
become a leading e-cigarette brand in the USA (16,17). Although pod systems 
lack the flexibility of advanced refillable e-cigarettes, their nicotine delivery and 
addictiveness are comparable to those of combustible cigarettes (18) due to very 
high nicotine concentrations in the liquid, which can reach 60 mg/mL, as in the 
US version of JUUL. This is three times higher than the upper limit of nicotine 
allowed in European products. Most pod systems contain nicotine salts, such as 
nicotine benzoate or salicylate, to limit the harshness of alkaline nicotine.
Until recently, e-cigarettes were considered mainly as devices for 
delivering nicotine, with no consideration of the harm they impose. ENNDS 
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were regarded by some as an acceptable nicotine-free version of combustible 
cigarettes. This may have been a limited perspective. Many novel technologies 
initially retain their original applications, while more applications are explored 
over time. Use of modified e-cigarettes to consume cannabis and other illicit 
compounds (19) may well be seen as an early indicator of an initially unintended 
use of these products. Recently, use of cannabidiol has emerged as a commercially 
relevant novel application that shows little relation to nicotine or tobacco use. 
Cannabidiol has defined pharmacological properties (20) and is claimed to have 
many beneficial effects. Some commercial products have been reported to contain 
other cannabinoids (21). It is therefore misleading to describe cannabidiol liquids 
as consumables for ENNDS because they do not contain nicotine, and terms such 
as “electronic cannabidiol inhalation system” or “electronic inhalation system” 
might be more appropriate. A growing number of electronic delivery products 
are now beyond the traditional reach of nicotine and tobacco control, and their 
increasing, often unregulated use in some countries is a cause of concern.
8.1.1 Challenges to quantifying risk
From the perspective of risk assessment, the important distinction between ENDS 
and combustible cigarettes is that the adverse health effects of e-cigarettes depend 
on factors such as the system itself, the way it is used, manipulation and the 
e-liquid. The technical developments described above were not, however, made 
primarily for health considerations. The aim of the manufacturers was to improve 
the delivery of nicotine and the palatability and other properties of the products 
that determine consumer acceptance and use. This aim is a double-edged sword. 
Acceptance of e-cigarettes is a prerequisite for potential use of these systems in 
smoking cessation, but their attractiveness, especially to children and adolescents, 
increases the risk of use by people who would otherwise not have done so.
It is increasingly difficult to assess the toxicological risks of the properties 
of ENDS, because they are diversifying so rapidly. Initial assessments of early 
products postulated a temperature range up to 100  oC. Novel high-powered 
systems can reach temperatures up to 250  oC, which could facilitate chemical 
degradation of some ingredients; however, other technical features, such as 
overheating control or replacement of parts containing tin or other metals, 
might have decreased the exposure of users to toxicants (14). The ambiguous 
role of technical features in modifying risk is also illustrated by pod systems, 
such as JUUL, with unique systems that influence their toxicological profiles. For 
example, closed systems are difficult to manipulate, prevent incidental dermal or 
oral contact with the liquids and form only minimal amounts of heat-dependent 
toxicants because of the low wattage. Pod systems pose a higher risk for young 
people, however, because of their addictiveness and attractiveness and the high 
nicotine content, especially in products sold in the USA (16,18).
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Further risks related to the ingredients and constituents of e-liquids 
are discussed below. Again, however, rapid product diversity makes it difficult 
to generalize, except for categories such as pod systems or sub-ohm devices, 
with very different properties. The rapid diversification also results in an 
information lag, in that, by the time studies are published, the market has moved 
on. An increasing challenge for both risk assessment and risk communication 
is distinguishing those products intended primarily to provide another means 
of delivering nicotine from those of unconventional liquids containing illicit or 
recreational drugs or other physiologically active compounds. Although it might 
be difficult to make this distinction for some products, it would, for example, be 
misleading to attribute any adverse effects of Δ9-tetrahydrocannabinol (THC) or 
synthetic cannabinoids to ENDS or ENNDS per se, even when they are delivered 
by electronic inhalation systems. Restrictions should be considered on use of 
ENDS to combine nicotine with other pharmacologically or physiologically 
active compounds. ENNDS and their liquids should be defined specifically, as 
the absence of nicotine is insufficient as a criterion for defining this emerging 
product group. Alternative assessment frameworks are required for products that 
contain cannabidiol, THC or other drugs. In principle, consideration should be 
given to whether products that are intended for the delivery of physiologically 
active compounds or drugs other than nicotine are within the scope of tobacco 
control.
Individual and population-based risk assessments also depend on 
e-cigarette use and smoking behaviour, including the prevalence of dual or poly 
use (i.e. parallel use with tobacco cigarettes or other tobacco products). (See also 
section 5.) In the USA, dual use is common, although the prevalence of smoking 
has decreased among adults who currently use e-cigarettes, from 56.9% in 2015 
to 40.8% in 2018 (22). Although ENDS can reduce exposure to toxicants, any 
putative health benefits will be limited if users continue to smoke cigarettes. Even 
when heavy smokers (> 15 cigarettes per day) reduced their smoking by > 50%, 
the incidence of lung cancer decreased by only 27%, and their lung cancer risk 
remained more than seven times higher than that of non-smokers (23). Gradual 
substitution of tobacco cigarettes with ENDS is of only limited value, as the risks 
associated with tobacco use remain. Unfortunately, epidemiological studies of 
the health effects of consistent, exclusive e-cigarette use are difficult to conduct 
because of limited data. In addition, the prevalence of e-cigarette smoking is 
highest among cigarette smokers and ex-smokers (22), and it is difficult to 
separate diseases putatively associated with e-cigarette use from continuing 
effects of previous tobacco consumption.
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8.2 Risk assessment and quantification of risks associated with 
use of ENDS and ENNDS
Quantitative risk assessment is a powerful tool for assessing the impact of 
cigarettes, ENDS, ENNDS or HTPs on human health. For example, modelling 
of tumour potency (4) allows estimates of the carcinogenic risk associated with 
individual constituents of cigarette smoke or the entire smoke, as described 
below. Modelling and risk quantification have confirmed the exceptionally high 
adverse effects of tobacco cigarettes in relation to ENDS, ENNDS and HTP (24). 
Although modelling might also be conducted for ENDS and ENNDS, it would 
be difficult to cover the entire product spectrum. Nevertheless, relevant hazards 
can be identified that substantially increase health risks. Regulators should be 
aware of the growing differences among types and categories of ENDS. Therefore, 
regulation should address the ingredients, emissions and technical features that 
have the strongest effects on risk.
In general, ENDS emit fewer toxicants than conventional cigarettes, with 
two notable exceptions. The first is nicotine, a highly toxic compound added 
to e-liquids at concentrations up to 60 mg/mL, depending on the jurisdiction, 
or even higher in so-called “nicotine shots”. Intake of 10 mL of a liquid that 
complies with European regulations corresponds to a dose of 2.8 mg/kg body 
weight for an adult (70 kg) or 20 mg/kg body weight for a small child (10 kg); 
the minimum potentially lethal dosage is estimated to be 6.5–13 mg/kg body 
weight (25), and the lethal dose for infants and small children can be < 5 mg/kg 
body weight (26). As refill containers may contain several hundred milligrams, 
the risk of accidental or intentional poisoning is high. Users of open systems and 
refill containers are at risk of dermal exposure, and incidental oral poisoning can 
occur, although oral absorption of nicotine is often limited by its emetic effects. 
A number of weak or moderate cases of intoxication were reported in 2018 (27), 
but fatal poisonings are very rare (28). The second exception to emission of fewer 
toxicants than conventional cigarettes is contaminants and intentionally added 
compounds, including essential oils, herbal extracts and certain flavours such as 
diacetyl and acetyl propionyl, which can cause serious (acute) lung injury.
Commercial products that comply with regulations in Europe, the USA 
and other countries should not pose such risks. Single cases of lipid pneumonia 
have been reported, probably caused by glycerol contaminated with fatty oils 
(29). Many users prepare their own e-liquids and sometimes make their own 
ingredients, perhaps because they are not aware of the risks. Such risks are 
avoidable and should not apply to commercial products if appropriately regulated. 
In the worst case, however, use of irregular, manipulated or faulty products could 
have acute and fatal toxic effects, while smoking-associated diseases take years to 
develop. Typical hazards of e-cigarettes are discussed below.
181
Exploration of methods for quantifying individual risks associated with electronic nicotine and non-nicotine 
delivery systems and heated tobacco products: impact on population health and implications for regulation
8.2.1 Health risks associated with specific ingredients or unintentionally 
added substances
The health effects that could occur from direct or indirect exposure to harmful 
and potentially harmful constituents of ENDS or ENNDS aerosols when inhaled 
by children or adolescents are summarized below. The actual occurrence of effects 
would depend on the quantity of the compound that is inhaled.
Nicotine
Tobacco smoking increases the risks for arteriosclerosis, myocardial infarction, 
stroke and other cardiovascular diseases. These are due not only to nicotine but 
also to other compounds, such as carbon monoxide, nitrogen oxides, metals and 
particulate matter. The pathogenesis is usually associated with inflammation 
(30,31). Some effects of nicotine, such as increased blood pressure and decreased 
perfusion of coronary vessels, can contribute to cardiovascular injuries. Limited 
data are available, however, on the cardiovascular effects of nicotine in ENDS. 
The cardiovascular toxicity of nicotine is lower without combustion products 
than in cigarette smoke (30), as indicated by studies on use of smokeless tobacco. 
For example, Swedish snus did not increase the risks of stroke or infarction (32), 
despite efficient nicotine absorption, although this requires further study (33). 
A meta-analysis of 11 studies in Sweden and the USA indicated that smokeless 
tobacco users had increased risks for myocardial infarction and stroke (34). 
Increased odds for myocardial infarction with smokeless tobacco use were 
also reported in the INTERHEART study of data on 27 089 participants in 52 
countries (35).
Modern e-cigarettes can be optimized to deliver nicotine at levels 
comparable to those in combustible cigarettes (15). In open systems, nicotine 
levels can usually also be adjusted with the power setting and increase with the 
amount of aerosolized liquid per puff. On inhalation, aerosolized nicotine might 
contribute to inflammation and vascular injuries (36); however, pathogenesis also 
depends on inflammatory co-factors (31) such as reactive oxygen species, and it 
is not known whether these factors are generated by e-cigarettes. Smoking during 
pregnancy can affect embryonic development, reduce birth weight and increase 
the risk for complications, such as premature delivery, stillbirth or sudden infant 
death. Further, both lung function and development can be impaired by maternal 
smoking. It is again, however, difficult to distinguish the adverse effects of smoke 
and combustion products from those of nicotine. Nicotine has been reported 
to limit the availability of oxygen to the fetus by constricting blood vessels in 
the umbilical cord and uterus (37). Prenatal exposure to nicotine interferes 
with development of the brain (38) and is associated with neurobehavioural 
impairment, including hyperactivity, anxiety and impaired cognitive function. 
Nicotine was confirmed as teratogenic to the nervous system in a study in rats 
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(39), and other experimental studies have suggested that developmental exposure 
to nicotine has long-term adverse effects such as impaired fertility, hypertension, 
obesity and respiratory dysfunction (40).
Nicotine may induce other adverse effects, such as insulin resistance, 
thus increasing the risk for diabetes type 2 (41), although the question should 
to be addressed in additional studies. One suggested that nicotine can inhibit 
mucociliary clearance in the lung (42), which could increase exposure to toxicants.
Hazardous constituents and emissions of ENDS and ENNDS
Glycerol and propylene glycol. Glycerol and propylene glycol are the most 
commonly used solvents for aerosolization and are the major constituent of 
e-liquids. Although mild adverse effects such as irritation have been described 
after inhalation (43,44), both compounds are considered relatively safe. The 
amount of evaporated liquid per puff varies, however, and is extremely high 
in sub-ohm devices (45). No comparison has yet been reported of the toxic 
properties of e-cigarette aerosols according to the density of the aerosol or the 
total mass of inhaled material, particularly in the long term. Other solvents, such 
as ethylene glycol, have been used (12), which have higher toxicological risks 
(46); however, it is not clear whether ENDS containing other nebulizing agents as 
major components are currently on the market.
Flavours and other ingredients. Some flavours, including diacetyl, are of 
concern, as they can cause bronchiolitis obliterans, a rare but serious lung disease. 
Diacetyl was detected in a large proportion of liquids tested (11), albeit 5 years 
ago, before the ban on its use in e-cigarettes in many jurisdictions. The sweetener 
sucralose, a halogenated disaccharide, can be degraded in e-liquids when 
devices reach temperatures > 200 °C, which can generate potentially harmful 
organochlorines (47). Other compounds in regular e-liquids include sensitizers. 
For example, limonene oxide, found in lemon-flavoured concentrates (13), is 
considered an important contact allergen (48). Rare cases of hypersensitivity 
pneumonitis have been reported that might be related to use of ENDS and 
ENNDS; however, no specific allergen has yet been identified in e-liquids (49). In 
2019, a further case of hypersensitivity pneumonitis was reported in the United 
Kingdom (50). This case was not related to e-cigarette- and vaping-associated 
lung injury (EVALI) (see HSP2) but indicates that inhalation of e-cigarette 
aerosol can induce allergic responses, although rarely. The etiology of these cases 
should therefore be elucidated, with monitoring of future developments. The 
increasing variety of e-liquids should be regarded as a potential hazard, as many 
of the constituents can generate thermal degradation products and undergo 
chemical conversions. Indeterminate chemical reactions are facilitated by coil 
temperatures of ≥ 250 °C (51).
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Carbonyls and thermal degradation products. Carbonyl compounds, 
including formaldehyde, acetaldehyde and acrolein, are considered the 
most relevant toxic emissions from commercial ENDS. They originate from 
degradation of glycerol and propylene glycol, depending on the device 
temperature. In low-powered devices, carbonyls occur mainly under dry-puff 
conditions due to overheating of the wire in the absence of liquid (12,52). In 
high-wattage devices, carbonyls are formed according to the applied power. Talih 
et al. (45) demonstrated enhanced carbonyl formation in high-power single-coil 
conventional ENDS and sub-ohm devices that varied with the coil surface and 
the amount of liquid consumed. The study showed total aldehyde emissions of 
≤ 400 µg per 15 puffs. The carbonyl content of the aerosol can approach that of 
conventional cigarettes but is highly variable. For example, it may be strongly 
enhanced by flavours (53), and puffing topography can account for variations in 
formaldehyde levels from 20 to 255 ng/puff (45). In general, carbonyls in ENDS 
and ENNDS occur at levels from hardly detectable to several micrograms per puff. 
Acetaldehyde not only has carcinogenic and other hazardous properties but also 
increases the addictiveness of nicotine (54) by inhibiting monoamine oxidase. 
Moderate levels of carbonyls might therefore increase consumer satisfaction by 
making products more attractive.
Adult smokers are less likely than non-smoking adolescents to use JUUL 
as an alternative to cigarettes, although this device delivers high levels of nicotine 
(). The trend to increasing the wattage to variable, higher levels may be partly to 
increase user satisfaction, as higher levels of carbonyls can enhance the effects 
of nicotine and possibly its addictiveness. Toxicological assessments should be 
conducted of various groups of ENDS and ENNDS products. A special category 
might be considered for ENDS that operate at ≥ 15 W, as these devices produce 
dense aerosols and markedly higher levels of toxicants than low-power devices. 
It has been reported that high-power ENDS and ENNDS increase the risk for 
lung injuries, including transient inflammation, and disturb gas exchange (56). 
Regulators should be aware that it would be difficult to impose upper limits on 
the levels of ingredients in high-capacity open-system ENDS and ENNDS, as 
they could be compensated by switching to a higher power (57). For example, 
the intake of nicotine per puff can be increased when a higher volume of liquid is 
aerosolized, increasing the risk to health.
Metals. Metals that occur in the aerosols of ENDS and ENNDS usually 
originate from the devices themselves (58). The levels remain below the limits 
of toxicological concern (59,60) but can be increased at high-power settings 
(61). As redox-active metals might increase the levels of reactive oxygen species, 
cardiovascular risk might be increased, especially in the presence of a high level of 
nicotine. Haddad et al. (62) showed that high-wattage ENDS can generate levels of 
reactive oxygen species that are comparable to those from combustible cigarettes.
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In summary, hazard analysis has confirmed that nicotine, carbonyls and 
metals are relevant risk factors, implying that e-cigarette use could enhance the 
risks for cardiovascular diseases. The high nicotine content, application of high 
wattages and low-quality standards also affect the levels of metals in emissions. 
As aerosols may contain irritants, the risks of respiratory diseases should also be 
assessed. ENDS generate levels of carcinogens that are lower than those typical 
for tobacco smoke, except those of carbonyls (63,64). This finding was recently 
confirmed for sub-ohm and high-wattage devices in an industry-sponsored study 
(65) but should be confirmed in independent research.
8.2.2 Potential health effects of ENDS and ENNDS
Smoking can increase the risks for arteriosclerosis, myocardial infarction, stroke 
and other cardiovascular diseases. The risk factors include a number of chemical 
species, such as carbon monoxide, nitrogen oxides, metals and particulate matter. 
Pathogenesis is usually linked to inflammation, and some nicotine-related effects, 
such as increased blood pressure and decreased perfusion of coronary vessels, can 
exacerbate cardiovascular injuries (30,31). There is still, however, some debate 
about whether e-cigarette use also increases cardiovascular risk. A systematic 
review of studies on the use of e-cigarettes and cardiovascular disease indicated 
potentially increased risks for thrombosis and atherosclerosis (66).
Short-term exposure to e-cigarette emissions can trigger vascular 
oxidative stress and dysfunction (67). e-Cigarettes can have an effect even after 
a single use and even without nicotine, with a transient effect on endothelial 
function (68). In a meta-analysis, Skotsimara et al. (69) found associations 
between e-cigarette use and endothelial damage, arterial stiffness and a long-term 
risk for coronary events; however, these findings were made in single studies and 
were not confirmed in others. Short-term effects on vascular function do not 
necessarily progress to clinically relevant disease. Analysis of data collected in 
the Behavioral Risk Factor Surveillance System in 2016 showed substantially 
increased risks for stroke, myocardial infarction and coronary artery disease 
among 70  000 respondents who reported use of e-cigarettes (70,71). Further, 
analysis of National Health Interview Surveys (2014–2016) confirmed a higher 
risk for myocardial infarction after adjustment for cigarette smoking and other 
risk factors (72). Analysis of pooled Behavioral Risk Factor Surveillance System 
data collected in 2016 and 2017 did not confirm an increased cardiovascular risk 
for e-cigarette users who never smoked cigarettes (73). No specific data are yet 
available on devices that might enhance such risks. A comprehensive review of 
preclinical findings and epidemiological evidence on the effects of e-cigarettes on 
cardiovascular and general health was inconclusive, and more data are needed. 
The authors concluded that, while it is reasonable to consider e-cigarettes less 
hazardous than combustible tobacco products, no smoke is better than electronic 
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smoke (70). One report showed that smokers who switched to e-cigarettes had 
significantly improved endothelial function and vascular health (74).
Other health effects include irritation of the respiratory tract, mainly 
the upper airways (75). Effects on lung function have also been reported, with 
decreased lung function capacity among e-cigarette users than non-users and 
possibly increased lung resistance (76,77). Furthermore, e-cigarette users 
may have a reduced response to infections (78). An analysis of the data in 
the Behavioral Risk Factor Surveillance System for 2016–2017 indicated that 
e-cigarettes enhance pulmonary toxicity. Increased risks of respiratory diseases 
have also been confirmed by others (79). Another study suggested that the 
health of patients with chronic obstructive pulmonary disease who smoked 
tobacco improved after they switched completely to e-cigarettes, including 
better outcomes and reversal of some of the harm caused by smoking (80). This 
illustrates the different perspectives of smokers and non-smokers on the health 
risks of e-cigarettes. A link between e-cigarette use and asthma has been reported; 
however, the high prevalence of e-cigarette use by adults with asthma could be 
related to quit attempts in this group (73).
In the summer of 2019, a series of cases of serious lung injury associated 
with use of vaping or e-cigarette product use was reported in the USA. (See also 
section 12.) The number of incident cases related to e-cigarette use increased, and 
fatalities with no history of lung disease were reported (81). The disease, named 
“E-cigarette- and Vaping-Associated Lung Injury” (EVALI), was restricted mainly 
to the USA. By 18 February 2020, 2807 hospitalized cases had been reported, 
including 68 EVALI-associated deaths (82,83). The patients presented similar 
clinical characteristics, such as dyspnoea and cough, and were hypoxaemic, with 
bilateral airspace opacities on chest imaging (84). As these symptoms are similar 
to those of other respiratory diseases, these cases were not immediately linked 
to use of specific types of e-cigarettes (85). Many, but not all, patients had used 
THC-containing e-liquids, and further research indicated that vitamin E acetate, 
which is added to THC-containing e-liquids as a thickener, was the probable cause 
of the respiratory injuries (86–88). The patients with respiratory disease were 
found to have used e-liquids containing THC more often than non-patients and, 
perhaps more importantly, reported more frequently obtaining products from 
informal sources (89). Cases also occurred, however, in patients who did not use 
THC-containing liquids. Patients showed respiratory effects within a few days to 
several weeks of inhaling vitamin E acetate, which allowed identification of the 
cause of the disease; however, an association is much more difficult to establish 
with long-term health effects. In one study that confirmed the association (88), 
exceptionally high levels of vitamin E acetate were found in products collected 
from EVALI patients. The reported concentrations were 31–88%, while the THC 
content was often lower than that advertised (90). It should be noted that these 
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products have little in common with typical e-cigarettes. Both risk assessment 
and public education are necessary to respond to the increasing proliferation 
of unconventional, often illicit uses of e-cigarettes to deliver drugs other than 
nicotine. Risk assessment would benefit from a clear distinction between these 
products and regular ENDS, which would be difficult to achieve in practice.
8.2.3 Risks for bystanders
Bystanders may be exposed to emissions of ENDS, ENNDS or HTP exhaled by 
users. Their actual exposure will depend largely on the size and ventilation of the 
room. Bystanders could experience irritation of the respiratory tract as a result of 
exposure to propylene glycol and glycerol. Systemic effects of nicotine might also 
be expected if nicotine-containing e-liquid is used, including heart palpitations 
and raised systolic blood pressure. Because tobacco-specific nitrosamines are 
present in some e-liquids, bystanders might be at increased risk of tumours in a 
worst-case scenario (91). Another study concluded that the health of bystanders 
was unlikely to be at risk due to e-cigarette use (92). Studies of bystander exposure 
to e-cigarettes and to tobacco cigarettes have shown that the health risk associated 
with second-hand e-cigarette aerosol was lower than that associated with second-
hand smoke (93,94). Other studies have shown that the concentration of nicotine 
in the air is much lower when e-cigarettes are used than with tobacco cigarettes 
(95), although bystanders can take up nicotine from second-hand smoke (96). 
Use of HTPs is considered to result in higher exposure of bystanders than use 
of e-cigarettes (97). Whether exposure of bystanders to second-hand HTP or 
e-cigarette emissions could have adverse effects is largely unknown. One study 
suggested an association between second-hand exposure to e-cigarettes and 
reported asthma attacks in the past 12 months (98). This indicates that some 
population groups, such as patients with airway disease and young children, are 
more vulnerable to adverse effects on exposure to second-hand emissions.
8.3  Methods for quantifying risk
Tobacco products differ not only in type but also in emissions and use, resulting in 
different health risks. Even products within a class, like ENDS and ENNDS, have 
different effects on health. Smokers of tobacco cigarettes who wish to switch to a 
potentially less harmful product require information on the relative risks of such 
products. A product that is potentially less harmful for a smoker is more harmful 
for a non-smoker. Quantitative hazard characterization, which includes a dose– 
or concentration–response relation, can be used to determine the potential health 
effects at population level when information is available on the number of users 
and their use pattern. Generalization of the health risk of a tobacco product is, 
however, not scientifically appropriate in view of the differences among products 
in a class and among users (99). Risk assessment for ENDS and ENNDS should 
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therefore be conducted separately for groups of devices or even for individual 
devices and liquids. A wide range of e-cigarette use parameters must also be 
considered in estimating human exposure.
Quantification of the risks of chemical mixtures is inherently difficult, 
and the appearance of novel nicotine and tobacco products adds to the challenges 
of the wide variety of products, compositions and diversity of use. Differences 
among products make quantification of both exposure and hazard uncertain. 
To measure exposure, information is necessary on the topography of e-cigarette 
use, the emissions inhaled and, depending on the method used, particle size and 
particle size distribution, which determines deposition in the respiratory tract 
and therefore local exposure and effects (100,101). Information on the chemical 
composition of the emissions is also necessary to identify the compounds to which 
users are exposed. The emissions from tobacco products contain many different 
compounds, which depend on the topography of e-cigarette use and device 
settings such as temperature and power (62,102). The compounds in emissions 
must be characterized and quantified in order to assess the risk of these products 
(9). Unfortunately, information on ingredients (contents) alone is insufficient, as 
they may degrade or burn during aerosolization or may originate from the device.
Information on hazard can be derived from toxicological studies of 
compounds, preferably administered by inhalation, the most relevant route of 
exposure for ENDS, ENNDS and tobacco products. Information on hazard is not 
available for all the compounds in each of these products. e-Liquids commonly 
contain flavours that have been tested for toxicity by oral administration for 
use in foods, and no information on toxicity resulting from inhalation of these 
compounds is available. Such information is necessary, as, in toxicity studies, 
some compounds, like diacetyl and cinnamaldehyde, can have local effects on the 
respiratory tract when inhaled (103,104). Furthermore, users of ENDS, ENNDS 
and HTP products are exposed to mixtures of compounds that may or may not 
interact biologically.
The risk associated with mixtures can be quantified by combining data on 
the hazard of individual compounds with the quantities present in the emissions 
of products. Alternatively, the risks of ENDS, ENNDS or HTP could be quantified 
case by case in toxicity studies; however, studies in experimental animals may not 
provide meaningful results for assessing the risks that tobacco products pose to 
humans. In addition, exposure in experimental studies is generally for 6 h/day, 
5 days/week, which is not comparable to use of ENDS, ENNDS or HTP, which 
result in irregular peak exposure for 7 days/week. The development and use of 
alternative models, such as cell models, are increasing rapidly, but this has not yet 
allowed hazard characterization of mixtures.
Some work has been conducted on the toxicological effects of mixtures 
(105). In a project by the European Union (106), EuroMix (https://www.euromix 
project.eu/), which ended in 2019, compounds were classified according to 
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their target organ and their mechanism of action. Compounds with similar and 
dissimilar modes of action were assessed in assays specific for a target organ 
to determine whether the effect of the mixture was different from those of the 
individual compounds. The project resulted in a toolbox for exposure scenarios 
and testing strategies outlined in a handbook of practical guidance. As in the 
EuroMix project, most studies of the toxicity of mixtures have addressed binary 
combinations; however, no reliable method is available even for these relatively 
simple mixtures to predict quantitatively the effects of any combination of the two 
compounds in the mixture without the input of at least some experimental data. 
It is difficult to predict whether the compounds in a mixture will interact, and this 
may be obscured by variations in the biological response. Binary mixtures often 
have an additive effect, such that the potency-adjusted doses of the individual 
compounds can be summed to predict their combined effect. Mathematical 
models are available to determine whether the toxicity of a mixture is due to 
interaction between the compounds. The two commonly used mathematical 
models used are the dose–concentration addition model and the independent 
action–response addition model (107–109). The dose–concentration addition 
model is based on the assumption that all compounds have a similar mode of 
action but may have different potency to induce an effect. Once the potency of 
one compound is determined relative to that of another, the concentrations of 
both compounds can be expressed relative to that of one of the compounds as a 
reference. When the concentrations are summed, they can be used to determine 
the effect of the binary mixture on the dose–response curve of the reference 
compound (110). In the concentration addition model, a similar mode of action 
is assumed, whereas the independent action model can be used to determine the 
effects of compounds that are due to different mechanisms or modes of action 
(111). Mathematical models can be used to determine whether compounds 
interact, which is the case in synergism or antagonism. These models cannot be 
used to predict the effects of complex mixtures such as tobacco smoke.
Risk assessment of the complex emissions of tobacco products, ENDS 
and ENNDS is even more complicated and is similar to the assessment of 
other complex mixtures, such as petroleum-derived and cement-like products. 
Generally, the approach to assessing the risks of such products is to assess 
the toxicity of a representative sample of the mixture as a whole, primarily in 
experimental animals. A similar approach may be used to assess the hazard of 
ENDS and ENNDS, while differentiating classes of products. Although studies 
in experimental animals are ethically debatable, various (tobacco) products have 
been tested; however, translating the results into human effects and assessing 
different products within a class remains a challenge.
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8.3.1 Threshold of toxicological concern
One approach to assessing exposure to complex mixtures is the threshold of 
toxicological concern (TTC) (112). In this approach, originally developed for 
assessing carcinogenicity, the compounds of greatest toxicological concern 
in a mixture are identified from structure–activity relations and read-across. 
TTC values (in µg/person or µg/kg body weight per day) have been defined for 
three classes (Cramer classes I–III) according to structural elements, but only 
after oral exposure. Cramer class III indicates the highest carcinogenic risk and 
consequently the lowest TTC value (113). The risk of a mixture is then assessed 
by comparing exposure to these compounds, either alone or summed, with the 
appropriate TTC value. This approach has been applied to complex mixtures 
such as botanical extracts (114), flavour complexes (115) and inhaled toxicants 
(116,117). This method does not indicate a risk to health but indicates that 
further testing is required if a compound exceeds the TTC threshold; otherwise, 
the probability of a health risk is low. This method might be used when no hazard 
data are available. As it is already known that tobacco products have adverse 
health effects, the TTC approach for risk assessment cannot be used to quantify 
health effects. For ENDS and ENNDS, however, it might be used to identify 
compounds that pose a health risk and to prioritize them for further testing.
8.3.2 Risk assessment based on individual compounds
Information on exposure to and the hazard of individual components could be 
used to assess the risk of a product as a whole. For cigarettes, compounds could 
be selected for their hazardous potential (6,118,119). For ENDS, the number of 
compounds in emissions is limited, and they do not necessarily overlap with 
known tobacco toxicants. Compounds that are generated by thermal degradation, 
such as aldehydes, should also be considered for ENDS and ENNDS. This method 
has been applied to assess the toxicity of e-cigarettes for users and bystanders 
(91). The data on hazards used in this approach are derived from studies for 
setting a safe level of exposure. In emissions from tobacco products, and in some 
cases also from ENDS and ENNDS, the concentrations are often above the safe 
level of exposure, so that the information can be used as an indicator of potential 
concern but not for quantifying risk. The effect seen in experimental animals may 
not directly reflect a similar effect at a similar exposure level in humans, as the 
exposure regime in experimental studies differs from human exposure patterns. 
Addition of the risks of individual compounds in order to estimate the risk of a 
complex mixture probably results in underestimates of health risks, as interactive 
effects among compounds in the mixture are ignored. Risk assessment based on 
individual compounds does not allow comparison of the risks of different (tobacco) 
products because of the design of many experimental studies. To compare the 
severity of effects, detailed information is necessary on the relations between 
exposure and health effects and how they can be extrapolated to effects in humans.
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8.3.3 Relative risk approaches
Studies have also been conducted to estimate the carcinogenic potency of a tobacco 
product as a whole and relative to a (reference) tobacco cigarette (3,24). In this 
approach, data from carcinogenicity studies in rodents are used to determine the 
carcinogenic potency of a compound, by using a modelled linear relation between 
exposure level and the number of tumours induced. For example, benchmark 
dose methods can be used to determine a lower confidence bound (usually 95%) 
of the effective dose that results in a tumour incidence of 10%. Quantitative 
data on carcinogenic potential can be used to calculate the relative carcinogenic 
potency of each compound according to technical guidance documents, such 
as that published by the Office of Environmental Health Hazard Assessment in 
California, USA (120). The total relative carcinogenic potency of mixtures or 
aerosols can then be calculated by adding the values for individual compounds. 
In this approach, it is assumed that relative potency factors are equal over the 
entire dose range and the mechanisms are comparable. Although the mechanisms 
of action differ among carcinogens, the outcomes may give an indication of 
carcinogenic risk and allow comparison of carcinogenic risk among products. 
The validity of the assumptions is assessed during validation of the method.
This relative risk approach depends on the availability of data on both 
emissions and carcinogenicity. Data on the emissions of as many compounds 
as possible is required, as the inclusion of more compounds improves the 
calculation of relative risk. The methods used to analyse emissions should be 
similar for both products, and information on variations in the emissions must 
be available to determine the uncertainty in the relative risk. Information on 
carcinogenic potency should be derived from studies in rodents; alternatively, 
data from other sources can be used that are indicators of carcinogenic potency, 
if data on dose and response are available. This approach currently appears to be 
the best for quantifying the (relative) risk of products; however, for systematic 
application, more data should be available on emissions and on hazard level. A 
similar method might be applicable to other health effects, such as cardiovascular 
disease or chronic obstructive pulmonary disease.
8.3.4 Margin-of-exposure approach
The margin-of-exposure approach is based on the ratio of the exposure level and 
the dose at which no effects occur or the dose at which a predefined adverse 
effect occurs (e.g. a benchmark dose level). The larger the margin of exposure 
of a compound, the higher the risk may be. This approach has been applied 
to compounds in tobacco products (121,122) and can be used to prioritize 
compounds that should be reduced in tobacco smoke emissions and to assess 
individual compounds in the emissions of ENDS and ENNDS. A margin of 
exposure is calculated for each compound from data on inhaled emissions and 
information on hazard and depends on the quality of the data. The approach does 
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not result in a quantitative risk characterization. Its main goal is to determine 
whether a specific exposure is of concern. The magnitude of the margin of 
exposure is not a measure of risk.
8.3.5 Non-carcinogenic effects
Many methods address risk evaluation of carcinogenic effects, which are easier 
to model than non-carcinogenic effects, as the end-point (cancer) is easier to 
compare and the dose–response curves for carcinogens are comparable. Inherently, 
non-carcinogenic effects are diverse. Local effects should be differentiated from 
systemic effects; different compounds have effects on different organs and, even if 
compounds have an effect on the same organ, their mechanism and result may be 
different. Quantification of non-carcinogenic effects might have to be conducted 
at the level of the mechanism of action (106); however, this approach requires 
dose–response data on the mechanism of action of compounds, which is limited. 
Non-cancer risk indices have, however, been generated for the cardiovascular 
and respiratory effects of cigarette smoke (4).
Alternatively, toxicological assays of emissions may be used to 
characterize the risk of a product. As mentioned above, bioassays in experimental 
animals may not be preferable, and the results of cellular assays are difficult to 
translate into effects in humans. In addition, not only should the effects (read-out 
parameters) be extrapolated to human effects, but the exposure should resemble 
human exposure. This includes smoking topography and, in the case of a lung 
model, deposition in the airways. This field is evolving, but in vitro assays for 
characterizing non-carcinogenic effects of ENDS, ENNDS and HTPs remain in 
the future.
8.3.6 Evaluation frameworks
Assessment of the health effects of ENDS and ENNDS could be based on an 
appropriate evaluation framework. In this approach, expert judgement is used 
to score aspects of a product in order to identify the most important risks of, for 
example, drugs (123). The Netherlands National Institute for Public Health and 
the Environment has developed an evaluation framework for tobacco products 
that summarizes all the factors that may influence the attractiveness, addictiveness 
and toxicity of a product and can be used to identify knowledge gaps or prioritize 
research on a specific product (124). These models allow evaluation of a product 
even when limited data are available. Evaluation improves with increasing 
knowledge about a product, but this approach is limited to qualitative results 
based on expert judgement.
The methods described above can be used to compare the hazards of 
different products. Table 8.1 summarizes the methods, their data requirements 
and their application. The feasibility of applying the methods is determined by the 
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information available and not by the product itself. The information necessary for 
full risk characterization is currently not available. In some methods, a weight-of-
evidence approach can be used for data of different quality. Many methods for risk 
quantification also require data on emissions, an indicator of human exposure. 
Tobacco smoke and emissions from ENDS and ENNDS are dynamic. Emissions 
cool as they pass from a heating element to the exit of the device, resulting in 
condensation of volatile compounds and agglomeration of particles. In addition, 
the inhaled air, which includes the emission, is humidified in the upper airways. 
These processes occur simultaneously and determine local deposition in the 
airways, which can result in high doses at specific locations in the airways, which 
could have site-specific adverse effects. Modelling of airway deposition of tobacco 
smoke and ENDS or ENNDS emissions is under way (100,125). The outcome of a 
qualitative risk assessment depends on the quality of dosimetry, which is limited.
Table 8.2 summarizes the limitations and advantages of the methods 
described in this paper. It should be noted that all the methods are intended for 
assessment of risk to users. Similar methods could be used to assess the risk of 
bystanders, provided that information is available on their exposure.
Table 8.1. Summary of methods for quantitative risk assessment of ENDS and ENNDS according to 
individual compounds or their mixture (1), the data required (2 and 3) and their application (4–7)
Method 1. Individual 
compounds 
or mixture?
2. Dependent 
on emission 
character-
ization?
3. Dependent 
on available 
hazard data?
4. Allows 
quantifica-
tion of risk 
of single 
compounds?
5. Allows 
quantifica-
tion of risk of 
the product 
as a whole?
6. Allows 
quantifica-
tion of risk of 
the product 
as a whole 
for vulner-
able groups?
7. Data 
required for 
a modified 
product
Threshold of 
toxicological 
concern
Individual Yes No No, allows 
identification 
of potential 
hazardous 
compounds
No No Emission 
data
Risk 
assessment 
based on 
individual 
compounds
Individual Yes Yes Yes Yes, but only 
if data for all 
compounds 
are available
Yes, but only 
if data for all 
compounds 
and specific 
hazard 
data on 
vulnerable 
groups are 
available 
Emission 
data
Relative risk 
approaches
Mixture Yes Yes Yes Yes, but only 
if data for all 
compounds 
are available
Yes, but only 
if data for all 
compounds 
and specific 
hazard 
data on 
vulnerable 
groups are 
available 
Emission 
data
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Method 1. Individual 
compounds 
or mixture?
2. Dependent 
on emission 
character-
ization?
3. Dependent 
on available 
hazard data?
4. Allows 
quantifica-
tion of risk 
of single 
compounds?
5. Allows 
quantifica-
tion of risk of 
the product 
as a whole?
6. Allows 
quantifica-
tion of risk of 
the product 
as a whole 
for vulner-
able groups?
7. Data 
required for 
a modified 
product
Margin-of-
exposure 
approach
Individual Yes Yes No No No Emission 
data
Bioassays 
for non-
carcinogenic 
effects
Mixture No No No Yes Yes, but only 
if specific data 
on hazards 
for vulnerable 
groups are 
available 
Toxicity 
bioassays
Evaluation 
frameworks
Mixture No Yes No No, only non-
quantitative 
risk
No, only non-
quantitative 
risk if data are 
available on 
vulnerable 
groups
Re-
evaluation of 
e.g. emission 
data 
Column 1: Applicability of the output of the method to individual compounds or to the emission as a mixture
Column 2: Requirement for quantitative data on (ideally) all compounds in the emission
Column 3: Requirement for data on dose–response related hazard
Column 4: Applicability of the method to quantify the risk of exposure to one of the compounds in the emission
Column 5: Applicability of the method to quantify the risk of exposure to the product
Column 6: Applicability of the method to quantify the risk of exposure to the product pf vulnerable groups, such as infants
Column 7: Data required to quantify the risk of a slightly changed product, such as a new flavour in an e-liquid or technical 
adaptation of the device
Table 8.2. Limitations and advantages of each method for quantifying the health risk of ENDS and ENNDS
Method Main limitations Main advantages Potential application for ENDS, 
ENNDS and HTPs
Threshold of toxicological concern Cannot assess risk of 
complete product
No quantification 
of risk
Information on 
possible risk from 
exposure
Prioritization of compounds for 
further testing
Risk assessment of individual 
compounds
Cannot assess risk of 
complete product
Identification of 
compounds with 
highest health risk
Health risk assessment based on 
available data
Relative risk approaches Currently only for 
carcinogens 
Allows comparison of 
risks between products
Health risk assessment based 
on available data and allows 
comparison of products
Margin-of-exposure approach Cannot assess risk of 
complete product
Information on 
exposure in relation to 
health concern
Prioritization of compounds for 
further testing
Bioassays for non-carcinogenic 
effects
Extensive testing 
required and 
extrapolation of 
exposure and results to 
humans
Does not require data 
on emissions or hazard 
Health risk assessment based on 
available bioassays
Evaluation frameworks Most subjective 
method
Requires limited data; 
more data will improve 
outcomes
Non-quantitative health risk 
assessment, can be used for setting 
priorities
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8.4 Heated tobacco products
Methods used to assess the risks of ENDS and ENNDS can in principle be 
applied to HTPs. HTPs currently vary less than the e-systems, and some reliable, 
independent data are available on the composition of the aerosol (9). Industry 
data must be verified independently before it can be used for risk assessment. 
Previous investigations addressed the toxicants that typically occur in cigarette 
smoke, and further independent research is required for a comprehensive 
analysis of emissions and health risks. The methods used to analyse cigarette 
smoke and standardization of inhalation topography must still be adapted to 
obtain user-representative measurements. Further, some toxicants might not be 
relevant in cigarette smoke but could occur preferentially in the aerosol of HTPs. 
This question has been addressed with untargeted screening methods (126–128), 
which have also been used by industry scientists (129). Some components 
of concern, including glycidol (classified in 2A by a working group at the 
International Agency for Research on Cancer) and furfuryl alcohol (classified 
in 2B) have been identified in HTP aerosol, and data for specified HTPs would 
allow risk modelling and comparative or quantitative assessment. Stephens (24) 
modelled the carcinogenic potency of aerosols from cigarettes, ENDS and an 
HTP device, and comparative modelling approaches have since been refined (3) 
to determine the relative cancer potency of individual compounds and product 
emissions, with confidence intervals. The ratio or change in cumulative exposure 
can then be calculated with a probabilistic approach for two products. For HTPs, 
the change in cumulative exposure to selected compounds was 10–25 times 
lower than from smoking cigarettes. With relevant information on human 
dose responses, the change in cumulative exposure can be translated into an 
associated health impact for each device. This approach was initially used for 
eight carcinogens that occur in the aerosol of HTP and in cigarette smoke but 
should be extended to compounds that are found at higher levels in HTP aerosols 
than in cigarette smoke.
These calculations illustrate the differences in the composition of HTP 
aerosol and that of tobacco smoke, which may affect the health risks. As HTPs 
continue to evolve, standards of performance and upper limits for key toxicants 
should be considered the most useful, feasible options for regulation. The 
methods for quantitative risk assessment of ENDS and ENNDS described above 
are based on data on emissions and hazards and can therefore be applied to HTPs 
as well, if the data are available.
8.5 Implications for regulation
Current methods for quantifying the health risk of ENDS, ENNDS and 
tobacco products are not yet adequate for use in regulation. Some approaches 
can be used, however, to obtain an indication of the absolute health risk of a 
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product. These methods are based on the risk associated with specific or unique 
compounds in emissions, which depends on the availability of data. Compounds 
in emissions should be identified and quantified, ideally in user-representative 
settings. In addition, (human) toxicological data on these compounds is required 
to quantify health risk; however, data are lacking for both these parameters. The 
risk assessment approaches described in this paper could be considered for use 
in regulation; however, currently, because of lack of data, this stage has not been 
reached, as the model is only as good as the quality of the data.
Quantified health risks could be used in models for estimating health 
risks at a population level. Although this has not yet been done, the feasibility of 
modelling population health effects has been explored (130). The health impact 
of ENDS, ENNDS or HTPs in smokers, non-smokers and former smokers can 
be estimated when monitoring their popularity and use and used as a reason for 
legislative measures to limit use of the product or as a basis for public education. 
The outcomes depend strongly on the input data, which, in this case, will also 
include epidemiological data. The observation that epidemiological data on 
product use and switching between products is inconsistent should be considered 
when applying population modelling.
Modelling has indicated that switching from cigarettes to HTPs can affect 
human health; however, the effect depends on the compliance of devices with 
substantially lower levels of previously documented toxicants in the emissions. 
Regulators should consider setting mandatory upper limits for carbonyls, carbon 
monoxide and other key toxicants to ensure that devices meet technical and 
performance standards.
Effective regulation of ENDS and ENNDS and their characteristics 
could also contribute to limiting their health risks. Priority should be given to 
closed systems, like pods or sealed cartridges that cannot be easily manipulated 
by consumers. Problematic ingredients and constituents (diacetyl, sucralose, 
essential oils and all carcinogenic, mutagenic and teratogenic compounds) 
should be prohibited, and upper limits for nicotine in the emissions of closed-
system ENDS might also be considered. Although prohibitions of hazardous 
compounds should apply to liquids in general, the emissions of flexible, usually 
high-powered open systems are difficult to regulate. The focus might therefore be 
shifted to technical features, such as overheating controls, maximum wattage or 
temperature. Further regulation would require detailed assessment of ENDS and 
ENNDS subcategories, especially of high-powered products, including aerosol 
chemistry, toxicology and the design and performance of devices.
The ambiguous terminology and definition of ENNDS are also matters 
of concern. For example, nicotine-free devices can be used to inhale compounds 
such as cannabidiol, for which some health benefits have been claimed. The 
impression that certain ENNDS might be beneficial for health, however, might 
distract from and confuse current assessments and should be avoided. Use of 
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ENDS to combine nicotine with other pharmacologically or physiologically 
active compounds should be prohibited, as this could increase the attractiveness 
of nicotine consumption. The terminology and definition of ENNDS should 
be specified, to identify them as products that are the same as ENDS products 
but without nicotine. This should be applied to both devices and consumables. 
The term “ENNDS” would still cover conventional e-liquids offered as nicotine-
free versions. The regulatory framework for ENDS and ENNDS might still 
include other electronic inhalation systems as related products, thus defining 
all devices equally. A clear separation of nicotine and tobacco substitutes from 
other electronic inhalation products would, however, be beneficial, for several 
reasons. First, specific rules could be adopted for ENDS, ENNDS and other 
electronic inhalation systems used to inhale other substances or materials. 
Second, the clarification would require specific risk communication, thus 
preventing a misleading generalization, as observed early in the EVALI episode. 
Third, regulators might gain more flexibility for dealing with any novel inhalation 
systems developed in the future.
It should be noted that quantification of health risks is not a static outcome 
but remains an estimation based on the available knowledge. Information on 
ENDS and ENNDS is increasing, as is, probably even more important for ENDS 
and ENNDS, the wide variety of devices, user settings and e-liquids, which will 
influence health risks. Providing public information on the health effects of 
ENDS and ENNDS is a challenge. It is difficult to convey to the general public the 
changing (relative) risks over time due to differences in devices or information. 
Furthermore, information on health risks could be used by the industry to 
promote alternative products inappropriately.
Several of the methods described in this paper are promising for assessing 
the risks of ENDS, ENNDS and HTPs, although probably more than one model 
will be required for a full assessment. At this time, not enough scientific data 
are available to make definitive assessments. As many of the methods require 
a substantial amount of data on hazards and exposure, we could prepare for 
the future by collecting those data and conducting standardized assays so that 
the results are suitable for feeding into a database for future use. Non-targeted 
screening can be used to identify product-specific compounds, and their hazard 
could be derived from the database. Information on the relation between 
actual human exposure and the occurrence of adverse effects is necessary for 
risk characterization. Development of risk assessment models should continue, 
and, at some point, they should be validated with human data. Models of airway 
deposition should also be developed for application in risk assessment, as this 
is a crucial step between emission quantification and hazard characterization. 
Ultimately, this would require only chemical analysis of a novel product, 
which, combined with models of deposition and risk assessment, would allow 
determination of the health effects.
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8.6  Discussion
A causal relation between ENDS or ENNDS use and acute effects (short-term 
health risk) is generally easier to identify, as the time between exposure and effect 
is short. In many cases, when users stop using the product the adverse effects 
are reversed. Assessment of the health risk of ENDS and ENNDS would benefit 
from data on health effects in long-time e-cigarette users; unfortunately, such 
data are not yet available, as e-cigarettes have not been available for the time 
necessary to develop chronic health effects such as cancer. In addition, current 
ENDS and ENNDS users are often former smokers. Thus, if an ENDS or ENNDS 
user develops disease, it may be a delayed effect of smoking and not necessarily 
related to ENDS and ENNDS use. The most robust data for assessing health risk 
would be for ENDS or ENNDS users who are not former smokers. The wide 
variety of devices and e-liquids, which continue to evolve rapidly, and the lack of 
information on the products in current use obviate conclusions on the risk posed 
by the group of ENDS and ENNDS as a whole. The lack of long-term data and of 
information on non-smokers may change over time as the products remain on 
the market for longer and if more non-smokers start using ENDS and ENNDS. 
The variation in products is not expected to stop; on the contrary, more and more 
products are entering the market. On the Dutch market, as in other countries, 
more than 20 000 different e-liquids are already available. A pragmatic approach 
would be to identify compounds in e-liquids or device settings that adversely 
affect health, as mentioned previously. The health risks of individual compounds 
could indicate the health risk of the product as a whole, and such information 
could inform policy on permissible constituents, device design features and the 
levels of certain constituents.
Risk modelling, epidemiological studies and assessments of individual 
compounds have resulted in consensus among some experts that unadulterated 
ENDS are less harmful than conventional cigarettes (131). Nevertheless, a number 
of health risks remain, as acknowledged and summarized by WHO (10). Although 
quantitative assessments remain difficult (70), ENDS use results in a substantial 
decrease in carcinogenic risk, as confirmed by modelling (24). ENDS are, however, 
associated with a high risk of nicotine addiction and increased risks for respiratory 
diseases and other adverse health effects that are especially relevant for children, 
adolescents and people who have never smoked. The rapid increase in use of pod 
systems in the USA is a concern (16); however, the potential benefits for established 
smokers who use ENDS as a substitute for cigarettes should also be considered. 
For example, patients with chronic obstructive pulmonary disease who switched 
to ENDS showed improvement (80). There is some evidence that ENDS are useful 
for smoking cessation (132); however, a general conclusion is not scientifically 
justified, as ENDS and ENNDS are a heterogeneous, changing group of products 
(99). Communication of health risks should avoid imprecise generalizations, 
especially because of the diversity of the products and their possible effects.
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ENDS and ENNDS are often still considered as a single group of products 
in terms of risk assessment and legislation. Regulators and ENDS users should, 
however, be aware of the highly variable risks, which might range from very low 
to levels comparable to those for HTPs with devices that reach ≥ 250  °C. The 
health risks even of individual compounds are highly variable, depending on 
the device and performance settings. Major subgroups of ENDS (i.e. pod, sub-
ohm) should therefore be categorized separately to ensure more specific terms of 
reference for both risk assessment and regulation.
Hazardous ingredients or device settings that lead to formation of (more) 
hazardous compounds could also be regulated. Although this would be beneficial 
from a health perspective, toxicological information on exposure to e-liquid 
ingredients by inhalation is very limited. Regulation or prohibition of specific 
ingredients on the basis of toxicological information might be a useful option. As 
noted above, flexible strategies will be required to cover different product groups 
and open and closed systems. Importantly, restrictions only on liquids should 
not imply that other ingredients are safe, as their risks especially in the context of 
inhalation are not yet known.
Furthermore, ENDS and ENNDS should be distinguished from inhalation 
devices used to deliver cannabidiol and other substances for their pharmacological 
or physiological effects and responses. Health risks and injuries caused, for 
example, by unconventional liquid constituents and modified devices that can 
aerosolize oils and waxes or are used to inhale illicit drugs must not be considered 
to be adverse outcomes related to vaping or e-cigarette use. Combination of 
nicotine with other physiologically or pharmacologically active compounds in 
ENDS should be prohibited, as this could increase the attractiveness of nicotine 
consumption. Tobacco control should include definition and specification of the 
framework for assessing ENDS and ENNDS according to these new challenges.
8.7 Recommendations
Risk assessment of mixtures is of great interest, not only for ENDS and ENNDS 
but also for tobacco products. Several models are available that can be used 
to assess the risk of mixtures, although most address carcinogenic effects. 
Implementation is limited by lack of data, which also implies that the models 
cannot yet be validated with data on human use. A few recommendations based 
on the findings of this review are listed below.
 ■ Data should be collected on the emissions, toxicity, use and effects of 
ENDS, ENNDS and HTPs on exposed populations for application of 
quantitative methods of risk assessment.
 ■ Characterization of toxicants should include non-targeted screening 
approaches to identify product-specific compounds that are not usu-
ally measured in tobacco smoke.
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 ■ Appropriate studies in experimental animals and epidemiological 
studies should be conducted on long-term adverse effects and of 
product switching.
 ■ The models used to justify any claim of a positive health impact of 
HTPs and in their marketing should be verified.
Each product and change in product may result in a change in risk. In addition, 
users can flexibly adapt the systems to their requirements, which may alter their 
exposure from that used in risk assessments and change their health risk. Other 
recommendations for consideration by regulators are listed below.
 ■ Limit product variations.
 ■ Regulators should define subcategories or classes and terminology 
for ENDS and ENNDS as a basis for differentiated risk assessments. 
Different product groups, such as “single-use” products, open, refill-
able and highly powered systems, might warrant specified technical 
standards or regulatory approaches to minimize health risks and ad-
dictiveness.
 ■ Neither ENDS nor ENNDS should contain any compound that might 
mediate drug-related effects or potentially lead to health effects, ex-
cept for nicotine in ENDS.
 ■ The term “ENNDS” should not be applied to electronic “vaping” 
products that contain pharmacologically active ingredients such as 
cannabidiol or hemp oils.
8.8 Conclusions
ENDS and ENNDS are highly variable categories of products, although they 
share many features. The variation in e-liquids and devices makes it impossible 
to assess the health risks of this group of products. Risks should therefore be 
assessed for each individual device, liquid and use. Alternatively, indicators of 
risk could be highlighted, such as specific ingredients or specific settings of a 
device, that could be applied to many products.
Several approaches have been used to quantify the health risk of tobacco 
products, either the absolute risk or that relative to a tobacco cigarette. Currently, 
the most promising approaches are those based on the relative potency of 
compounds in the emissions. Their applicability depends, however, on the 
availability of data, which are often limited. None of the methods is ready to be 
used in regulation, although this may be possible in due time, and care should 
be used in communicating health risks to the general public to ensure that the 
message is clear.
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Abstract
Nicotine and tobacco products contain characterizing flavours that mask their 
harshness, ease their use and increase their acceptability. Recent estimates 
indicate that flavour use is common, and thousands of flavours are now available 
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for electronic nicotine delivery systems. Non-traditional flavours, like fruit 
and confectionery, are particularly appealing to young people, and use of these 
flavours is also increasing among adults, especially among adult smokers who are 
trying to quit smoking. Flavours in all nicotine and tobacco products have been 
shown not only to increase the appeal and first use of the products but may also 
contribute to extent of use, progression from experimental to regular use and 
dependence. Another concern is that chemicals in flavours may contribute to 
the toxicity of these products. Flavours are not regulated uniformly in nicotine 
and tobacco products or among countries. Some countries ban all flavours in all 
products, others have bans on only some flavours (e.g. excluding menthol), while 
others include only certain products (e.g. traditional products, such as cigarettes 
and smokeless tobacco) in regulations. This report on flavours in nicotine 
and tobacco products calls for adoption of common terminology for flavours 
in nicotine and tobacco products and consideration of policy for reducing the 
availability of flavoured nicotine and tobacco products on the market to those 
for which there is clear evidence of benefit in assisting smokers in quitting use of 
traditional smoked tobacco products.
9.1 Background and introduction
Addition of flavours to tobacco products dates back to the nineteenth century, 
when fruity flavours were added to smokeless tobacco products (1). Now, almost 
all nicotine and tobacco products, including traditional smoked tobacco products 
such as cigarettes and cigars, newer products such as snuff and snus, heated 
tobacco products (HTPs) and electronic nicotine delivery systems (ENDS) are 
available with a variety of flavours, which contributes to their increased appeal, 
the prevalence of use and the perception of reduced harm (2,3). Flavourings mask 
the harshness of nicotine and tobacco, ease their use and also reduce second-
hand exposure to harsh odours, thus increasing their acceptability and potentially 
leading to progression and maintenance of dependence on these products. 
Flavourings also enhance the appeal of nicotine and tobacco products to novice 
users and vulnerable populations, thus increasing initiation and progression in 
the use of these products (4). The dual role that flavours play in enticing novice 
users, especially young people, to initiate nicotine and tobacco product use and 
in prolonging use by current users should be addressed by health authorities and 
public health communities to ensure the best regulations to address the inclusion 
of flavours in nicotine and tobacco products (5–8).
Flavoured nicotine and tobacco products are used all over the world. 
There is limited systematic evidence about their availability and use globally, 
and preferences for such products are often specific to countries and regions. 
For example, traditional cigarettes that contain cloves and oils (kretek) are highly 
popular in Indonesia, and spiced smokeless tobacco containing tobacco mixed 
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with spices, oils, flavouring, betel nut and other ingredients (pan masala, gutka) is 
widely used in India. Hookah smoking, which involves heating heavily flavoured, 
sweetened tobacco, originated in India and the Middle East but has become 
increasingly popular among young people in Europe and North America.
Restrictions on the use of flavours in nicotine and tobacco products 
differ by country. Some countries, such as Brazil, Chile, Ethiopia, the Republic 
of Moldova, and some Canadian provinces restrict all flavours in nicotine and 
tobacco products, including menthol, although flavours that impart a port, wine, 
rum or whisky flavour are allowed in Canada (9). In May 2020, the European 
Union, with 28 Member States, implemented a ban on menthol cigarettes and roll-
your-own tobacco (10). Brazil, Canada, Chile and Ethiopia include non-cigarette 
smoked products, such as little cigars and cigarillos, in flavour restrictions, while 
others, including those in the European Union, the Republic of Moldova and 
Turkey, do not extend the restrictions to products other than cigarettes and roll-
your-own tobacco (11). There is also variation in whether menthol is included 
in restrictions; for example, while Brazil has banned all characterizing flavours 
(defined as flavours with a taste or aroma, apart from tobacco, distinguishable 
before, during or after tobacco consumption (12)), including menthol, in all 
tobacco products, in the USA, characterizing flavours except menthol are banned 
only in cigarettes and roll-your-own tobacco in most jurisdictions (13), although 
some localities (e.g. San Francisco, California) have banned all characterizing 
flavours, including menthol (14) in tobacco products. In the European Union, 
as in the Republic of Moldova, Turkey and the USA, this ruling does not extend 
to other tobacco products, such as cigars, cigarillos, little cigars and smokeless 
tobacco products (15).
ENDS may be regulated differently from tobacco products, as they do not 
contain tobacco. While WHO does not consider them to be tobacco products 
(16), some countries include these products under existing tobacco product laws, 
while others consider these products separately from tobacco products. 
The sale of these products is banned in 30 countries, and several 
countries have regulations to restrict the availability of flavours (17) and limit 
the maximal nicotine concentration. Restrictions on the addition of flavours to 
pod-based ENDS were instituted in the USA in late 2019, but many states have 
local restrictions on sales of flavoured nicotine and tobacco products (18). The 
sale of nicotine-containing e-cigarettes is banned in some countries, including 
Australia and Japan (19). e-Cigarettes that do not contain nicotine are referred 
to as electronic non-nicotine delivery systems (ENNDS) and, depending on 
regulations, are still available with flavours. In countries in which ENDS are 
available, the rate of ENNDS use is reported to be low (20); as a result, they are 
often included with ENDS in evaluations of flavoured electronic systems. In 
this review, we have distinguished the two where possible in descriptions of the 
patterns of ENDS use.
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Since the introduction of ENDS onto the global market in 2003, there has 
been renewed interest in the role of flavours. The popularity of ENDS has grown 
globally, but they are arguably most popular in Canada, Europe and the USA (21). 
ENDS are available in an ever-growing range of customizable e-liquid flavours. A 
study of the online ENDS marketplace in 2013–2014 found 7764 unique e-liquid 
flavours (22), and a follow-up in 2018 showed that the figure had doubled, to 
15  586 flavours (23). The availability of ENDS has led to debate in the public 
health field about use of these devices to reduce harm by helping smokers quit 
use of more harmful traditional smoked tobacco products. The debate has carried 
over into one on the risk versus benefit of flavours in ENDS. Some researchers 
and advocates argue that addition of flavours to ENDS products is beneficial, 
as it may potentially help smokers to quit smoking (24–26), while others argue 
that the presence of flavours only enhances the appeal of these devices to young 
people and leads to increased use and dependence (26–29).
ENDS are not the only relatively new product on the market. Heated 
tobacco products (HTPs), which have unique characteristics but are tobacco 
products, emerged in their current iteration in 2013. These products do not 
have the variety of ENDS flavours but are marketed similarly, in that they are 
advertised as potential alternatives to traditional tobacco products. 
Given the relatively recent appearance of HTPs on the market and the fact 
that they may be marketed as a lower-risk product, it is important to understand 
how flavours contribute to their appeal and use, especially among non-users and 
young people (30).
This report is an update to that in the seventh report of the WHO Study 
Group on Tobacco Product Regulation (31). We describe the epidemiology of 
flavoured products, the impact of flavours on appeal, experimentation and 
continual use of nicotine and tobacco products, the most commonly used 
flavours, their health effects and current regulation of flavours in these products.
9.2 Epidemiology of flavoured products (frequency, patterns and 
reasons for use by sociodemographic variables)
Although flavoured nicotine and tobacco products are used globally, there is 
limited systematic information on their use. Most of the information is for the 
USA, where surveys indicate high rates of use. The National Adult Tobacco Survey 
in 2013–2014 indicates that an estimated 10.2 million ENDS users (68.2%), 6.1 
million hookah users (82.3%), 4.1 million cigar smokers (36.2%) and 4.0 million 
smokeless tobacco users (50.6%) had used flavoured products in the past 30 days 
(32). In the same survey, among cigarette smokers, the use of cigarettes flavoured 
with menthol (the only characterizing flavour in cigarettes in the USA at the 
time of the survey) was relatively high, comprising 39% of cigarettes used (33). 
Similar results were reported from a population-based survey in 2014–2015, 
211
Flavours in novel and emerging nicotine and tobacco products
which showed that 41.4% of nicotine and tobacco users reported use of flavoured 
products, ranging by product from 28.3% of cigar smokers to 87.2% of hookah 
users (34).
Limited data exist on global use of flavoured nicotine and tobacco products 
and are sorely needed to evaluate the scope of flavour use worldwide. Information 
should be generated on use of flavoured nicotine and tobacco products elsewhere 
in the world. Although data for the USA provide a reasonable estimate, the types 
of flavoured nicotine and tobacco products used and regulation of these products 
differ by country, which may affect the use of different flavours. The patterns of 
use of flavoured tobacco products may differ according to their availability and 
popularity. Nevertheless, there is a higher prevalence of use among adolescents 
and young adults than among older adults. Evidence on the epidemiology of 
flavour use in different tobacco products is described below.
9.2.1 Electronic nicotine and non-nicotine delivery systems
Flavours are increasingly available for use in ENDS, because of both the dynamic 
growth in the number of flavours available (23) and their popularity among 
adolescents and young adults (8). The Population Assessment of Tobacco and 
Health (PATH), a longitudinal national survey conducted in the USA, indicated 
that use of flavoured ENDS by current vapers was most prevalent among 
adolescents aged 12–17 (97%), followed by young adults aged 18–24 (97%) and 
adults aged ≥ 25 years (81%). A similar pattern was observed in initiation of 
ENDS products, 93% of adolescents, 84% of young adults and 55% of adults 
reporting initiation of ENDS with a flavoured product (35). These patterns of use 
of flavoured ENDS are confirmed by other studies (36–38) and recent reviews 
(39,40), which suggest that use of flavoured ENDS use is more prevalent among 
adolescents and young adults than among older adults. A report from the National 
Youth Tobacco Survey in the USA on tobacco product use by middle- and high-
school students in 2019 indicated that use of flavours by current ENDS users was 
most prevalent among non-Hispanic white adolescents (77%) and similar among 
males (71%) and females (69%) (41).
Use of non-traditional flavours (i.e. other than tobacco or menthol 
flavours) is more prevalent among adolescents and young adults; however, a shift 
in flavour preferences towards non-traditional flavours appears to be occurring 
in all age groups. Wave 2 of the PATH study suggested that fruit flavours were the 
category most commonly reported by adolescents, and menthol or mint, a flavour 
traditionally found in tobacco products, was most commonly reported by adults 
(42). A follow-up study of wave 3 showed that fruit flavours were those most 
commonly used by both young and adult users and that dessert or confectionery 
was also highly popular among young and adult users (29). These findings are 
consistent with other recent work; specifically, evidence that fruit flavours are 
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the most highly endorsed flavour category across age groups, including youth, 
young adults and adults (36,43,44). A study of long-term use of flavours in ENDS 
in the USA found that a preference for tobacco and menthol or mint flavours 
decreased over time, preference for fruit flavours remained stable, and preference 
for dessert and sweet flavours increased (45).
Research has also been conducted on the flavour preferences of ENDS 
users who are current or former users of other tobacco products (i.e. cigarettes). 
This is important because, particularly in Europe and the USA, there is debate 
about whether and how flavours reduce the appeal of ENDS for young people 
or enhance their appeal for users of tobacco products, such as cigarette smokers, 
who wish to switch to ENDS. Fruit flavours appear to be popular regardless of the 
type of tobacco use. A global Internet survey of former and current adult cigarette 
smokers found that, while fruit and sweet flavours were the most popular (69% 
and 61%, respectively), current cigarette smokers were more likely to report 
use of tobacco flavours and less likely to report use of fruit and sweet flavours 
than former cigarette smokers (24). In a study in New Zealand, fruit flavour 
was preferred by exclusive ENDS users, former cigarette smokers and current 
cigarette smokers (46). Even as flavour preferences appear to be shifting to non-
traditional flavours in all age groups, it is important to note that the prevalence of 
use of non-traditional flavours in ENDS products appears still to be the highest 
among young people (47).
Many users of flavoured ENDS report that they use several flavours (e.g. 
fruit, dessert or confectionery, menthol or mint). A study of ENDS users in the 
USA suggested that multiple flavour use is more prevalent among adolescents 
(46%) than adults (32%) (29). In India, adult ENDS users reported a relatively 
high rate (65%) of use of several flavours (48). The global Internet survey of 
current and former adult cigarette smokers who used ENDS (24) indicated that 
switching between flavours was common; 68% reported switching at least daily, 
16% weekly and 10% less than weekly. 
Although there is limited evidence on use of flavoured ENNDS, a study 
among adolescents and young adults (18–29 years) in Japan, where these products 
are banned, indicated use by 4.3% of the group. Although flavour use was not 
directly studied, the main reason reported for using the product use was fruit 
flavours, suggesting that flavours are a reason for using ENNDS (49).
9.2.2 Traditional smoked and smokeless tobacco products
Although ENDS offer by far the most flavours of all nicotine and tobacco 
products, flavours are also used in other nicotine and tobacco products, both 
smokeless and smoked. As for ENDS, use of flavoured tobacco products is more 
prevalent among adolescents and young adults than adults. In a nationally 
representative sample of Canadian young people who used tobacco products 
213
Flavours in novel and emerging nicotine and tobacco products
(cigarettes, pipes, cigars, cigarillos, bidis, smokeless tobacco, hookah, blunts, roll-
your-own cigarettes), 52% reported using flavoured products (50). Similarly, a 
national survey in Poland showed that younger smokers were more likely to use 
flavoured cigarettes (51). In the PATH study in the USA, about half of users of all 
ages who reported current use of cigarillos and filtered cigars said that they used 
a flavoured product, while relatively low proportions of current cigar smokers 
reported use of flavoured products, from 24% of adults, 27% of adolescents to 
36% of young adults. In the same study, the proportions of those who reported 
that their first tobacco product had been flavoured were 68% of adolescents, 63% 
of young adults and 42% of adults for cigarillos; and 56% of adolescents, 54% of 
young adults and 40% of adults for filtered cigars. Among traditional cigar users, 
the overall prevalence was lower, but the graded effect of age was still evident, 
with 39% of adolescents, 35% of young adults and 22% adults reporting that their 
first product had been flavoured (35).
The types of flavours used in more traditional tobacco products were 
shown in 2013–2014 in the National Adult Tobacco Survey in the USA to be 
menthol or mint in smokeless tobacco (77%), fruit in hookah tobacco (74%); 
fruit (52%), confectionery, chocolate and other sweet flavours (22%) and alcohol 
(14%) in cigars, cigarillos and filtered little cigars; and fruit (57%), confectionery, 
chocolate and other sweet flavours (26%) and menthol or mint (25%) in pipe 
tobacco (32).
Capsules have been inserted in cigarettes to incorporate flavours other 
than traditional tobacco and menthol, and capsule cigarettes appear to be 
capturing a growing portion of the global market (52). The flavours range from 
menthol to green tea and whisky and others. Capsule cigarettes are popular 
among adolescents and young adult smokers. Over half of adolescent cigarette 
smokers in Australia reported capsule use (53), and young adults in the United 
Kingdom and the USA expressed a preference for these products (53,54). This 
may change, as flavour capsules have been banned in Brazil and the European 
Union since spring 2020 (55).
9.2.3 Heated tobacco products
HTPs have been developed since the 1960s in the USA and globally since the 
1980s; however, the early products were unsuccessful. A new generation of HTPs 
has been marketed since 2013 (30), and they are currently available in about 
50 countries, including Canada, Israel, Italy, Japan, the Republic of Korea and, 
most recently, the USA (56,57). HTPs contain flavours, which may increase 
their appeal and use (58). These devices produce aerosols containing nicotine 
and toxic chemicals when tobacco is heated or when a device containing tobacco 
is activated, and users inhale the aerosol by sucking or smoking. The products 
have been marketed as a safer alternative to combustible cigarettes (59). They 
214
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
02
9,
 2
02
1
WHO Study Group on Tobacco Product Regulation   Eighth report
have fewer flavour options than ENDS, the main choices being either tobacco or 
menthol; other flavour options include “mentholated-fruity” and coffee.
Japan has been a recent test markets for these products. Data from wave 
1 of the International Tobacco Control Japan Survey, collected in 2018, indicated 
that the prevalence of HTP use was only 2.7%. The popularity of flavours appeared 
to be similar among exclusive HTP users and HTP users who used other products, 
menthol flavour being the most popular, followed by tobacco and mentholated-
fruity flavour (60). Given the evidence that flavours increase the appeal of other 
nicotine and tobacco products, particularly for adolescents and young adults 
who do not use tobacco, the alarm has been sounded that these products might 
appeal as a function of their flavours (58). Comprehensive research should be 
conducted on the use of flavours in these products as the market for HTPs is 
extended to other countries.
9.3 Effects of flavours on appeal, experimentation, uptake  
and sustained use (See also section 3.)
9.3.1 Adolescents and young adults
Appeal
As adolescent and young adult tobacco product users appear to use flavoured 
products and ENDS at greater rates than adults (36,51), it is important to 
understand the appeal of these products to adolescents and how it may differ 
from that to adult users. Comparisons of smoked product use by age show 
that flavoured cigars, cigarettes and hookahs are more appealing to young than 
to adult users (61,62). Young people have reported that flavours are the main 
reason for both initiation and continued use of ENDS (63,64), and sweet and 
fruit-flavoured e-liquid solutions were more appealing to adolescents and young 
adults than non-sweet (e.g. tobacco-flavoured) e-liquids (65,66). Similarly, young 
people reported that flavours were the main reason for cigarillo use (67).
Notably, appeal for flavoured tobacco products may begin even before 
using the flavour. ENDS.  Flavours in both smoked tobacco products and ENDS 
may appeal not only because of a positive experience associated with flavours 
(68–70) but also because they reduce the perceived risk of the harm of these 
products (71–75). ENDS are not only provided in non-traditional tobacco flavours 
but are also advertised with colourful images and appealing descriptions of the 
flavours. Functional magnetic resonance imaging showed that, in young adults 
susceptible to using ENDS, just viewing advertisements showing fruit, mint and 
sweet flavours for ENDS products increased activity in the nucleus acumens to a 
greater extent than advertisements for tobacco flavours. Heightened activity was 
also seen when participants viewed advertisements for non-ENDS fruit, mint and 
sweet flavours, indicating that the appeal of non-traditional flavours may begin 
before an ENDS is sampled and the advertisements may lead to initiation (76).
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Experimentation, uptake and sustained use
Flavours may play an important role in initiation of ENDS use and progression by 
adolescents and young adults. Thus, initial use of flavoured ENDS was associated 
not only with continued use but also with more days of use, suggesting heavier 
use with time (77). In another study, preference for specific flavours and the total 
number of flavours used were associated with more days of ENDS use by young 
people and not by adult users (28), indicating that flavour preferences play a 
different role in adolescent use from that of adults. Sweet non-traditional flavours, 
in particular, appeal to young people and may contribute to the uptake and use of 
ENDS (28,37,63,78,79). In a study in young people, use of flavoured ENDS was 
associated with non-traditional flavours (i.e. not tobacco, mint or menthol) and 
continuation but not with the number of days of ENDS use over time, suggesting 
that use of non-traditional flavours may sustain use (37). This may be due in part 
to perceived sensory effects of non-traditional flavours. In a laboratory study of 
ENDS with six commercially available flavours, fruit flavours were considered 
the sweetest and tobacco flavour the most bitter. When flavours were rated for 
coolness and harshness, sweetness and coolness were positively correlated and 
harshness and bitterness negatively correlated with liking (80).
Flavours in nicotine and tobacco products may increase their addictive 
potential, which will sustain their use (81). It has been reported that green apple 
tobacco flavour in ENDS alters smoking behaviour, which may be associated with 
upregulation of nicotinic acetylcholine receptors (82), as suggested by a study of 
the biological mechanisms by which menthol alters tobacco smoking behaviour, 
including reinforcing sensory cues associated with nicotine, upregulating 
nicotinic acetylcholine receptors and altering nicotine metabolism to increase its 
bioavailability (83).
Initiation with flavoured ENDS results in continued, heavier use by young 
people, and this pattern may also occur with other tobacco products and in older 
age groups. Longitudinal results from the PATH study indicated that first use of 
a flavoured (i.e. menthol) cigarette was associated with continued cigarette use in 
adolescents, young adults and adult smokers, and, in young adults and adults, this 
pattern extended to other tobacco products. Thus, first use of a flavoured ENDS, 
cigar, cigarillo, filtered cigar, hookah or any smokeless tobacco was associated 
with continued use of the product (38).
9.3.2 Adults
Appeal
In adults, flavours also appear to contribute to the appeal of tobacco products. 
As in young people, flavoured ENDS products in particular appear to be highly 
appealing. In studies of ENDS users in the Netherlands, New Zealand and the 
USA, ENDS were rated as appealing as a function of the availability of flavours 
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(46,84). A study of university students (from undergraduates to doctoral 
candidates) in the Asian–Pacific rim found that 34% of e-cigarettes users used 
the products because of the flavours offered (85). Flavours may contribute to the 
appeal in adults by raising positive expectancy about the product (86) and an 
overall positive perception among both users and non-users (87).
Experimentation, uptake and sustained use
Flavours play a role in uptake not only among adolescents and young adults but 
also among older adults. In a sample of adults (≥ 25 years), regular current use of 
flavoured cigarettes, cigars, cigarillos, filtered cigars, hookah, smokeless tobacco 
and e-cigarettes was associated with flavoured products but not with first use of a 
non-flavoured product, as among adolescents and younger adults (38). Smokeless 
tobacco users had a similar pattern of flavour use, whereby those who started 
with an unflavoured product were likely to switch to a flavoured product, while 
those who started with a flavoured product were likely to continue using it (88).
There is evidence in adults that the use of flavoured tobacco products 
leads to greater dependence, which contributes to sustained use. Two markers of 
dependence on tobacco products, daily use and time to first use in the morning, 
were associated with use of flavoured products in a survey in the USA in 
2014–2015. The same study indicated that use of flavoured ENDS was more likely 
to be daily than use of unflavoured products. More users of flavoured cigars (large 
cigars, cigarillos and little cigars) than of unflavoured cigars reported first use in 
the morning within 30 min of waking (89).
Flavoured products may sustain use because they influence the reward 
and reduce the aversiveness of nicotine, the dependence-producing constituent 
in these products (90). There is extensive literature on the interaction of nicotine 
and menthol in combustible cigarettes, which suggests that menthol serves as a 
cue for the sensory effects of nicotine (91) and enhances both the reward from 
nicotine (92) and the withdrawal symptoms (93). This finding may indicate why 
menthol cigarette use is growing among smokers of combustible cigarettes even 
as overall use decreases (94) and why smokers of menthol cigarettes have more 
difficulty in quitting smoking (95). Fruit flavours in ENDS have been shown to 
enhance the reward and reinforcing effects of nicotine (78,96) and to suppress its 
aversive effects (97). Menthol flavours improve the taste of e-liquids in ENDS and 
make higher nicotine concentrations less aversive and more rewarding (96–98). 
Similar patterns have been observed for combustible products. Tobacco industry 
documents suggest that flavoured cigar products increase their appeal to naïve 
users by reducing throat irritation and making emissions easier to inhale (99).
Another mechanism that may sustain use is the perception that, in general, 
flavoured tobacco products, including ENDS, are less harmful than unflavoured 
tobacco products. Flavours in ENDS give a false perception of safety not only to 
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users but also to bystanders (100). This attitude is, however, changing, as more 
voices rise for the inclusion of use of ENDS in designated smoke-free indoor areas, 
as second-hand aerosols from flavoured ENDS can leave pungent odours (101). 
Chemical and toxicological assessment of second-hand aerosols from flavoured 
ENDS is lagging behind their excessive use indoors and in public spaces (102,103).
Questions remain about the role of flavours in switching from 
conventional smoked products to other products, such as ENDS or HTPs. No 
studies have yet been reported on the relation between HTPs, flavours and 
switching behaviour. The flavours in ENDS may appeal to users of smoked 
products, and use of flavoured ENDS may be associated with a greater likelihood 
of short and longer attempts to quit use of smoked tobacco products (104,105). 
There have been no experimental investigations of the specific role ENDS flavours 
play in switching from traditional smoked products, although many describe the 
abuse liability of ENDS in adolescents and young adults and in users of non-
combustible products. Proof is required to determine the role flavours in ENDS 
play in product switching.
9.4 Common flavours, properties, health effects and implications 
for public health
9.4.1 Common flavours in electronic nicotine delivery systems and tobacco 
products
The National Institute for Public Health and the Environment in The Netherlands 
has published a “flavour library” of flavours added to tobacco cigarettes and roll-
your-own products (106). The flavours are listed in eight main categories: fruit, 
spice, herb, alcohol, menthol, sweet, floral and miscellaneous. A year later, a 
similar report was issued in which the authors classified flavours in ENDS into 
13 categories: tobacco, menthol, fruit, dessert, alcohol, nut, spices, confectionery, 
coffee/tea, beverages, sweet-like flavours, unspecified and unflavoured (107). As 
noted above, the number of unique ENDS flavours on the market has increased 
dramatically in recent years, from 7764 in 2013–2014 to 15 586 in 2016–2017 
(22,23). Unique to ENDS products, users commonly mix and match flavours in 
refillable ENDS (108), and “do-it-yourself ” is common practice, sometimes with 
the addition of illicit substances (109), and researchers should also consider the 
impact of such additives on ENDS use.
9.4.2 Chemical and physical properties of common flavours  
in flavoured products
Flavour ingredients in tobacco cigarettes
The above-mentioned flavour library (106) includes chemical analyses of flavours 
in tobacco cigarettes and roll-your-own products. This complements analyses of 
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the total tobacco matrix in cigarette filler. Identification of flavour ingredients 
in tobacco cigarettes and studies to assess their fate after pyrolysis have been 
reported (110).
Flavour additives in ENDS
Several studies have reported chemical profiling of flavoured ENDS liquids 
(111,112), indicating the complexity that flavours add to the ENDS matrix (113). 
Although no comprehensive study is available of the thousands of possible 
flavours, analysis of commercial flavours showed that some chemicals are 
commonly used in more than one flavour (114). A meta-analysis of the reported 
literature (115–117) was recently published by one of the authors of this report of 
the recurrence of certain chemicals, which indicates the frequency of chemicals 
such as ethyl maltol (47%), vanillin (37%), menthol (29%), ethyl vanillin (23%), 
linalool (23%), benzaldehyde (22%), benzyl alcohol (21%), maltol (20%), 
cinnamaldehyde (20%), ethyl butanoate (19%) and hydroxyacetone (16%). The 
work also describes the possible contributions of these flavouring additives to the 
toxicity of the aerosols generated by ENDS activation (115). Flavours are either 
distilled intact into the aerosol (their contribution to toxicity depends on their 
properties and emission levels) (118), react with ENDS carriers (propylene glycol 
and glycerol) to form acetal compounds with unique toxicological properties 
(119) or undergo thermal degradation to toxicants such as carbonyls (120), 
reactive oxygen species (121) and volatile organic compounds (122). The gas–
particle-phase partitioning coefficients of several flavour ingredients have been 
determined; they are relevant to assessment of toxicity as they may determine the 
site of absorption of these chemicals into the body (123).
Flavours added to ENDS not only impart a specific flavour but also 
increase sweetness (e.g. sucrose) (124), as observed in other products, including 
smokeless products (125) and cigars (126). Sweeteners, including artificial ones 
(e.g. sucralose), can increase the appeal of nicotine and tobacco products (65), 
although there is limited evidence for direct effects of sweeteners (127).
Flavours in other tobacco products
Flavour additives in smokeless tobacco products have been addressed in two 
studies (128,129). Flavour compounds have also been identified and quantified 
in bidis (130), clove cigarettes (131) and flavoured waterpipe tobacco (132).
9.4.3 Toxicity of flavours
Flavours in ENDS can strongly increase the general toxicity of the aerosols (133). 
Several targeted analyses of ENDS liquids included quantification of diacetyl in 
nutty-flavoured ENDS liquids (134) and found that emission of this chemical and 
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its inhalation by ENDS users increased their risk of bronchiolitis obliterans or 
“popcorn lung” disease (135). Some cherry-flavoured ENDS liquids expose users 
to benzaldehyde, albeit at low levels (136). To assess disease risk, the levels of 
these toxicants in ENDS aerosols are usually compared with workspace exposure 
limits. Toxicological assessment of flavours in ENDS liquids and aerosols, in cell 
lines and in animals, showed that flavours increase the toxicity of ENDS aerosols 
in various ways (121,137). One report showed that adducts of flavours with ENDS 
carriers are more cytotoxic than their parent flavour compounds (119).
Flavours may also increase the toxicity of ENDS aerosols by adding 
to toxicant emissions. For example, flavours in liquids increase emissions of 
carbonyl compounds and other compounds that are known or possible human 
carcinogens (120). Flavours also increase toxicity by disturbing the oxidative 
balance in the body, as they increase the presence of radicals and reactive oxygen 
species in ENDS aerosols over that produced by plain liquids composed only of 
carriers (138). This type of contribution to the toxicity of aerosols depends on the 
device operating parameters, such as power input and liquid composition (139), 
as higher power increases the temperature of the heating coil, resulting in greater 
degradation of flavour compounds.
At present, the net effect of flavours on the toxicity of emissions from 
tobacco and nicotine products cannot be determined for products other than 
ENDS.
9.5 Regulation of flavoured products
9.5.1 Global regulation of flavoured ENDS
The contentious issue of the impact of flavours on the acceptability of ENDS and 
satisfaction among smokers who are seeking cessation and on the appeal of ENDS 
for experimentation and continued use by young people is highly polarized and 
intense (81,140,141). This controversy is reflected in the different approaches 
used to tackle the ENDS use epidemic by public health authorities in different 
countries: flavours are banned, restricted or allowed (Table 9.1), depending on the 
authorities’ assessment of the available information and view of the arguments on 
both sides of the debate (142,143). Currently, about 100 countries regulate use of 
ENDS with new regulations or, mainly, by adapting regulations for other tobacco 
products (144). About 30 countries ban the marketing and sale of ENDS (145,146). 
A search in June 2020 on the website of the Institute for Global Tobacco Control 
at the Johns Hopkins Bloomberg School of Public Health in Baltimore (USA) 
indicated that the policies of 35 countries on ENDS referred to ingredients or 
flavours (147). Most focus on labelling and ensuring that high-quality ingredients 
are used, and only five, Canada, Finland, Luxembourg, Saudi Arabia and the USA, 
had specific regulations on flavours in ENDS (142). Finland bans characterizing 
flavours (e.g. fruity, confectionery) in all ENDS; Luxembourg’s policy prohibits 
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additives that influence the perceptions of ENDS users with regard to health; 
Saudi Arabia allows fruit flavours and menthol but prohibits other characterizing 
flavours (e.g. cocoa, vanilla, coffee, tea, spices, confectionery, chewing-gum, 
cola and alcohol) (149), while the US Food and Drug Administration (FDA) 
has issued a policy banning all flavoured cartridge ENDS (except tobacco- and 
menthol-flavoured products) on the basis of evidence that flavours strongly 
influence young people’s use of ENDS, especially the extremely popular cartridge 
products (e.g. JUUL) (150). It also exempts the flavoured liquids used in open-
system ENDS (150,151). Canada restricts marketing flavours that may appeal 
to young people, and, recently, the province of Nova Scotia banned flavoured 
ENDS; other provinces are considering doing the same (152,153).
Table 9.1. Country regulatory approaches to flavoured e-cigarettes (as of June 2020)
Country Regulation
Argentina, Australia, Azerbaijan, Bahrain, Barbados, Brazil, 
Brunei Darussalam, Cambodia, Chile, Colombia, Costa Rica, 
Ecuador, Egypt, El Salvador, Fiji, Gambia, Georgia, Honduras, 
Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of ), 
Israel, Jamaica, Japan, Jordan, Kuwait, Lao People’s Democratic 
Republic, Lebanon, Malaysia, Maldives, Mauritius, Mexico, 
Nepal, New Zealand, Nicaragua, Norway, Oman, Palau, 
Panama, Paraguay, Philippines, Qatar, Republic of Korea, 
Republic of Moldova, Seychelles, Singapore, South Africa, Sri 
Lanka, Suriname, Switzerland, Syrian Arab Republic, Tajikistan, 
Thailand, Timor-Leste, Togo, Turkey, Turkmenistan, Uganda, 
Ukraine, United Arab Emirates, Uruguay, Venezuela (Bolivarian 
Republic of ), Viet Nam
No specific regulation
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, 
Estonia, France, Germany, Greece, Ireland, Italy, Latvia, 
Lithuania, Malta, Netherlands, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, United Kingdom (England, 
Northern Ireland, Wales)
e-Liquid should not contain certain additives (not specified).
High-quality ingredients should be used in e-cigarette 
manufacture.
Only ingredients that do not pose a risk to human health in 
heated or unheated form can be used.
Canada Marketing and sale of e-cigarettes that contain certain 
additives is prohibited (not specified).
Restrictions on the marketing of flavours that may appeal to 
young people (including flavour suggestions, confectionery, 
dessert, cannabis, soft drink and energy drink).
Finland e-Liquid should not contain certain additives and 
characterizing flavours (such as confectionery or fruit flavours).
High-quality ingredients should be used in e-cigarette 
manufacture.
Only ingredients that do not pose a risk to human health in 
heated or unheated form can be used.
Saudi Arabia Flavours in e-cigarette liquids are partially prohibited. Fruit 
flavours and menthol are allowed, but cocoa, vanilla, coffee, 
tea, spices, confectionery, chewing-gum, cola and alcohol 
flavours are banned.
USA All flavoured cartridge-based ENDS except tobacco- and 
menthol-flavoured products are banned.
Flavoured liquids used in open-system ENDS are exempted.
221
Flavours in novel and emerging nicotine and tobacco products
Country Regulation
Luxembourg Additives that may create the impression that an e-cigarette 
product has a health benefit or presents a reduced health risk 
are prohibited (e.g. vitamins).
Caffeine, taurine and other stimulants associated with energy 
or vitality are prohibited.
Any additives that add colour, alter the properties of emissions 
or facilitate inhalation or nicotine uptake are prohibited.
Only ingredients that do not pose a risk to human health in 
heated or unheated form can be used.
Additives that have carcinogenic, mutagenic or reproductive 
toxic properties in their unburnt form are also prohibited.
High-quality ingredients should be used in e-cigarette 
manufacture.
9.5.2 Global regulation of flavoured tobacco products
As for ENDS, regulation of other flavoured tobacco products also differs among 
countries. Table 9.2 lists countries and territories with different regulatory 
approaches from an analysis of regulations by the Campaign for Tobacco-Free 
Kids (154). These can be summarized as no regulations, partial bans on specific 
categories of flavours (with or without menthol) and full bans on all characterizing 
flavours (the definition may differ by jurisdiction), which may include menthol.
Table 9.2. Countries and territories approaches to regulation of the contents of tobacco products, 
including flavours (As of June 2020)
Countries and Territories Regulation
Afghanistan, Argentina, Azerbaijan, Bangladesh, Belarus, 
Benin, Bhutan, Botswana, Burkina Faso, Burundi, Cambodia, 
Cameroon, Cabo Verde, Chad, China, Colombia, Comoros, 
Congo, Côte d’Ivoire, Djibouti, Egypt, El Salvador, Eritrea, 
Eswatini, Fiji, France, Gabon, Germany, Ghana, Guinea, 
Iceland, India, Iran (Islamic Republic of ), Israel, Jamaica, Japan, 
Jordan, Kazakhstan, Lao People’s Democratic Republic, Latvia, 
Lebanon, Liberia, Madagascar, Malawi, Malaysia, Maldives, 
Mali, Mauritius, Mexico, Myanmar, Namibia, Nepal, New 
Zealand, Norway, Oman, Pakistan, Panama, Peru, Philippines, 
Poland, Qatar, Saudi Arabia, Seychelles, Singapore, Solomon 
Islands, South Africa, Spain, Suriname, Sweden, Syrian Arab 
Republic, Timor-Leste, Togo, Turkmenistan, United Arab 
Emirates, Venezuela (Bolivarian Republic of ), Viet Nam, 
occupied Palestinian territory, including east Jerusalem
The law does not grant authority to regulate the contents of 
cigarettes. 
Algeria, Brunei Darussalam, Chile, Costa Rica, Democratic 
Republic of the Congo, Ecuador, Gambia, Georgia, Guatemala, 
Guyana, Honduras, Indonesia, Iraq, Kenya, Rwanda, Thailand, 
Ukraine, United Republic of Tanzania, Uruguay
The law grants authority to regulate the contents of cigarettes; 
however, no regulations have been issued.
Australia The contents and ingredients of cigarettes are not regulated 
at national level; however, fruit- and confectionery-flavoured 
cigarettes are banned in all states and territories. Mint is 
banned in at least one state.
Armenia, Russian Federation The law regulates specified contents of cigarettes, including 
banning mint and some herbs, and other, unspecified 
flavourings.
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Country Regulation
Brazil, Canada,a Ireland,a Italy, Mauritania, Republic of 
Moldova, Niger,b Romania,a Senegal, Slovenia,a Sri Lanka, 
Turkey, Uganda, United Kingdom (England, Northern Ireland, 
Wales) a
The law regulates specified contents of cigarettes, including 
banning of sugars and sweeteners, characterizing flavours, 
menthol, mint and spearmint, spices and herbs, ingredients 
that facilitate nicotine uptake, ingredients that create the 
impression of health benefits, other flavourings, ingredients 
associated with energy and vitality and colouring agents.
Ethiopia, Nigeria The law regulates specified contents of cigarettes, including 
banning characterizing flavours, ingredients that create the 
impression of health benefits and ingredients associated with 
energy and vitality.
a Menthol as a characterizing flavour was banned as of 20 May 2020.
b Menthol is not prohibited.
In 2009, the FDA banned all characterizing flavours in cigarettes except for 
menthol (13). In 2014, the European Union followed suit, with a series of policies 
banning flavours other than menthol in cigarettes and roll-your-own tobacco 
(28,155), and the Tobacco Products Directive banned menthol in cigarettes and 
roll-your-own tobacco in May 2020 (156,157), although the regulations do not 
apply to other tobacco products (28). Other countries have banned flavours in 
tobacco products (158), including cigarettes; however, the regulations are either 
still at legislative level, as in Brazil (159) and Uganda (160), or were recently 
implemented, as in Turkey (161). In 2014, Singapore prohibited fruit flavours 
in waterpipe tobacco (63). In 2010, Canada prohibited the sale of all flavoured 
cigarettes and little cigars but exempted menthol cigarettes, and banned all 
flavours in other tobacco products, including waterpipe, smokeless tobacco and 
bidis. In 2017, the provinces of Alberta and Ontario banned the sale of menthol 
cigarettes (161).
In a study of the response to regulations, quitting behaviour was 
observed in Canadians who reported daily, some or “never” (i.e. users of non-
menthol cigarettes) use of menthol cigarettes after the menthol product ban and 
found that more daily and occasional users than non-menthol product users 
had attempted to or had quit cigarette use (162). In a study of residents of San 
Francisco, USA, menthol product and e-cigarette use decreased among young 
(18–24 years) and older adults (25–34 years) after a ban on menthol flavour, but 
cigarette smoking increased among young adults, and 65% of participants did not 
believe that the ban was enforced uniformly across the city (14). Ethiopia provides 
an ideal example of a strict tobacco control strategy, with a ban on the sale and 
distribution of all flavoured tobacco products, including those with menthol, and 
all ENDS are banned in a comprehensive approach to protect public health (163). 
Use of tobacco products in the country is lower than in other countries with a low 
human development index (164).
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9.5.3 Pros and cons of common approaches
Flavours in tobacco products increase their appeal and the perceptions of users 
and bystanders of their safety (100,165–166). National regulatory offices have 
therefore attempted to reduce the effect of use of these products on public health. 
As noted above, only a few countries ban characterizing flavours in nicotine 
and tobacco products, either to respond to their obligations under the WHO 
Framework Convention on Tobacco Control or to protect young people and 
public health (158).
The different approaches to regulating flavours globally present a mosaic 
of policies that could be weighed according to their estimated benefit to public 
health. Some do not mention flavours, tobacco ingredients or content in general. 
Such lack of specificity could leave loopholes through which the tobacco industry 
could address young people. Partial banning of some flavours or banning of 
flavours in some nicotine and tobacco products also leaves a wide margin for 
the tobacco industry to advertise other flavours or alternative flavoured nicotine 
and tobacco products and thus challenge the work of regulators. A full ban on all 
flavours in all nicotine and tobacco products would appear to be a strong approach 
to curbing young people’s use of tobacco products, although regulators should 
consider the potential argument that flavours might be tools to accommodate 
switching from use of traditional smoked products to other products which could 
be substitutes. Regulators should make sure that customizable products that can 
be used to deliver nicotine in products such as open-system ENDS are removed 
from the market; otherwise, users will add unorthodox and illicit additives to 
their products (167). There have also been several calls for the removal of flavours 
from ENDS, as the associated risks outweigh their potential public health benefit 
(168,169). Both the supply and demand should be addressed in all regulations 
through widespread advocacy and awareness campaigns to seek support from 
the public to enforce implementation (170–172).
9.5.4 Impact of regulation of specific flavoured nicotine products
As most regulations on flavoured tobacco products were introduced recently, 
limited information about their impact is available (173–175). Lessons can 
nevertheless be learnt of the effects of policies to restrict flavours in tobacco 
products on their consumption (176–178). For example, assessment of the 
effect of restrictions of the sale of flavoured cigars (< 1.4 g) in Canada on the 
sale of other cigars showed an overall decrease. Furthermore, after the ban on 
mentholated combustible products, more menthol cigarette smokers quit and 
made quit attempts than smokers of non-mentholated products (162), although 
the authors noted that the exemption of certain flavours and product types might 
have reduced the effectiveness of the policy (179). Similarly, evaluation of the effect 
of the ban on flavoured tobacco products (e.g. cigars, little cigars, roll-your-own) 
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in New York City, USA, showed a significant decrease (28%) in the odds of 
adolescents using any tobacco product (180), although evaluation of the effect of 
the ban on menthol in San Francisco, USA, indicated a decrease in e-cigarette use 
but not cigarette use among younger people (14). Another report suggested that 
making flavoured tobacco products less accessible and less affordable could help 
reduce the use of all tobacco products (181).
As there are no or only relatively new regulations on flavouring in ENDS, 
there are no longitudinal data on their use in ENDS or other tobacco products 
(182). Impact analysis and modelling have been used to estimate the possible 
effect of a regulation on use of flavours in ENDS (143,183,184), including the net 
effect on use of all tobacco products (185). One report showed that restrictive 
regulations on ENDS flavours could increase the intention of young adults to 
use cigarettes and both ENDS and combustible cigarettes (183), although re-
evaluation of the data showed that the net effect of regulation of both products 
is favourable to public health (185). Estimation of the impact of a ban on all 
flavours in ENDS, menthol in cigarettes or all flavours in cigarettes showed that 
the measure that would reduce both smoking and vaping rates would be a ban 
on all flavours in both products, although use of cigarettes would still be 2.7% 
higher than the status quo (169). As HTPs are considered to be tobacco products 
and are included with ENDS in some policies, there are no specific regulations 
on flavours in these products (186). We have demonstrated that flavours in ENDS 
increase the abuse liability of these products, specifically among adolescents and 
young adults, and we have no evidence that specific flavours in ENDS would 
help cigarette smokers to quit. In considering regulatory measures, it might 
be important to consider whether unflavoured ENDS have an effect similar to 
flavoured ENDS in supporting attempts to quit combustible cigarette use and 
reducing the abuse liability of these products.
9.5.5 Future regulation of flavours
Flavours increase the appeal, continued use, extent of use, dependence and 
toxicity of nicotine and tobacco products and increase the risk of new generations 
of nicotine and tobacco addicts. Addiction to nicotine and exposure to the other 
toxicants emitted place a significant burden on public health (187). The only 
way in which flavours could benefit public health would be in tobacco products 
proven to be less toxic, less risky and that support reduced use of combustible 
tobacco (81). Even so, users of such alternative flavoured tobacco products should 
be encouraged to stop using them in order to withdraw from nicotine addiction 
and to avoid any lapse or relapse to use of tobacco or nicotine products.
The section in the seventh report of the WHO Study Group on Tobacco 
Product Regulation (31) on flavours in tobacco and nicotine products noted that 
the research priorities were systematic monitoring of the global epidemiology 
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of flavoured conventional, traditional, new and emerging tobacco products, 
identification of how flavours contribute to the appeal of these products and 
identification of flavour chemicals, their toxicity and their health effects. This 
report confirms that flavours are still widely prevalent in all nicotine and tobacco 
products, that the popularity of ENDS products has increased, that, while there 
are regulations on the availability of flavours in nicotine and tobacco products, 
they vary widely by country and that the global epidemiology of flavoured 
nicotine and tobacco product use should be monitored systematically.
This report also raises concern about the appeal of flavoured products 
to adolescents and young adults. ENDS are the most commonly used nicotine 
and tobacco products in these groups, and they have the highest use of flavours 
of all age groups. Flavours in ENDS may therefore be uniquely appealing to 
adolescents and young adults. One explanation may be the wide availability 
of non-traditional flavours (23), which are more popular in these groups than 
among older adults (47). It has been shown that fruit flavours in ENDS enhance 
the reward and reinforcing effects of nicotine delivered to the user (24,91).
To better understand the impact of ENDS flavours on use, they have 
been grouped into categories, similar to those for combustible tobacco (107). For 
example, flavours such as blueberry and green apple are considered fruit flavours, 
while muffin and cupcake flavours are categorized as “dessert”. This grouping is 
useful for interpreting results for products with a wide, growing variety of flavour 
options.
Use of flavoured products is associated with a greater likelihood of use of 
other tobacco products (188), especially among young people (189). Policies to 
reduce all tobacco use must therefore be based on actual use patterns (190). The 
effect of flavours on the appeal and use of ENDS is controversial from a regulatory 
perspective, as there is hot debate about whether the availability of many flavours 
assists in switching from combustible products to ENDS or increases the uptake 
of ENDS by naïve young people. It has been shown that the availability of flavours 
in ENDS is an important consideration for acceptance of these products by 
cigarette smokers (24,191,192).
Flavours in nicotine and tobacco products, especially ENDS, are 
marketed by vivid descriptions of the taste and sensory experiences associated 
with them (193). Perhaps not surprisingly, the overwhelming majority of ENDS 
users – adolescents, young adults and adults – endorsed “Come in flavours I like” 
as a reason for using ENDS (35), and ENDS users ranked a choice of flavours 
and unique flavours as two of the most important factors in choosing between 
competing vape shops (157). The availability of many flavours may make it more 
likely that users will find a product that appeals to them and may explain why 
flavours are used to a greater extent in ENDS products than in other tobacco and 
nicotine products. Flavours are still prevalent in other products with demonstrated 
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appeal and sustained use, such as smokeless and combustible products and newer 
tobacco products such as HTPs. As tobacco regulations globally increasingly 
focus on ENDS, regulatory agencies should continue to monitor use of other 
nicotine and tobacco products in order to reduce their use.
Regulation of ENDS began some time after the major tobacco companies 
began their production (194). Some advocacy groups have criticized the FDA for 
not acting fast enough to prevent young people from using ENDS, which may 
have contributed to the high rates of use by young people in the USA, and health 
organizations won a lawsuit that obliged the FDA to bring forward the deadline 
for submission of studies on the safety of ingredients in premarketing applications 
for ENDS products from 2022 to 12 May 2020 (196–198). Regulation of flavours 
in other tobacco products, including cigarettes, also lagged behind their spread 
in the population (37). Flavours were introduced in smokeless tobacco in the 
nineteenth century, while flavouring of cigarettes flourished only a few decades 
ago (1,4,199). Flavours are used extensively in other tobacco products such as 
waterpipes and bidis (2,32), and the wide choice of flavours contributes to their 
popularity, especially among young people (27,61). Flavours not only increase 
the addictiveness of tobacco products but also increase their toxic emissions 
exponentially. Regulation of flavours is therefore at the intersection of harm 
reduction and a precautionary approach in tobacco regulation (200). The best 
regulatory approach to stop the tobacco epidemic is to develop complementary 
policies on all flavoured tobacco products that will eventually bring this epidemic 
to an end (201,202).
9.6 Discussion
The use of flavours in nicotine and tobacco products is controversial, as they 
have been clearly shown to contribute to the use and appeal of these products, 
particularly among young people. ENDS products continue to be a major concern, 
as their popularity is growing. A major feature of their appeal is the wide variety 
of flavours, which promote experimentation and prolonged use. Additionally, 
emerging evidence suggests that flavours may contribute to the toxicity of newer 
products such as ENDS in unique ways. Increased use of tobacco and nicotine 
due to flavours increases the burden on public health; however, flavours might be 
used to reduce the burden, as some adult smokers have reported that the flavours 
in products like ENDS contribute to their efforts to stop or reduce cigarette use. 
Policy-makers should consider this aspect when regulating flavours in tobacco 
products. Regulation of flavouring in tobacco products should be a priority in 
all regulatory approaches to limit the spread and progression of nicotine and 
tobacco use and to reduce use of combustible tobacco products.
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9.7 Research gaps, priorities and questions
Research is necessary on the following aspects of flavoured nicotine and tobacco 
products, especially ENDS:
 ■ surveillance studies on the global epidemiology of use of flavoured 
nicotine and tobacco products;
 ■ longitudinal studies of ENDS use characteristics, reasons for uptake, 
flavour use over time and continued use;
 ■ scientific classification to provide a means to categorize flavoured 
tobacco products and their chemical constituents;
 ■ consensus on a current definition of a “characterizing flavour”;
 ■ impact analyses of regulations, restrictions and bans on flavours in 
new and emerging nicotine and tobacco products, especially ENDS, 
including modelling of responses to flavour-related policies in hypo-
thetical scenarios and tasks;
 ■ biomedical and behavioural studies on the impact of flavour on the 
experience of reward with use of nicotine and tobacco products, by 
age group and tobacco use status; and
 ■ the toxicity of individual flavour ingredients and of chemicals in nic-
otine and tobacco products and of newly formed combined moieties.
Global priorities are to:
 ■ build evidence of the impact of flavours on use of nicotine and to-
bacco products by age group and on use of different products in dif-
ferent countries;
 ■ determine the impact of flavours in nicotine and tobacco products 
on the decades-long effort to reduce nicotine and tobacco use in the 
population; and
 ■ exchange experience among countries in the regulation of flavours in 
tobacco products.
Questions to policy-makers and international organizations such as WHO include:
 ■ How can concerns about the use of flavours in nicotine and tobacco 
products be addressed rapidly to prevent a new generation of users 
from becoming dependent on nicotine and tobacco?
 ■ What can be done to outpace industry manoeuvres to use flavours to 
enhance the appeal and use of their products?
 ■ Can a robust, self-developing, sustainable regulatory model be built to 
address similar concerns for any new or modified risk tobacco product?
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9.8 Policy recommendations
A piecemeal approach to regulating flavoured nicotine and tobacco products 
will not turn the tide of the tobacco epidemic. A multi-pronged combination of 
various policy tools with a panoramic view of all nicotine and tobacco product 
use will help health agencies to address the issue of flavoured products (203,204). 
ENDS could be used as an opportunity to increase the regulation of all tobacco 
products (205) to achieve the ultimate objective of nicotine- and tobacco-free 
future generations (206). Policies on flavours in novel and emerging nicotine and 
tobacco products should include the following.
 ■ Where flavours are not banned, their regulation in nicotine and to-
bacco products should be consistent globally; i.e. the availability of 
flavours should be regulated similarly for all nicotine and tobacco 
products rather than for each product.
 ■ Research should be conducted on the possible role of characterizing 
flavours in products like ENDS or HTPs in helping smokers to quit.
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Abstract
Global tobacco use has decreased in the past few decades due, in large part, 
to successful work by the public health community to discourage use through 
evidence-based tobacco control strategies. Recently, nicotine and tobacco 
manufacturers have developed novel products, including electronic nicotine 
delivery systems (ENDS), electronic non-nicotine delivery systems (ENNDS) 
and heated tobacco products (HTPs). The introduction of these products is 
complicating global progress in tobacco control. In many markets, these devices 
are particularly popular among adolescents and young adults. Many users 
and non-users perceive these devices to be harmless, despite evidence of the 
potential harm of tobacco and nicotine use. The marketing of these products 
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leads to experimentation, including by adolescents and young adults who have 
never used tobacco; robust, worldwide surveillance of product advertising, 
marketing, promotion and use is therefore essential. Continuous surveillance of 
ENDS, ENNDS and HTP marketing, including advertising in traditional media, 
direct-to-consumer marketing, point-of-sale marketing, online marketing 
(including social media), cross-border marketing and sponsorship, may prove to 
be a valuable comprehensive strategy to prevent the use of novel and emerging 
nicotine and tobacco products from undermining work to reduce the global 
public health burden of tobacco.
10.1 Background
Progress has been made in reducing the public health burden of tobacco use in 
many countries, due in large part to decreasing use. The global prevalence of 
tobacco use among people aged ≥ 15 years fell from 33.3% in 2000 to 24.9% in 
2015 and is projected to fall to 20.9% by 2025 (1). Surveillance of tobacco use 
indicates a significant turning-point in 2018, the first year in which a decrease in 
tobacco use was observed among males, who accounted for approximately 81% 
of global tobacco users in 2015 (1). An estimated 1.05 billion men used tobacco 
products in 2000, and this number increased by 22 million between 2000 and 
2005, 13 million between 2005 and 2010 and 7 million between 2010 and 2015. 
The number of male tobacco users in 2018 was 1.093 billion, and this number is 
expected to drop by 2 million by 2020 and by another 4 million by 2025 (1).
In 2018, 23.6% of the global population aged ≥ 15 years used tobacco, 
18.9% used combusted tobacco, and 16.1% used cigarettes (1). Thus, approximately 
80% of global tobacco users in 2018 used combusted products. Globally, more 
than 5.3 trillion cigarettes were sold in 2018 (2). While global cigarette sales are 
expected to fall by approximately 7% by 2023 (2), the emergence of novel nicotine 
and tobacco products, such as ENDS, ENNDS and HTPs, has raised concern. It 
is estimated that 1.2% of adults globally were current ENDS users in 2018, with 
significant variation in ENDS use by country, WHO region and demographic 
group (3). The use of these products by children and young adults, including 
some who had never used tobacco previously, is a particular concern. There is 
evidence that ENDS use is associated with later use of combusted tobacco, raising 
concern that both ENDS and HTPs may contribute to re-“normalizing” smoking 
after decades of work to discourage tobacco use (4,5).
In the USA, increasing use of ENDS by children and young adults 
contributed to the first increase in overall tobacco use measured in recent 
decades (6) (Fig. 10.1). Results from the 2019 National Youth Tobacco Survey 
show that the rate of ENDS use among young people has continued to increase 
dramatically (7). The percentage of high-school students in the USA who 
currently use e-cigarettes increased from 20.8% in 2018 to 27.5% in 2019, and 
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the rate among middle-school students increased from 4.9% in 2018 to 10.5% in 
2019 (6,7). These increases in ENDS use among the young have motivated federal 
and state policy-makers to look more closely at strategies to reduce the appeal of 
these products (8). The results of the 2020 survey had not been published at the 
time of writing.
Fig. 10.1. Proportions of middle- and high-school students in the USA who currently use e-cigarettes and 
any tobacco product, 2011–2018
Source: reference 6.
Policy-makers around the world are considering and implementing various 
policies to include ENDS and HTPs in existing tobacco prevention frameworks 
or to regulate or ban these products specifically. The evolving market for such 
products and the popularity of ENDS among children and young adults lends 
urgency to sharing information and evidence on the effects of such policies. A 
substantial body of evidence links marketing of tobacco and nicotine products 
to greater susceptibility to use of these products and increased rates of product 
use among both young people and adults. An increased focus on the role of 
marketing in promoting nicotine and tobacco use is therefore vital for ensuring 
effective public health measures to reduce tobacco use.
This report extends a background paper prepared for the third meeting 
of the Global Tobacco Regulators Forum,1 at which ENDS use and marketing 
1  Kennedy RD, Clawson C. Global landscape of electronic nicotine delivery system (ENDS) marketing and 
promotion. Paper prepared for the Third Meeting of the Global Tobacco Regulators Forum, Geneva, 11–12 
September 2019 (unpublished).
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was discussed, to include marketing and promotion of ENNDS and HTPs. This 
report also makes a distinction between ENDS/ENNDS and HTPs with regard to 
marketing strategies. We address the decisions of the seventh and eighth sessions 
of the Conference of the Parties to the WHO Framework Convention on Tobacco 
Control (FCTC/COP7 and FCTC/COP8) to continue monitoring and reporting 
on market developments, including advertising and promotion, for ENDS and 
ENNDS as well as HTPs (9,10).
10.2 Electronic nicotine delivery systems and electronic  
non-nicotine delivery systems
10.2.1 Introduction
ENDS and ENNDS heat a solution (e-liquid) to create an aerosol that frequently 
contains flavour additives. e-Liquid usually consists of propylene glycol and/or 
glycerine. ENDS products contain nicotine, whereas ENNDS products do not. 
While electronic cigarettes are the most common types of these products, ENDS 
and ENNDS also include electronic hookahs and electronic shishas (11,12). The 
WHO FCTC defines tobacco products as “products entirely or partly made of leaf 
tobacco as raw material, which are manufactured to be used for smoking, sucking, 
chewing or snuffing” (13); therefore, according to the WHO FCTC, ENDS and 
ENNDS are not tobacco products because they do not contain tobacco. They 
do not involve combustion or pyrolysis and therefore do not produce “smoke”. 
The concentrations of most toxicants present in ENDS and ENNDS aerosols are 
much lower than in tobacco smoke; however, ENDS and ENNDS solutions and 
aerosols contain potentially harmful toxic substances (14).
In order to understand the patterns of use, the diverse array of products 
on the market and the nonstandard nomenclature of ENDS and ENNDS devices 
must be identified (4). Many devices resemble traditional tobacco products, 
such as cigarettes, pipes, hookahs and cigars, while others resemble non-tobacco 
products, including pens and USB flash drives. Many terms are used to refer to 
ENDS and ENNDS, including “e-cigarettes”, “e-cigs”, “cigalikes”, “e-hookahs”, 
“mods”, “vape pens”, “vapes”, “shisha pens” and “tank systems”. In this report, 
the terms “ENDS” and “ENNDS” are used to refer to a heterogeneous class of 
products in a rapidly evolving market.
ENDS and ENNDS have been widely marketed and sold in recent years by 
the major transnational tobacco companies, with soaring uptake by adolescents 
in Europe and North America, to levels high enough to alarm public health 
experts, parents and elected officials (15). According to Euromonitor market 
research published in 2017, the consumption of “e-vapour” products grew by 
818% between 2011 and 2016 (16). Between 2011 and 2014, expenditure for 
marketing ENDS products increased by nearly 10 times in some markets (e.g. 
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from US$12 million to > US$ 125 million in the USA for e-cigarettes), stimulating 
a sharp rise in ENDS use in many countries (17,18). In this section, we focus 
on major ENDS markets, products and strategies, the prevalence of ENDS use 
globally, regulation of marketing, monitoring and surveillance of marketing and 
measures to control advertising, promotion and sponsorship of ENDS.
10.2.2 Markets, products and strategies used in marketing ENDS and ENNDS
During the past two decades, the global market for combusted cigarettes has 
seen consolidation of manufacturers into powerful transnational tobacco 
companies. In 2001, the market share of combusted cigarette sales of the five 
largest transnational tobacco companies, Philip Morris, British American 
Tobacco (BAT), Japan Tobacco International (JTI), Reemsta and Altadis, was 
43% (19). By 2017, the market share of the five largest companies, China National 
Tobacco Corporation, Philip Morris International (PMI), BAT, Japan Tobacco, 
Inc. (parent company of JTI) and Imperial Tobacco Group had grown to 81% 
(2). PMI, BAT, Japan Tobacco and Imperial Tobacco held four of the top six 
market positions for combusted cigarette retail volume in 2019 (2), in addition to 
offering a variety of ENDS products. New entrants to the ENDS market, such as 
JUUL Labs, have received significant investment from the transnational tobacco 
companies in order to maintain their influence and reach into the global market 
(20). Significant investment in ENDS innovation by these companies may further 
complicate efforts to discourage tobacco and nicotine use and to achieve public 
health goals.
Market players, products and market share
JUUL Labs Inc. (35% owned by Altria). JUUL currently occupies the largest 
(26.2%) share of the world market for ENDS with its popular nicotine salt variant 
and the small, ergonomic design of their devices (16). In 2019, JUUL announced 
plans to launch its product line in India and the Philippines (21); however, the 
Indian Government banned the production, manufacture, import, export, sale 
and distribution of ENDS because of concerns about trends in use among young 
people (22). JUUL is currently testing an app that would allow users to track 
their nicotine consumption and allow the company to track second-hand sales 
of newly manufactured products (23). In October 2018, JUUL Labs bought V2 
and the parent company VMR Products LLC for US$ 75 million (24), and V2 
Cigs closed permanently on 1 November 2018. JUUL Labs currently markets its 
products in 20 countries (25).
Altria. In December 2018, Altria, the parent company of Philip Morris 
USA, announced its decision to refocus its work on innovative products, including 
discontinuation of the production and distribution of all Nu Mark ENDS 
products, such as MarkTen and Green Smoke products, which had a significant 
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market share in Canadian and US markets in recent years (26). Additionally, on 
20 December 2018, Altria purchased shares of non-voting convertible common 
stock of JUUL Labs for US$  12.8 billion through a wholly owned subsidiary, 
representing a 35% economic interest in JUUL. Altria has since generally agreed 
not to compete with JUUL in ENDS marketing for at least 6 years (20).
PMI. The PMI website for its “smoke-free” product line notes that the 
company is “exploring new e-vapour products” and states that
We are also developing products inspired by technology that we acquired 
in 2011…. Our scientists continue to develop this technology to replicate 
the feel and ritual of smoking without tobacco and without burning. One 
of these products under development is called STEEM…[which] unlike 
an e-cigarette... generates a nicotine-containing vapor in the form of a 
nicotine salt (27).
Euromonitor reports sales of other PMI ENDS brands, including Solaris in Spain 
and Nicocig, Vivid Vapour and MESH in the United Kingdom (28).
JTI. JTI’s annual report for 2018 states that “RRP [Reduced Risk Products] 
is one of the key pillars of our growth strategy in the tobacco business, and we will 
prioritize allocation of resources into the category” (29). Logic is the company’s 
flagship e-cigarette brand, with products available in 26 countries, including 
the United Kingdom and the USA (30). On 17 September 2018, JTI launched 
Logic Compact, a pocket-sized device, in the United Kingdom. Its design bears a 
striking resemblance to that of JUUL, an ENDS device that has taken a dramatic 
share of the ENDS market in recent years. Logic Compact has since become 
available in 25 countries (29). JTI also produces “E-lites”, another ENDS product, 
which is available in Bulgaria and Germany.
BAT. BAT claims that it “is at the forefront of the development and sale 
of a whole range of potentially reduced-risk products that provide much of the 
enjoyment of smoking without burning tobacco” (32). Its growing portfolio of 
what they claim as “potentially reduced-risk products” includes a range of ENDS 
products. BAT launched their flagship brand Vype in 2013 (33). In 2017, BAT 
acquired Reynolds Vapor Co., which had launched Vuse in 2013. While BAT 
has since acquired a number of ENDS brands, including Ten Motives (United 
Kingdom), Chic (Poland) and VIP (United Kingdom), the company announced on 
28 November 2019 that it was migrating its ENDS brands, when possible, to Vuse 
during 2020 in order to simplify its “new category product portfolio”, the other new 
category products being Velo for “modern oral products” and glo for HTPs (34). By 
the end of December 2019, BAT’s ENDS products were available in 27 markets (33).
Reynolds American Inc. (now owned by BAT). Vuse was the number 
one e-cigarette product sold in convenience shops in the USA in 2016 (35). The 
company noted that “The future success of Vuse and other RJR Vapor e-cigarette 
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offerings, including Vuse Vibe, will depend on the ability to innovate in an evolving 
category of alternative tobacco products”. Vuse products are sold in the USA. 
Imperial Brands. The company stated in its annual report in 2018 that, 
“Through our growing portfolio of Next Generation Products we are providing 
adult smokers with a range of less harmful alternatives to cigarettes, with a 
particular focus on the vapour category”. The company has prioritized “building 
a presence in the specialist vape channel and online” (36). Its flagship e-cigarette 
brand is blu, and it launched myblu and myblu Intense in 2018 (36) as the brand’s 
closed-system e-cigarettes, with prefilled pods. myblu Intense is a nicotine salt 
variant, which the company claims “more closely replicates the experience and 
satisfaction of smoking a cigarette” (37). Both myblu and myblu Intense have 
nicotine-free variants (36,38). The blu brand also includes an open-system 
product, blu pro, and Imperial Brands launched another open-system product, 
blu ACE, in 2018, which has since been discontinued (36,39,40). At the end of 
2019, blu products were available in 16 markets (38).
Marketing strategies to promote sales of ENDS and ENNDS
Nicotine and tobacco companies use a wide range of strategies to market ENDS 
and ENNDS. These marketing strategies have demonstrated a trend in aggressive 
marketing to youth, with teenagers increasingly exposed to ENDS advertising 
from a variety of sources (41–43). Additionally, e-liquids containing nicotine are 
marketed in thousands of flavours, including confectionery and fruit flavours 
that appeal to young people. Unless marketing of ENDS and ENNDS is regulated, 
their use could re-normalize nicotine and tobacco use (44). The following general 
marketing strategies are used for ENDS and ENNDS.
 ■ Advertisement (45)
 ■ online, including social media (e.g. Facebook, Instagram, Twitter) 
(46) and use of social media influencers
 ■ television, cinemas (42)
 ■ radio (42)
 ■ print media (e.g. newspapers, magazines) (47)
 ■ billboards and posters (47)
 ■ displays and advertisements at points of sale (48)
 ■ Sponsorship
 ■ sports, cultural and artistic events (49,50)
 ■ events, including school programmes (51)
 ■ Youth-oriented marketing tactics
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 ■ use of cartoon characters (52)
 ■ flavours, especially confectionery, fruit and other sweet flavours (53)
 ■ marketing near schools (54)
 ■ targeting schools and youth camps (55)
 ■ marketing with popular online or mobile games (e.g. Pokémon Go) (56)
 ■ Glamourizing product use
 ■ endorsement by celebrities (45)
 ■ promotion at “glamorous” events, e.g. free handouts at New York 
Fashion Week (57)
 ■ Pricing strategies
 ■ coupons, discounts, discount codes, rebates (58)
 ■ “multi-buy”, e.g. buy one, get one free (59)
 ■ free samples (60)
 ■ Product innovation (61)
 ■ Product design
 ■ ease of concealment (especially for young people) (62)
 ■ customization with colours and patterns (63)
 ■ sleek, modern design (64)
 ■ Sexualization of product use (49,65)
 ■ Claims of health or harm reduction (66–68)
 ■ ENDS-branded merchandise (69)
 ■ Funding of front groups, including (70):
 ■ think tanks (e.g. European Policy Information Center)
 ■ public relations firms (e.g. Blue Star Strategies)
 ■ Lobbying and hiring others to lobby on behalf of the industry (71)
 ■ Corporate social responsibility and philanthropy to boost the image of the 
industry (72)
Common strategies
Of the six major market players that do not produce only ENDS and ENNDS 
products, five intend to extend innovation and/or production of their product 
ventures. The abrupt, substantial surge in ENDS use in some jurisdictions has 
newly motivated development of novel nicotine and tobacco products, and 
many recently introduced products that offer higher nicotine concentrations 
than previous generations of ENDS. For example, JUUL and NJOY offer 
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products containing 5% and 6% nicotine, respectively(73); and, in 2018, JUUL’s 
manufacturer claimed that one 5% nicotine JUUL pod contained approximately 
the same amount of nicotine as 20 cigarettes (74). In ENDS products available in 
2013–2015, the highest concentration of nicotine was 4.9% (73). Furthermore, 
as the market moves towards nicotine salt variants, popularized by JUUL, many 
can deliver high concentrations of nicotine more effectively than previous 
generations of these products (75). These include PMI’s STEEM, JTI’s Logic 
Compact, Imperial Brand’s Myblu and less influential brands such as Shenzhen 
IVPS Technology’s Smok Nord (64). The products being developed by the 
major market players are exclusively closed systems, meaning that users are not 
intended to refill their devices with e-liquid but must instead purchase refills 
in the form of pods or capsules. Former smokers and those attempting to quit 
smoking combusted cigarettes have shown a preference for open systems (76), 
although this may change with the rising popularity of closed systems with 
nicotine salts (77). The tobacco industry is purchasing stock and/or majority 
shares in competitive companies, as seen in the cases of Altria, JUUL Labs and 
VMR. Expansion into new markets has been a priority, and Imperial Brands, JTI 
and JUUL have explicitly announced geographical development.
e-Cigarette companies also use indirect marketing tactics to reach 
consumers, including the young. This is often achieved through front groups, 
which are defined as organizations that claim to be independent but in reality “serve 
[an]other party or interest whose sponsorship is hidden or rarely mentioned” 
(70).  Notable front groups include the Foundation for a Smoke-Free World, 
which has been funded solely by PMI since 2019, and the Freedom Organisation 
for the Right to Enjoy Smoking Tobacco (Forest), which has fought against 
revision of the European Union Tobacco Products Directive that would require 
licensing of e-cigarettes containing nicotine above a certain level (78,79). Front 
groups also include think tanks, public relations firms and lobbying groups (70).
e-Cigarette manufacturers also use corporate social responsibility 
strategies to boost their public image and to promote their brands. Corporate 
social responsibility “refers to voluntary corporate action that claims to act in the 
public interest by prioritising social goals” (72). The companies frequently use 
philanthropy as a partial demonstration of their corporate social responsibility, 
including charitable donations to youth-oriented organizations and to causes 
relevant to other groups that are disproportionately impacted by tobacco use, 
including LGBTQ+ communities and racial and ethnic minorities (72,80). For 
example, in 2018, Altria made charitable contributions to the National Museum 
of African American History and Culture and to the Boys and Girls Clubs of 
America (80).
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10.2.3 Global use of ENDS and prevalence of use
Sales of ENDS worldwide are increasing rapidly. The global market reached 
US$ 2.76 billion in sales in 2014 (81), US$ 9.39 billion in 2017 and is expected to 
reach up to US$ 58.32 billion by 2026 (82).
In 2018, approximately one third of the world’s men (32.4%) and 5.5% of 
women were smokers (1). It is estimated that, in 2018, 1.2% of adults worldwide 
used ENDS, comprising 1.7% of men and 0.7% of women (3). Use of combusted 
tobacco and ENDS varies by WHO region. The prevalence of smoking is highest 
in the European Region (26.2%), and ENDS use is highest in the Western Pacific 
Region (2.4%) (Table 10.1).
Table 10.1. Prevalence of smoking of combusted tobacco and of ENDS use by WHO region, 2018
Region and country Smoking (%) ENDS use (%)
All Males Females All Males Females
African Region (3 of 46 
countries represented)
 Algeria 18.4 33.5 3.2 3.8 7.0 0.6
 Nigeria 10.8 16.1 5.4 0.0 0.0 0.0
 South Africa 18.9 31.1 7.3 0.4 0.6 0.2
Americas Region (9 of 35 countries represented)
 Canada 14.8 17.1 12.6 3.5 3.7 3.3
 Chile 31.8 36.7 27.2 0.5 0.5 0.5
 Colombia 11.6 17.0 6.6 0.1 0.1 0.0
 Costa Rica 12.5 17.0 8.0 0.2 0.3 0.2
 Dominican Republic 9.3 10.4 8.3 0.1 0.1 0.1
 Ecuador 15.2 21.8 8.7 0.1 0.1 0.1
 Guatemala 6.8 11.4 2.5 0.2 0.3 0.2
 Peru 11.4 19.3 3.8 0.4 0.4 0.3
 USA 13.7 15.5 11.9 3.8 4.1 3.5
Eastern Mediterranean Region (5 of 22 countries represented)
 Egypt 30.6 54.9 5.3 0.7 1.3 0.1
 Morocco 20.3 37.6 3.7 0.7 1.4 0.0
 Pakistan 21.0 34.6 6.9 0.0 0.0 0.0
 Saudi Arabia 29.8 39.2 15.5 0.3 0.4 0.3
 Tunisia 32.1 54.4 11.0 0.6 1.1 0.1
European Region (38 of 53 countries represented)
 Austria 26.2 28.1 24.4 1.2 1.3 1.1
 Azerbaijan 26.0 33.1 19.3 0.3 0.5 0.1
 Belarus 24.8 46.2 7.0 2.1 3.3 1.1
 Belgium 22.0 23.0 21.0 4.4 4.8 4.0
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Region and country Smoking (%) ENDS use (%)
All Males Females All Males Females
 Bosnia and Herzegovina 38.2 44.5 32.3 1.3 1.3 1.3
 Bulgaria 32.2 36.6 28.1 1.1 1.9 0.4
 Croatia 27.5 35.5 20.3 1.2 1.6 0.8
 Czechia 33.4 37.0 30.0 5.7 6.9 4.5
 Denmark 21.1 21.0 21.1 4.8 4.8 4.8
 Estonia 23.4 31.0 17.0 1.6 2.2 1.1
 Finland 12.2 12.8 11.6 2.0 2.8 1.3
 France 26.2 30.5 22.3 4.3 5.0 3.6
 Georgia 28.5 54.1 6.2 1.4 2.9 0.1
 Germany 21.4 24.0 19.0 5.3 6.6 4.1
 Greece 42.1 52.5 32.6 2.4 3.2 1.7
 Hungary 28.6 34.5 23.4 2.1 2.9 1.3
 Ireland 19.5 19.8 19.3 5.4 5.4 5.3
 Israel 23.5 31.3 16.0 0.4 0.5 0.3
 Italy 21.1 25.5 17.0 1.5 1.8 1.3
 Kazakhstan 30.3 42.0 20.0 4.0 8.2 0.3
 Latvia 27.0 42.5 14.4 1.1 2.0 0.4
 Lithuania 26.3 37.4 17.1 1.6 1.9 1.3
 Netherlands 22.5 25.7 19.3 3.6 4.0 3.3
 North Macedonia 31.0 33.0 29.0 1.0 1.1 0.9
 Norway 11.0 11.5 10.5 1.5 1.5 1.5
 Poland 33.1 34.1 32.2 5.4 7.7 3.3
 Portugal 19.1 26.4 12.8 2.2 3.2 1.3
 Romania 30.2 39.8 21.2 3.3 5.0 1.8
 Russian Federation 33.3 44.4 24.2 1.5 2.2 1.0
 Serbia 32.3 35.3 29.5 0.5 0.6 0.5
 Slovakia 31.4 45.5 18.3 1.9 2.2 1.6
 Slovenia 23.4 26.1 20.9 0.9 1.5 0.2
 Spain 25.5 28.7 22.4 1.7 1.8 1.7
 Sweden 10.1 11.0 9.2 1.1 1.2 1.0
 Switzerland 25.0 28.5 21.6 1.8 2.5 1.2
 Ukraine 28.8 36.3 22.7 2.0 2.5 1.6
 United Kingdom 14.7 16.5 13.0 6.1 7.7 4.6
 Uzbekistan 11.3 19.9 3.1 0.5 0.2 0.7
South-East Asia Region (2 of 11 countries represented)
 India 3.8 6.9 0.6 0.1 0.1 0.0
 Indonesia 36.4 67.9 5.0 0.5 1.1 0.0
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Region and country Smoking (%) ENDS use (%)
All Males Females All Males Females
Western Pacific Region (7 of 27 countries represented)
 Australia 13.7 15.5 11.9 0.8 1.0 0.6
 China 27.8 51.9 2.8 0.2 0.5 0.0
 Japan 18.2 29.0 8.1 0.2 0.3 0.1
 Malaysia 21.5 40.1 1.5 2.7 4.3 1.0
 New Zealand 14.9 16.2 13.6 4.1 2.0 6.1
 Philippines 23.3 42.0 4.8 0.3 0.6 0.1
 Republic of Korea 22.0 36.7 7.5 4.1 7.1 1.1
Source: reference 3.
The total prevalence of ENDS use ranged from 0.0% to 6.1% for both sexes, 0.0% 
to 8.2% for men and 0.0% to 6.1% for women. National data available for 2018 
showed that ENDS use tended to be higher in countries in the European Region, in 
Canada and the USA in the Americas, in New Zealand and the Republic of Korea 
in the Western Pacific and in Algeria in the African Region. These numbers are 
consistent with earlier published data (83–85). Nigeria and Pakistan reported no use 
of ENDS. Consistent with trends in combusted tobacco use, ENDS use rates were 
typically higher among men than women. ENDS use by WHO region is listed below.
 ■ African Region. Information on the prevalence of ENDS use was 
available for only three of the 46 countries in the Region: Algeria, 
Nigeria and South Africa. ENDS use among males in Algeria was no-
tably high, at 7.0%.
 ■ Region of the Americas. ENDS data were available for nine countries. 
The highest reported prevalence of ENDS use was in the USA (3.8%), 
followed by Canada (3.5%). The rates in the other countries in the Re-
gion were < 1.0%. The rates were similar by gender, except in Canada 
and the USA. 
 ■ Eastern Mediterranean Region. The prevalence of ENDS use was 
available for Egypt, Morocco, Pakistan, Saudi Arabia and Tunisia. 
Although smoking rates remain high in several countries in the Re-
gion, ENDS have yet to penetrate the market in any significant way, 
remaining at < 1% in all countries for which data were available.
 ■ European Region. The prevalence of ENDS use was available for 38 
countries. The highest total prevalence was in the United Kingdom, 
at 6.1%. The rates were ≥ 5.0% in Czechia, Ireland and Poland and 
relatively high among males in Kazakhstan (8.2%), France (5.0%), 
Germany (6.6%) and Romania (5.0%). Consistent with the demo-
graphics of smoking, the prevalence of ENDS use in the Nordic states 
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was similar for men and women. Interestingly, the prevalence in Uz-
bekistan was higher among women (0.7%) than among men (0.2%)
 ■ South-East Asia Region. Data on ENDS use were available only for In-
dia and Indonesia. While both countries report high smoking rates, 
particularly among males, ENDS use is almost non-existent.
 ■ Western Pacific Region. ENDS data were available for seven countries. 
Use is particularly high among men in the Republic of Korea (7.1%). 
In New Zealand, men are more likely to smoke than women, but 
women are more likely to use ENDS (6.1%) than men (2.0%).
While these data show the prevalence of ENDS use among adults, in several 
countries, more young adults aged 18–24 years than adults aged ≥ 25 years have 
ever or currently use ENDS, and the rate has been increasing steadily in recent 
years (84–86). The prevalence of ever use of ENDS was 23.5% among adults aged 
18–24 years in the USA in 2016 (875), 28% among adults in this age group in 
the European Union and 29% among adults aged 20–24 years in Canada in 2017 
(84–86). Data for 2017–2018 suggest that the introduction into the Canadian 
and US markets of new-generation products with refillable or disposable pods 
(pod mods) containing nicotine salt has contributed to recent, more dramatic 
increases in use of ENDS in the previous 30 days among high-school students 
(28% in 2019) (8,88). Canada and the USA also reported greater increases in the 
prevalence of ENDS use by young people between 2017 and 2019 than in the 
United Kingdom (England), where more comprehensive policies regulate access 
to and distribution of ENDS (75).
10.2.4 Trends in advertising, promotion and sponsorship of ENDS products
How ENDS manufacturers advertise in markets through social media
Social media platforms represent an important channel for advertising ENDS, with 
sites that can promote these products worldwide. A scan of ENDS advertisements 
and promotions was conducted on Instagram and Twitter, the search terms 
consisting of hashtags with either the brand names of specific ENDS (e.g. #JUUL) 
or generic terms associated with ENDS use (e.g. #vape), accompanied by the 
name of a WHO Member State (e.g. #Belarus). As Instagram’s search function 
allows only one search term, the ENDS brand name or search term was combined 
with the name of a WHO Member State (e.g. #VapeCanada), whereas Twitter’s 
search function accommodated multiple search terms and Boolean operators 
(e.g. #JUUL AND #Canada).
The survey showed that ENDS are marketed on the social media platforms 
Twitter and Instagram in at least 149 (77%) WHO Member States. A content analysis 
of up to six advertisements (three Twitter, three Instagram) per country revealed 
several common advertising strategies used in the six WHO regions (Table 10.2).
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Table 10.2. Common ENDS advertising strategies by WHO region, 2019
WHO 
region
No. of 
coun-
tries
Data 
avail-
able No. 
(%)
No. of 
adver-
tise-
ments
Health 
warning 
No. (%)
Nicotine 
lexical 
No. (%)
Flavour 
lexical 
No. (%)
Design 
feature 
lexical 
No. (%)
Image 
device 
No. (%)
Image 
of 
e-liquid 
No. (%)
Africa 46 26 (57) 84 1 (1) 24 (29) 63 (75) 15 (18) 22 (26) 61 (73)
Americas 35 26 (74) 135 3 (2) 14 (10) 55 (41) 72 (53) 86 (64) 59 (44)
South-
East Asia
11 9 (82) 42 0 3 (7) 19 (45) 21 (50) 25 (60) 19 (45)
European 53 53 (100) 267 5 (2) 44 (16) 141 (53) 117 (44) 142 (53) 148 (55)
Eastern 
Mediter-
ranean
22 21 (95) 102  1 (1) 17 (16) 50 (49) 47 (46) 51 (50) 50 (49)
Western 
Pacific
27 14 (52) 70 3 (4) 11 (16) 34 (49) 36 (51) 42 (60) 35 (50)
All 194 149 (77) 700 13 (2) 113 (16) 362 (52) 308 (44) 368 (53) 372 (53)
Very few of the advertisements identified in this search included a health warning. 
The advertisements commonly had images of devices or e-liquids and lexical 
content describing flavours or other design features.
Impact of COVID-19 on ENDS marketing strategies
During the COVID-19 pandemic, several ENDS product manufacturers, retailers 
and users have aligned their marketing and promotion strategies on social media 
with messages relevant to the pandemic and containment strategies. Several 
themes are found in ENDS marketing on Instagram and Twitter.
Coping with boredom and isolation. For example, one Twitter ad by an 
e-liquid manufacturer stated “Covid lockdowns got you feeling blue? We’ve got 
the Antidote. Blue Raspberry and Mango ice in perfect sync – for your dipper, 
tank or favorite pod system.”
Online shopping. For example, one Instagram post from Vuse Middle 
East states, “Order online with Instashop! We’re all hangin’ around these days, so 
while you’re staying in, your Vuse order will come right to you.”
Working from home. Retailers and manufacturers have used this theme to 
encourage users to purchase their products online when they are busy “working 
from home”. ENDS users have posted photos of their ENDS products in their 
home offices.
Obtaining protective equipment and supplies. Some manufacturers have 
posted advertisements offering protective equipment and supplies, such as masks 
and hand sanitizer. For example, one Instagram advertisement for the e-cigarette 
brand MOTI America states, “Compared with cigarettes, #vapes are 95% less 
harmful to the #lungs. During #Covid_19 pandemic, we recommend using 
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MOTI to alternate cigarettes for your #health. [What can you get?] 2 pieces of 
Disposable #SurgicalMasks” (66).
Staying healthy (especially promoting lung health). The above example 
from MOTI America also shows that brands have also capitalized on a harm 
reduction theme during the COVID-19 pandemic (66).
Supporting businesses affected by the pandemic. Manufacturers and 
retailers have posted messages of support for businesses affected by the pandemic 
in their advertisements. For example, INNOPHASE, a manufacturer and exporter 
of ENDS products, stated, “Currently, we have a great promotion on the VPOD, 
to help our partners in these difficult COVID-19 times” in an advertisement on 
Twitter.
10.2.5 Measures to control advertising, promotion and sponsorship  
of ENDS products
Many countries currently restrict advertising, promotion or sponsorship of ENDS 
and ENNDS; however, the regulatory strategies vary significantly. For example, 
eight countries (Costa Rica, Ecuador, Georgia, Japan, Mexico, New Zealand, 
Palau and Republic of Moldova) regulate marketing of ENDS products but not 
ENNDS products, in that the advertising restrictions apply only to “e-cigarettes 
that contain nicotine or that are regulated as medicines” (89). In European Union 
Member States, bans on distinctive branding elements are intended to reduce 
advertising potential, and some have further reduced that potential by requiring 
out-of-sight retail sales and reduced branding opportunities on packaging. In the 
USA, the Food and Drug Administration passed several regulations in 2016 on 
the marketing and promotion of e-cigarettes, including prohibiting free sampling 
of e-liquid solutions inside shops (90). The Food and Drug Administration also 
passed measures to prohibit false or misleading advertising (e.g. use of descriptors 
such as “light”, “mild” or “low”) and require manufacturers to submit applications 
for authorization as “modified risk tobacco products”, with a full scientific review 
of the impact of marketing of the product on population health before it can be 
marketed as modified risk (90,91).
Several countries have focused specifically on marketing to young 
people. As increasing rates of use among the young are of particular concern, the 
United States Food and Drug Administration issued a policy in January 2020 that 
prioritizes enforcement of regulations on flavoured “cartridge-based e-cigarettes” 
(excluding menthol and tobacco flavours) in an attempt to limit the access of 
young people to certain flavoured ENDS products (92). Canada has banned all 
marketing, packaging elements that indicate flavour and design attributes that 
would appeal to young people (93,94).
Regulation of marketing towards the young, and indeed marketing of any 
kind, is important in light of evidence linking exposure to tobacco and nicotine 
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product marketing, advertising and promotion with susceptibility to use of ENDS 
and ENNDS. It has been noted that social media influencers have been used to 
promote ENDS. A minimum age is required to open an account on most social 
media platforms, and several platforms do not accept or run advertisements for 
tobacco products; however, it is unclear if these policies limit social media in-
fluencers from promoting ENDS products. Discussions in the United Kingdom 
have identified possible solutions for regulating social media influencers, includ-
ing a minimum number of followers in order to be defined as an “influencer” and 
requiring online influencers to disclose payment for endorsing any product.
Increased exposure to tobacco advertising and access to price promotions 
has been associated with increased susceptibility to use of both ENDS and 
combusted products among adults (95), and increased exposure to ENDS 
advertisements specifically is associated with greater susceptibility to use and 
an increased likelihood of current use of ENDS among both adults and young 
people (96,97). Receptivity to ENDS advertising has also been shown to increase 
with exposure (96).
Certain aspects of ENDS advertising appear to be associated with an 
increased likelihood of reporting interest in using ENDS and later ENDS use by 
young people. ENDS advertising with a social rather than a health message and 
advertising seen on social media platforms were associated with increased interest 
in using ENDS and increased ENDS use, respectively (98,99). Endorsements by 
inspirational figures or celebrities in advertisements are also associated with 
an increased likelihood of use (100). The newer generation of high-tech ENDS 
devices associated with some of these advertising strategies and marketing of 
confectionery- and fruit-flavoured products have quickly become popular among 
adolescents and young adults (43,52,101).
10.2.6 Recommendations
 Recommendations for monitoring trends in marketing, advertising, 
promotion and sponsorship of ENDS and ENNDS
 ■ Better surveillance of ENDS and ENNDS marketing, with attention 
to social media, marketing at points of sale and sponsorship
Social media. In order that policy-makers fully understand the mar-
keting tactics of the industry, it is important to monitor traditional 
and social media advertising channels, paying attention to how the 
practices are changing over time. Monitoring can be performed in-
dependently within government ministries or by using media and 
Internet monitoring services, industry reports and population-level 
surveys. Reports should emphasize the extent to which young people 
are exposed to marketing.
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Point-of-sale marketing. The tobacco industry has long used market-
ing at points of sale as an opportunity for promotion campaigns. This 
strategy can be monitored through surveillance on the ground.
Sponsorship. Sponsorship continues to be integral to the marketing 
campaigns of nicotine and tobacco industries. All events should be 
monitored for sponsorship and the use of testimonials in advertising 
to understand how the industry uses sponsorship as a promotional 
tactic and the populations who are exposed to this type of marketing.
 ■ Collaboration in monitoring marketing trends among governments
Cross-border advertising, including through media into bordering 
jurisdictions, will require collaboration among governments.
 ■ Monitoring of the access of young people to direct marketing
Direct-to-consumer marketing (through the post and e-mail) is a key 
strategy of the tobacco industry. Policies could be implemented to 
ensure that material from marketing campaigns is received only by 
adults and only those who consent to receive such material. Popu-
lation-level surveys could aid regulators in monitoring this type of 
advertising.
 ■ Monitoring of policies for regulating ENDS and ENNDS globally
Evidence is lacking on how differences in policies and in the market-
ing of different products and product characteristics affect percep-
tions of risk or harm associated with use of ENDS and ENNDS and 
differences in use of tobacco and nicotine products. Some countries 
regulate ENNDS differently from ENDS, adding complexity and am-
biguity to the regulation of new and emerging products (89). More 
robust reporting of policy developments will result in more timely, 
more effective strategies for all Parties to the WHO FCTC.
 ■ Monitoring of disparities in ENDS and ENNDS marketing
Given the tobacco industry’s history of targeted advertising to spe-
cific demographic groups, such as low-income communities, racial 
and ethnic minorities and sexual and gender minorities (102,103), 
differences in both the volume and content of ENDS and ENNDS 
advertisements in communities and in print and digital media should 
be monitored.
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Recommendations for regulators
 ■ Consider supporting state, provincial and local regulation of ENDS 
and ENNDS products.
State, provincial and local health departments and local coalitions 
play important roles in advancing tobacco control and decreasing 
the burden of tobacco use (104–106).key informants (e.g. local public 
health center directors Local coalitions have shifted social norms on 
tobacco use, built support for tobacco control policies and enforced 
tobacco control measures (105), and such local actors can be used to 
regulate marketing of ENDS and ENNDS.
 ■ Consider strategies and policies to protect tobacco control from in-
dustry interference.
e-Cigarette companies have used various strategies to undermine the 
regulation of ENDS and ENNDS and efforts to prevent young people 
from using these products, including sponsoring prevention pro-
grammes in schools (51), lobbying against policies to regulate ENDS 
and ENNDS and corporate social responsibility and philanthropic 
activities (107,108). Regulators can take measures to implement Arti-
cle 5.3 of the WHO FCTC, which requires that
in setting and implementing their public health policies with 
respect to tobacco control, Parties shall act to protect these poli-
cies from commercial and other vested interests of the tobacco 
industry in accordance with national law (109).
These steps include avoiding entering into partnerships with compa-
nies that produce ENDS and ENNDS and initiatives funded by those 
companies (e.g. Foundation for a Smoke-Free World, which received 
initial funding from PMI) (110), refusing industry contributions (fi-
nancial or otherwise) and prohibiting industry sponsorship of events, 
particularly for youth-oriented events (107,108).
 ■ Remain focused on evidence-based smoking prevention strategies.
Governments and health organizations should maintain use of 
evidence-based measures to reduce smoking (as outlined in the 
WHO FCTC) and should not be distracted from action in these areas 
by the promotion and marketing of novel products such as ENDS and 
ENNDS.
259
Global marketing and promotion of novel and emerging nicotine and tobacco products and their impacts
 ■ Consider cost-effective counter-marketing strategies.
Given the global reach of promotion of ENDS and ENNDS on social 
media, both governments and social media platforms have difficulty 
in effectively regulating such content, particularly when generated 
by users. Therefore, counter-marketing may be the most feasible op-
tion. Counter-marketing strategies can take various forms, includ-
ing social media campaigns, which may be more cost-effective than 
traditional media campaigns. Counter-marketing may also include 
educating the public about industry activities, in addition to discour-
aging nicotine and tobacco use.
 ■ Consider banning all tobacco advertising, promotion and sponsor-
ship, where possible.
Throughout its history, the tobacco industry has circumvented nearly 
all restrictions on advertising, promotion and sponsorship to reach 
consumers, including young people. Therefore, a complete ban on to-
bacco marketing might be necessary to minimize exposure of young 
people to marketing for nicotine and tobacco products. Such a ban 
would ensure that most information about these products came from 
national and local governments and public health agencies.
 ■ Foster collaboration among governments and government sectors 
in considering, implementing and enforcing marketing regulations 
for ENDS and ENNDS.
Cross-border advertising, including through the media, will require 
collaboration among governments.
 ■ Maintain awareness of industry strategies to market ENDS and 
ENNDS, particularly to young people.
In order that policies on ENDS and ENNDS marketing are effective, 
regulators must learn to recognize the strategies used by the industry 
to market these products, including targeted advertising, sponsorship 
and price promotions.
10.2.7 Research gaps for ENDS and ENNDS
 ■ Additional research on ENDS and ENNDS marketing, especially 
on social media, is necessary to inform regulators about the mar-
keting and promotion strategies used by companies and retailers.
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As advertising on social media platforms has been associated with in-
creased interest in using ENDS, researchers should continue to build 
evidence on the marketing tactics used by ENDS and ENNDS manu-
facturers and retailers on social media (98,99).
 ■ Additional research should be conducted specifically on ENNDS 
marketing and its impact on perceptions of risk.
As ENNDS are regulated differently from ENDS in some jurisdic-
tions, they may be marketed differently. Many people incorrectly be-
lieve that nicotine is the main carcinogen in cigarettes, and, in one 
study, many participants believed that a cigarette with very low nico-
tine content was less carcinogenic than currently available cigarettes 
(111). Studies should therefore be conducted on consumers’ percep-
tions of risk associated with ENNDS and with ENDS and how the 
marketing and promotion of ENNDS shapes those perceptions.
 ■ Additional research should be conducted on social media content 
on ENDS and ENNDS generated by users and its potential effects 
on risk perceptions, product use and the effectiveness of regula-
tions on marketing.
Social media user content has increased the presence of these prod-
ucts. For example, content related to JUUL continued to be posted 
widely on social media among peers, even after JUUL stopped post-
ing its own content (112). Given that user-generated content has 
been used as an important marketing tactic for ENDS and ENNDS 
companies, it should be monitored in order to understand its impact 
on risk perception, product use and the effectiveness of marketing 
regulations.
10.3 Heated tobacco products
10.3.1 Introduction
HTPs “produce aerosols containing nicotine and toxic chemicals when tobacco 
is heated or when a device containing tobacco is activated” (113). The distinction 
between HTPs and ENDS is that ENDS deliver nicotine derived from tobacco, 
whereas HTPs heat tobacco to deliver nicotine to the user (5,114). They also 
contain non-tobacco additives and are often flavoured. HTPs mimic conventional 
cigarette smoking behaviour, and some are specially designed as cigarettes that 
contain tobacco for heating. Although HTP technology has existed since the 
1980s, the early products were unsuccessful (Fig. 10.2) (115).
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Heated tobacco products (Htps) 
market monitoring information sHeet  
What are heated tobacco products?
Heated tobacco products (HTPs) are those that produce aerosols containing nicotine and 
other chemicals, which are inhaled by users through the mouth. They contain the highly 
addictive substance nicotine (in the tobacco), which makes them addictive. They also contain 
non-tobacco additives, and are often flavoured. HTPs mimic the behaviour of conventional 
cigarette smoking, and some make use of specially designed cigarettes to contain the tobacco 
for heating. Although HTP technology has existed since the 1980s (see Fig. 1), the early 
products were unsuccessful (see Fig. 2).  
Fig. 1: HTP Timeline
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Fig. 10.2. Timeline of h ated tobacco products
Source: reference 115.
10.3.2 Market players, products and strategies
On the basis of data and trends in tobacco sales in 2016, Euromonitor International 
predicted that the proportion of total tobacco sales represented by combusted 
cigarett s will continue to decrease but will be offset by market gains from novel 
a d emerging nicotine and tobacco p oducts, such as HTPs (116). Sales of HTPs 
are expected to grow rapidly, to a market value of US$ 22 billion globally by 2024, 
from US$ 6.3 billion in 2018 (117). The global market for ENDS was valued at 
US$ 9.39 billion in 2017 and is expected to reach US$ 58.32 billion by 2026 (82). 
While continued rapid growth is projected for both ENDS and HTPs, the global 
market for combusted cigarettes still dwarfs both, as it was valued at US$ 888 
billion in 2018 and is expected to reach US$ 1124 billion by 2024 (118).
Market players, products and market share
The HTP market is currently dominated by three leading manufacturers: PMI, 
JTI and BAT (115). As mentioned above, these three transnational tobacco 
companies also ranked among the top six manufacturers in terms of combusted 
cigarette retail sales volume in 2019 (119) and have invested significantly in 
ENDS production globally to augment their product portfolios. Diversification 
of their production to include ENDS and HTP allows significant consolidation of 
market power and complicates efforts to combat tobacco use.
PMI. PMI launched IQOS in Japan at the end of 2014. As of 30 June 2020, 
IQOS was available in 57 markets (120). PMI’s report for the second quarter of 
2020 and its website note that it is investing in not only the next generation of 
IQOS products but also new HTPs such as TEEPS, which has a carbon source 
to heat tobacco (120,121). The total estimated number of IQOS users reached 
15.4 million in the second quarter of 2020 (120). Profit margins for PMI’s IQOS 
are 30–50% higher than those for conventional cigarettes (115), and IQOS now 
makes up more than 10% of PMI’s sales volume (120).
JTI. JTI presented the first new-generation HTP in 2013, with the launch 
of Ploom, which was developed in a joint venture with a company of that name in 
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the USA, which is now called Pax Labs. After dissolution of the partnership, JTI 
acquired the Ploom technology and launched a new HTP called Ploom TECH in 
several Japanese cities in March 2016, in Switzerland in July 2017 (122) and in the 
Republic of Korea in July 2019 (123). JTI has since added three more products to 
the Ploom brand: Ploom TECH+ (June 2019), Ploom S (August 2019) (124) and 
Ploom S 2.0 (July 2020) (125). Ploom TECH and Ploom TECH+ are the brand’s 
“low-temperature” HTPs, offering “less smell and increased usability”, while 
Ploom S and Ploom S 2.0 are the brand’s “high-temperature” tobacco HTPs, 
which allow consumers “to enjoy an authentic and familiar tobacco taste” and 
“delivers a superior taste of tobacco leaves” (126,127). Ploom S 2.0 is specifically 
designed for use with menthol, with “a new heating mode, ‘TASTE ACCEL’, 
which lengthens the duration of the peak heating temperature, compared to that 
of the current Ploom S” (127).
BAT. BAT was the third entrant into the new-generation HTP market, 
with the introduction of iFuse in Romania in 2015 (115). In 2016, BAT developed 
and launched glo in Japan and has since launched additional products under the 
glo brand (128). In 2019, the company launched glo pro which has induction 
heating instead of the “two-zone heating chamber” of previous glo products 
in order to improve “consumer satisfaction and their sensorial experience” 
(129,130). BAT also launched glo nano, a slimmer device, and glo sens, a hybrid 
product which “combines vaping technology with real tobacco” (131). In 2020, the 
company launched glo Hyper in Germany, Italy, Japan, Romania and the Russian 
Federation. glo Hyper is designed to work with the company’s “Neo demi-slim 
range” products, which “contain 30% more tobacco than the existing Neo sticks” 
(132,133). BAT’s tobacco heating products were available in 17 markets at the end 
of 2019 (130). Its growing portfolio of what it claims to be “potentially reduced-
risk products” includes a range of HTPs under the names of five subsidiaries (32).
Korea Tobacco and Ginseng Corporation (KT&G). KT&G entered the 
HTP market with the launch of lil in the fourth quarter of 2017 in the Republic 
of Korea. KT&G is the country’s leading cigarette producer, in a market that has 
witnessed the rapid conversion of cigarette users to HTPs; lil was intended to 
create a domestic presence (115). In 2018, the company launched three products 
with HTP technology under the lil brand: lil plus, lil mini and lil hybrid (134). Lil 
plus and lil mini are exclusively HTPs, while lil hybrid has both HTP and ENDS 
technology (135). In January 2020, KT&G and PMI reached an agreement that 
will allow PMI to distribute KT&G’s smoke-free products, including the HTPs 
under the lil brand and lil’s ENDS product, lil Vapour (135).
Marketing strategies to promote sales of HTPs
Tobacco companies have used a wide range of marketing strategies to promote 
HTPs, often targeting adolescents and young adults (136,137). The strategies for 
HTPs include those listed below.
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 ■ Advertisements
 ■ Online, including social media (e.g. Facebook, Instagram, Twitter) 
(138)
 ■ Television (138)
 ■ Radio (138)
 ■ Newspapers and magazines (138)
 ■ Billboards and posters (138)
 ■ Displays and advertisements at points of sale (139)
 ■ Dedicated retail stores for HTPs (115)
 ■ Bars and pubs (138)
 ■ Emphasis on similarities to cigarettes (115)
 ■ Acknowledgement of the harms of cigarettes, while presenting HTPs as 
“cleaner alternatives” (140)
 ■ In the USA, capitalizing on this potential has led manufacturers to try 
to circumvent stringent regulations on advertising language by apply-
ing for designation of HTPs as “modified risk tobacco products” (92) 
For example, in July 2020, PMI successfully obtained an “exposure 
modification” order from the US Food and Drug Administration for 
the IQOS system and three of its Marlboro Heatsticks, which “per-
mits the marketing of the products with certain claims”.
 ■ Use of brand “ambassadors” (in person and on social media) and demon-
strations (115,141)
 ■ Product design
 ■ Sleek, high-tech appearance (138,142)
 ■ Rapid charging (115)
 ■ Less odour (142)
 ■ Less emission of second-hand smoke (141)
 ■ Customization with colours and limited-edition designs (115)
 ■ Sponsorship (141)
 ■ Sporting events
 ■ Art shows
 ■ Concerts
 ■ Food and wine festivals
 ■ Pricing strategies
 ■ “Bait and hook” pricing: discounted prices for devices and recurrent 
cost for specially designed refills or inserts (115)
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 ■ Free samples (141)
 ■ Customer service
 ■ Call centre support (115)
 ■ Dedicated brand retail stores and websites (115)
 ■ Apps to help customers locate nearby stores and to troubleshoot their 
device (141,143)
 ■ Marketing to young people
 ■ Placement of HTPs near youth-oriented merchandize at points of 
sale (139)
 ■ Sponsorship of youth-oriented events (e.g. Tel Aviv’s TLV Student 
Day) (141)
 ■ Funding front groups (e.g. Foundation for a Smoke-Free World) (70)
 ■ Lobbying (144)
 ■ Corporate social responsibility to boost industry image (72)
Common strategies
The latest generation of HTPs are not only targeted at a specific sub-segment of 
tobacco users but are marketed and distributed non-traditionally. In expectation 
of increased sales, tobacco firms are investing heavily in increasing their HTP 
portfolios. For example, BAT is creating additional features for its glo HTPs, 
which includes the next generation of devices, additional flavours and blending 
technologies. PMI’s website notes that it is following a similar strategy, with 
investments in not only the next generation of IQOS products but also new HTPs 
like TEEPS, which has an alternative source to heat tobacco (121).
HTP manufacturers also use indirect marketing tactics to reach consumers, 
including young people. This often involves the use of front groups, including the 
Foundation for a Smoke-Free World, and lobbying (70). HTP companies also 
use corporate social responsibility strategies to boost their public image and to 
promote their brands (72), citing philanthropy as evidence of their corporate 
social responsibility, often making charitable donations to environmental causes, 
child labour prevention organizations and organizations that extend access to 
education (145).
10.3.3 Global use and prevalence of use of HTPs
While there are currently no robust, publicly available data from global 
surveillance of trends in the prevalence of HTP use, national and regional trends 
have been reported. The Asia–Pacific region currently reports the largest share 
of revenue from HTP sales and use concentrated in the age group 18–39 years. 
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Japan accounted for the largest share of revenue at 85% of the global HTP market 
in 2018 (146), and the fastest rate of growth in HTP revenue was in the Republic 
of Korea (147). In Japan in 2018, 2.7% of adults had used in HTPs in the previous 
30 days and 1.7% had used them daily; nearly all the HTP users surveyed were 
also current or former smokers of combusted cigarettes (148).
In the Republic of Korea, ever and current use of HTPs among young 
adults aged 19–24 years grew rapidly after IQOS was introduced in 2017; 5.7% 
of those surveyed reported ever use after it had been on the market for only 
3 months, and 3.5% reported current use (149). HTP inserts accounted for 
2.2% of cigarette sales in 2017 and for 9.6% by 2018. One year after HTPs were 
introduced onto market, 2.8% of Korean adolescents aged 12–18 years reported 
ever use of HTPs (150).
Market projections for 2019–2025 show significant investment by 
manufacturers and expectations of robust sales in Europe due to growth in Croatia, 
Germany, Italy, Poland and the Russian Federation (151). In 2019, Euromonitor 
reported that Italy represented the largest HTP market outside the Asia–Pacific 
region; other countries with rapid growth in the market between 2018 and 2019 
were Czechia, Germany, Romania, Russian Federation and Ukraine (152). In 
2017, only 0.7% of adults in the USA reported ever use of HTPs (2.7% of current 
smokers of combusted cigarettes); however, that rate increased significantly in 
only 1 year to 2.4% of adults in 2018 (6.7% of current cigarette smokers) (124). 
Euromonitor data have also been used to predict the market value of HTPs by 
2021; Germany, Japan, the Republic of Korea, Turkey and the USA were those 
predicted to be highest (153).
While many countries are beginning to survey and report on trends in 
use of HTPs in adults, evidence is lacking on use of these products by young 
people and on the preferences and use patterns of adult users. Both are critical 
areas for future research.
10.3.4 Trends in advertising, promotion and sponsorship of HTPs
How HTPs are advertised in markets through social media
Social media platforms are an emerging channel for advertising HTPs, as sites 
such as Twitter and Instagram are used by both adult and young populations 
worldwide. A scan of HTP advertisements and promotions was conducted on 
Instagram and Twitter with search terms consisting of hashtags with HTP brand 
names (e.g. #IQOS) and the name of a WHO Member State (e.g. #Belarus). 
As Instagram’s search function allows only one search term, the HTP brand 
name or search term was combined with the WHO Member State name (e.g. 
#IQOSCanada), whereas Twitter’s search function accommodates several search 
terms and Boolean operators (e.g. #IQOS AND #Canada). The search showed 
that HTPs are marketed on Twitter and Instagram in at least 95 WHO Member 
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States (Table 10.3). Analysis of the content of up to six advertisements (three 
Twitter, three Instagram) per country indicated use of similar advertisement 
strategies in the six WHO regions.
Table 10.3. Common HTP advertising strategies on social media, by WHO region, 2020
WHO 
region
No. of 
countries
Data 
avail-
able No. 
(%) 
No. of 
ad-
vertise-
ments
Health 
warning 
No. (%)
Nicotine 
lexical 
No. (%)
Flavour 
lexical 
No. (%)
Design 
feature 
lexical 
No. (%)
Image 
device 
No. (%)
Image of 
e-liquid 
No. (%)
African 46 3 (7) 9 1 (11) 3 (33) 0 0 7 (78) 4 (44)
Americas 35 12 (34) 42 17 (40) 3 (7) 12 (29) 9 (21) 38 (90) 12 (29)
South-
East Asia
11 6 (56) 16 11 (69) 3 (19) 3 (19) 4 (25) 14 (89) 4 (25)
European 53 48 (91) 186 86 (46) 21 (11) 41 (22) 22 (12) 146 (78) 30 (16)
Eastern 
Mediter-
ranean
22 15 (68) 62 12 (19) 17 (27) 17 (27) 4 (6) 55 (89) 18 (29)
Western 
Pacific
27 11 (41) 39 13 (33) 2 (5) 8 (21) 13 (33) 38 (97) 8 (21)
All 194 95 (49) 354 140 (40) 49 (14) 81 (23) 52 (15) 298 (84) 76 (21)
HTP advertisements were present in approximately half of WHO Member States, 
and most included an image of the device. Less than half of the social media 
advertisements for HTPs included a health warning, and almost one quarter 
mentioned a flavour.
Impact of COVID-19 on marketing strategies for HTPs
During the COVID-19 pandemic, several HTP manufacturers, retailers and users 
have posted messages relevant to COVID-19 and related containment strategies 
in marketing and promotion strategies on social media. Themes related to the 
pandemic and containment that emerged in HTP marketing on Instagram and 
Twitter included the following.
Coping with boredom and isolation: Manufacturers have marketed their 
products as a means for users to enjoy themselves safely at home during lockdown 
measures. For example, an Instagram post from glo’s worldwide account stated 
“Left brain says stay in. Right brain wants to go out. We’re loving these new tools 
that let you party from home with no compromise. #BreakBinary #NetflixParty 
#Discoverglo #Myglo” (66).
Stocking up on essential supplies: Users have implied that people should 
“stock up” on their favourite HTPs in preparation for lockdown or quarantine, 
equating these products to “essential” supplies for the duration of the lockdown. 
For example, one user posted a photo of several HTP devices (primarily IQOS) 
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and several packages of HEETS (heated tobacco units inserted into IQOS devices), 
with the statement “I’m ready for quarantine!” Another user posted a photo on 
both Instagram and Twitter of an IQOS device and three packages of HEETS, 
with the caption “#lockdown #essentials and/or #quarantine #addictions. Thanks 
for the gift @iqos_it”.
Stay at home campaigns. Some HTP brands are using “stay at home” 
campaigns and messages on social media to promote their products. For example, 
glo Greece held a “stay home challenge”, in which participants could win prizes 
(66). This post capitalized on the #menoumespiti message on Instagram, a 
popular hashtag meaning “we stay home” in Greek.
Obtaining protective equipment and supplies. Some manufacturers 
are offering branded face masks and hand sanitizer with the purchase of their 
products. For example, one Instagram advertisement by glo Kazakhstan shows a 
woman wearing a glo-branded face mask, with the caption “...Can‘t find a mask 
anywhere? We’ll give it to you [winking face emoji]. Until Thursday 26 March, 
you can get a mask for free in the glo space on Nazarbayev 100G. Well, after that 
you can get the same mask by placing a purchase of the device on the website or 
in our outlet…” (66).
10.3.5 Measures to control advertising, promotion and sponsorship of HTPs
In the countries that regulate advertising, promotion or sponsorship of HTPs, 
many have done so by including HTPs in existing regulations, some as novel 
tobacco products and some in other categories, whereas others have specific 
regulations for these products. Furthermore, some countries consider HTPs 
to be tobacco products rather than giving them a separate designation, so that 
they are subjected to all current national tobacco product regulations (113,154). 
Continued monitoring of such trends and their effects on use will provide 
valuable insight for policy-makers across the world who are observing trends 
in HTP use and for the design of a comprehensive regulatory framework or for 
updating existing regulations to reduce the harm associated with tobacco use.
While no peer-reviewed evidence is yet available on an association 
between HTP advertising and promotion and use, researchers have pointed to 
youth-friendly HTP advertising that has also been used to market ENDS, such 
as high-tech, novel design features, claims that HTPs are less harmful than 
combusted products and messages that HTPs may be more socially acceptable 
than combusted products (136,150). Given the evidence of successful use of these 
strategies to advertise ENDS products, HTP advertising, promotional messaging 
and media should be closely monitored, with trends in the susceptibility of 
children and adolescents to using HTPs.
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10.3.6 Recommendations for monitoring trends in marketing, advertising, 
promoting and sponsorship of HTPs
 ■ Better surveillance of trends in HTP use and sales
To increase the impact of the recommendations below, more robust 
data should be collected in various countries on trends in HTP use, 
including demographic data and product preferences. While the new 
generation of HTPs are relatively new on the tobacco product market, 
the rapid rise in the popularity of ENDS indicates that more rapid 
surveillance of HTP use and sales and reporting on national policies 
will be critical to including HTPs in existing control frameworks.
 ■ Better surveillance of HTP marketing, with particular attention to 
social media
The robust presence of marketing for alternative tobacco products on 
youth-friendly social media platforms suggests that increased surveil-
lance of marketing trends is necessary to better understand whether 
exposure to such marketing is associated with attitudes about and use 
of HTPs. This should include surveillance of content generated by 
HTP companies, retailers and users.
 ■ Scanning of how governments globally are regulating HTPs, in-
cluding their advertisement, promotion and sponsorship
Additional information should be collected on the regulation, mar-
keting and promotion of HTPs in order to understand the global pic-
ture. Better reporting of key policy developments across the world 
will assist in the development of timely, effective strategies for all Par-
ties to the WHO FCTC.
10.3.7 Recommendations for regulators
 ■ Remain focused on evidence-based smoking prevention strategies.
Governments and health organizations should maintain a focus 
on evidence-based measures to reduce smoking (as outlined in the 
WHO FCTC) and should not be distracted from action by the pro-
motion and marketing of novel products such as HTPs.
 ■ Consider cost-effective counter-marketing strategies.
Given the global reach of HTP advertising on social media, neither 
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governments nor social media platforms can effectively regulate the 
content, particularly when generated by users. Counter-marketing 
may be the most feasible option. Various forms could be used, includ-
ing social media campaigns, which may be more cost-effective than 
traditional media campaigns. Counter-marketing can include educa-
tion about industry activity, in addition to discouraging nicotine and 
tobacco use.
 ■ Apply relevant lessons learnt from regulation of ENDS and ENNDS
As HTP companies have adopted many of the same marketing strate-
gies that they used to promote ENDS and ENNDS, regulators can 
apply lessons learnt from ENDS and ENNDS marketing to regulating 
HTP marketing and promotion.
 ■ Foster collaboration among governments and government sectors 
for implementing and enforcing marketing regulations for HTPs.
Cross-border advertising, including transmission of media into 
neighbouring countries, should be addressed collaboratively at gov-
ernment level.
 ■ Consider banning all tobacco advertising, promotion and sponsor-
ship, where possible.
The tobacco industry has circumvented nearly all restrictions on ad-
vertising, promotion and sponsorship to reach consumers, including 
young people. Therefore, a complete ban on tobacco marketing may 
be necessary to minimize exposure to marketing for nicotine and to-
bacco products. Such a ban would ensure that most communication 
about these products came from national and local governments and 
public health agencies.
 ■ Keep informed of industry strategies to market HTPs, particularly 
to young people.
In order for policies to control HTP marketing to be effective, reg-
ulators must learn to recognize the strategies used by the industry, 
including use of health-related claims, sponsorship and price promo-
tions.
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10.3.7 Gaps in research on HTPs
 ■ Additional evidence is required to understand the relations among 
HTP regulation, perception of the risk of these products and prod-
uct use.
Much of the evidence on novel and emerging nicotine and tobacco 
products addresses the association between policies and trends in 
use; however, evidence specific to HTPs is insufficient. Further evalu-
ation is necessary of how different policies and product character-
istics change perceptions of risk and/or product use (particularly 
among young people).
 ■ Additional research is necessary on HTP marketing, with particu-
lar attention to social media, to inform regulators of the marketing 
and promotion strategies used by HTP companies and retailers.
Social media platforms are an important channel for advertising and 
promoting HTPs worldwide. As advertising seen on social media 
platforms has been associated with increased interest in using tobac-
co and nicotine products and also their actual use, research should be 
conducted on the impact of HTP marketing and promotion on these 
platforms (98,99).
 ■ Additional research should be conducted on user-generated HTP 
content on social media and its effect on risk perception, product 
use and the effectiveness of marketing regulations.
User-generated content has been used as an important marketing 
tactic for ENDS and ENNDS companies. Therefore, trends in user-
generated content related to HTPs should be monitored, with studies 
of its impact on risk perceptions and product use and on the effec-
tiveness of marketing regulations.
10.4 Summary
Globally, ENDS, ENNDS and HTPs are marketed through both traditional and 
emerging channels, such as social media. The evidence gathered for this report 
indicates that ENDS and HTPs are heavily marketed on Twitter and Instagram. 
The strategies used to regulate the marketing and promotion of these products 
differ widely among countries, some banning certain products, some regulating 
only products containing nicotine and others imposing restrictions on flavours, 
packaging and advertisements. Global systems are necessary to monitor 
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marketing of ENDS, ENNDS and HTP to understand how these products are 
advertised; additional evidence is necessary to understand how marketing of 
these products influences product perception and product use, particularly 
among adolescents and young adults. All levels of government should regulate 
the advertising, promotion and sponsorship of ENDS, ENNDS and HTPs when 
such regulations do not exist.
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Abstract
The impact of the form of nicotine, i.e. free base or salt, on its delivery from 
tobacco products and electronic nicotine delivery systems (ENDS) has been 
debated by scientists and regulators. In this paper, we briefly discussed the 
various ways of modifying the ratio of nicotine forms in tobacco products and 
ENDS. We focus on partitioning of nicotine forms in ENDS liquids, especially 
in the recently introduced pod-based ENDS. We discuss the influence of various 
parameters on nicotine delivery from ENDS, such as the form of nicotine, 
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counter-anions in nicotine salts, the power output of devices and user puffing 
topography. Recommendations are made on means to avoid capping nicotine 
concentrations in ENDS liquids as the sole measure for regulating nicotine 
delivery from ENDS and on adoption of “nicotine flux” as a regulatory tool that 
accounts for all the parameters that affect nicotine delivery from ENDS. We 
highlight the importance of including the form of nicotine in constructing a 
nicotine flux model and of minimizing possible customization of ENDS by users. 
While research is still necessary on methods for testing nicotine forms in ENDS 
liquids and aerosols and on absorption of the different forms by the body in the 
presence or absence of flavours, it is recommended that WHO urge countries to 
include nicotine flux and form in ENDS regulation to better inform users about 
nicotine delivery from their devices.
11.1  Background
This paper served as a “horizon” paper for the 10th meeting of the WHO Study 
Group on Tobacco Product Regulation and a platform for discussion and 
consideration of nicotine in ENDS products.
Nicotine can exist either as a free base or in combination with organic 
acids as various salts. This report provides a brief review of relevant published 
scientific information on nicotine, its presence in tobacco products, its 
modifications before manufacture and its forms in finished tobacco products. 
We also discuss the implications of the form of nicotine in ENDS for their 
appeal, addictive potential and health impact. The effect of the form of nicotine 
on tobacco control, regulation and research is also presented. In addition, we 
briefly discuss the relevance of nicotine flux for regulation of nicotine delivery 
from ENDS, arguing that the form of nicotine could be incorporated into the 
flux model.
Nicotine is the primary alkaloid in tobacco (1) and is the most abundant 
pyridine alkaloid in the leaves of 33 species; nornicotine is the most abundant 
in 24 species, anabasine in two species (N. glauca and N. debneyi) and anatabine 
in one species (N. otophora). In the roots, nicotine predominates in 51 species, 
nornicotine in two species (N. alata and N. africana) and anabasine in seven 
species (N. glauca, N. solanifolia, N. benavidesii, N. cordifolia, N. debneyi, N. 
maritima and N. hesperis) (2). Nicotine is synthesized in the roots of tobacco (3) 
by an enzymatic pathway, with condensation of nicotinic acid (pyridine ring) and 
N-methyl-Δ1-pyrrolinium cation (pyrrolidine ring) (4). The amounts of nicotine 
and three other major pyridine alkaloids in selected Nicotiana species are shown 
in Table 11.1.
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Table 11.1. Nicotine and major alkaloids contents in selected Nicotiana species
Subgenus, 
section
Species Content (mg/g 
dry weight)
Percentage of total
Nicotine Nornicotine Anabasine Anatabine
Leaves Root Leaves Root Leaves Root Leaves Root Leaves Root
Rustica, 
Paniculatae
N. glauca 8 872 5 246 12.5 35.5 1.5 2.8 85.1 51.3 0.9 10.4
N. solanifolia 
Walpers
848 9 326 3.2 27.7 81.4 10.0 15.4 60.3 Trace 2.0
N. benavidesii 
Goodspeed*
2 166 14 666 82.7 44.9 1.3 0.8 14.8 48.1 1.2 6.2
N. cordifolia 
Philippi
789 13 435 58.4 26.4 6.1 2.5 29.0 64.4 6.5 6.7
Rustica, 
Rusticae
N. rustica L. 7 752 8 439 96.4 81.6 0.9 1.7 1.1 6.6 1.6 10.1
Tabacum, 
Tomentosae
N. otophora 
Grisebach* 
377 7 924 6.9 61.3 32.9 27.0 Trace 0.6 60.2 11.1
Tabacum, 
Genuinae
N. tabacum 
L. 
11 462 2 176 94.8 81.3 3.0 6.0 0.3 1.7 1.9 11.0
Petunioides, 
Alatae
N. alata Link 
& Otto
26 1 998 100 37.7 Trace 46.4 – Trace – 15.8
Petunioides, 
Suaveolentes
N. debneyi 
Domin
2 457 3 038 31.1 34.7 15.8 1.4 46.0 53.2 7.1 10.7
N. maritima 
Wheeler
608 14 030 7.2 20.8 70.4 30.0 15.8 44.5 6.6 4.6
N. hesperis 
Burbridge
4 108 1 930 52.1 22.1 0.4 1.2 44.3 74.9 3.2 1.8
N. africana 
Merxmuller & 
Buttler*
6 776 7 698 4.7 45.0 92.4 45.1 0.3 1.0 2.6 8.9
Source: reproduced from reference 2.
* Species did not bloom.
The amount of biosynthesized nicotine in cultivated tobacco (N. tabacum L. 
and N. rustica L.) has been through gene modifications (5) and targeted gene 
manipulation for industrial applications (6–8). N. tabacum L. and N. rustica 
L. are the major species used in the manufacturing of tobacco products due to 
the abundant level of nicotine present in these species (9,10). Typical nicotine 
concentrations range from 15 to 35 mg per g tobacco (3), with total alkaloid 
concentrations reaching up to 79 mg per g tobacco (11).
The structure of nicotine comprises a pyrrolidine ring connected to a 
pyridine ring. The form of nicotine, free base, monoprotonated or diprotonated 
nicotine, depends on protonation of two nitrogen centres by naturally occurring 
acids in the leaves (Fig. 11.1). Protonated forms, also known as nicotine salts, 
predominate in unprocessed tobacco leaves; however, tobacco products have 
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different ratios of free base to salts. At pH 7, 8 and 9, free base is present in the 
solution at 9%, 49% and 90.5%, respectively; correspondingly, the nicotine salt is 
available at 91%, 51% and 9.5%.
Fig. 11.1. Free-base nicotine and monoprotonated and diprotonated nicotine salts
Source: references 12 and 13.
The lower part of the figure shows protonation of nicotine with benzoic acid, which may occur naturally in tobacco leaves or during 
manufacture of tobacco products.
The stimulatory and addictive effects of nicotine are attributed to the action of 
the pyridine alkaloid on neuronal nicotinic acetylcholine receptors in the brain. 
Currently, cigarette smoking is the most effective form of nicotine delivery. 
Nicotine in mainstream smoke from combusted tobacco is rapidly absorbed 
into the lungs and can reach the brain in as little as 7 s (14). Although tobacco 
smoking has been the most prevalent form of nicotine intake for decades, 
alternative tobacco products recently introduced onto the market (e.g. ENDS, 
heated tobacco products) are becoming popular around the globe, leading to an 
overall increase in total use of nicotine and tobacco products, especially among 
vulnerable populations such as young people. Thus, despite significant progress 
in tobacco control and prevention, nicotine and tobacco product use continues 
to grow. This report addresses nicotine abuse liability with one of the most widely 
marketed and most popular nicotine delivery products: ENDS. ENDS products, 
which are marketed in myriad combinations, allow users more customization than 
other nicotine and tobacco products (14), hence the challenge of implementing 
one standard set of regulations. The impact of the form of nicotine (free base vs 
salt) on delivery from these devices is therefore being investigated (15).
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11.2 Chemical modification of nicotine and influence on  
nicotine delivery
11.2.1  Brief summary of the effect of curing on nicotine
The main determinant of the dependence potential of a nicotine and tobacco 
product is its ability to deliver pharmacologically active levels of nicotine rapidly 
(16,17). Nicotine dosage is carefully controlled by manufacturers to ensure that it 
is sufficient to produce the desired effects, such as relaxation and mental acuity, 
while minimizing the risk of undesirable effects, such as nausea and intoxication 
(18). Nicotine constitutes 2–8% of the dry weight of cured tobacco leaf, with 
wider ranges for some Nicotiana species (19). The three main types of tobacco leaf 
used in commercial cigarettes are flue-cured, Burley and oriental (20, Table 11.2). 
Conventional cigarettes are made up of blends of these tobaccos. The primary 
blend differs among countries, but flue-cured and Burley tobaccos are used in the 
highest volume in commercial cigarettes. Most cigarettes contain primarily either 
flue-cured tobacco (e.g. in Canada) or a mixture of mainly flue-cured and Burley, 
with a minor amount of oriental tobacco (American blend) added.
Table 11.2. Types of tobacco, curing processes and nicotine content in tobacco leaf from the upper stalk 
position reported in literature
Tobacco type Curing process Tobacco products Nicotine content (mg/g)
Virginia (or Bright) Flue-cured by hanging the 
tobacco leaves in an enclosed 
area with heated air for 1 
week
Blended cigarettes
Virginia cigarettes
6.52–60.4 
Burley Air-cured in an air-ventilated 
area for 4–8 weeks
Blended cigarettes
Kretek cigarettes (clove-
flavoured)
35.6–47.73
Oriental Cured by hanging tobacco 
leaves in the sun for 2 weeks
Blended cigarettes 1.80–12.6
Source: reference 21.
Air-curing may decrease the final level of nicotine in tobacco leaves (22–24) due 
to oxidation of nicotine to cotinine or other oxidation products and conversion of 
nicotine to nornicotine by demethylation (23,25,26). Flue-curing retains higher 
levels of sugars in the leaves; as these are precursors of organic acids in tobacco 
smoke, there is a smaller fraction of free-base nicotine in the smoke (27).
11.2.2  Modification with alkali
Tobacco and “smoke pH” can be raised by using ammonia compounds (e.g. 
diammonium phosphate) and other substances (e.g. calcium carbonate) in 
tobacco processing. Calcium and sodium carbonates are added to cigarette filters 
to increase “smoke pH”, possibly eliminating the addition of bases to tobacco 
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filler (28,29). Ammonia has been used in the manufacture of tobacco since the 
accidental finding in the 1960s that elevated pH facilitates nicotine absorption, 
increasing free-base nicotine in cigarette smoke and tobacco products (30–32), 
despite industry denial (33,34). Ammonia also reacts with natural organic 
hydroxy compounds from tobacco and improves the quality of smoke, giving a 
smoother, “chocolate-like”, less acidic taste (35,36).
Other commonly used alkaline substances that increase smoke pH and 
improve smoke flavour include urea, diammonium phosphate, ethanolamines 
and carbonates (37,38). In an alkaline or high-pH environment, nicotine in its 
un-ionized (free base) form is rapidly absorbed across mucous membranes; 
however, this rapid flux is irritating to the user.
11.2.3  Modification with acid
When cigarette smoke is perceived as too harsh, smokers inhale less deeply 
(39). Additives such as levulinic acid make smoke appear smoother to the upper 
respiratory tract by lowering the fraction of free-base nicotine. As a result, the 
smoke is easier to inhale into the lungs (40). Levulinic acid has also been reported 
to increase nicotine yield (41). Addition of inorganic salts such as magnesium 
nitrate was found to lower the transfer of nicotine to tobacco smoke (42). In acidic 
conditions, nicotine is ionized (protonated) and therefore crosses biological 
membranes much more slowly and is less irritating (43). Table 11.3 summarizes 
the results of studies of the addition of acids to tobacco products.
Table 11.3. Results of adding acids to tobacco products
Type of acid Purpose of addition
Lactic acid Decreased harshness and bitterness, resulting in a sweeter flavour and smoothness (44) 
Citric acid Reduced harshness, modified flavour, lowered smoke pH, “neutralized” the impact of nicotine, 
enhanced sheet formation in reconstituted tobacco (45,46) 
Tartaric acid Similar to lactic acid, reduced the pH of smoke (46,47) 
Malic acid Did not promote migration in typical construction and storage procedures (48,49)
Formic acid Increased nicotine delivery, but had a distinct sour taste and failed to improve subjective 
performance (50,51) 
Levulinic acid Reduced harshness without decreasing nicotine delivery in smoke and with no unpleasant taste. 
Nicotine salt of levulinic acid also increased smoke nicotine delivery (41,52). 
Benzoic and sorbic acid Reduced harshness, increased nicotine delivery. Form salts with nicotine.
Pyruvic and lauric acid Typically added to form nicotine salt (53,54)
11.3 Implications for ENDS products and diversity
11.3.1  Free-base nicotine vs nicotine salt in ENDS
The previous section showed that the form and dosage of nicotine in combustible 
cigarettes can be controlled by the manufacturer during tobacco curing or 
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processing. We reported above that the distribution of different forms of nicotine 
in tobacco smoke affects the inhalability of nicotine. Free-base nicotine is readily 
absorbed in the upper respiratory tract, while nicotine salts are delivered to the 
bronchioalveolar region (55). Although the sites of absorption of the different 
nicotine forms are known, there is still controversy about how the site affects the 
rate of nicotine delivery to the brain (56).
ENDS allow users greater customization of their experience with nicotine 
in terms of dose and form. The ratios of nicotine forms in ENDS liquids results 
in pH in the entire range (5.3–9.3) (57), although the aerosol of the most popular 
ENDS (e.g. pod-based ENDS) has a low pH and high levels of nicotine salts. 
Added acids, such as levulinic acid, form monoprotonated and diprotonated 
nicotine forms, making inhalation of aerosols from ENDS smoother on the throat 
and upper airways. Other common acids used to form nicotine salts are lactic, 
benzoic, sorbic, pyruvic, salicylic, malic, lauric and tartaric acids (54). One report 
stated that flavour additives such as phenols, vanillin and ethyl vanillin can act as 
protonating agents in e-liquids (58). A study based on a randomized controlled 
trial (59) indicated that the presence of nicotine salts in ENDS reduces craving to 
the same extent as conventional cigarettes. Pharmacokinetics and subjective data 
demonstrate that nicotine lactate delivers nicotine via the pulmonary route for 
rapid absorption, albeit with a maximum nicotine level that does not exceed that 
in conventional cigarettes, and also showed acceptable subjective satisfaction and 
relief of a desire to smoke (59).
Nicotine in its three forms is considered the main addictive chemical 
in tobacco products. By the 1990s, it was increasingly accepted that tobacco 
products without nicotine would not sustain addiction (16,60). It is therefore 
important to focus on the interaction between flavours and nicotine in user 
perceptions of ENDS aerosols. Flavours could reduce the upper respiratory tract 
irritation of high nicotine levels in ENDS aerosols or contribute to the sensory 
impact of aerosols with low nicotine levels, as was shown with menthol (61). 
Moreover, published data show that some flavours, like apple, may increase the 
reinforcing effects of nicotine in ENDS aerosols (62), as was shown to be the case 
with menthol in cigarette smoke (63).
Nicotine salts such as nicotine benzoate are monoprotonated salts. These 
are reported to produce a high degree of satisfaction in users, as evidenced by 
the popular JUUL product (64), a patented formulation with benzoate salts (54) 
and similar ENDS (65). During aerosolization, nicotine salt dissociates during 
evaporation to give free-base nicotine and acid molecules that recombine 
upon contact with ambient air to condense into inhalable aerosols (54). 
Chromatography identifies the counter-anions derived from added acids, such as 
salicylate, tartrate, levulinate and malate in e-liquid or aerosols (66,67).
290
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
02
9,
 2
02
1
WHO Study Group on Tobacco Product Regulation   Eighth report
11.3.2  Feasible concentrations and abuse liability
Several investigators have adapted or developed analytical methods for 
determining the nicotine content of ENDS liquids and aerosols (68–70). The 
concentrations in ENDS liquids and prefilled cartridges range widely, from 0 in 
nicotine-free cartridges and liquids to about 130 mg/mL in some “do-it-yourself ” 
liquids (71–73). In the early years of the ENDS epidemic, cartridge-based ENDS 
(closed systems) had lower nicotine concentrations than open systems (71); 
however, the recently introduced pod-based ENDS contain very high levels of 
nicotine of > 60 mg/mL (69,74). The appeal of ENDS is related not only to the 
nicotine concentration but also to the form of nicotine, free base or salt (75–
77). The few reports to date of analyses of the form of nicotine in ENDS liquids 
showed a wide range of pH values and ratios of nicotine forms (68,78,79). A 
variety of approaches was used in these studies, including pH measurement and 
then estimation of the ratio of nicotine forms with the Henderson–Hasselbalch 
equation or an organic solvent extraction of nicotine from ENDS liquid dissolved 
in water to measure the different forms of nicotine by gas chromatography 
(68) or determining the ratios of different forms of nicotine by proton nuclear 
magnetic resonance spectroscopy (80). Moreover, nicotine present in the liquid 
is transferred efficiently to the aerosol and subsequently influences the resulting 
subjective effects (67). Recent work by the authors of this report showed that the 
form of nicotine does not affect the total yield of nicotine delivered in aerosols (81).
Several factors contribute to the appeal and continued use of ENDS, 
including flavours, high “customizability” and nicotine delivery (82,83). In the 
USA, use of ENDS, unlike any other non-cigarette tobacco product in the past 
decade, has surpassed cigarette smoking among children and young adults (84). 
The possibility of unlimited combinations of operating parameters (i.e. power, 
liquid composition, puff topography) in some ENDS allows delivery of nicotine 
at doses ranging from trace amounts to orders of magnitude higher than those 
delivered by a combustible cigarette (71,85,86). This wide range of nicotine 
delivery may increase the risk of abuse liability and nicotine dependence for users 
(87). Addiction to nicotine, like other drugs, is a function of the dose delivered 
and the speed of delivery (88). Smoking a combustible tobacco cigarette is an 
efficient, rapid means of nicotine delivery, hence its addictive character (89). The 
same applies to ENDS: recent brain imaging studies showed that ENDS can deliver 
nicotine to the brain at a rate similar to that of a combustible cigarette (90,91).
It is important to note that ENDS (and heated tobacco products) are 
often used as complements to cigarette smoking and not as substitutes, especially 
in smoke-free environments (92). Thus, dual use of ENDS and cigarettes is a 
common practice that sustains nicotine dependence (93). Longitudinal studies 
have also shown that ENDS users concurrently smoke combustible cigarettes, 
perhaps due to greater nicotine dependence (94,95). There is thus a growing 
trend of dual use of ENDS with combustible cigarettes (96,97).
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11.3.3  Potential masking of the harshness of products
Nicotine delivery is one of the main reasons for using ENDS (98). Another factor 
that contributes to the popularity of ENDS is the wide availability of unique 
flavours (99,100), the number of which has grown dramatically in recent years 
(101). The most common flavours are tobacco, menthol or mint, fruit, candy or 
dessert and beverages (102–104). Flavours can mask the harshness associated 
with inhaled free-base nicotine, especially if they induce a cool sensation, such 
as mint and menthol (105). An interesting area of research would therefore be 
the correlation between flavour choice and nicotine form used by novice and by 
experienced users.
11.3.4  Health implications and potential regulations
ENDS are commonly perceived as safer and less addictive than cigarette smoking, 
which may contribute to their rising popularity (106,107). Global use of ENDS 
has increased rapidly in the past decade, especially among young people, and 
there is evidence of nicotine dependence in this population (81,108–113). Early 
ENDS devices were deemed inefficient in delivering nicotine to the user (114); 
however, as the devices evolved and users became more experienced in their use, 
the efficiency of nicotine delivery greatly increased (115–117).
ENDS products are notably heterogeneous, with differences in materials, 
configurations, electrical power output, solvents and composition (118). Nicotine 
yield therefore depends on a combination of variables, such as device power, liquid 
composition and user puffing behaviour (84,119). As noted above, ENDS provide 
users unprecedented opportunities for customizing the nicotine concentration 
and sometimes form, and thus their nicotine dose, by preparing their own liquids 
and modifying operating parameters.
Nicotine delivery from ENDS is a subject of much debate among 
scientists and policy-makers. Some argue that, if ENDS products deliver nicotine 
at a dose and rate comparable to those of a combustible cigarette, ENDS may help 
smokers to reduce or quit smoking and subsequently reduce their exposure to 
the associated harm (120). Comparably efficient nicotine delivery may, however, 
make ENDS users, including previously nicotine-naïve individuals, more 
addicted to nicotine (110,121,122). A recent study showed that imposing a limit 
on the nicotine concentration of ENDS liquid is not sufficient to ensure nicotine 
yields lower than those of a combustible cigarette (123), as users can increase 
the power of the device to obtain the levels of nicotine in combustible cigarettes. 
Moreover, users who switch to higher-power devices inhale more aerosol and 
thus more toxicants, with unintended health consequences (86).
Most countries have not revised their legislation to include regulations 
on ENDS. Researchers and regulators, mainly in Europe, have considered that 
a first regulatory measure to mitigate risk could be to cap the nicotine content 
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of ENDS liquids to control nicotine delivery. Such a policy has been effective 
in the European Union since 2014, with a limit of 20 mg/mL on the nicotine 
concentration in ENDS liquids. Similar approaches could be considered in other 
jurisdictions. This policy does not, however, account for variations in ENDS 
product characteristics, such as power and puff topography. For example, users in 
a jurisdiction in which the nicotine concentration is limited may circumvent the 
aim of the regulation by choosing devices with higher power to obtain a nicotine 
yield that exceeds that of a combustible cigarette. Shihadeh and Eissenberg 
(124) proposed measurement of “nicotine flux”, which is the amount of nicotine 
delivered from a mouthpiece in a unit time (mg/s), as a suitable regulatory tool 
that encapsulates all the relevant operating parameters of ENDS that affect the 
rate and dose of nicotine delivered to the user. Current work from this group 
focuses on incorporating the form of nicotine into the nicotine flux construct. 
Clinical studies of the addictiveness and abuse liability of ENDS will determine 
the impact of the form of nicotine on the speed of delivery. The form of nicotine 
may also affect toxicity, as demonstrated by Pankow et al. (125), who showed that 
use of benzoic acid in the preparation of nicotine salt may lead to formation of 
benzene in ENDS emissions.
11.4  Discussion
Industry has used many approaches to enhance the efficiency of nicotine delivery 
from cigarettes, including manipulating the ratio of nicotine forms in cigarette 
filler. Nonetheless, a balance between nicotine delivery and harshness in the 
generated smoke dictated the manufacture of conventional cigarettes. A similar 
approach has recently been taken in the design of ENDS (126). The liquids used 
in ENDS that have the largest market share have a lower pH, due to the addition 
of organic acids, which masks the harshness of the large quantity of nicotine 
delivered during aerosolization. Nicotine salts, however, may contribute to the 
toxicity of electronic cigarette aerosols due to the degradation of counter-anions 
(125).
11.5  Research gaps, priorities and questions to members 
regarding further work or a full paper
The evidence indicates that various forms of nicotine, i.e. free-base nicotine 
and monoprotonated and diprotonated nicotine salts, are already available on 
the market of nicotine and tobacco products and are spreading quickly to other 
products. Recently, the industry has begun to manufacture synthetic nicotine, 
which is becoming cheaper to produce than previous technologies. It has already 
been used in e-liquids (127). This may be a challenge for regulation in certain 
jurisdictions, as the nicotine is not of tobacco origin.
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Research and development are required to:
 ■ develop and/or validate standard methods for measuring free-base 
nicotine and determining the ratio of free base to protonated and 
diprotonated nicotine in e-liquids and aerosols of ENDS;
 ■ quantify total and different forms of nicotine and organic acids in 
ENDS liquids and aerosols (68,81);
 ■ determine the impact of the form of nicotine on nicotine delivery to 
ENDS users and the dependence potential, including maintenance of 
addiction in a study conducted in the presence and absence of con-
founders;
 ■ investigate the health implications of the use of organic acids to 
change nicotine pharmacokinetics (128) and the impact on toxicity; 
and
 ■ validate nicotine flux, with nicotine form, as a tool for regulating 
nicotine delivery from ENDS.
 ■ If these gaps are addressed, the global priorities could be to:
 ■ ensure that the ratio of nicotine forms in ENDS helps smokers of 
combustible cigarettes to quit and does not lead novice users to be-
come nicotine addicts; and
 ■ on the basis of rigorous evidence, restrict manipulation of nicotine 
concentration and form by manufacturers.
In view of the importance of nicotine delivery from ENDS and the possible 
combined effect of nicotine form and concentration in ENDS liquids on its appeal, 
attractiveness and addictiveness, consideration should be given to requesting a 
full paper in the future.
11.6 Recommendation
Consideration should be given to preparation of a full paper on nicotine forms for 
a future meeting, if the topic is considered a priority and sufficient information 
is available.
11.7 Considerations
When countries strengthen their tobacco regulatory framework, a primary 
goal should be to reduce exposure to nicotine, the most important addictive 
substance in tobacco. Many countries have the authority to regulate products 
made of or derived from tobacco, as covered in Article 1 of the WHO Framework 
Convention on Tobacco Control. So far, the only regulation on nicotine delivery 
from ENDS is that of the European Union, which limits the nicotine content of 
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ENDS liquids. We argue above that this may be ineffective in addressing all the 
capabilities of this new category of nicotine delivery product, as it does not reflect 
the fact that the nicotine yield from ENDS is a result of many factors, such as 
nicotine concentration, power output and user puffing regime. Nicotine flux may 
be an option for regulatory consideration.
Moreover, the impact of the form of nicotine on its delivery, pharmaco-
kinetics and pharmacodynamics is not well studied, and more research is neces-
sary. Regulators should also consider minimizing the extent of possible custom-
ization of ENDS by users in terms of nicotine load and form and other features 
such as flavours.
Countries might have to review their legislation to regulate nicotine-
containing products comprehensively, regardless of the origin of the nicotine, in 
the interests of public health. If nicotine delivery products are not regulated, the 
work of countries and WHO in reducing tobacco use and nicotine abuse liability 
may be compromised. Finally, WHO should consider discussion of the inclusion 
of ENDS in the WHO Framework Convention on Tobacco Control or a provision 
within the Convention to address regulatory issues specific to these products.
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Abstract
The beneficial or detrimental effects of electronic nicotine delivery systems 
(ENDS, e-cigarettes) on lung health have been heavily debated over the past 
decade, both in academic circles and by the press. In the summer of 2019, the 
debates took a new direction after reports of several clusters of e-cigarette users 
who presented with acute respiratory failure, resulting in hospitalization and, 
in some cases, death. We describe the outbreak of e-cigarette or vaping product 
use-associated lung injury (EVALI), the latest information on its clinical features 
and lung pathology and investigations of the causal chemicals identified in 
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many commercial and/or illicit products used by affected individuals. Although 
news reports highlighted several clusters of EVALI in the USA, isolated case 
reports of vaping-associated respiratory failure have also been reported in other 
jurisdictions, including European countries. Many unanswered questions remain 
about the acute and long-term effects of exposure to the chemicals in the aerosols 
of e-cigarettes and other vaping products. A comprehensive approach, guided by 
epidemiological, translational and basic research, is necessary to assess the risks 
associated with inhalation of the emissions of these products, which are used in 
many countries around the world.
12.1 Background
12.1.1 Respiratory effects associated with e-cigarettes and vaping
Use of electronic nicotine delivery system (ENDS), commonly known as 
e-cigarettes or vape devices, is relatively new but is rapidly evolving among 
people of all ages in many countries and especially among young people in some 
countries, such as Canada and the USA. Vaping devices deliver nicotine to the 
lungs by aerosolizing liquid carriers that contain hydrophilic solvents, propylene 
glycol and vegetable glycerine. As the taste of the combinations of these heated 
chemicals is not appealing, >  99% of e-liquids contain chemical flavourings. 
While the long-term respiratory and/or systemic effects of these devices remain 
unknown, their use has been associated with acute and subacute effects on the 
lungs, including eosinophilic pneumonia, hypersensitivity pneumonitis, lipoid 
pneumonia, acute respiratory distress syndrome and diffuse alveolar haemorrhage 
(1,2). “Vaping”, an informal term used to refer to the use of these products, has 
also been reported to exacerbate pre-existing lung disease, particularly airway 
hyperreactivity and cough in asthma (3). This report provides information on the 
outbreak of lung injury associated with vaping products in 2019.
N.B. The term “vaping” may have positive connotations because of the 
association with “water vapour”, which may imply that the products are risk-free; 
however, e-cigarettes are not harmless.
12.1.2  E-cigarette or vaping product use-associated lung injury (EVALI)
In the summer of 2019, several clusters of lung injuries caused by vaping or 
e-cigarette use were recognized in the USA. The term EVALI was coined by the 
US Centers for Disease Control and Prevention (US CDC) on 11 October 2019. 
Epidemiological analyses in the USA have confirmed that the specific disease 
entity EVALI did not exist before 2019. Although lung diseases induced by 
e-cigarette or vaping were reported before 2019, EVALI is believed to have been 
caused by different chemical exposures, via disparate pathological mechanisms 
(4). EVALI reached epidemic levels in September 2019; however, although the 
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number of emergency department visits associated with EVALI has decreased, 
cases are still occurring across the country. As of February 2020, more than 2800 
cases requiring hospitalization had been confirmed, with 68 deaths. Various types 
of lung pathology have been identified, including diffuse alveolar damage (5).
12.1.3  Products and chemicals implicated in EVALI
Survivors of EVALI reported using various e-cigarettes, vaping devices, e-liquids 
and flavours, and no specific brand or device was common to all cases. Over 
80% of affected individuals reported that marijuana and other cannabinoids 
(Δ9-tetrahydrocannabinol; THC) were present in their e-liquids, and half vaped 
both THC and nicotine. All THC-containing e-liquids have been identified as 
potentially dangerous. e-Liquids containing vitamin E acetate have also been 
incriminated in this illness, as this substance was detected in the majority of 
e-liquids used by the affected patients as well as in their bronchoalveolar lavage 
fluid (6). Although many brands of e-liquid have been associated with this disease, 
dealers often fill empty cartridges with “in-house blends” of e-liquids. Therefore, 
no e-devices or e-liquids can be considered safe.
As over 80% of patients with EVALI reported using THC, and most of 
the e-liquids they used tested positive for THC, THC-containing e-cigarette 
or vaping products are believed to have played a major role in the outbreak. 
Although 14% of the people with EVALI vaped only nicotine, experts believe 
that they had other forms of vaping-induced lung injury and not EVALI. This 
conclusion is supported by the broad, nonspecific definition of EVALI and the 
fact that most of the patients in this nicotine-only cohort were older women. 
The carriers used for these products, particularly those from in-person or online 
dealers, have been strongly implicated. Of the 152 different THC-containing 
product brands identified, Dank Vapes (cartridges containing THC liquids of 
unknown source sold at many sites) are the most common in north-east and 
southern USA; TKO and Smart Cart brands have been reported in the west, and 
Rove has been found in mid-west states. These findings suggest that EVALI is 
associated with THC-containing products and is probably not due to a single 
brand. Both public health agencies and the US Food and Drug Administration 
have identified vitamin E acetate as the chemical most strongly associated with 
EVALI, as vitamin E acetate was detected in 48 of 51 bronchoalveolar lavage fluid 
samples obtained from EVALI patients (6).
12.2 EVALI
12.2.1 Detailed description and history
The first outbreaks of EVALI in the United States were identified in Illinois and 
Wisconsin in July 2019 (7,8). The features of EVALI cases were identified as: 
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vaping within 90 days of symptom onset, bilateral lung infiltrates on either chest 
X-ray or chest computed topography and the absence or unlikely evidence of an 
infectious cause. The US CDC then categorized EVALI cases as either probable, 
when microbial studies were positive but were unlikely to have caused the clinical 
presentation, or confirmed, if clinicians could rule out a respiratory infection (9). 
For example, if Staphylococcus aureus grew from a sputum culture, the case could 
be considered probably EVALI, with S. aureus as merely a colonizer and not 
the cause of the symptoms. If the most common tests for respiratory microbes 
were negative (e.g. for influenza, other respiratory viruses, including SARS-
CoV2, sputum Gram stain and culture, Streptococcus pneumonia urine antigen, 
and Legionella pneumonia urine antigen), the case would meet the criteria for 
confirmed EVALI.
After categorization by the US  CDC, several hundred additional cases 
were confirmed across the USA (10,11). The peak of the epidemic occurred in 
September 2019, since when the numbers of reported and confirmed cases has 
dropped. Possible explanations for the subsequent decrease include the following.
 ■ The intense media interest in EVALI may have led vapers to quit e-
cigarettes, buy them from reliable sources or quit vaping THC-con-
taining products in particular. 
 ■ Fewer health care professionals were reporting cases, as the diagnosis 
is not unique or novel. 
 ■ Makers of e-cigarette or vaping liquid may have stopped adding 
chemicals associated with EVALI to e-liquids.
12.2.2  Symptoms
The concurrent presence of gastrointestinal and respiratory symptoms is the 
most specific sign of EVALI. The most frequent findings in EVALI cases include 
abdominal pain, nausea, vomiting or diarrhoea with shortness of breath, cough, 
dyspnoea on exertion or chest pain. Less specific symptoms include fever, malaise, 
fatigue and weight loss (12,13).
12.2.3  Clinical presentation
Some patients sought clinical care within hours of the appearance of their first 
symptoms, but others had symptoms for weeks to months before their initial 
presentation, complicating understanding of variations in disease onset. Half 
of hospitalized EVALI patients have hypoxia that requires admission to an 
intensive care unit, and approximately half require mechanical ventilation and or 
extracorporeal membrane oxygenation. Moderate cases in which patients require 
2–6 L of oxygen are quite common. Mild cases are increasingly recognized 
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in which patients do not require supplemental oxygen to maintain oxygen 
saturation > 94% but have symptoms and findings similar to those in moderate 
and severe cases. Pneumothorax and pneumomediastinum have been reported 
commonly, raising the spectre of damage to the lung parenchyma leading to 
bronchopulmonary fistulas (12,13). Recently, several EVALI patients have been 
reported to have died 2–3 days after discharge from hospital, perhaps due to 
sudden pneumothorax.
12.2.4  Reported cases
The US CDC reported only the number of hospitalized patients from January 2020, 
reflecting a bias to reporting moderate-to-severe cases, and stopped reporting the 
numbers of EVALI cases completely on 25 February 2020. Canada, Japan, Mexico 
and the United Kingdom are among other countries that have reported cases 
of vaping-associated lung injury. Some of these reports predate the description 
of EVALI. Most patients required hospitalization, and the radiographic and 
clinical descriptions of their illness mirrored those of EVALI. As vaping was 
known to cause a wide variety of lung diseases before the emergence of EVALI 
and inhalation-induced lung diseases have similar presentations, it is likely that 
the cases were not related to THC or vitamin E acetate and were not EVALI. No 
systematic review of cases of vaping-induced lung disease, trends, prevalence or 
clusters of case reports has been reported from other countries.
12.3 Identification of EVALI
A universal definition of EVALI could be established if it has one causal agent, 
as for the global consensus among international pulmonary experts on the 
definition of acute respiratory distress syndrome. Any definition will have to be 
more specific and detailed than the current one (9), which includes everyone who 
has vaped within 90 days, has bilateral lung infiltration and no clear infectious 
cause. Ideally, the definition of EVALI will exclude other vaping-related lung 
diseases as well as non-vaping-related diseases. The addition of specific testing to 
exclude lung diseases that are idiopathic or vaping-related but not EVALI would 
be helpful. The pathological picture of EVALI is broad and overlaps with those 
of acute interstitial pneumonia, hypersensitivity pneumonitis, diffuse alveolar 
haemorrhage, lipoid pneumonia and adult respiratory disease syndrome.
12.4 Surveillance for EVALI
12.4.1  National surveillance mechanisms
It has been difficult to collect all the cases in the USA, as the US  CDC and 
the Food and Drug Administration rely on local and regional public health 
departments, which are robust and reliable but decide to share their data 
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according to local priorities and state health privacy laws. Another difficulty 
has been in educating health care providers, as most have not asked specifically 
about the use of e-cigarettes, vaping devices or THC-specific devices. It has been 
proposed that an open portal for reporting be established for both patients and 
health care providers in order to identify more cases (14). Privacy issues are the 
main deterrent; however, a similar method has been used for other diseases, such 
as lead poisoning and infectious diseases.
12.4.2  Regional surveillance mechanisms
A regional surveillance mechanism was described recently (11). Regional 
surveillance could help each health care system to accurately detect and track 
all EVALI cases, and the data could then be shared with regional public health 
departments and with the US CDC and the Food and Drug Administration in 
the USA. The United Kingdom has a system known as the “yellow card scheme”, 
which is available on the website of the Medicines and Healthcare Products 
Regulatory Agency (15). The scheme allows reporting of information on adverse 
or suspected adverse events related to medicines and makes provision for 
reporting of any side-effects of the use of e-cigarettes or safety concerns related to 
these products or their e-liquids. Members of the public and health care personnel 
in each country of the United Kingdom can file reports through the system.
12.4.3  International surveillance mechanisms and validation
One challenge in surveillance is identifying cases in both medical centres and 
rural areas in similar investigations and with similar confirmation methods to 
control and respond in each case. WHO sponsors a global network of over 250 
institutions dedicated to responding and raising awareness about acute public 
health events, the Global Outbreak Alert and Response Network (16).
Another difficulty is in defining EVALI, as the current definition is broad, 
making identification difficult. To improve surveillance, standards (e.g. case 
definitions) and training in recognition of EVALI are required at national and 
international levels. The US CDC has reported that nearly 3% of EVALI patients 
have required rehospitalization, and nearly one in seven deaths from EVALI has 
occurred after hospital discharge, particularly among people with one or more 
chronic diseases (17).
12.5 Discussion
It is estimated that 35–40 million adults and children globally vape, indicating a 
large number of people who are vulnerable to EVALI and other vaping-associated 
health outcomes. e-Cigarette use or vaping itself carries health risks and may harm 
health beyond the lungs. Further, the risks are increased by lacing of products 
with drugs and other substances, and the products should be properly regulated.
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The outbreak of EVALI in the USA highlights the importance of broadening 
the definition of e-cigarette toxicity beyond that of smoking, as vaping results 
in disease risks that are different from those associated with smoking (18). A 
major concern during the coronavirus disease 2019 (COVID-19) pandemic is the 
delay in recognizing and reporting EVALI in patients admitted with respiratory 
failure. For example, in April 2020, eight patients admitted to hospital for 
respiratory failure met the US CDC case definition of EVALI, but physicians first 
considered EVALI in differential diagnoses only 1–8 days (median day 3) after 
hospitalization (19). This report highlights some of the difficulties in recognizing 
respiratory failure due to EVALI, which may therefore be underdiagnosed during 
COVID-19 pandemic.
A priority at national and international level is to establish registries of 
EVALI patients that can be accessed by researchers and clinicians in order to assess 
the long-term effects and clinical outcomes. Further, acquisition and analysis of 
specimens from humans (e.g. whole blood, tracheal aspirates, bronchoalveolar 
lavage fluid, lung biopsy specimens, urine and autopsy specimens) could provide 
insight into the pathophysiology of EVALI. More mechanistic studies should 
be conducted to understand the toxic effect of vaping products in the lungs. 
Specifically, it is unclear whether and how vaping of propylene glycol or vegetable 
glycerine before exposure to vitamin E acetate causes lung injury. Further, vaping 
temperature, especially in high-powered devices, plays a role in lung injury (20). 
Animal models of EVALI would be useful for studying the potential causes of 
toxicity to the lungs related to vaping and use of THC products (14).
12.6 Considerations
A full report on the many aspects of the EVALI disease spectrum and its potential 
contribution to lung injury in other countries is recommended. Several key 
questions should be addressed to improve current understanding of care for 
patients who develop EVALI and respiratory failure.
 ■ A significant challenge is ensuring that physicians recognize an EVALI 
case, particularly during the COVID-19 pandemic. Physicians should 
be made aware of the risk of EVALI and ask about nicotine or THC 
use in electronic products as part of a routine history for patients who 
present with respiratory failure.
 ■ EVALI must be better defined to guide primary care and paediatric 
physicians in the correct diagnosis.
 ■ Studies should address whether e-cigarette use also increases vulner-
ability to SARS-CoV-2 infection in adults and children. Preclinical 
models of e-cigarette product use have provided strong evidence that 
chronic use alters lung defence immunity against influenza, a com-
mon viral pathogen (18).
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12.7 Recommendations
12.7.1 Key recommendations
 ■ National and international registries of EVALI patients and people 
with other vaping-associated lung diseases should be established to 
improve monitoring of long-term clinical outcome in survivors.
 ■ A strong international campaign should be organized to alert parents, 
children and young adults to the hazards of inhaling the chemicals 
contained in the aerosols of electronic vaping products.
 ■ Consideration should be given to writing a full paper on EVALI when 
more information becomes available.
12.7.2 Other recommendations
 ■ Specimens such as blood, tracheal aspirates, bronchoalveolar lavage 
fluid, lung tissue and urine should be obtained and analysed in order 
to better understand the pathophysiology of EVALI.
 ■ Animal models of EVALI should be developed to gain insight into the 
cellular and molecular mechanisms underlying the toxicity caused in 
the lungs and systemically by vaping both nicotine and THC and also 
the health effects of the vehicle and flavour chemicals contained in 
these products.
 ■ Research should be pursued to define the mechanisms by which vap-
ing products harm the lungs.
12.8 References
1. Arter ZL, Wiggins A, Hudspath C, Kisling A, Hostler DC, Hostler JM. Acute eosinophilic pneu-
monia following electronic cigarette use. Respir Med Case Rep. 2019;27:100825.
2.  Sommerfeld CG, Weiner DJ, Nowalk A, Larkin A. Hypersensitivity pneumonitis and acute re-
spiratory distress syndrome from e-cigarette use. Pediatrics. 2018;141(6):20163927.
3.  Lappas AS, Tzortzi AS, Konstantinidi EM, Teloniatis SI, Tzavara CK, Gennimata SA et al. Short-
term respiratory effects of e-cigarettes in healthy individuals and smokers with asthma. Re-
spirology. 2018;23:291–7.
4.  McCauley L, Markin C, Hosmer D. An unexpected consequence of electronic cigarette use. 
Chest. 2012;141:1110–3.
5.  Butt YM, Smith ML, Tazelaar HD, Vaszar LT, Swanson KL, Cecchini MJ et al. Pathology of va-
ping-associated lung injury. N Engl J Med. 2019;381(18):1780–1.
6.  Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M et 
al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med. 
2020;382:697–705.
7.  Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde M et al. Pulmonary illness related to 
309
EVALI: E-cigarette or vaping product use-associated lung injury
e-cigarette use in Illinois and Wisconsin – preliminary report. N Engl J Med. 2020;382:903–16.
8.  Ghinai I, Pray IW, Navon L, O’Laughlin K, Saathoff-Huber L, Hoots B et al. e-Cigarette product 
use, or vaping, among persons with associated lung injury – Illinois and Wisconsin, April–Sep-
tember 2019. Morb Mortal Wkly Rep. 2019;68:865–9.
9. 2019 lung injury surveillance. Primary case definitions. September 18, 2019. Atlanta (GA): Cen-
ters for Disease Control and prevention; 2019 (https://www.cdc.gov/tobacco/basic_informa-
tion/e-cigarettes/assets/2019-Lung-Injury-Surveillance-Case-Definition-508.pdf, accessed 
10 January 2021).
10.  Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa MJ. Clinical presentation, tre-
atment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a 
prospective observational cohort study. Lancet. 2019;394(10214):2073–83.
11.  Alexander LEC, Perez MF. Identifying, tracking, and treating lung injury associated with e-ci-
garettes or vaping. Lancet. 2019;394(10214):2041–3.
12. Zou RH, Tiberio PJ, Triantafyllou GA, Lamberty PE, Lynch MJ, Kreit JW et al. Clinical characte-
rization of e-cigarette, or vaping, product use associated lung injury in 36 patients in Pitts-
burgh, PA. Am J Respir Crit Care Med. 2020;201(10):1303–6.
13. Chatham-Stephens K, Roguski K, Jang Y, Cho P, Jatlaoui TC, Kabbani S et al. Characteristics of 
hospitalized and nonhospitalized patients in a nationwide outbreak of e-cigarette, or vaping, 
product use-associated lung injury – United States, November 2019. Morb Mortal Wkly Rep. 
2019;68:1076–80.
14. Crotty Alexander LE, Ware LB, Calfee CS, Callahan SJ, Eissenberg T, Farver C et al. NIH works-
hop report: E-cigarette or vaping product use associated lung injury: Developing a research 
agenda. Am J Respir Crit Care Med. 2020;202(6):795–802.
15. Yellow card. London: Medicines and Healthcare Products Regulatory Agency; 2020 (https://
yellowcard.mhra.gov.uk/the-yellow-card-scheme/#:~:text=The%20Yellow%20Card%20
scheme%20is,by%20health%20professionals%20and%20patients, accessed 10 January 
2021).
16. Global Outbreak Alert and Response Network. Geneva: World Health Organization; 2020 (htt-
ps://extranet.who.int/goarn/, accessed 10 January 2021).
17.  Evans ME, Twentyman E, Click ES, Goodman AB, Weissman DN, Kiernan E et al. Update: Inte-
rim guidance for health care professionals evaluating and caring for patients with suspected 
E-cigarette, or vaping, product use-associated lung injury and for reducing the risk for rehos-
pitalization and death following hospital discharge – United States, December 2019. Morb 
Mortal Wkly Rep.2020;68(5152):1189–94.
18.  Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R et al. Electronic cigarettes dis-
rupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest. 
2019;129:4290–304.
19.  Armatas C, Heinzerling A, Wilken JA. Notes from the field: e-cigarette, or vaping, product 
use-associated lung injury cases during the COVID-19 response – California, 2020. Morb Mor-
tal Wkly Rep. 2020;69:801–2.
20. Chaumont M, Bernard A, Pochet S, Mélot C, El Khattabi C, Reye F et al. High-wattage e-ciga-
rettes induce tissue hypoxia and lower airway injury: A randomized clinical trial. Am J Crit 
Care Med. 2018;198(1):123–6.
310
311
13.  Overall recommendations
The WHO Study Group on Tobacco Product Regulation publishes reports to 
provide a scientific basis for tobacco product regulation. In line with Articles 9 
and 10 of the WHO Framework Convention on Tobacco Control (FCTC), the 
reports identify evidence-based approaches to the regulation of the contents, 
emissions and design features of tobacco products.
The 10th meeting of the Study Group, the deliberations, outcomes and 
recommendations of which are included in this report, specifically addressed 
novel and emerging nicotine and tobacco products, including electronic 
nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems 
(ENNDS) and heated tobacco products (HTPs). Despite this focus, which is 
partly informed by the decision of the Eighth Conference of the Parties (COP8) 
to the WHO FCTC on novel and emerging tobacco products (decision FCTC/
COP8(22) (1), all tobacco products fall under the remit of the Study Group. This 
allows a comprehensive approach to synthesizing and making available evidence 
to countries on both conventional and newer products to address challenges in 
tobacco control, which remains a global priority.
Regulators are reminded that tobacco kills more than 8 million people 
a year (2,3), with more than 7 million of those deaths attributed to direct 
tobacco use and about 1.3 million to exposure of non-smokers to second-hand 
smoke (4,5). Tobacco also eventually kills up to half of its users and therefore 
remains a global health emergency (2). The introduction of novel and emerging 
nicotine and tobacco products, which are aggressively marketed and promoted 
by manufacturers, including to children and adolescents, in some jurisdictions 
further complicates tobacco control and has been a distraction for regulators. 
Thus, the recommendations of this report are intended to be taken in the context 
of wider tobacco control and to complement the recommendations of the Study 
Group in other reports on tobacco product regulation (6–12), which addressed 
cigarettes, smokeless tobacco and waterpipe tobacco.
The aggressive marketing and promotion of novel and emerging nicotine 
and tobacco products poses a serious threat to tobacco control. The Study Group, 
having considered the requests by countries for technical support on regulating 
these products, concluded that a focus must be maintained on wider tobacco 
control and that regulators should not allow themselves to be distracted by 
tobacco and related industry tactics and aggressive promotion of these products. 
The report highlights the importance of the following:
 ■ good science and verification of industry research;
 ■ full disclosure of product information to regulators;
 ■ clarification of the source of research funding to identify undue influ-
ence;
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 ■ independent research;
 ■ application of tobacco control laws to all tobacco products, without 
exception;
 ■ monitoring the activities of tobacco and related industries; and
 ■ protecting policies from the influence of nicotine and tobacco indus-
tries, especially in the context of Article 5.3 of the WHO FCTC and 
its guidelines (13,14). 
Sections 2–12 of the report provide scientific information, policy recommen-
dations and guidance to bridge regulatory gaps in tobacco control. The report 
also identifies areas for further work and research, with a focus on the regula-
tory needs of countries while accounting for regional differences, thus providing 
a strategy for continued, targeted technical support to all countries, especially 
WHO Member States. The main recommendations of the Study Group are out-
lined below.
13.1 Main recommendations
The main recommendations to policy-makers and all other interested parties are 
the following:
 ■ to ensure continued focus on evidence-based measures to reduce to-
bacco use as outlined in the WHO FCTC and seek to avoid being dis-
tracted from tobacco industry actions to promote novel and emerg-
ing tobacco products, such as heated tobacco products;
 ■ to use existing regulations for tobacco products to regulate heated 
tobacco products (including the device) and consider broadening the 
scope of existing regulations in which regulatory loopholes may be 
exploited by the tobacco industry, including in countries in which 
heated tobacco products are currently not legally available;
 ■ to apply the most restrictive tobacco control regulations to heated to-
bacco products (including the device), as appropriate within national 
laws, taking into account a high level of protection for human health;
 ■ to prohibit all manufacturers and associated groups from making 
claims about reduced harm of heated tobacco products, as compared 
with other products, or portraying heated tobacco products as an ap-
propriate approach for cessation of use of any tobacco product and 
to ban their use in public spaces unless robust independent evidence 
emerges to support a change in policy;
 ■ to ensure that the public is well informed about the risks associated 
with use of heated tobacco products, including the risks of dual use 
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with conventional cigarettes and other smoked tobacco products, and 
also their use during pregnancy; to correct false perceptions, counter 
misinformation and stress that reduced exposure does not necessar-
ily mean reduced harm;
 ■ to rely on independent data and to support continuing independent 
research on the public health impact of use of heated tobacco prod-
ucts, with critical analysis and interpretation of tobacco industry-
funded data, including data on the emissions and toxicity of heated 
tobacco products and associated exposures and effects in users and 
non-users;
 ■ to require tobacco manufacturers to disclose all product information 
– including product design, chemical profile, total nicotine content, 
nicotine forms, toxicity, other findings of product testing and testing 
methods – to appropriate regulatory agencies at least once a year; any 
modifications to products should require updating of the report;
 ■ to ban all commercial marketing of electronic nicotine delivery sys-
tems, electronic non-nicotine delivery systems and heated tobacco 
products, including in social media and through organizations fund-
ed by and associated with the tobacco industry;
 ■ to prohibit the sale of electronic nicotine delivery systems and elec-
tronic non-nicotine delivery systems in which the user can control 
device features and liquid ingredients (that is, open systems);
 ■ to prohibit the sale of electronic nicotine delivery systems with a 
higher abuse liability than conventional cigarettes, for example by 
restricting the emission rate or flux of nicotine; and
 ■ to prohibit the addition of pharmacologically active substances such 
as cannabis and tetrahydrocannabinol (in jurisdictions where they 
are legal), other than nicotine in electronic nicotine delivery systems, 
to electronic nicotine delivery systems and electronic non-nicotine 
delivery systems.
Countries are urged to implement the above recommendations, as there is 
enough information about nicotine and tobacco products for countries to act to 
protect the health of their populations, especially the younger generation. While 
the report acknowledges that still more is to be learnt about these products and 
emphasizes that continued independent research is necessary to build further 
intelligence on the products, including their marketing, features, prevalence of 
use and availability, and on the promotional strategies of tobacco and related 
industries, there are more than a billion tobacco users, and millions of people use 
the newer products. Therefore, the public health community should answer the 
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call for continued acceleration of evidence-based policies and recommendations, 
such as those in the WHO FCTC, WHO MPOWER measures and the relevant 
COP reports. Countries should thus implement proven policy measures and, in 
addition, consider implementing the recommendations in this report. Specific 
recommendations on each of the topics considered can be found in sections 2.8, 
3.5.4, 4.9, 5.11, 6.7, 7.11, 8.5, 8.7, 9.8, 10.2.6, 10.3,7, 11.6 and 12.7.
13.2 Significance for public health policies
The Study Group’s report provides helpful guidance to the science, research 
and evidence on all tobacco products, including cigarettes, smokeless tobacco 
and waterpipe tobacco. Recently, the Study Group has extended its work by 
providing much needed information to regulators on the contents, emissions, 
variation in and features of novel and emerging nicotine and tobacco products, 
in particular, ENDS, ENNDS and HTPs. The report highlights the public health 
impact of these products and their features on users and non-users, including: 
their addictive potential; perception and use of the products; their attractiveness; 
their potential role in initiating and stopping tobacco use; marketing, including 
promotional strategies and impacts; claims of reduced harm; variation in products; 
quantification of risk to the health of individuals and populations; regulatory 
mapping and the experience of selected countries; impact on tobacco control; 
and research gaps. The Study Group’s recommendations, outlined above, directly 
address some of the unique regulatory challenges faced by certain Member States 
because of the penetration of these products into their markets. Further, the 
report will help Member States to update their knowledge on novel and emerging 
nicotine and tobacco products and aid in the formulation of effective regulatory 
strategies for nicotine and tobacco products.
The Study Group, because of its unique composition of regulatory, 
technical and scientific experts, navigates and distils complex data and research 
and synthesizes them into policy recommendations, which inform policy 
development at national, regional and global levels. This authoritative report by 
a multidisciplinary team of experts goes to the heart of the challenges faced by 
governments on novel and emerging products. The nature of the report means 
that regulators, governments and interested parties can rely on the science and 
evidence presented to counter the arguments of tobacco and related industries, 
as appropriate. The identification of gaps in policy and research on nicotine 
and tobacco products indicates areas in which there is insufficient information. 
Countries, in formulating their research agendas, could focus on areas pertinent 
to their policy goals, objectives and national context. This is a critical role of the 
Study Group, especially for governments with inadequate resources or capacity 
to navigate technical information on tobacco product regulation.
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Overall recommendations
The recommendations made in the report promote international 
coordination of regulatory efforts and the adoption of best practices in product 
regulation, strengthen capacity in product regulation in all WHO regions, 
provide a ready resource for Member States that is based on sound science 
and support implementation of the WHO FCTC by its States Parties. Tobacco 
product regulation complements other provisions of the WHO FCTC on demand 
reduction. The recommendations of the Study Group, if effectively implemented, 
would contribute to reducing tobacco use, thus reducing tobacco use prevalence 
and promoting good health.
13.3 Implications for the Organization’s programmes
The report fulfils the mandate of the WHO Study Group on Tobacco Product 
Regulation to provide the Director-General with scientifically sound, evidence-
based recommendations for Member States about tobacco product regulation,1 
which is a highly technical area of tobacco control in which Member States face 
complex regulatory challenges. The outcomes of the Study Group’s deliberations 
and main recommendations will improve Member States’ understanding of 
ENDS, ENNDS and HTPs and the implications of the proliferation of these 
products on markets in many countries in the broader context of tobacco control.
The contribution of the report to the body of knowledge on product 
regulation will inform the work of the tobacco programme in WHO’s Department 
of Health Promotion, especially in providing technical support to Member 
States. It will also contribute to updating Member States and regulators through 
meetings of the WHO Global Tobacco Regulators’ Forum and information-
sharing via the Forum’s EZCollab network. States Parties to the WHO  FCTC 
will be updated through a comprehensive report on research and evidence on 
novel and emerging tobacco products, which was requested by the Conference of 
the Parties at its eighth session.2 The comprehensive report will include the key 
messages and recommendations of the eighth report of the Study Group. All of 
these will contribute to meeting target 3.a of the Sustainable Development Goals 
(that is, strengthening implementation of the WHO Framework Convention 
on Tobacco Control) and the triple billion targets of WHO’s Thirteenth Global 
Programme of Work.
The report, which is a WHO global public health good (i.e. an initiative 
developed or undertaken by WHO that is of benefit either globally or to many 
countries in many regions (15)), is available to all countries to help drive impact 
at country level and globally, towards reducing tobacco use and improving overall 
public health.
1 In November 2003, the Director-General formalized the status of the former Scientific Advisory Committee 
on Tobacco Product Regulation from a scientific advisory committee to a study group.
2 See decision FCTC/COP8(22), paragraph 2(a).
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This report fulfils the mandate of the WHO Study Group on Tobacco Product 
Regulation to provide the Director-General with scientifically sound, evidence-based 
recommendations for Member States about tobacco product regulation. This report 
presents the outcomes and recommendations made by the members of the Study 
Group at its tenth meeting, which addressed novel and emerging nicotine and tobacco 
products, such as electronic nicotine delivery systems (ENDS), electronic non-nicotine 
delivery systems (ENNDS) and heated tobacco products (HTPs).  The group reviewed 
nine background papers and two horizon scanning papers, specially commissioned 
for the meeting, which addressed the following topics:
1. Toxicants in HTPs, exposure, health effects and claims of reduced risk (section 2);
2. The attractiveness and addictive potential of HTPs: effects on perception and use 
and associated effects (section 3);
3. Variations among HTPs, considerations and implications (section 4);
4. Use of HTPs: product switching and dual or poly product use (section 5);
5. Regulations on HTPs, ENDS and ENNDS, with country approaches, barriers to 
regulation and regulatory considerations (section 6);
6. Estimation of exposure to nicotine from use of ENDS and from conventional 
cigarettes (section 7);
7. Exploration of methods for quantifying individual risks associated with ENDS, 
ENNDS and HTPs: impact on population health and implications for regulation 
(section 8).
8. Flavours in novel and emerging nicotine and tobacco products (section 9);
9. Global marketing and promotion of novel and emerging nicotine and tobacco 
products and their impacts (section 10);
10. Forms of nicotine in tobacco plants, chemical modifications and implications for 
ENDS products (section 11); and 
11. EVALI: “e-cigarette or vaping product use-associated lung injury” (section 12).
The Study Group’s recommendations on each of these topics are set out at the end of 
the relevant section, and overall recommendations are summarized in the final section 
of the report. These, as well as the deliberations of the Study Group, will improve 
Member States’ understanding of ENDS, ENNDS and HTPs.  The report, which is a 
WHO global public health good (i.e. an initiative developed or undertaken by WHO 
that is of benefit either globally or to many countries in many regions), is available to 
all countries to help in reducing tobacco use and improving overall public health at 
country level and globally.
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